U.S. patent application number 15/048158 was filed with the patent office on 2017-02-09 for compounds and methods for inhibiting phosphate transport.
The applicant listed for this patent is Ardelyx, Inc.. Invention is credited to Noah Bell, Christopher Carreras, Han-Ting Chang, Dominique Charmot, Tao Chen, Jeffrey W. Jacobs, Eric Labonte, Michael R. Leadbetter, Jason G. Lewis, Marc Navre, Nicholas Reich.
Application Number | 20170037010 15/048158 |
Document ID | / |
Family ID | 45975794 |
Filed Date | 2017-02-09 |
United States Patent
Application |
20170037010 |
Kind Code |
A1 |
Lewis; Jason G. ; et
al. |
February 9, 2017 |
COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
Abstract
Compounds having activity as phosphate transport inhibitors,
more specifically, inhibitors of intestinal apical membrane
Na/phosphate co-transport, are disclosed. The compounds have the
following structure (I): ##STR00001## including stereoisomers,
pharmaceutically acceptable salts and prodrugs thereof, wherein X,
Y, A, R.sub.1 and R.sub.2 are as defined herein. Methods associated
with preparation and use of such compounds, as well as
pharmaceutical compositions comprising such compounds, are also
disclosed.
Inventors: |
Lewis; Jason G.; (Castro
Valley, CA) ; Jacobs; Jeffrey W.; (San Mateo, CA)
; Reich; Nicholas; (Hillsboro, OR) ; Leadbetter;
Michael R.; (San Leandro, CA) ; Bell; Noah;
(Berkeley, CA) ; Chang; Han-Ting; (Livermore,
CA) ; Chen; Tao; (Palo Alto, CA) ; Navre;
Marc; (Belmont, CA) ; Charmot; Dominique;
(Campbell, CA) ; Carreras; Christopher; (Belmont,
CA) ; Labonte; Eric; (Belmont, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ardelyx, Inc. |
Fremont |
CA |
US |
|
|
Family ID: |
45975794 |
Appl. No.: |
15/048158 |
Filed: |
February 19, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14536509 |
Nov 7, 2014 |
9301951 |
|
|
15048158 |
|
|
|
|
13734547 |
Jan 4, 2013 |
8916569 |
|
|
14536509 |
|
|
|
|
PCT/US2011/043267 |
Jul 7, 2011 |
|
|
|
13734547 |
|
|
|
|
61362117 |
Jul 7, 2010 |
|
|
|
61443632 |
Feb 16, 2011 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 5/18 20180101; A61K
31/496 20130101; C07D 239/34 20130101; C07D 405/12 20130101; C07D
213/50 20130101; C07D 417/12 20130101; A61K 31/785 20130101; C07D
417/14 20130101; A61K 31/551 20130101; A61K 31/44 20130101; A61P
3/00 20180101; A61K 31/59 20130101; A61P 5/16 20180101; C07D 213/30
20130101; C07D 403/12 20130101; C07D 401/06 20130101; C07D 405/14
20130101; A61K 45/06 20130101; A61K 31/4418 20130101; C07D 401/10
20130101; A61P 13/12 20180101; A61K 31/593 20130101; A61K 31/5377
20130101; C07D 239/42 20130101; C07D 213/38 20130101; C07D 401/14
20130101; A61K 31/541 20130101; C07D 401/12 20130101; A61K 31/506
20130101; C07D 213/81 20130101; C07D 213/82 20130101; A61K 31/4545
20130101; A61P 7/08 20180101; A61P 3/12 20180101 |
International
Class: |
C07D 213/81 20060101
C07D213/81; C07D 401/06 20060101 C07D401/06; C07D 405/12 20060101
C07D405/12; C07D 417/12 20060101 C07D417/12; C07D 401/10 20060101
C07D401/10; C07D 239/34 20060101 C07D239/34; C07D 213/50 20060101
C07D213/50; C07D 213/30 20060101 C07D213/30; C07D 213/38 20060101
C07D213/38; C07D 401/12 20060101 C07D401/12; C07D 239/42 20060101
C07D239/42 |
Claims
1. A compound having the following structure (I): ##STR00527## or a
stereoisomer, prodrug or pharmaceutically acceptable salt thereof,
wherein: A is --CR.sub.1-- or --N--; X is substituted aryl or
substituted heteroaryl; Y is halogen, optionally substituted
alkylamino, optionally substituted alkoxy, optionally substituted
thioalkyl, optionally substituted cycloalkyl, optionally
substituted heterocyclyl, optionally substituted aryl,
--O(optionally substituted cycloalkyl), --O(optionally substituted
heterocyclyl) or --O(optionally substituted aryl); each R.sub.1 is,
independently, hydrogen, halogen, C.sub.1-6alkyl or
C.sub.1-6haloalkyl; R.sub.2 is --C(.dbd.O)NR.sub.2aR.sub.2b,
--NR.sub.2aC(.dbd.O)R.sub.2b, --C(.dbd.O)R.sub.2b,
--NR.sub.2aR.sub.2b, --OR.sub.2b or --R.sub.2b; R.sub.2a is
hydrogen or optionally substituted C.sub.1-6alkyl; and R.sub.2b is
optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted cycloalkylalkyl, optionally substituted
heterocyclyl, optionally substituted heterocyclylalkyl, optionally
substituted aryl, optionally substituted aralkyl, optionally
substituted heteroaryl, or optionally substituted
heteroarylalkyl.
2-32. (canceled)
33. A pharmaceutical composition comprising a compound of claim 1,
or a stereoisomer, pharmaceutically acceptable salt or prodrug
thereof, and a pharmaceutically acceptable carrier, diluent or
excipient.
34-38. (canceled)
39. A method of inhibiting phosphate transport in a mammal,
comprising administering to the mammal an effective amount of a
compound of claim 1 or a pharmaceutical composition of claim
33.
40-43. (canceled)
44. A method of treating hyperphosphatemia in a mammal in need
thereof, comprising administering to the mammal an effective amount
of a compound of claim 1 or a pharmaceutical composition of claim
33.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 14/536,509, filed Nov. 7, 2014, now pending,
which is a continuation of U.S. patent application Ser. No.
13/734,547, filed Jan. 4, 2013, now U.S. Pat. No. 8,916,569, which
is a continuation of PCT International Application No.
PCT/US2011/043267, filed Jul. 7, 2011, which claims the benefit
under 35 U.S.C. .sctn.119(e) of U.S. Provisional Patent Application
No. 61/362,117 filed Jul. 7, 2010; and U.S. Provisional Patent
Application No. 61/443,632 filed Feb. 16, 2011. The foregoing
applications are incorporated herein by reference in their
entireties.
BACKGROUND
[0002] Field
[0003] The present invention is directed to novel phosphate
transport inhibitors, more specifically, inhibitors of intestinal
apical membrane Na/phosphate co-transport, and methods for their
preparation and use as therapeutic or prophylactic agents.
[0004] Description of the Related Art
[0005] Patients with inadequate renal function, hypoparathyroidism,
or certain other medical conditions (such as hereditary
hyperphosphatemia, Albright hereditary osteodystrophy, amyloidosis,
etc.) often have hyperphosphatemia, or elevated serum phosphate
levels (wherein the level, for example, is more than about 6
mg/dL). Hyperphosphatemia, especially if present over extended
periods of time, leads to severe abnormalities in calcium and
phosphorus metabolism, often manifested by secondary
hyperparathyroidism, bone disease and ectopic calcification in the
cardiovascular system, joints, lungs, eyes and other soft tissues.
Higher serum phosphorus levels are strongly associated with the
progression of renal failure, cardiovascular calcification and
mortality in end-stage renal disease (ESRD) patients. High-normal
serum phosphorus levels have been associated with cardiovascular
events and mortality among individuals who have chronic kidney
disease (CKD) and among those who have normal kidney function (see,
e.g., Joy, M. S., P. C. Karagiannis and F. W. Peyerl, Outcomes of
Secondary Hyperparathyroidism in Chronic Kidney Disease and the
Direct Costs of Treatment, J. Manag. Care Pharm., 13(5):397-411
(2007)) The progression of kidney disease can be slowed by reducing
phosphate retention. Thus, for renal failure patients who are
hyperphosphatemic and for chronic kidney disease patients who have
serum phosphate levels within the normal range or only slightly
elevated, therapy to reduce phosphate retention is beneficial.
[0006] For patients who experience hyperphosphatemia, calcium salts
have been widely used to bind intestinal phosphate and prevent its
absorption. Different types of calcium salts, including calcium
carbonate, acetate, citrate, alginate, and ketoacid salts have been
utilized for phosphate binding. A problem with all of these
therapeutics is the hypercalcemia, which often results from
absorption of high amounts of ingested calcium. Hypercalcemia
causes serious side effects such as cardiac arrhythmias, renal
failure, and skin and vascular calcification. Frequent monitoring
of serum calcium levels is required during therapy with
calcium-based phosphate binders. Other calcium and aluminum-free
phosphate binders, such as sevelamer, a crosslinked polyamine
polymer, have drawbacks that include the amount and frequency of
dosing required to be therapeutically active. The relatively modest
phosphate binding capacity of those drugs in vivo obliges patients
to escalate the dose (up to 7 grs per day or more). Such quantities
have been shown to produce gastrointestinal discomfort, such as
dyspepsia, abdominal pain and, in some extreme cases, bowel
perforation.
[0007] An alternative approach to the prevention of phosphate
absorption from the intestine in patients with elevated phosphate
serum levels is through inhibition of the intestinal transport
system which mediates phosphate uptake in the intestine. It is
understood that phosphate absorption in the upper intestine is
mediated at least in part by a carrier-mediated mechanism which
couples the absorption of phosphate to that of sodium. Inhibition
of intestinal phosphate transport will reduce body phosphorus
overload. In patients with advanced kidney disease (e.g. stage 4
and 5), the body phosphorus overload manifests itself by serum
phosphate concentration above normal levels, i.e.
hyperphosphatemia. Hyperphosphatemia is directly related to
mortality and morbidity. Inhibition of intestinal phosphate
transport will reduce serum phosphate concentration and therefore
improve outcome in those patients. In chronic kidney disease
patients stage 2 and 3, the body phosphorus overload does not
necessarily lead to hyperphosphatemia, i.e. patients remain
normophosphatemic, but there is a need to reduce body phosphorus
overload even at those early stages to avoid associated bone and
vascular disorders, and ultimately improve mortality rate.
Similarly, inhibition of intestinal phosphate transport would be
particularly advantageous in patients that have a disease that is
treatable by inhibiting the uptake of phosphate from the
intestines. Inhibition of phosphate absorption from the glomerular
filtrate within the kidneys would also be advantageous for treating
chronic renal failure. Furthermore, inhibition of phosphate
transport may slow the progression of renal failure and reduce risk
of cardiovascular events.
[0008] While progress has been made in this field, there remains a
need in the art for novel phosphate transport inhibitors. The
present invention fulfills this need and provides further related
advantages.
BRIEF SUMMARY
[0009] In brief, the present invention is directed to compounds
having activity as phosphate transport inhibitors, more
specifically, inhibitors of intestinal apical membrane Na/phosphate
co-transport, including stereoisomers, pharmaceutically acceptable
salts and prodrugs thereof, and the use of such compounds to
inhibit sodium-mediated phosphate uptake and to thereby treat any
of a variety of conditions or diseases in which modulation of
sodium-mediated phosphate uptake provides a therapeutic
benefit.
[0010] In one embodiment, compounds having the following structure
(I) are provided:
##STR00002##
or a stereoisomer, prodrug or pharmaceutically acceptable salt
thereof,
[0011] wherein:
[0012] A is --CR.sub.1-- or --N--;
[0013] X is substituted aryl or substituted heteroaryl;
[0014] Y is halogen, optionally substituted alkylamino, optionally
substituted alkoxy, optionally substituted thioalkyl, optionally
substituted cycloalkyl, optionally substituted heterocyclyl,
optionally substituted aryl, --O(optionally substituted
cycloalkyl), --O(optionally substituted heterocyclyl) or
--O(optionally substituted aryl);
[0015] each R.sub.1 is, independently, hydrogen, halogen,
C.sub.1-6alkyl or C.sub.1-6haloalkyl;
[0016] R.sub.2 is --C(.dbd.O)NR.sub.2aR.sub.2b,
--NR.sub.2aC(.dbd.O)R.sub.2b, --C(.dbd.O)R.sub.2b,
--NR.sub.2aR.sub.2b, --OR.sub.2b or --R.sub.2b;
[0017] R.sub.2a is hydrogen or optionally substituted
C.sub.1-6alkyl; and
[0018] R.sub.2b is optionally substituted alkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, or
optionally substituted heteroarylalkyl.
[0019] In another embodiment, a pharmaceutical composition is
provided comprising a compound having structure (I), or a
stereoisomer, pharmaceutically acceptable salt or prodrug thereof,
and a pharmaceutically acceptable carrier, diluent or excipient. In
further embodiments, the pharmaceutical composition further
comprises one or more additional biologically active agents. In
more specific embodiments, the additional biologically active agent
is selected from vitamin D.sub.2 (ergocalciferol), vitamin D.sub.3
(cholecalciferol), active vitamin D (calcitriol) and active vitamin
D analogs (e.g. doxercalciferol, paricalcitol). In other more
specific embodiments, the additional biologically active agent is a
phosphate binder, and the compound does not interfere with the
phosphate binder. For example, in certain embodiments, the
phosphate binder is selected from the group consisting of Renvela,
Renagel, Fosrenol, calcium carbonate, calcium acetate (e.g.
Phoslo), MCI-196, Zerenex.TM., Fermagate, APS1585, SBR-759 and
PA-21. In other further embodiments, the compound is substantially
active as an inhibitor of Na/phosphate co-transport and the
Na/phosphate co-transport is mediated by NaPi2b.
[0020] In another embodiment, a method of inhibiting phosphate
transport in a mammal is provided, comprising administering to the
mammal an effective amount of a compound having structure (I), or a
stereoisomer, pharmaceutically acceptable salt or prodrug thereof,
or a pharmaceutical composition comprising such compound. In
further embodiments, the method inhibits sodium-mediated phosphate
uptake. In other further embodiments, the method is selected from
the group consisting of: (a) a method for treating
hyperphosphatemia; (b) a method for treating a renal disease; (c) a
method for delaying time to dialysis; (d) a method for attenuating
intima localized vascular calcification; (e) a method for reducing
the hyperphosphatemic effect of active vitamin D; (f) a method for
reducing FGF23 levels; (g) a method for attenuating
hyperparathyroidism; (h) a method for improving endothelial
dysfunction induced by postprandial serum phosphate; (i) a method
for reducing urinary phosphorous; (j) a method for normalizing
serum phosphorus levels; (k) a method for treating proteinuria; and
(l) a method for reducing serum PTH and phosphate concentrations or
levels. In certain embodiments, the renal disease is chronic kidney
disease or end stage renal disease. In other certain embodiments,
the method for treating a renal disease further comprises
administering to the mammal an effective amount of a phosphate
binder.
[0021] In another embodiment, a method of treating
hyperphosphatemia in a mammal in need thereof is provided,
comprising administering to the mammal an effective amount of a
compound having structure (I), or a stereoisomer, pharmaceutically
acceptable salt or prodrug thereof, or a pharmaceutical composition
comprising such compound.
[0022] These and other aspects of the invention will be apparent
upon reference to the following detailed description.
DETAILED DESCRIPTION
[0023] In the following description, certain specific details are
set forth in order to provide a thorough understanding of various
embodiments of the invention. However, one skilled in the art will
understand that the invention may be practiced without these
details.
[0024] Unless the context requires otherwise, throughout the
present specification and claims, the word "comprise" and
variations thereof, such as, "comprises" and "comprising" are to be
construed in an open, inclusive sense, that is as "including, but
not limited to".
[0025] Reference throughout this specification to "one embodiment"
or "an embodiment" means that a particular feature, structure or
characteristic described in connection with the embodiment is
included in at least one embodiment of the present invention. Thus,
the appearances of the phrases "in one embodiment" or "in an
embodiment" in various places throughout this specification are not
necessarily all referring to the same embodiment. Furthermore, the
particular features, structures, or characteristics may be combined
in any suitable manner in one or more embodiments.
[0026] "Amino" refers to the --NH.sub.2 radical.
[0027] "Cyano" refers to the --CN radical.
[0028] "Hydroxy" or "hydroxyl" refers to the --OH radical.
[0029] "Imino" refers to the .dbd.NH substituent.
[0030] "Nitro" refers to the --NO.sub.2 radical.
[0031] "Oxo" refers to the .dbd.O substituent.
[0032] "Thioxo" refers to the .dbd.S substituent.
[0033] "Alkyl" refers to a straight or branched hydrocarbon chain
radical consisting solely of carbon and hydrogen atoms, which is
saturated or unsaturated (i.e., contains one or more double and/or
triple bonds), having from one to twelve carbon atoms (C.sub.1-12
alkyl), preferably one to eight carbon atoms (C.sub.1-C.sub.8
alkyl) or one to six carbon atoms (C.sub.1-C.sub.6 alkyl), and
which is attached to the rest of the molecule by a single bond,
e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl,
n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl,
2-methylhexyl, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl,
penta-1,4-dienyl, ethynyl, propynyl, butynyl, pentynyl, hexynyl,
and the like. Unless stated otherwise specifically in the
specification, an alkyl group may be optionally substituted.
[0034] "Alkylene" or "alkylene chain" refers to a straight or
branched divalent hydrocarbon chain linking the rest of the
molecule to a radical group, consisting solely of carbon and
hydrogen, which is saturated or unsaturated (i.e., contains one or
more double and/or triple bonds), and having from one to twelve
carbon atoms, e.g., methylene, ethylene, propylene, n-butylene,
ethenylene, propenylene, n-butenylene, propynylene, n-butynylene,
and the like. The alkylene chain is attached to the rest of the
molecule through a single or double bond and to the radical group
through a single or double bond. The points of attachment of the
alkylene chain to the rest of the molecule and to the radical group
can be through one carbon or any two carbons within the chain.
Unless stated otherwise specifically in the specification, an
alkylene chain may be optionally substituted.
[0035] "Alkoxy" refers to a radical of the formula --OR.sub.a where
R.sub.a is an alkyl radical as defined above containing one to
twelve carbon atoms. Unless stated otherwise specifically in the
specification, an alkoxy group may be optionally substituted.
[0036] "Alkylamino" refers to a radical of the formula --NHR.sub.a
or --NR.sub.aR.sub.a where each R.sub.a is, independently, an alkyl
radical as defined above containing one to twelve carbon atoms.
Unless stated otherwise specifically in the specification, an
alkylamino group may be optionally substituted.
[0037] "Thioalkyl" refers to a radical of the formula --SR.sub.a
where R.sub.a is an alkyl radical as defined above containing one
to twelve carbon atoms. Unless stated otherwise specifically in the
specification, a thioalkyl group may be optionally substituted.
[0038] "Aryl" refers to a hydrocarbon ring system radical
comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic
ring. For purposes of this invention, the aryl radical may be a
monocyclic, bicyclic, tricyclic or tetracyclic ring system, which
may include fused or bridged ring systems. Aryl radicals include,
but are not limited to, aryl radicals derived from aceanthrylene,
acenaphthylene, acephenanthrylene, anthracene, azulene, benzene,
chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane,
indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene,
and triphenylene. Unless stated otherwise specifically in the
specification, the term "aryl" or the prefix "ar-" (such as in
"aralkyl") is meant to include aryl radicals that are optionally
substituted.
[0039] "Aralkyl" refers to a radical of the formula
--R.sub.b-R.sub.c where R.sub.b is an alkylene chain as defined
above and R.sub.c is one or more aryl radicals as defined above,
for example, benzyl, diphenylmethyl and the like. Unless stated
otherwise specifically in the specification, an aralkyl group may
be optionally substituted.
[0040] "Cycloalkyl" or "carbocyclic ring" refers to a stable
non-aromatic monocyclic or polycyclic hydrocarbon radical
consisting solely of carbon and hydrogen atoms, which may include
fused or bridged ring systems, having from three to fifteen carbon
atoms, preferably having from three to ten carbon atoms, and which
is saturated or unsaturated and attached to the rest of the
molecule by a single bond. Monocyclic radicals include, for
example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, and cyclooctyl. Polycyclic radicals include, for
example, adamantyl, norbornyl, decalinyl,
7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise
stated specifically in the specification, a cycloalkyl group may be
optionally substituted.
[0041] "Cycloalkylalkyl" refers to a radical of the formula
--R.sub.bR.sub.d where R.sub.d is an alkylene chain as defined
above and R.sub.g is a cycloalkyl radical as defined above. Unless
stated otherwise specifically in the specification, a
cycloalkylalkyl group may be optionally substituted.
[0042] "Fused" refers to any ring structure described herein which
is fused to an existing ring structure in the compounds of the
invention. When the fused ring is a heterocyclyl ring or a
heteroaryl ring, any carbon atom on the existing ring structure
which becomes part of the fused heterocyclyl ring or the fused
heteroaryl ring may be replaced with a nitrogen atom.
[0043] "Halo" or "halogen" refers to bromo, chloro, fluoro or
iodo.
[0044] "Haloalkyl" refers to an alkyl radical, as defined above,
that is substituted by one or more halo radicals, as defined above,
e.g., trifluoromethyl, difluoromethyl, trichloromethyl,
2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl,
1,2-dibromoethyl, and the like. Unless stated otherwise
specifically in the specification, a haloalkyl group may be
optionally substituted.
[0045] "Heterocyclyl" or "heterocyclic ring" refers to a stable 3-
to 18-membered non-aromatic ring radical which consists of two to
twelve carbon atoms and from one to six heteroatoms selected from
the group consisting of nitrogen, oxygen and sulfur. Unless stated
otherwise specifically in the specification, the heterocyclyl
radical may be a monocyclic, bicyclic, tricyclic or tetracyclic
ring system, which may include fused or bridged ring systems; and
the nitrogen, carbon or sulfur atoms in the heterocyclyl radical
may be optionally oxidized; the nitrogen atom may be optionally
quaternized; and the heterocyclyl radical may be partially or fully
saturated. Examples of such heterocyclyl radicals include, but are
not limited to, dioxolanyl, thienyl[1,3]dithianyl,
decahydroisoquinolyl, imidazolinyl, imidazolidinyl,
isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl,
octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl,
2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl,
4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl,
thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,
thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and
1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in
the specification, Unless stated otherwise specifically in the
specification, a heterocyclyl group may be optionally
substituted.
[0046] "N-heterocyclyl" refers to a heterocyclyl radical as defined
above containing at least one nitrogen and where the point of
attachment of the heterocyclyl radical to the rest of the molecule
is through a nitrogen atom in the heterocyclyl radical. Unless
stated otherwise specifically in the specification, a
N-heterocyclyl group may be optionally substituted.
[0047] "Heterocyclylalkyl" refers to a radical of the formula
--R.sub.bR.sub.e where R.sub.b is an alkylene chain as defined
above and R.sub.e is a heterocyclyl radical as defined above, and
if the heterocyclyl is a nitrogen-containing heterocyclyl, the
heterocyclyl may be attached to the alkyl radical at the nitrogen
atom. Unless stated otherwise specifically in the specification, a
heterocyclylalkyl group may be optionally substituted.
[0048] "Heteroaryl" refers to a 5- to 14-membered ring system
radical comprising hydrogen atoms, one to thirteen carbon atoms,
one to six heteroatoms selected from the group consisting of
nitrogen, oxygen and sulfur, and at least one aromatic ring. For
purposes of this invention, the heteroaryl radical may be a
monocyclic, bicyclic, tricyclic or tetracyclic ring system, which
may include fused or bridged ring systems; and the nitrogen, carbon
or sulfur atoms in the heteroaryl radical may be optionally
oxidized; the nitrogen atom may be optionally quaternized. Examples
include, but are not limited to, azepinyl, acridinyl,
benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl,
benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl,
benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl,
benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl,
benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl
(benzothiophenyl), benzotriazolyl,
benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl,
dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl,
isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl,
isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl,
isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl,
oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl,
1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl,
phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl,
pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl,
isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl,
triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl).
Unless stated otherwise specifically in the specification, a
heteroaryl group may be optionally substituted.
[0049] "N-heteroaryl" refers to a heteroaryl radical as defined
above containing at least one nitrogen and where the point of
attachment of the heteroaryl radical to the rest of the molecule is
through a nitrogen atom in the heteroaryl radical. Unless stated
otherwise specifically in the specification, an N-heteroaryl group
may be optionally substituted.
[0050] "Heteroarylalkyl" refers to a radical of the formula
--R.sub.bR.sub.f where R.sub.b is an alkylene chain as defined
above and R.sub.f is a heteroaryl radical as defined above. Unless
stated otherwise specifically in the specification, a
heteroarylalkyl group may be optionally substituted.
[0051] The term "substituted" used herein means any of the above
groups (i.e., alkyl, alkylene, alkoxy, alkylamino, thioalkyl, aryl,
aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl,
N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or
heteroarylalkyl) wherein at least one hydrogen atom is replaced by
a bond to a non-hydrogen atoms such as, but not limited to: a
halogen atom such as F, Cl, Br, and I; an oxygen atom in groups
such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur
atom in groups such as thiol groups, thioalkyl groups, sulfone
groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in
groups such as amines, amides, alkylamines, dialkylamines,
arylamines, alkylarylamines, diarylamines, N-oxides, imides, and
enamines; a silicon atom in groups such as trialkylsilyl groups,
dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl
groups; and other heteroatoms in various other groups.
"Substituted" also means any of the above groups in which one or
more hydrogen atoms are replaced by a higher-order bond (e.g., a
double- or triple-bond) to a heteroatom such as oxygen in oxo,
carbonyl, carboxyl, and ester groups; and nitrogen in groups such
as imines, oximes, hydrazones, and nitriles. For example,
"substituted" includes any of the above groups in which one or more
hydrogen atoms are replaced with --NR.sub.gR.sub.h,
--NR.sub.gC(.dbd.O)R.sub.h, --NR.sub.gC(.dbd.O)NR.sub.gR.sub.h,
--NR.sub.gC(.dbd.O)OR.sub.h, --NR.sub.gSO.sub.2R.sub.h,
--OC(.dbd.O)NR.sub.gR.sub.h, --OR.sub.g, --SR.sub.g, --SOR.sub.g,
--SO.sub.2R.sub.g, --OSO.sub.2R.sub.g, --SO.sub.2OR.sub.g,
.dbd.NSO.sub.2R.sub.g, and --SO.sub.2NR.sub.gR.sub.h. "Substituted"
also means any of the above groups in which one or more hydrogen
atoms are replaced with --C(.dbd.O)R.sub.g, --C(.dbd.O)OR.sub.g,
--C(.dbd.O)NR.sub.gR.sub.h, --CH.sub.2SO.sub.2R.sub.g,
--CH.sub.2SO.sub.2NR.sub.gR.sub.h,
--(CH.sub.2CH.sub.2O).sub.1-10R.sub.g,
--(CH.sub.2CH.sub.2O).sub.2-10R.sub.g,
--(OCH.sub.2CH.sub.2).sub.1-10R.sub.g and
--(OCH.sub.2CH.sub.2).sub.2-10R.sub.g. In the foregoing, R.sub.g
and R.sub.h are the same or different and independently hydrogen,
alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl,
heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
"Substituted" further means any of the above groups in which one or
more hydrogen atoms are replaced by a bond to an amino, cyano,
hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy,
alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl,
heteroaryl, N-heteroaryl and/or heteroarylalkyl group. The above
non-hydrogen groups are generally referred to herein as
"substituents" or "non-hydrogen substituents". In addition, each of
the foregoing substituents may also be optionally substituted with
one or more of the above substituents.
[0052] "Prodrug" is meant to indicate a compound that may be
converted under physiological conditions or by solvolysis to a
biologically active compound of the invention. Thus, the term
"prodrug" refers to a metabolic precursor of a compound of the
invention that is pharmaceutically acceptable. A prodrug may be
inactive when administered to a subject in need thereof, but is
converted in vivo to an active compound of the invention. Prodrugs
are typically rapidly transformed in vivo to yield the parent
compound of the invention, for example, by hydrolysis in blood. The
prodrug compound often offers advantages of solubility, tissue
compatibility or delayed release in a mammalian organism (see,
Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier,
Amsterdam)). A discussion of prodrugs is provided in Higuchi, T.,
et al., A.C.S. Symposium Series, Vol. 14, and in Bioreversible
Carriers in Drug Design, Ed. Edward B. Roche, American
Pharmaceutical Association and Pergamon Press, 1987.
[0053] The term "prodrug" is also meant to include any covalently
bonded carriers, which release the active compound of the invention
in vivo when such prodrug is administered to a mammalian subject.
Prodrugs of a compound of the invention may be prepared by
modifying functional groups present in the compound of the
invention in such a way that the modifications are cleaved, either
in routine manipulation or in vivo, to the parent compound of the
invention. Prodrugs include compounds of the invention wherein a
hydroxy, amino or mercapto group is bonded to any group that, when
the prodrug of the compound of the invention is administered to a
mammalian subject, cleaves to form a free hydroxy, free amino or
free mercapto group, respectively. Examples of prodrugs include,
but are not limited to, acetate, formate and benzoate derivatives
of alcohol or amide derivatives of amine functional groups in the
compounds of the invention and the like.
[0054] The invention disclosed herein is also meant to encompass
the in vivo metabolic products of the disclosed compounds. Such
products may result from, for example, the oxidation, reduction,
hydrolysis, amidation, esterification, and the like of the
administered compound, primarily due to enzymatic processes.
Accordingly, the invention includes compounds produced by a process
comprising administering a compound of this invention to a mammal
for a period of time sufficient to yield a metabolic product
thereof. Such products are typically identified by administering a
radiolabelled compound of the invention in a detectable dose to an
animal, such as rat, mouse, guinea pig, monkey, or to human,
allowing sufficient time for metabolism to occur, and isolating its
conversion products from the urine, blood or other biological
samples.
[0055] "Stable compound" and "stable structure" are meant to
indicate a compound that is sufficiently robust to survive
isolation to a useful degree of purity from a reaction mixture, and
formulation into an efficacious therapeutic agent.
[0056] "Mammal" includes humans and both domestic animals such as
laboratory animals and household pets (e.g., cats, dogs, swine,
cattle, sheep, goats, horses, rabbits), and non-domestic animals
such as wildlife and the like.
[0057] "Optional" or "optionally" means that the subsequently
described event or circumstances may or may not occur, and that the
description includes instances where said event or circumstance
occurs and instances in which it does not. For example, "optionally
substituted aryl" means that the aryl radical may or may not be
substituted and that the description includes both substituted aryl
radicals and aryl radicals having no substitution.
[0058] "Pharmaceutically acceptable carrier, diluent or excipient"
includes without limitation any adjuvant, carrier, excipient,
glidant, sweetening agent, diluent, preservative, dye/colorant,
flavor enhancer, surfactant, wetting agent, dispersing agent,
suspending agent, stabilizer, isotonic agent, solvent, or
emulsifier which has been approved by the United States Food and
Drug Administration as being acceptable for use in humans or
domestic animals.
[0059] "Pharmaceutically acceptable salt" includes both acid and
base addition salts.
[0060] "Pharmaceutically acceptable acid addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free bases, which are not biologically or
otherwise undesirable, and which are formed with inorganic acids
such as, but are not limited to, hydrochloric acid, hydrobromic
acid, sulfuric acid, nitric acid, phosphoric acid and the like, and
organic acids such as, but not limited to, acetic acid,
2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid,
aspartic acid, benzenesulfonic acid, benzoic acid,
4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid,
capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic
acid, citric acid, cyclamic acid, dodecylsulfuric acid,
ethane-1,2-disulfonic acid, ethanesulfonic acid,
2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric
acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic
acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid,
glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric
acid, lactic acid, lactobionic acid, lauric acid, maleic acid,
malic acid, malonic acid, mandelic acid, methanesulfonic acid,
mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic
acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid,
orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic
acid, pyroglutamic acid, pyruvic acid, salicylic acid,
4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid,
tartaric acid, thiocyanic acid, p-toluenesulfonic acid,
trifluoroacetic acid, undecylenic acid, and the like.
[0061] "Pharmaceutically acceptable base addition salt" refers to
those salts which retain the biological effectiveness and
properties of the free acids, which are not biologically or
otherwise undesirable. These salts are prepared from addition of an
inorganic base or an organic base to the free acid. Salts derived
from inorganic bases include, but are not limited to, the sodium,
potassium, lithium, ammonium, calcium, magnesium, iron, zinc,
copper, manganese, aluminum salts and the like. Preferred inorganic
salts are the ammonium, sodium, potassium, calcium, and magnesium
salts. Salts derived from organic bases include, but are not
limited to, salts of primary, secondary, and tertiary amines,
substituted amines including naturally occurring substituted
amines, cyclic amines and basic ion exchange resins, such as
ammonia, isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, diethanolamine, ethanolamine,
deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol,
dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine,
hydrabamine, choline, betaine, benethamine, benzathine,
ethylenediamine, glucosamine, methylglucamine, theobromine,
triethanolamine, tromethamine, purines, piperazine, piperidine,
N-ethylpiperidine, polyamine resins and the like. Particularly
preferred organic bases are isopropylamine, diethylamine,
ethanolamine, trimethylamine, dicyclohexylamine, choline and
caffeine.
[0062] Often crystallizations produce a solvate of the compound of
the invention. As used herein, the term "solvate" refers to an
aggregate that comprises one or more molecules of a compound of the
invention with one or more molecules of solvent. The solvent may be
water, in which case the solvate may be a hydrate. Alternatively,
the solvent may be an organic solvent. Thus, the compounds of the
present invention may exist as a hydrate, including a monohydrate,
dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and
the like, as well as the corresponding solvated forms. The compound
of the invention may be true solvates, while in other cases, the
compound of the invention may merely retain adventitious water or
be a mixture of water plus some adventitious solvent.
[0063] A "pharmaceutical composition" refers to a formulation of a
compound of the invention and a medium generally accepted in the
art for the delivery of the biologically active compound to
mammals, e.g., humans. Such a medium includes all pharmaceutically
acceptable carriers, diluents or excipients therefor.
[0064] "Effective amount" or "therapeutically effective amount"
refers to that amount of a compound of the invention which, when
administered to a mammal, preferably a human, is sufficient to
inhibit phosphate transport, inhibit sodium-mediated phosphate
uptake, reduce serum PTH, calcium, calcitriol, and phosphate
concentrations or levels, treat renal disease or treat
hyperphosphatemia in the mammal, preferably a human. The amount of
a compound of the invention which constitutes a "therapeutically
effective amount" will vary depending on the compound, the
condition and its severity, the manner of administration, and the
age of the mammal to be treated, but can be determined routinely by
one of ordinary skill in the art having regard to his own knowledge
and to this disclosure.
[0065] "Treating" or "treatment" as used herein covers the
treatment of the disease or condition of interest in a mammal,
preferably a human, having the disease or condition of interest,
and includes:
[0066] (i) preventing the disease or condition from occurring in a
mammal, in particular, when such mammal is predisposed to the
condition but has not yet been diagnosed as having it;
[0067] (ii) inhibiting the disease or condition, i.e., arresting
its development;
[0068] (iii) relieving the disease or condition, i.e., causing
regression of the disease or condition; or
[0069] (iv) relieving the symptoms resulting from the disease or
condition, i.e., relieving pain without addressing the underlying
disease or condition. As used herein, the terms "disease" and
"condition" may be used interchangeably or may be different in that
the particular malady or condition may not have a known causative
agent (so that etiology has not yet been worked out) and it is
therefore not yet recognized as a disease but only as an
undesirable condition or syndrome, wherein a more or less specific
set of symptoms have been identified by clinicians.
[0070] The compounds of the invention, or their pharmaceutically
acceptable salts may contain one or more asymmetric centers and may
thus give rise to enantiomers, diastereomers, and other
stereoisomeric forms that may be defined, in terms of absolute
stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino
acids. The present invention is meant to include all such possible
isomers, as well as their racemic and optically pure forms.
Optically active (+) and (-), (R)- and (S)-, or (D)- and
(L)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques, for example,
chromatography and fractional crystallization. Conventional
techniques for the preparation/isolation of individual enantiomers
include chiral synthesis from a suitable optically pure precursor
or resolution of the racemate (or the racemate of a salt or
derivative) using, for example, chiral high pressure liquid
chromatography (HPLC). When the compounds described herein contain
olefinic double bonds or other centres of geometric asymmetry, and
unless specified otherwise, it is intended that the compounds
include both E and Z geometric isomers. Likewise, all tautomeric
forms are also intended to be included.
[0071] A "stereoisomer" refers to a compound made up of the same
atoms bonded by the same bonds but having different
three-dimensional structures, which are not interchangeable. The
present invention contemplates various stereoisomers and mixtures
thereof and includes "enantiomers", which refers to two
stereoisomers whose molecules are nonsuperimposeable mirror images
of one another.
[0072] A "tautomer" refers to a proton shift from one atom of a
molecule to another atom of the same molecule. The present
invention includes tautomers of any said compounds.
[0073] As noted above, in one embodiment of the present invention,
compounds having activity as phosphate transport inhibitors, more
specifically, inhibitors of intestinal apical membrane Na/phosphate
co-transport, are provided, the compounds having the following
structure (I):
##STR00003##
or a stereoisomer, prodrug or pharmaceutically acceptable salt
thereof,
[0074] wherein:
[0075] A is --CR.sub.1-- or --N--;
[0076] X is substituted aryl or substituted heteroaryl;
[0077] Y is halogen, optionally substituted alkylamino, optionally
substituted alkoxy, optionally substituted thioalkyl, optionally
substituted cycloalkyl, optionally substituted heterocyclyl,
optionally substituted aryl, --O(optionally substituted
cycloalkyl), --O(optionally substituted heterocyclyl) or
--O(optionally substituted aryl);
[0078] each R.sub.1 is, independently, hydrogen, halogen,
C.sub.1-6alkyl or C.sub.1-6haloalkyl;
[0079] R.sub.2 is --C(.dbd.O)NR.sub.2aR.sub.2b,
--NR.sub.2aC(.dbd.O)R.sub.2b, --C(.dbd.O)R.sub.2b,
--NR.sub.2aR.sub.2b, --OR.sub.2b or --R.sub.2b;
[0080] R.sub.2a is hydrogen or optionally substituted
C.sub.1-6alkyl; and
[0081] R.sub.2b is optionally substituted alkyl, optionally
substituted cycloalkyl, optionally substituted cycloalkylalkyl,
optionally substituted heterocyclyl, optionally substituted
heterocyclylalkyl, optionally substituted aryl, optionally
substituted aralkyl, optionally substituted heteroaryl, or
optionally substituted heteroarylalkyl.
[0082] In further embodiments, Y is halogen, such as chloro.
[0083] In other further embodiments, Y is alkylamino, such as
diethylamino.
[0084] In other further embodiments, Y is alkoxy.
[0085] In other further embodiments, Y is heterocyclyl, such as
1-piperidinyl and the compound has the structure:
##STR00004##
[0086] In other further embodiments, Y is --O(cycloalkyl).
[0087] In other further embodiments, X is --ZR.sub.3, where Z is
aryl or heteroaryl and R.sub.3 represents a non-hydrogen
substituent as defined above, or as more specifically defined
below.
[0088] In more specific embodiments, Z is aryl, such as phenyl and
the compound has the structure:
##STR00005##
[0089] In other more specific embodiments, Z is heteroaryl, such as
pyridinyl and the compound has the structure:
##STR00006##
[0090] In more specific embodiments of the foregoing, R.sub.3 is:
[0091] (a) -(optionally substituted
C.sub.1-6alkyl)-S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)NR.sub.7R.sub.4, [0092] (b) -(optionally
substituted C.sub.1-6alkyl)-S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)NR.sub.7R.sub.4, [0093] (c) -(optionally substituted
C.sub.1-6alkyl)-S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)OR.sub.5, [0094] (d) -(optionally
substituted C.sub.1-6alkyl)-S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)OR.sub.5, [0095] (e) -(optionally substituted
C.sub.1-6alkyl)-S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)R.sub.6, [0096] (f) -(optionally substituted
C.sub.1-6alkyl)-S(O).sub.0-2R.sub.6, [0097] (g) -(optionally
substituted C.sub.1-6alkyl)-S(O).sub.0-2NR.sub.7R.sub.4, [0098] (h)
-(optionally substituted
C.sub.1-6alkyl)-S(O).sub.0-2(CH.sub.2CH.sub.2O).sub.xR.sub.5, or
[0099] (i) -(optionally substituted
C.sub.1-6alkyl)-S(O).sub.0-2(CH.sub.2CH.sub.2O).sub.x(CH.sub.2).sub.2NHSO-
.sub.2(phenyl)R.sub.5,
[0100] wherein: [0101] R.sub.4 is hydrogen, hydroxyl, alkoxy,
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted heterocyclyl or optionally substituted
heteroaryl; [0102] R.sub.5 is hydrogen, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heterocyclyl or optionally substituted heteroaryl; [0103] R.sub.6
is optionally substituted aryl, optionally substituted heterocyclyl
or optionally substituted heteroaryl; [0104] R.sub.7 is hydrogen or
optionally substituted C.sub.1-6alkyl; and [0105] x is an integer
from 2 to 10.
[0106] For example, in certain embodiments, R.sub.3 is: [0107] (a)
--CH.sub.2S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)NR.sub.7R.sub.4, [0108] (b)
--CH.sub.2S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)NR.sub.7R.sub.4, [0109] (c)
--CH.sub.2S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)OR.sub.5, [0110] (d)
--CH.sub.2S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)OR.sub.5, [0111] (e)
--CH.sub.2S(O).sub.0-2(optionally substituted
C.sub.1-6alkyl)R.sub.6, [0112] (f) --CH.sub.2S(O).sub.0-2R.sub.6,
[0113] (g) --CH.sub.2S(O).sub.0-2NR.sub.7R.sub.4, [0114] (h)
--CH.sub.2S(O).sub.0-2(CH.sub.2CH.sub.2O).sub.xR.sub.6, or [0115]
(i)
--CH.sub.2S(O).sub.0-2(CH.sub.2CH.sub.2O).sub.x(CH.sub.2).sub.2NHSO.sub.2-
(phenyl)R.sub.6.
[0116] In other more specific embodiments of the foregoing, R.sub.3
is: [0117] (a) -(optionally substituted
C.sub.1-6alkyl)-CH.sub.2NR.sub.7(CH.sub.2CH.sub.2O).sub.xR.sub.5,
or [0118] (b) -(optionally substituted
C.sub.1-6alkyl)-CH.sub.2NR.sub.7(CH.sub.2CH.sub.2O).sub.x
(CH.sub.2).sub.2NHSO.sub.2(phenyl)R.sub.5,
[0119] wherein: [0120] R.sub.5 is hydrogen, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heterocyclyl or optionally substituted heteroaryl; [0121] R.sub.7
is hydrogen or optionally substituted C.sub.1-6alkyl; and [0122] x
is an integer from 2 to 10.
[0123] For example, in certain embodiments, R.sub.3 is: [0124] (a)
--CH.sub.2NR.sub.7(CH.sub.2CH.sub.2O).sub.xR.sub.5, or [0125] (b)
--CH.sub.2NR.sub.7(CH.sub.2CH.sub.2O).sub.x(CH.sub.2).sub.2NHSO.sub.2(phe-
nyl)R.sub.5.
[0126] In other more specific embodiments of the foregoing, R.sub.3
is: [0127] (a) --C(.dbd.O)NR.sub.7(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)NR.sub.7R.sub.4, [0128] (b)
--C(.dbd.O)NR.sub.7(optionally substituted
C.sub.1-6alkyl)NR.sub.7R.sub.4, [0129] (c)
--C(.dbd.O)NR.sub.7(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)OR.sub.5, [0130] (d)
--C(.dbd.O)NR.sub.7(optionally substituted C.sub.1-6alkyl)OR.sub.5,
[0131] (e) --C(.dbd.O)NR.sub.7(optionally substituted
C.sub.1-6alkyl)R.sub.6, [0132] (f)
--C(.dbd.O)NR.sub.7(CH.sub.2CH.sub.2O).sub.xR.sub.5, or [0133] (g)
--C(.dbd.O)NR.sub.7(CH.sub.2CH.sub.2O).sub.x(CH.sub.2).sub.2NHSO.sub.2(ph-
enyl)R.sub.5,
[0134] wherein: [0135] R.sub.4 is hydrogen, hydroxyl, alkoxy,
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted heterocyclyl or optionally substituted
heteroaryl; [0136] R.sub.5 is hydrogen, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heterocyclyl or optionally substituted heteroaryl; [0137] R.sub.6
is optionally substituted aryl, optionally substituted heterocyclyl
or optionally substituted heteroaryl; [0138] R.sub.7 is hydrogen or
optionally substituted C.sub.1-6alkyl; and [0139] x is an integer
from 2 to 10.
[0140] In other more specific embodiments of the foregoing, R.sub.3
is: [0141] (a) --O(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)NR.sub.7R.sub.4, [0142] (b) --O(optionally
substituted C.sub.1-6alkyl)NR.sub.7R.sub.4, [0143] (c)
--O(optionally substituted C.sub.1-6alkyl)C(.dbd.O)OR.sub.5, [0144]
(d) --O(optionally substituted C.sub.1-6alkyl)OR.sub.5, [0145] (e)
--O(optionally substituted C.sub.1-6alkyl)R.sub.6, [0146] (f)
--O(CH.sub.2CH.sub.2O).sub.xR.sub.5, or [0147] (g)
--O(CH.sub.2CH.sub.2O).sub.x(CH.sub.2).sub.2NHSO.sub.2(phenyl)R.sub.5,
[0148] wherein: [0149] R.sub.4 is hydrogen, hydroxyl, alkoxy,
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted heterocyclyl or optionally substituted
heteroaryl; [0150] R.sub.5 is hydrogen, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heterocyclyl or optionally substituted heteroaryl; [0151] R.sub.6
is optionally substituted aryl, optionally substituted heterocyclyl
or optionally substituted heteroaryl; [0152] R.sub.7 is hydrogen or
optionally substituted C.sub.1-6alkyl; and [0153] x is an integer
from 2 to 10.
[0154] In other more specific embodiments of the foregoing, R.sub.3
is: [0155] (a) --S(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)NR.sub.7R.sub.4, [0156] (b) --S(optionally
substituted C.sub.1-6alkyl)NR.sub.7R.sub.4, [0157] (c)
--S(optionally substituted C.sub.1-6alkyl)C(.dbd.O)OR.sub.5, [0158]
(d) --S(optionally substituted C.sub.1-6alkyl)OR.sub.5, [0159] (e)
--S(optionally substituted C.sub.1-6alkyl)R.sub.6, [0160] (f)
--S(CH.sub.2CH.sub.2O).sub.xR.sub.5, or [0161] (g)
--S(CH.sub.2CH.sub.2O).sub.x(CH.sub.2).sub.2NHSO.sub.2(phenyl)R.sub.5,
[0162] wherein: [0163] R.sub.4 is hydrogen, hydroxyl, alkoxy,
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted heterocyclyl or optionally substituted
heteroaryl; [0164] R.sub.5 is hydrogen, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heterocyclyl or optionally substituted heteroaryl; [0165] R.sub.6
is optionally substituted aryl, optionally substituted heterocyclyl
or optionally substituted heteroaryl; [0166] R.sub.7 is hydrogen or
optionally substituted C.sub.1-6alkyl; and [0167] x is an integer
from 2 to 10.
[0168] In other more specific embodiments of the foregoing, R.sub.3
is: [0169] (a) --NR.sub.7(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)NR.sub.7R.sub.4, [0170] (b)
--NR.sub.7(optionally substituted C.sub.1-6alkyl)NR.sub.7R.sub.4,
[0171] (c) --NR.sub.7(optionally substituted
C.sub.1-6alkyl)C(.dbd.O)OR.sub.5, [0172] (d) --NR.sub.7(optionally
substituted C.sub.1-6alkyl)OR.sub.5, [0173] (e)
--NR.sub.7(optionally substituted C.sub.1-6alkyl)R.sub.6, [0174]
(f) --NR.sub.7(CH.sub.2CH.sub.2O).sub.xR.sub.5, or [0175] (g)
--NR.sub.7(CH.sub.2CH.sub.2O).sub.x(CH.sub.2).sub.2NHSO.sub.2(phenyl)R.su-
b.5,
[0176] wherein: [0177] R.sub.4 is hydrogen, hydroxyl, alkoxy,
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted heterocyclyl or optionally substituted
heteroaryl; [0178] R.sub.5 is hydrogen, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heterocyclyl or optionally substituted heteroaryl; [0179] R.sub.6
is optionally substituted aryl, optionally substituted heterocyclyl
or optionally substituted heteroaryl; [0180] R.sub.7 is hydrogen or
optionally substituted C.sub.1-6alkyl; and [0181] x is an integer
from 2 to 10.
[0182] In other more specific embodiments of the foregoing, R.sub.3
is: [0183] (a) -(optionally substituted
C.sub.1-6alkyl)-(OCH.sub.2CH.sub.2).sub.yOR.sub.5, or [0184] (b)
-(optionally substituted
C.sub.1-6alkyl)-(OCH.sub.2CH.sub.2).sub.yO(CH.sub.2).sub.2
NHSO.sub.2(phenyl)R.sub.5,
[0185] wherein: [0186] R.sub.5 is hydrogen, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heterocyclyl or optionally substituted heteroaryl; and [0187] y is
an integer from 1 to 10.
[0188] For example, in certain embodiments, R.sub.3 is: [0189] (a)
--(CH.sub.2).sub.3(OCH.sub.2CH.sub.2).sub.yOR.sub.5, or [0190] (b)
--(CH.sub.2).sub.3(OCH.sub.2CH.sub.2).sub.yO(CH.sub.2).sub.2NHSO.sub.2(ph-
enyl)R.sub.5.
[0191] In other further embodiments, A is --CH--.
[0192] In other further embodiments, A is N.
[0193] In other further embodiments, each R.sub.1 is hydrogen.
[0194] In other further embodiments, R.sub.2 is
--C(.dbd.O)NR.sub.2aR.sub.2b. In more specific embodiments,
R.sub.2a is hydrogen and R.sub.2b is:
##STR00007##
[0195] It is understood that any embodiment of the compounds of
structure (I), as set forth above, and any specific substituent set
forth herein for a X, Y, Z, A, R.sub.1, R.sub.2, R.sub.2a,
R.sub.2b, R.sub.3, R.sub.4, R.sub.5, R.sub.6 or R.sub.7 group in
the compounds of structure (I), as set forth above, may be
independently combined with other embodiments and/or substituents
of compounds of structure (I) to form embodiments of the inventions
not specifically set forth above. In addition, in the event that a
list of substitutents is listed for any particular substituent in a
particular embodiment and/or claim, it is understood that each
individual substituent may be deleted from the particular
embodiment and/or claim and that the remaining list of substituents
will be considered to be within the scope of the invention.
[0196] In accordance with the present disclosure, it has been
discovered that phosphate absorption from the intestine in patients
with elevated phosphate serum levels may be limited, and preferably
substantially prevented, through inhibition of the intestinal
transport system which mediates phosphate uptake in the intestine.
This inhibition may be achieved by the administration of certain
compounds, and/or pharmaceutical compositions comprising them,
which may advantageously be designed such that little, or
substantially none, of the compound is absorbed into the blood
stream (that is, it is designed to be non-systemic or substantially
non-systemic). In this regard, the compounds have features that
give rise to little or substantially no systemic availability. In
other words, the compounds are not absorbed into the bloodstream at
meaningful levels and therefore have no activity there, but instead
have their activity localized substantially within the GI
tract.
[0197] Therefore, in certain illustrative embodiments as further
described herein, the compounds of the invention generally require
a combination of structural and/or functional features relating or
contributing to their activity in the GI tract and/or their
substantial non-systemic bioavailability. Such features may
include, for example, one or more of (i) specific tPSA and/or MW
values (e.g., at least about 190 .ANG..sup.2 and/or at least about
736 Daltons, respectively), (ii) specific levels of fecal recovery
of the compound and/or its metabolites after administration (e.g.,
greater than 50% at 72 hours); (iii) specific numbers of NH and/or
OH and/or potentially hydrogen bond donor moieties (e.g., greater
than about five); (iv) specific numbers of rotatable bonds (e.g.,
greater than about five); (iv) specific permeability features
(e.g., P.sub.app less than about 100.times.10.sup.-6 cm/s); and/or
any of a number of other features and characteristics as described
herein.
[0198] The compounds of the present invention offer numerous
advantages in the treatment of GI tract and other disorders. For
example, the compounds are active on the phosphate transporter
apically located in the intestine and essentially do not reach
other phosphate transporters expressed in other tissues and organs.
For instance the NaPi2b transporter is primarily expressed in the
apical membrane of intestinal enterocytes, but is also found in
salivary glands, mammary glands, lung, kidney, pancreas, ovary,
prostate, testis and liver (Feild et al., 1999, Biochem Biophys Res
Commun, v. 258, no. 3, p. 578-582; Bai et al., 2000, Am J Physiol
Cell Physiol, v. 279, no. 4, p. C1135-C1143; Virkki et al., 2007,
Am J Physiol Renal Physiol, v. 293, no. 3, p. F643-F654). Genome
wide single-nucleotide polymorphism analysis in patients with
pulmonary alveolar microlithiasis (PAM) has revealed a link between
a mutated NaPi2b gene and disorder in which microliths are formed
in the lung alveolar space. Homozygous inactivating mutations of
pulmonary NaPi2b have also been implicated in the pathophysiology
of PAM (Huqun et al., 2007, Am J Respir Crit Care Med, v. 175, no.
3, p. 263-268). Consistent with this human study, calcification
nodules were evident in NaPi2b conditional knockout mice but not in
wild type animals after NaPi2b deletion. In contrast, analysis of
kidney and ileum samples revealed no pathologic abnormalities
associated with Npt2b deletion (Sabbagh et al., 2009, J Am Soc.
Nephrol., 20: 2348-2358).
[0199] The essentially non-systemic NaPi2b inhibitors of the
present invention do not interfere with the pulmonary function of
NaPi2b and, therefore, potential pulmonary toxicity is minimized.
In addition, certain patient populations to whom the compounds of
the invention may be administered are expected to have limited
kidney clearance rate secondary to a declining kidney function.
Thus, systemic compounds with some kidney clearance contribution in
their excretion pathway can accumulate in the plasma, potentially
leading to undesired side-effects in those patients with chronic
kidney disease (Sica, 2008, J Clin Hypertens. (Greenwich.), v. 10,
no. 7, p. 541-548). The compounds of the invention do not give rise
to these same concerns because of their limited systemic
availability.
[0200] As further detailed below, phosphate absorption in the upper
intestine is mediated, at least in part, by a carrier-mediated
mechanism which couples the absorption of phosphate to that of
sodium. Accordingly, inhibition of intestinal phosphate transport
will reduce body phosphorus overload. In patients with advanced
kidney disease (e.g. stage 4 and 5), the body phosphorus overload
manifests itself by serum phosphate concentration above normal
levels, i.e. hyperphosphatemia. Hyperphosphatemia is directly
related to mortality and morbidity. Inhibition of intestinal
phosphate transport will reduce serum phosphate concentration and
therefore improve outcome in those patients. In stage 2 and 3
chronic kidney disease patients, the body phosphorus overload does
not necessarily lead to hyperphosphatemia, i.e. patients remain
normophosphatemic, but there is a need to reduce body phosphorus
overload even at those early stages to avoid associated bone and
vascular disorders, and ultimately improve mortality rate.
Similarly, inhibition of intestinal phosphate transport will be
particularly advantageous in patients that have a disease that is
treatable by inhibiting the uptake of phosphate from the
intestines. Inhibition of phosphate absorption from the glomerular
filtrate within the kidneys would also be advantageous for treating
chronic renal failure. Furthermore, inhibition of phosphate
transport may slow the progression of renal failure and reduce risk
of cardiovascular events.
[0201] Without being held to any particular theory, it is generally
believed that, in vertebrates, phosphate (Pi) transporters use the
inwardly directed electrochemical gradient of Na+ ions, established
by the Na/K ATPase transporter, to drive Pi influx. These
transporters fall in three distinct and unrelated Pi transporters
proteins named type I, II and III. NaPi type I transporters
comprise NaPi-I, mainly expressed in the proximal and distal renal
tubules. NaPi type II transporters comprise NaPi2a, NaPi2b, and
NaPi2c. NaPi2a is localized in the apical membrane of proximal
renal tubule, but is also detected in rat brain, osteoclasts and
osteoblast-like cells. NaPi2b is expressed in the apical membrane
of enterocytes, but also found in lung, colon, testis and liver
(see, e.g., Virkki, L. V., et al., Phosphate Transporters: A Tale
of Two Solute Carrier Families, Am. J. Physiol. Renal. Physiol.,
293(3):F643-54 (2007)). Type III NaPi transporters comprise PiT-1
and PiT-2, which are now emerging as important players in bone Pi
metabolism and vascular calcification.
[0202] NaPi2a is believed to play a key role in phosphorus
homeostasis by controlling the reabsorption of Pi in the renal
proximal tubule. This is exemplified in NaPi2a KO mice, which
develop hyperphosphaturia and hypophosphatemia. NaPi2b is believed
responsible for transepithelial absorption in the small intestine
and is regulated by dietary Pi and vitamin D (Calcitriol
(1,25-Dihydroxycholecalciferol)). NaPi2c is expressed in renal
tubule and other tissues (see, e.g., Virkki, L. V., et al.,
Id.).
[0203] The basic transport mechanism of NaPi2a and NaPi2b is the
same (see, e.g., Murer, H., et al., Proximal Tubular Phosphate
Reabsorption: Molecular Mechanisms, Physiol. Rev., 80(4):1373-409
(2000)); both are electrogenic with a stoichiometry of about 3:1
Na.sup.+:HPO.sub.4.sup.2-, meaning that 3 Na.sup.+ are
co-transported with one phosphate anion. The additional Na cations
translocated are excreted on the basolateral membrane via the K/Na
ATPase active transporters to preserve cell polarization. Renal Pi
transporter NaPi2a activity is increased in the kidney in response
to low dietary Pi (see, e.g., Murer, et al., Id.). This results
from an increase in transporter expression on the apical membrane
of the kidney tubule. Histochemical analysis suggests a
"recruitment" phenomenon. It is to be noted that, in contrast, the
type I Na-Pi transporter does not respond to change in dietary P.
The change in NaPi2a expression is paralleled by alteration in
parathyroid hormone PTH plasma concentration and vice-versa (e.g.,
injection of PTH in rats leads within minutes to a reduction in
brush border membrane transporter content). Acid-base change can
also alter expression of NaPi2a. Chronic metabolic acidosis in rats
significantly decreases NaPi2a protein and mRNA content. The same
is observed in CKD rats induced by 5/6.sup.th nephrectomy. The
regulation of apical NaPi2a transporters involves complex membrane
retrieval and re-insertion mechanisms. Control in transport
activity can also be controlled by changes in intra-tubular and
intracellular pH, in transmembrane potential difference and
posttranslational modification.
Substantially Impermeable or Substantially Systemically
Non-Bioavailable Phosphate Transport Inhibitor Compounds
[0204] A. Physical and Performance Properties
[0205] In accordance with the present disclosure, the compounds
described herein are designed to be substantially active or
localized in the gastrointestinal lumen of a human or animal
subject. The term "gastrointestinal lumen" is used interchangeably
herein with the term "lumen," to refer to the space or cavity
within a gastrointestinal tract (GI tract, which can also be
referred to as the gut), delimited by the apical membrane of GI
epithelial cells of the subject. In some embodiments, the compounds
are not absorbed through the layer of epithelial cells of the GI
tract (also known as the GI epithelium). "Gastrointestinal mucosa"
refers to the layer(s) of cells separating the gastrointestinal
lumen from the rest of the body and includes gastric and intestinal
mucosa, such as the mucosa of the small intestine. A
"gastrointestinal epithelial cell" or a "gut epithelial cell" as
used herein refers to any epithelial cell on the surface of the
gastrointestinal mucosa that faces the lumen of the
gastrointestinal tract, including, for example, an epithelial cell
of the stomach, an intestinal epithelial cell, a colonic epithelial
cell, and the like.
[0206] "Substantially systemically non-bioavailable" and/or
"substantially impermeable" as used herein (as well as variations
thereof) generally refer to situations in which a statistically
significant amount, and in some embodiments essentially all of the
compound of the present disclosure, remains in the gastrointestinal
lumen. For example, in accordance with one or more embodiments of
the present disclosure, preferably at least about 70%, about 80%,
about 90%, about 95%, about 98%, about 99%, or even about 99.5%, of
the compound remains in the gastrointestinal lumen. In such cases,
localization to the gastrointestinal lumen refers to reducing net
movement across a gastrointestinal layer of epithelial cells, for
example, by way of both transcellular and paracellular transport,
as well as by active and/or passive transport. The compound in such
embodiments is hindered from net permeation of a layer of
gastrointestinal epithelial cells in transcellular transport, for
example, through an apical membrane of an epithelial cell of the
small intestine. The compound in these embodiments is also hindered
from net permeation through the "tight junctions" in paracellular
transport between gastrointestinal epithelial cells lining the
lumen.
[0207] In this regard it is to be noted that, in one particular
embodiment, the compound is essentially not absorbed at all by the
GI tract or gastrointestinal lumen. As used herein, the terms
"substantially impermeable" or "substantially systemically
non-bioavailable" refers to embodiments wherein no detectable
amount of absorption or permeation or systemic exposure of the
compound is detected, using means generally known in the art.
[0208] In this regard it is to be further noted, however, that in
alternative embodiments "substantially impermeable" or
"substantially systemically non-bioavailable" provides or allows
for some limited absorption in the GI tract, and more particularly
the gut epithelium, to occur (e.g., some detectable amount of
absorption, such as for example at least about 0.1%, 0.5%, 1% or
more and less than about 30%, 20%, 10%, 5%, etc., the range of
absorption being for example between about 1% and 30%, or 5% and
20%, etc.); stated another way, "substantially impermeable" or
"substantially systemically non-bioavailable" refers to compounds
that exhibit some detectable permeability to an epithelial layer of
cells in the GI tract of less than about 20% of the administered
compound (e.g., less than about 15%, about 10%, or even about 5%,
and for example greater than about 0.5%, or 1%), but then are
cleared by the liver (i.e., hepatic extraction) and/or the kidney
(i.e., renal excretion).
[0209] In this regard it is to be further noted, that in certain
embodiments, due to the substantial impermeability and/or
substantial systemic non-bioavailability of the compounds of the
present invention, greater than about 50%, 60%, 70%, 80% or 90% of
a compound of the invention is recoverable from the feces over, for
example, a 24, 48 or 72 hour period following administration to a
patient in need thereof. In this respect, it is understood that a
recovered compound can include the sum of the parent compound and
its metabolites derived from the parent compound, e.g., by means of
hydrolysis, conjugation, reduction, oxidation, N-alkylation,
glucuronidation, acetylation, methylation, sulfation,
phosphorylation, or any other modification that adds atoms to or
removes atoms from the parent compound, wherein the metabolites are
generated via the action of any enzyme or exposure to any
physiological environment including, pH, temperature, pressure, or
interactions with foodstuffs as they exist in the digestive milieu.
Measurement of fecal recovery of compound and metabolites can be
carried out using standard methodology. For example, compound can
be administered orally at a suitable dose (e.g., 10 mg/kg) and
feces are then collected at predetermined times after dosing (e.g.,
24 hours, 48 hours, 72 hours). Parent compound and metabolites can
be extracted with organic solvent and analyzed quantitatively using
mass spectrometry. A mass balance analysis of the parent compound
and metabolites (including, parent=M, metabolite 1 [M+16], and
metabolite 2 [M+32]) can be used to determine the percent recovery
in the feces.
[0210] In certain preferred embodiments, the phosphate transport
inhibitors of the present invention are not competitive inhibitors
with respect to phosphate of Na/phosphate co-transport. In certain
other preferred embodiments, the phosphate transport inhibitors of
the invention are non-competitive inhibitors. Non-competitive
inhibitors maintain their degree of inhibition irrespective of the
local phosphate concentration. This feature is an important aspect
in providing an efficient blockade of intestinal transport in
postprandial state, where the local concentration of dietary
phosphate can attain concentration as high as 10 mM. It is believed
that competitive inhibitors are too sensitive to local phosphate
concentration and unable to block phosphate uptake following a high
phosphorus meal. Various methods are available for determining
whether a phosphate transport inhibitor is non-competitive or
competitive. For example, a phosphate uptake assay can be performed
and the IC.sub.50 values for a compound at different phosphate
concentrations can be determined (e.g., "Enzyme kinetics", I.
Segel, 1975, John-Wiley & Sons, p. 123). IC.sub.50 values for
non-competitive inhibitors will remain the same or similar with
respect to the phosphate concentration, whereas IC.sub.50 values
for competitive inhibitors will increase (i.e lose potency) as
phosphate concentration increases.
[0211] (i) Permeability
[0212] In this regard it is to be noted that, in various
embodiments, the ability of the compound to be substantially
systemically non-bioavailable is based on the compound charge,
size, and/or other physicochemical parameters (e.g., polar surface
area, number of hydrogen bond donors and/or acceptors therein,
number of freely rotatable bonds, etc.). More specifically, it is
to be noted that the absorption character of a compound can be
selected by applying principles of pharmacokinetics, for example,
by applying Lipinski's rule, also known as "the rule of five."
Although not a rule, but rather a set of guidelines, Lipinski shows
that small molecule drugs with (i) a molecular weight, (ii) a
number of hydrogen bond donors, (iii) a number of hydrogen bond
acceptors, and/or (iv) a water/octanol partition coefficient
(Moriguchi Log P), greater than a certain threshold value,
generally do not show significant systemic concentration (i.e., are
generally not absorbed to any significant degree). (See, e.g.,
Lipinski et al., Advanced Drug Delivery Reviews, 46, 2001 3-26,
incorporated herein by reference.) Accordingly, substantially
systemically non-bioavailable compounds (e.g., substantially
systemically non-bioavailable phosphate transport inhibitor
compounds) can be designed to have molecular structures exceeding
one or more of Lipinski's threshold values. (See also Lipinski et
al., Experimental and Computational Approaches to Estimate
Solubility and Permeability in Drug Discovery and Development
Settings, Adv. Drug Delivery Reviews, 46:3-26 (2001); and Lipinski,
Drug-like Properties and the Causes of Poor Solubility and Poor
Permeability, J. Pharm. & Toxicol. Methods, 44:235-249 (2000),
incorporated herein by reference.)
[0213] In some embodiments, for example, a substantially
impermeable or substantially systemically non-bioavailable
phosphate transport inhibitor compound of the present disclosure
can be constructed to feature one or more of the following
characteristics: (i) a MW greater than about 500 Da, about 1000 Da,
about 2500 Da, about 5000 Da, about 10,000 Da or more (in the
non-salt form of the compound); (ii) a total number of NH and/or OH
and/or other potential hydrogen bond donors greater than about 5,
about 10, about 15 or more; (iii) a total number of O atoms and/or
N atoms and/or other potential hydrogen bond acceptors greater than
about 5, about 10, about 15 or more; (iv) a Moriguchi partition
coefficient greater than about 10.sup.5 (i.e., Log P greater than
about 5, about 6, about 7, etc.), or alternatively less than about
10 (i.e., a Log P of less than 1, or even 0); and/or (v) a total
number of rotatable bonds greater than about 5, about 10 or about
15, or more.
[0214] In addition to the parameters noted above, the molecular
polar surface area (i.e., "PSA"), which may be characterized as the
surface belonging to polar atoms, is a descriptor that has also
been shown to correlate well with passive transport through
membranes and, therefore, allows prediction of transport properties
of drugs. It has been successfully applied for the prediction of
intestinal absorption and Caco2 cell monolayer penetration. (For
Caco2 cell monolayer penetration test details, see for example the
description of the Caco2 Model provided in Example 31 of U.S. Pat.
No. 6,737,423, the entire contents of which are incorporated herein
by reference, and the text of Example 31 in particular, which may
be applied for example to the evaluation or testing of the
compounds of the present disclosure.) PSA is expressed in {acute
over (.ANG.)}.sup.2 (squared angstroms) and is computed from a
three-dimensional molecular representation. A fast calculation
method is also available (see, e.g., Ertl et al., Journal of
Medicinal Chemistry, 2000, 43, 3714-3717, the entire contents of
which are incorporated herein by reference for all relevant and
consistent purposes) using a desktop computer and commercially
available chemical graphic tools packages, such as ChemDraw. The
term "topological PSA" (tPSA) has been coined for this
fast-calculation method. tPSA is well correlated with human
absorption data with common drugs (see, e.g., Table 1, below):
TABLE-US-00001 TABLE 1 name % FA.sup.a TPSA.sup.b metoprolol 102
50.7 nordiazepam 99 41.5 diazepam 97 32.7 oxprenolol 97 50.7
phenazone 97 26.9 oxazepam 97 61.7 alprenolol 96 41.9 practolol 95
70.6 pindolol 92 57.3 ciprofloxacin 69 74.6 metalazone 64 92.5
tranexamic acid 55 63.3 atenolol 54 84.6 sulpiride 36 101.7
mannitol 26 121.4 foscarnet 17 94.8 sulfasalazine 12 141.3
olsalazine 2.3 139.8 lactulose 0.6 197.4 raffinose 0.3 268.7
(from Ertl et al., J. Med. Chem., 2000, 43:3714-3717). Accordingly,
in some embodiments, the compounds of the present disclosure may be
constructed to exhibit a tPSA value greater than about 100
.ANG..sup.2, about 120 .ANG..sup.2, about 130 .ANG..sup.2, or about
140 .ANG..sup.2, and in some instances about 150 .ANG..sup.2, about
160 .ANG..sup.2, about 170 .ANG..sup.2, about 180 .ANG..sup.2,
about 190 .ANG..sup.2, about 200 .ANG..sup.2, about 225
.ANG..sup.2, about 250 .ANG..sup.2, about 270 .ANG..sup.2, about
300 .ANG..sup.2, about 350 .ANG..sup.2, about 400 .ANG..sup.2,
about 450 .ANG..sup.2, about 500 .ANG..sup.2, about 750
.ANG..sup.2, or even about 1000 .ANG..sup.2, such that the
compounds are substantially impermeable or substantially
systemically non-bioavailable (as defined elsewhere herein).
[0215] Because there are exceptions to Lipinski's "rule," or the
tPSA model, the permeability properties of the compounds of the
present disclosure may be screened experimentally. The permeability
coefficient can be determined by methods known to those of skill in
the art, including for example by Caco-2 cell permeability assay
and/or using an artificial membrane as a model of a
gastrointestinal epithelial cell. A synthetic membrane impregnated
with, for example, lecithin and/or dodecane to mimic the net
permeability characteristics of a gastrointestinal mucosa may be
utilized as a model of a gastrointestinal mucosa. The membrane can
be used to separate a compartment containing the compound of the
present disclosure from a compartment where the rate of permeation
will be monitored. Also, parallel artificial membrane permeability
assays (PAMPA) can be performed. Such in vitro measurements can
reasonably indicate actual permeability in vivo. (See, for example,
Wohnsland et al., J. Med. Chem., 2001, 44:923-930; Schmidt et al.,
Millipore Corp. Application Note, 2002, n.sup.o AN1725EN00, and
n.sup.o AN1728EN00, incorporated herein by reference.)
[0216] Accordingly, in some embodiments, the compounds utilized in
the methods of the present disclosure may have a permeability
coefficient, P.sub.app, of less than about 100.times.10.sup.-6
cm/s, or less than about 10.times.10.sup.-6 cm/s, or less than
about 1.times.10.sup.-6 cm/s, or less than about
0.1.times.10.sup.-6 cm/s, when measured using means known in the
art (such as for example the permeability experiment described in
Wohnsland et al., J. Med. Chem., 2001, 44. 923-930, the contents of
which is incorporated herein by reference).
[0217] As previously noted, in accordance with the present
disclosure, phosphate transport inhibitors may be modified to
hinder their net absorption through a layer of gut epithelial
cells, rendering them substantially systemically non-bioavailable.
In some particular embodiments, the compounds of the present
disclosure comprise a phosphate transport inhibitor linked, coupled
or otherwise attached to a non-absorbable moiety, which may be an
oligomer moiety, a polymer moiety, a hydrophobic moiety, a
hydrophilic moiety, and/or a charged moiety, which renders the
overall compound substantially impermeable or substantially
systemically non-bioavailable. In some preferred embodiments, the
phosphate transport inhibitor is coupled to a multimer or polymer
portion or moiety, such that the resulting molecule is
substantially impermeable or substantially systemically
non-bioavailable. The multimer or polymer portion or moiety may be
of a molecular weight greater than about 500 Daltons (Da), about
1000 Da, about 2500 Da, about 5000 Da, about 10,000 Da or more, and
in particular may have a molecular weight in the range of about
1000 Daltons (Da) to about 500,000 Da, preferably in the range of
about 5000 to about 200,000 Da, and more preferably may have a
molecular weight that is sufficiently high to essentially preclude
any net absorption through a layer of gut epithelial cells of the
compound. In these or other particular embodiments, the phosphate
transport inhibitor is modified to substantially hinder its net
absorption through a layer of gut epithelial cells.
[0218] (ii) Persistent Inhibitory Effect
[0219] In other embodiments, the substantially impermeable or
substantially systemically non-bioavailable compounds utilized in
the treatment methods of the present disclosure may additionally
exhibit a persistent inhibitor effect. This effect manifests itself
when the inhibitory action of a compound at a certain concentration
in equilibrium with epithelial cells (e.g., at or above its
inhibitory concentration, IC) does not revert to baseline (i.e.,
phosphate transport without inhibitor) after the compound is
depleted by simple washing of the luminal content.
[0220] This effect can be interpreted as a result of the tight
binding of the compounds to the phosphate transport protein at the
intestinal apical side of the gut epithelial cell. The binding can
be considered as quasi-irreversible to the extent that, after the
compound has been contacted with the gut epithelial cell and
subsequently washed off said gut epithelial cell, the flux of
phosphate transport is still significantly lower than in the
control without the compound. This persistent inhibitory effect has
the clear advantage of maintaining drug activity within the GI
tract even though the residence time of the active in the upper GI
tract is short, and when no entero-biliary recycling process is
effective to replenish the compound concentration near its site of
action.
[0221] Such a persistent inhibitory effect has an obvious advantage
in terms of patient compliance, but also in limiting drug exposure
within the GI tract.
[0222] The persistence effect can be determined using in vitro
methods; in one instance, cell lines expressing phosphate
transporters are split in different vials and treated with a
phosphate transport inhibiting compound and phosphate solution to
measure the rate of phosphate uptake. The cells in one set of vials
are washed for different periods of time to remove the inhibitor,
and phosphate uptake measurement is repeated after the washing.
Compounds that maintain their inhibitory effect after
multiple/lengthy washing steps (compared to the inhibitory effect
measured in the vials where washing does not occur) are persistent
inhibitors. Persistence effect can also be characterized ex vivo by
using the everted sac technique, whereby transport of phosphate is
monitored using an excised segment of GI perfused with a solution
containing the inhibitor and shortly after flushing the bathing
solution with a buffer solution free from inhibitor. A persistence
effect can also be characterized in vivo by observing the time
needed for phosphate balance to return to normal when the inhibitor
treatment is discontinued. The limit of the method resides in the
fact that apical cells (and therefore apical phosphate
transporters) are sloughed off after a period of 3 to 4 days, the
typical turnover time of gut epithelial cells. A persistence effect
can be achieved by increasing the residence time of the active
compound at the apical surface of the gut epithelial cells; this
can be obtained by designing phosphate transport inhibitors with
several phosphate transport inhibiting moieties built-in the small
molecule or oligomer (wherein "several" as used herein typically
means at least about 2, about 4, about 6 or more). Examples of such
structures in the context of analogs of the antibiotic vancomycin
are given in Griffin, et al., J. Am. Chem. Soc., 2003, 125,
6517-6531. Alternatively the compound comprises groups that
contribute to increase the affinity towards the gut epithelial cell
so as to increase the time of contact with the gut epithelial cell
surface. Such groups are referred to as being "mucoadhesive." More
specifically, the Core or L moiety can be substituted by such
mucoadhesive groups, such as polyacrylates, partially deacetylated
chitosan or polyalkylene glycol. (See also Patil, S. B. et al.,
Curr. Drug. Deliv., 2008, October 5(4), pp. 312-8.)
[0223] (iii) GI Enzyme Resistance
[0224] Because the compounds utilized in the treatment methods of
the present disclosure are preferably substantially systemically
non-bioavailable, and/or preferably exhibit a persistent inhibitory
effect, it is also desirable that, during their prolonged residence
time in the gut, these compounds resist the hydrolytic conditions
prevailing in the upper GI tract. In such embodiments, compounds of
the present disclosure are resistant to phase 1 and phase 2
metabolism. For example, administered compounds are preferably
resistant to the activity of P450 enzymes, glucurosyl transferases,
sulfotransferases, glutathione S-transferases, and the like, in the
intestinal mucosa, as well as gastric (e.g., gastric lipase, and
pepsine), pancreatic (e.g., trypsin, triglyceride pancreatic
lipase, phospholipase A2, endonucleases, nucleotidases, and
alpha-amylase), and brush-border enzymes (e.g., alkaline
phosphatase, glycosidases, and proteases) generally known in the
art.
[0225] The compounds that are utilized in methods of the present
disclosure are also preferably resistant to metabolism by the
bacterial flora of the gut; that is, the compounds are not
substrates for enzymes produced by bacterial flora. In addition,
the compounds administered in accordance with the methods of the
present disclosure may be substantially inactive towards the
gastrointestinal flora, and do not disrupt bacterial growth or
survival. As a result, in various embodiments herein, the minimal
inhibitory concentration (or "MIC") against GI flora is desirably
greater than about 15 .mu.g/ml, about 30 .mu.g/ml, about 60
.mu.g/ml, about 120 .mu.g/ml, or even about 240 .mu.g/ml, the MIC
in various embodiments being for example between about 16 and about
32 .mu.g/ml, or between about 64 and about 128 .mu.g/ml, or greater
than about 256 .mu.g/ml.
[0226] To one skilled in the art of medicinal chemistry, metabolic
stability can be achieved in a number of ways. Functionality
susceptible to P450-mediated oxidation can be protected by, for
example, blocking the point of metabolism with a halogen or other
functional group. Alternatively, electron withdrawing groups can be
added to a conjugated system to generally provide protection to
oxidation by reducing the electrophilicity of the compound.
Proteolytic stability can be achieved by avoiding secondary amide
bonds, or by incorporating changes in stereochemistry or other
modifications that prevent the drug from otherwise being recognized
as a substrate by the metabolizing enzyme.
[0227] (iv) C.sub.max and IC.sub.50
[0228] It is also to be noted that, in various embodiments of the
present disclosure, one or more of the compounds detailed herein,
when administered either alone or in combination with one or more
additional pharmaceutically active compounds or agents to a patient
in need thereof has a C.sub.max that is less than the IC.sub.50 for
NaPi2b, more specifically, less than about 10.times. (10 times) the
IC.sub.50, and, more specifically still, less than about 100.times.
(100 times) the IC.sub.50.
[0229] Additionally, or alternatively, it is also to be noted that,
in various embodiments of the present disclosure, one or more of
the compounds detailed herein, when administered either alone or in
combination with one or more additional pharmaceutically active
compounds or agents to a patient in need thereof, may have a
C.sub.max of less than about 10 ng/ml, about 7.5 ng/ml, about 5
ng/ml, about 2.5 ng/ml, about 1 ng/ml, or about 0.5 ng/ml, the
C.sub.max being for example within the range of about 1 ng/ml to
about 10 ng/ml, or about 2.5 ng/ml to about 7.5 ng/ml.
[0230] Additionally, or alternatively, it is also to be noted that,
in various embodiments of the present disclosure, one or more of
the compounds detailed herein, when administered either alone or in
combination with one or more additional pharmaceutically active
compounds or agents to a patient in need thereof, may have a
IC.sub.50 of less than about 10 .mu.M, about 7.5 .mu.M, about 5
.mu.M, about 2.5 .mu.M, about 1 .mu.M, or about 0.5 .mu.M, the
IC.sub.50 being for example within the range of about 0.5 .mu.M to
about 10 .mu.M, or about 0.5 .mu.M to about 7.5 .mu.M, or about 0.5
.mu.M to about 5 .mu.M, or about 0.5 .mu.M to about 2.5 .mu.M.
[0231] Additionally, or alternatively, it is also to be noted that,
in various embodiments of the present disclosure, one or more of
compounds detailed herein, when administered to a patient in need
thereof, may have a ratio of IC.sub.50:C.sub.max, wherein IC.sub.50
and C.sub.max are expressed in terms of the same units, of at least
about 10, about 50, about 100, about 250, about 500, about 750, or
about 1000.
[0232] Additionally, or alternatively, it is also to be noted that,
in various embodiments of the present disclosure, wherein one or
more of the compounds as detailed herein is orally administered to
a patent in need thereof, within the therapeutic range or
concentration, the maximum compound concentration detected in the
serum, defined as C.sub.max, is lower than the NaPi2b inhibitory
concentration IC.sub.50 of said compound. As previously noted, as
used herein, IC.sub.50 is defined as the quantitative measure
indicating the concentration of the compound required to inhibit
50% of the NaPi2b transport activity in a cell based assay.
Pharmaceutical Compositions and Methods of Treatment
[0233] For the purposes of administration, the compounds of the
present invention may be administered to a patient or subject as a
raw chemical or may be formulated as pharmaceutical compositions.
Pharmaceutical compositions of the present invention generally
comprise a compound of the invention and a pharmaceutically
acceptable carrier, diluent or excipient. The compound is present
in the composition in an amount which is effective to treat a
particular disease or condition of interest, as described herein,
and preferably with acceptable toxicity to the patient. The
activity of compounds can be determined by one skilled in the art,
for example, as described in the Example below. Appropriate
concentrations and dosages can be readily determined by one skilled
in the art.
[0234] A compound or composition of the invention may be used in a
method for treating essentially any disease or other condition in a
patient which would benefit from phosphate uptake inhibition in the
gastrointestinal tract.
[0235] For example, by way of explanation, but not limitation,
kidney damage reduces the production and activity of renal 1-alpha
hydroxylase, leading to lower 1,25-dihydroxy vitamin D. Decreased
vitamin D levels limit gastrointestinal calcium absorption, leading
to a decline in serum calcium levels. The combination of lower
1,25-dihydroxy vitamin D and lower serum calcium levels
synergistically stimulate parathyroid tissue to produce and secrete
PTH. A loss of nephrons also impairs Pi excretion, but serum P
levels are actively defended by the actions of PTH and FGF-23, and
by higher serum P levels, which considerably enhance urinary
PO.sub.4 excretion. However, tubular actions of PTH and FGF-23
cannot maintain serum P levels in the face of continual nephron
loss. Once renal insufficiency progresses to the loss of about
40-50% of renal function, the decrease in the amount of functioning
renal tissue does not allow excretion of the full amount of
ingested phosphate required to maintain homeostasis. As a result,
hyperphosphatemia develops. In addition, a rise in serum P levels
impedes renal 1-alpha hydroxylase activity, further suppressing
activated vitamin D levels, and further stimulating PTH, leading to
secondary hyperparathyroidism (sHPTH).
[0236] Phosphorus imbalance, however, does not necessarily equate
with hyperphosphatemia. In fact, the vast majority of CKD patients
not yet on dialysis are normophosphatemic but their phosphorus
balance is positive with the excess phosphorus being disposed in
the vasculature in the form of ectopic calcification, e.g. intima
localized vascular calcification. Clinically, patients with CKD
have elevated levels of FGF-23 that are significantly associated
with deteriorating renal function and with decreased calcitriol
levels, and it has been hypothesized that the synthesis of FGF-23
is induced by the presence of excess P in the body consecutive to
renal failure.
[0237] Furthermore, an unrecognized effect on cardiovascular
disease is postprandial phosphatemia, i.e. serum P excursion
secondary to meal intake. Further still, studies have investigated
the acute effect of phosphorus loading on endothelial function in
vitro and in vivo. Exposing bovine arotic endothelial cells to a
phosphorus load increased production of reactive oxygen species and
decreased nitric oxide, a known vasodilator agent. In the acute P
loading study in healthy volunteers described above, it was found
that the flow mediated dilation correlated inversely with
postprandial serum P (Shuto et al., 2009b, J. Am. Soc. Nephrol., v.
20, no. 7, p. 1504-1512).
[0238] Accordingly, in certain more specific embodiments, a
compounds or composition of the invention can be used in a method
selected from the group consisting of: (a) a method for treating
hyperphosphatemia; (b) a method for treating a renal disease (e.g.,
chronic kidney disease or end stage renal disease); (c) a method
for delaying time to dialysis; (d) a method for attenuating intima
localized vascular calcification; (e) a method for reducing the
hyperphosphatemic effect of active vitamin D; (f) a method for
reducing FGF23 levels; (g) a method for attenuating
hyperparathyroidism; (h) a method for improving endothelial
dysfunction induced by postprandial serum phosphate; (i) a method
for reducing urinary phosphorous; (j) a method for normalizing
serum phosphorus levels; (k) a method for treating proteinuria; and
(l) a method for reducing serum PTH, calcium, calcitriol and/or
phosphate concentrations or levels.
[0239] Administration of the compounds of the invention, or their
pharmaceutically acceptable salts, in pure form or in an
appropriate pharmaceutical composition, can be carried out via any
of the accepted modes of administration of agents for serving
similar utilities. The pharmaceutical compositions of the invention
can be prepared by combining a compound of the invention with an
appropriate pharmaceutically acceptable carrier, diluent or
excipient, and may be formulated into preparations in solid,
semi-solid, liquid or gaseous forms, such as tablets, capsules,
powders, granules, ointments, solutions, suppositories, injections,
inhalants, gels, microspheres, and aerosols. Typical routes of
administering such pharmaceutical compositions include, without
limitation, oral, topical, transdermal, inhalation, parenteral,
sublingual, buccal, rectal, vaginal, and intranasal. The term
parenteral as used herein includes subcutaneous injections,
intravenous, intramuscular, intrasternal injection or infusion
techniques. Pharmaceutical compositions of the invention are
formulated so as to allow the active ingredients contained therein
to be bioavailable upon administration of the composition to a
patient. Compositions that will be administered to a subject or
patient take the form of one or more dosage units, where for
example, a tablet may be a single dosage unit, and a container of a
compound of the invention in aerosol form may hold a plurality of
dosage units. Actual methods of preparing such dosage forms are
known, or will be apparent, to those skilled in this art; for
example, see Remington: The Science and Practice of Pharmacy, 20th
Edition (Philadelphia College of Pharmacy and Science, 2000). The
composition to be administered will, in any event, contain a
therapeutically effective amount of a compound of the invention, or
a pharmaceutically acceptable salt thereof, for treatment of a
disease or condition of interest in accordance with the teachings
of this invention.
[0240] A pharmaceutical composition of the invention may be in the
form of a solid or liquid. In one aspect, the carrier(s) are
particulate, so that the compositions are, for example, in tablet
or powder form. The carrier(s) may be liquid, with the compositions
being, for example, an oral syrup, injectable liquid or an aerosol,
which is useful in, for example, inhalatory administration.
[0241] When intended for oral administration, the pharmaceutical
composition is preferably in either solid or liquid form, where
semi-solid, semi-liquid, suspension and gel forms are included
within the forms considered herein as either solid or liquid.
[0242] As a solid composition for oral administration, the
pharmaceutical composition may be formulated into a powder,
granule, compressed tablet, pill, capsule, chewing gum, wafer or
the like form. Such a solid composition will typically contain one
or more inert diluents or edible carriers. In addition, one or more
of the following may be present: binders such as
carboxymethylcellulose, ethyl cellulose, microcrystalline
cellulose, gum tragacanth or gelatin; excipients such as starch,
lactose or dextrins, disintegrating agents such as alginic acid,
sodium alginate, Primogel, corn starch and the like; lubricants
such as magnesium stearate or Sterotex; glidants such as colloidal
silicon dioxide; sweetening agents such as sucrose or saccharin; a
flavoring agent such as peppermint, methyl salicylate or orange
flavoring; and a coloring agent.
[0243] When the pharmaceutical composition is in the form of a
capsule, for example, a gelatin capsule, it may contain, in
addition to materials of the above type, a liquid carrier such as
polyethylene glycol or oil.
[0244] The pharmaceutical composition may be in the form of a
liquid, for example, an elixir, syrup, solution, emulsion or
suspension. The liquid may be for oral administration or for
delivery by injection, as two examples. When intended for oral
administration, preferred composition contain, in addition to the
present compounds, one or more of a sweetening agent,
preservatives, dye/colorant and flavor enhancer. In a composition
intended to be administered by injection, one or more of a
surfactant, preservative, wetting agent, dispersing agent,
suspending agent, buffer, stabilizer and isotonic agent may be
included.
[0245] The liquid pharmaceutical compositions of the invention,
whether they be solutions, suspensions or other like form, may
include one or more of the following adjuvants: sterile diluents
such as water for injection, saline solution, preferably
physiological saline, Ringer's solution, isotonic sodium chloride,
fixed oils such as synthetic mono or diglycerides which may serve
as the solvent or suspending medium, polyethylene glycols,
glycerin, propylene glycol or other solvents; antibacterial agents
such as benzyl alcohol or methyl paraben; antioxidants such as
ascorbic acid or sodium bisulfite; chelating agents such as
ethylenediaminetetraacetic acid; buffers such as acetates, citrates
or phosphates and agents for the adjustment of tonicity such as
sodium chloride or dextrose. The parenteral preparation can be
enclosed in ampoules, disposable syringes or multiple dose vials
made of glass or plastic. Physiological saline is a preferred
adjuvant. An injectable pharmaceutical composition is preferably
sterile.
[0246] A liquid pharmaceutical composition of the invention
intended for either parenteral or oral administration should
contain an amount of a compound of the invention such that a
suitable dosage will be obtained.
[0247] The pharmaceutical composition of the invention may be
intended for topical administration, in which case the carrier may
suitably comprise a solution, emulsion, ointment or gel base. The
base, for example, may comprise one or more of the following:
petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil,
diluents such as water and alcohol, and emulsifiers and
stabilizers. Thickening agents may be present in a pharmaceutical
composition for topical administration. If intended for transdermal
administration, the composition may include a transdermal patch or
iontophoresis device.
[0248] The pharmaceutical composition of the invention may be
intended for rectal administration, in the form, for example, of a
suppository, which will melt in the rectum and release the drug.
The composition for rectal administration may contain an oleaginous
base as a suitable nonirritating excipient. Such bases include,
without limitation, lanolin, cocoa butter and polyethylene
glycol.
[0249] The pharmaceutical composition of the invention may include
various materials, which modify the physical form of a solid or
liquid dosage unit. For example, the composition may include
materials that form a coating shell around the active ingredients.
The materials that form the coating shell are typically inert, and
may be selected from, for example, sugar, shellac, and other
enteric coating agents. Alternatively, the active ingredients may
be encased in a gelatin capsule.
[0250] The pharmaceutical composition of the invention in solid or
liquid form may include an agent that binds to the compound of the
invention and thereby assists in the delivery of the compound.
Suitable agents that may act in this capacity include a monoclonal
or polyclonal antibody, a protein or a liposome.
[0251] The pharmaceutical composition of the invention may consist
of dosage units that can be administered as an aerosol. The term
aerosol is used to denote a variety of systems ranging from those
of colloidal nature to systems consisting of pressurized packages.
Delivery may be by a liquefied or compressed gas or by a suitable
pump system that dispenses the active ingredients. Aerosols of
compounds of the invention may be delivered in single phase,
bi-phasic, or tri-phasic systems in order to deliver the active
ingredient(s). Delivery of the aerosol includes the necessary
container, activators, valves, subcontainers, and the like, which
together may form a kit. One skilled in the art, without undue
experimentation may determine preferred aerosols.
[0252] The pharmaceutical compositions of the invention may be
prepared by methodology well known in the pharmaceutical art. For
example, a pharmaceutical composition intended to be administered
by injection can be prepared by combining a compound of the
invention with sterile, distilled water so as to form a solution. A
surfactant may be added to facilitate the formation of a
homogeneous solution or suspension. Surfactants are compounds that
non-covalently interact with the compound of the invention so as to
facilitate dissolution or homogeneous suspension of the compound in
the aqueous delivery system.
[0253] The compounds of the invention, or their pharmaceutically
acceptable salts, are administered in a therapeutically effective
amount, which will vary depending upon a variety of factors
including the activity of the specific compound employed; the
metabolic stability and length of action of the compound; the age,
body weight, general health, sex, and diet of the patient; the mode
and time of administration; the rate of excretion; the drug
combination; the severity of the particular disorder or condition;
and the subject undergoing therapy.
[0254] In certain embodiments, a typical dosage of the
substantially impermeable or substantially systemically
non-bioavailable, compound may be between about 0.2 mg per day and
about 2 g per day, or between about 1 mg and about 1 g per day, or
between about 5 mg and about 500 mg, or between about 10 mg and
about 250 mg per day, which is administered to a subject in need of
treatment.
[0255] The frequency of administration of the compounds and
compositions described herein may vary from once-a-day (QD) to
twice-a-day (BID) or thrice-a-day (TID), etc., the precise
frequency of administration varying with, for example, the
patient's condition, the dosage, etc.
[0256] Compounds of the invention, or pharmaceutically acceptable
derivatives thereof, may also be administered simultaneously with,
prior to, or after administration of one or more other therapeutic
agents. Such combination therapy includes administration of a
single pharmaceutical dosage formulation which contains a compound
of the invention and one or more additional active agents, as well
as administration of the compound of the invention and each active
agent in its own separate pharmaceutical dosage formulation. For
example, a compound of the invention and the other active agent can
be administered to the patient together in a single oral dosage
composition such as a tablet or capsule, or each agent administered
in separate oral dosage formulations. Where separate dosage
formulations are used, the compounds of the invention and one or
more additional active agents can be administered at essentially
the same time, i.e., concurrently, or at separately staggered
times, i.e., sequentially; combination therapy is understood to
include all these regimens.
[0257] For example, in certain embodiments, the additional
biologically active agent included in a pharmaceutical composition
(or method) of the invention is selected, for example, from vitamin
D.sub.2 (ergocalciferol), vitamin D.sub.3 (cholecalciferol), active
vitamin D (calcitriol) and active vitamin D analogs (e.g.
doxercalciferol, paricalcitol).
[0258] In other specific embodiments, the additional biologically
active agent included in a pharmaceutical composition (or method)
of the invention is a phosphate binder, such as Renvela, Renagel,
Fosrenol, calcium carbonate, calcium acetate (e.g. Phoslo),
MCI-196, Zerenex.TM., Fermagate, APS1585, SBR-759, PA-21, and the
like.
[0259] The compounds of the invention have been found to act
synergistically with phosphate binders by providing a higher
efficacy than the sum of the efficacy of a NaPi2b inhibitor and
that of a phosphate binder administered alone. Without wishing to
be bound by theory, it is believed that the synergy results from
the distinct mechanisms of action of a phosphate transport
inhibitor and a phosphate binder. More specifically, a phosphate
transport inhibitor blocks the epithelial inward transport of
phosphate ions whereas phosphate binders sequester free phosphate
ions in the lumen of the intestine.
[0260] The efficacy of a phosphate binder, as measured by its vivo
binding capacity (mole of phosphate ions bound per gram of binder)
is essentially dictated by: i) the density of binding sites (i.e.
amine groups in Renvela/Sevelamer, a polymeric amine material; or
multivalent cations such calcium or lanthanum in Phoslo (Calcium
acetate) or Fosrenol (lanthanum carbonate)); and ii) the affinity
of said binding sites for phosphate ions. Notably only a fraction
of the binding sites is available for phosphate binding in vivo as
other anions, such as bile acids and fatty acids compete for the
binding sites and therefore lowers efficacy. Bound phosphate ions
are in equilibrium with free phosphate in the intestinal lumen and
are themselves subject to intense pumping from phosphate transport
proteins lining up the epithelia. Experiments have shown that the
efficacy of phosphate intestinal uptake is remarkably high,
exceeding 95% of the phosphate presented to the epithelia. It is
believed that the active transport of phosphate contributes to
lower the luminal free phosphate concentration and therefore to
drive the binding equilibrium of a phosphate binder to lower
binding capacity. It is also believed that by reducing the
phosphate intestinal transport using a phosphate transport
inhibitor, one restores a higher in vivo binding capacity of
phosphate sequestering agents. The synergistic effect is thought to
be even more pronounced when the contribution of active phosphate
transport is increased as a result of, e.g. vitamin D treatment, an
agent promoting NaPi2b expression.
[0261] It is understood that in the present description,
combinations of substituents and/or variables of the depicted
formulae are permissible only if such contributions result in
stable compounds.
[0262] It will also be appreciated by those skilled in the art that
in the process described herein the functional groups of
intermediate compounds may need to be protected by suitable
protecting groups. Such functional groups include hydroxy, amino,
mercapto and carboxylic acid. Suitable protecting groups for
hydroxy include trialkylsilyl or diarylalkylsilyl (for example,
t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl),
tetrahydropyranyl, benzyl, and the like. Suitable protecting groups
for amino, amidino and guanidino include t-butoxycarbonyl,
benzyloxycarbonyl, and the like. Suitable protecting groups for
mercapto include --C(O)--R'' (where R'' is alkyl, aryl or
arylalkyl), p-methoxybenzyl, trityl and the like. Suitable
protecting groups for carboxylic acid include alkyl, aryl or
arylalkyl esters. Protecting groups may be added or removed in
accordance with standard techniques, which are known to one skilled
in the art and as described herein. The use of protecting groups is
described in detail in Green, T. W. and P. G. M. Wutz, Protective
Groups in Organic Synthesis (1999), 3rd Ed., Wiley. As one of skill
in the art would appreciate, the protecting group may also be a
polymer resin such as a Wang resin, Rink resin or a
2-chlorotrityl-chloride resin.
[0263] It will also be appreciated by those skilled in the art,
although such protected derivatives of compounds of this invention
may not possess pharmacological activity as such, they may be
administered to a mammal and thereafter metabolized in the body to
form compounds of the invention which are pharmacologically active.
Such derivatives may therefore be described as "prodrugs". All
prodrugs of compounds of this invention are included within the
scope of the invention.
[0264] Furthermore, all compounds of the invention which exist in
free base or acid form can be converted to their pharmaceutically
acceptable salts by treatment with the appropriate inorganic or
organic base or acid by methods known to one skilled in the art.
Salts of the compounds of the invention can be converted to their
free base or acid form by standard techniques.
[0265] The following Examples illustrate various methods of making
compounds of this invention, i.e., compounds of structure (I), or a
stereoisomer, prodrug or pharmaceutically acceptable salt thereof:
It is understood that one skilled in the art may be able to make
these compounds by similar methods or by combining other methods
known to one skilled in the art. It is also understood that one
skilled in the art would be able to make, in a similar manner as
described below, other compounds of structure (I) not specifically
illustrated below by using the appropriate starting components and
modifying the parameters of the synthesis as needed. In general,
starting components may be obtained from sources such as Sigma
Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific,
TCI, and Fluorochem USA, etc. or synthesized according to sources
known to those skilled in the art (see, e.g., Advanced Organic
Chemistry: Reactions, Mechanisms, and Structure, 5th edition
(Wiley, December 2000)) or prepared as described in this
invention.
[0266] The following examples are provided for purposes of
illustration, not limitation.
EXAMPLES
Example 1.1
3-(3-((2-(4-((3-(Trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperid-
in-1-yl)phenyl)carbamoyl)benzylthio)propanoic acid
##STR00008## ##STR00009## ##STR00010##
[0267] Intermediate 1.1a: 3-(acetylthiomethyl)benzoic acid
[0268] Into a 250-mL round-bottom flask, was placed a solution of
3-(bromomethyl)benzoic acid (7 g, 32.56 mmol, 1.00 equiv) in
ethanol (80 mL), and potassium ethanethioate (9.65 g, 84.65 mmol,
2.60 equiv). The resulting solution was stirred overnight at room
temperature. The resulting mixture was concentrated under vacuum.
The resulting solution was diluted with 80 mL of water and adjusted
to pH 3-4 with 10% hydrochloric acid. The resulting solution was
extracted with 3.times.50 mL of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 1.times.50
mL of brine. The mixture was dried over sodium sulfate and
concentrated under vacuum. This resulted in 4.4 g (64%) of
3-(acetylthiomethyl)benzoic acid as a brown solid.
Intermediate 1.1b: 3-(mercaptomethyl)benzoic acid
[0269] Into a 500-mL round-bottom flask, was placed a solution of
3-(acetylthiomethyl)benzoic acid (16.4 g, 78.10 mmol, 1.00 equiv)
in methanol (150 mL), and a solution of potassium carbonate (26.9
g, 194.93 mmol, 2.50 equiv) in water (70 mL). The resulting
solution was stirred for 4 h at 60.degree. C. The resulting mixture
was concentrated under vacuum. The resulting solution was diluted
with 200 mL of water and adjusted to pH 3 with 10% hydrochloric
acid. The resulting solution was extracted with 3.times.(100/20 mL)
of ethyl acetate/tetrahydrofuran and the organic layers combined.
The resulting mixture was washed with 1.times.100 mL of brine. The
mixture was dried over sodium sulfate and concentrated under
vacuum. This resulted in 12 g (91%) of 3-(mercaptomethyl)benzoic
acid as a brown solid.
Intermediate 1.1c: 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic
acid
[0270] Into a 500-mL round-bottom flask, was placed a solution of
3-(mercaptomethyl)benzoic acid (12 g, 71.43 mmol, 1.00 equiv) in
acetonitrile (200 mL), and tert-butyl acrylate (60 mL), DBU (21.7
g, 142.76 mmol, 2.00 equiv). The resulting solution was stirred
overnight at 80.degree. C. in an oil bath. The resulting mixture
was concentrated under vacuum. The resulting solution was diluted
with 200 mL of water and adjusted to pH 2.about.3 with 10%
hydrochloric acid. The resulting solution was extracted with
3.times.200 mL of ethyl acetate and the organic layers combined.
The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with petroleum ether/ethyl acetate (50:1).
This resulted in 10.5 g (47%) of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid as red oil.
.sup.1H-NMR (300 MHz, CDCl.sub.3, ppm): .delta. 8.08 (s, 1H), 8.04
(d, J=7.8 Hz, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.46 (t, 1H), 3.81 (s,
2H), 2.68 (t, 2H), 2.50 (t, 2H), 1.48 (s, 9H). MS (ES, m/z): 295
[M-H].sup.-.
Intermediate 1.1d: 1-(3-bromo-4-nitrophenyl)piperidine
[0271] Into a 1000-mL round-bottom flask, was placed a solution of
2-bromo-4-fluoro-1-nitrobenzene (30 g, 137.61 mmol, 1.00 equiv) in
N,N-dimethylformamide (450 mL), piperidine (13.974 g, 162.68 mmol,
1.20 equiv), and potassium carbonate (56.718 g, 411.00 mmol, 2.99
equiv). The resulting solution was stirred overnight at 75.degree.
C. in an oil bath. The solids were filtered out. The resulting
mixture was concentrated under vacuum. The resulting solution was
diluted with 300 mL of dichloromethane. The resulting mixture was
washed with 2.times.100 mL of water and 2.times.100 mL of brine.
The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with ethyl acetate/petroleum ether (1:50).
This resulted in 19 g (49%) of 1-(3-bromo-4-nitrophenyl)piperidine
as a yellow solid.
Intermediate 1.1e:
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
phenyl)-piperidine
[0272] Into a 50-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of 1-(3-bromo-4-nitrophenyl)piperidine (8.00 g, 28.07
mmol, 1.00 equiv) in DMSO (25 mL), PdCl.sub.2(dppf) (620 mg, 0.85
mmol, 0.03 equiv),
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-
-dioxaborolane (10.74 g, 42.45 mmol, 1.50 equiv), and potassium
acetate (7.09 g, 72.24 mmol, 2.57 equiv). The resulting solution
was stirred overnight at 80.degree. C. in an oil bath. The mixture
was concentrated under vacuum. The resulting solution was diluted
with 100 mL of water. The resulting solution was extracted with
2.times.200 mL of ethyl acetate and the organic layers combined.
The resulting mixture was washed with 2.times.100 mL of water and
2.times.100 mL of brine. The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:50.about.1:10). This resulted in 8.0 g
(86%) of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piper-
idine as a yellow solid. .sup.1H-NMR (300 MHz, CDCl.sub.3, ppm):
.delta. 8.047-8.077 (d, J=9.0 Hz, 1H), 6.770-6.829 (m, 2H), 3.453
(s, 4H), 1.586-1.702 (m, 6H), 1.499 (s, 12H). MS (ES, m/z): 333.15
[M+H].sup.+.
Intermediate 1.1f: methyl 2-bromoisonicotinate hydrochloride
[0273] Into a 500-mL round bottom flask, was placed a solution of
2-bromoisonicotinic acid (10 g, 49.75 mmol, 1.00 equiv) in methanol
(200 mL). This was followed by dropwise addition of thionyl
chloride (24 g, 203.39 mmol, 4.09 equiv) with stirring at 0.degree.
C.-5.degree. C. The resulting solution was stirred for 5 h at
70.degree. C. in an oil bath. The resulting mixture was
concentrated under vacuum, to yield 10 g (80%) of methyl
2-bromoisonicotinate hydrochloride as a white solid.
Intermediate 1.1g: methyl
2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinate
[0274] Into a 250-mL 3-neck round bottom flask purged and
maintained with an inert atmosphere of nitrogen, were placed a
solution of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidi-
ne (4 g, 12.05 mmol, 1.00 equiv) in ethylene glycol dimethyl ether
(60 mL), methyl 2-bromoisonicotinate hydrochloride (2.6 g, 12.09
mmol, 1.02 equiv), a solution of sodium carbonate (6.4 g, 60.38
mmol, 5.01 equiv) in water (30 mL), and Pd(PPh.sub.3).sub.4 (1.4 g,
1.21 mmol, 0.10 equiv). The resulting solution was stirred for 3 h
at 95.degree. C. The resulting solution was diluted with 100 mL of
water. The resulting solution was extracted with 3.times.100 mL of
ethyl acetate and the organic layers combined. The resulting
mixture was washed with 3.times.100 mL of brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column and eluted with
petroleum ether/ethyl acetate (10:1). This resulted in 1.8 g (44%)
of methyl 2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinate as a
red semi-solid.
Intermediate 1.1h: methyl
2-(2-amino-5-(piperidin-1-yl)phenyl)isonicotinate
[0275] Into a 100-mL round bottom flask, was placed a solution of
methyl 2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinate (1.8 g,
5.28 mmol, 1.00 equiv) in methanol (15 mL), and a solution of
NH.sub.4Cl (850 mg, 15.89 mmol, 3.00 equiv) in water (7.9 mL). This
was followed by the addition of iron (2.9 g, 51.79 mmol, 9.99
equiv) in several batches at 70.degree. C. The resulting solution
was stirred for 4 h at 70.degree. C. in an oil bath. The solids
were filtered out. The resulting mixture was concentrated under
vacuum. The resulting solution was diluted with 10 mL of water,
extracted with 3.times.20 mL of ethyl acetate, and the organic
layers combined. The resulting mixture was washed with 3.times.10
mL of brine, dried over anhydrous sodium sulfate, and concentrated
under vacuum. This resulted in 1.4 g (85%) of methyl
2-(2-amino-5-(piperidin-1-yl)phenyl)isonicotinate as a black
semi-solid.
Intermediate 1.1i: methyl
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)
benzamido)-5-(piperidin-1-yl)phenyl)isonicotinate
[0276] Into a 50-mL round bottom flask, was placed a solution of
methyl 2-(2-amino-5-(piperidin-1-yl)phenyl)isonicotinate (800 mg,
2.57 mmol, 1.00 equiv) in dichloromethane (2 mL), EDC.HCl (608 mg,
3.09 mmol, 1.20 equiv), 4-dimethylaminopyridine (380 mg, 3.11 mmol,
1.20 equiv), and 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic
acid (837 mg, 2.83 mmol, 1.00 equiv). The resulting solution was
stirred for 4 h at room temperature. The mixture was concentrated
under vacuum. The residue was applied onto a silica gel column and
eluted with petroleum ether/ethyl acetate (10:1-5:1). This resulted
in 600 mg (40%) of methyl
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)isonicotinate as yellow oil.
Intermediate 1.1j:
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)isonicotinic acid
[0277] Into a 50-mL round bottom flask, was placed a solution of
methyl
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)isonicotinate (160 mg, 0.27 mmol, 1.00 equiv) in
tetrahydrofuran (5 mL), and a solution of lithium hydroxide hydrate
(160 mg, 3.81 mmol, 14.02 equiv) in water (5 mL). The resulting
solution was stirred overnight at room temperature. The resulting
mixture was concentrated under vacuum. The solution was adjusted to
pH 3 with hydrochloric acid (2 mol/L). The resulting solution was
extracted with 3.times.10 mL of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 3.times.10
mL of brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. This resulted in 140 mg (90%) of
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)isonicotinic acid as a yellow semi-solid.
Intermediate 1.1k: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl) carbamoyl)
pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)propanoate
[0278] Into a 50 mL round bottom flask, was placed
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)isonicotinic acid (220 mg, 0.38 mmol, 1.00 equiv),
3-(trifluoromethyl)benzylamine (134 mg, 0.77 mmol, 2.00 equiv),
EDC.HCl (124 mg, 0.63 mmol, 1.65 equiv), 4-dimethylaminopyridine
(76 mg, 0.62 mmol, 1.63 equiv), and dichloromethane (10 mL). The
resulting solution was stirred overnight at room temperature. The
reaction progress was monitored by LCMS. The resulting mixture was
washed with 5.times.30 mL of aqueous NH.sub.4Cl. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
This resulted in 360 mg (90%) of tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)benzylthio)propanoate as yellow oil.
Example 1.1
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperid-
in-1-yl)phenyl)carbamoyl)benzylthio)propanoic acid
[0279] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)-benzylthio)propanoate (360 mg, 0.49
mmol, 1.00 equiv) in dichloromethane (2 mL), and
2,2,2-trifluoroacetic acid (2 mL). The resulting solution was
stirred for 1 h at room temperature. The reaction progress was
monitored by LCMS. The resulting mixture was concentrated under
vacuum. The crude product was purified by reverse phase HPLC
eluting with a water/CH.sub.3CN gradient containing 0.05% TFA. The
product was obtained as 217.9 mg (66%) of a white solid.
.sup.1H-NMR (300 MHz, DMSO-d.sub.6+DCl, ppm): .delta.
9.06.about.9.04 (d, J=5.7 Hz, 1H), 8.86 (s, 1H), 8.75 (s, 1H),
8.74.about.8.47 (m, 1H), 8.44.about.8.10 (m, 2H), 7.88 (s, 2H),
7.88.about.7.84 (d, J=7.8 Hz, 2H), 7.75.about.7.48 (m, 4H), 4.60
(s, 2H), 3.86 (s, 2H), 3.78 (s, 4H), 2.63.about.2.58 (m, 2H),
2.31.about.1.75 (m, 6H). MS (ES, m/z): 677[M+H].sup.+.
Example 1.2
3-((3-((4-(Piperidin-1-yl)-2-(4-(((6-(trifluoromethyl)pyridin-3-yl)methyl)-
carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic
acid
##STR00011##
[0280] Intermediate 1.2a: tert-butyl
3-((3-((4-(piperidin-1-yl)-2-(4-(((6-(trifluoromethyl)
pyridin-3-yl)methyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)
propanoate
[0281] Into a 8-mL sealed tube, was placed a solution of
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)isonicotinic acid 1.1j (90 mg, 0.16 mmol, 1.00 equiv) in
N,N-dimethylformamide (2 mL), HATU (90 mg, 0.24 mmol, 1.51 equiv),
N,N-diisopropylethylamine (30.6 mg, 0.24 mmol, 1.52 equiv), and
(6-(trifluoromethyl)pyridin-3-yl)methanamine (54 mg, 0.31 mmol,
1.96 equiv). The resulting solution was stirred overnight at room
temperature. The resulting mixture was concentrated under vacuum.
The residue was dissolved in ethyl acetate. The resulting mixture
was washed with water and brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum to yield
114.7 mg (crude) of tert-butyl
3-(3-((2-(4-(((6-(trifluoromethyl)pyridin-3-yl)methyl)carbamoyl)pyridin-2-
-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)propanoate as
red oil.
Example 1.2
3-(3-((2-(4-(((6-(trifluoromethyl)pyridin-3-yl)methyl)carbamoyl)
pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)propanoic
acid, trifluoroacetate salt
[0282] Example 1.2 was prepared from intermediate 1.2a using the
procedure used to prepare Example 1.1 from intermediate 1.1k.
.sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 9.064 (d, J=5.1 Hz,
1H), 8.777 (d, J=9.0 Hz, 1H), 8.425 (s, 1H), 8.108-8.163 (m, 2H),
7.997 (s, 1H), 7.896-7.811 (m, 3H), 7.704-7.667 (m, 1H),
7.620-7.595 (m, 1H), 7.547-7.496 (m, 1H), 4.764 (s, 2H), 3.912 (s,
2H), 3.690-3.656 (m, 4H), 2.751-2.690 (m, 2H), 2.614-2.568 (m, 2H),
2.046 (s, 4H), 1.823 (s, 2H). MS (ES, m/z): 678 [M+H].sup.+.
Example 1.3
3-((3-((2-(4-((4-(Tert-butyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-
-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00012##
[0283] Intermediate 1.3a: methyl tert-butyl
3-(3-((2-(4-((4-tert-butylbenzyl)carbamoyl)
pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)propanoate
[0284] Into a 50-mL round bottom flask, was placed a solution of
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)isonicotinic acid 1.1j (90.0 mg, 0.16 mmol, 1.00 equiv)
in dichloromethane (15 mL),
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (45.0
mg, 0.23 mmol, 1.50 equiv), N,N-dimethylpyridin-4-amine (28.0 mg,
0.23 mmol, 1.50 equiv), and (4-tert-butylbenzylamine (25.2 mg, 0.15
mmol, 1.00 equiv). The resulting solution was stirred for 8 h at
25.degree. C. in an oil bath. The resulting solution was diluted
with 10 mL of water. The resulting solution was extracted with
2.times.20 mL of ethyl acetate and the organic layers combined. The
resulting mixture was washed with brine, dried over sodium sulfate,
and concentrated under vacuum. This resulted in 100 mg (89%) of
tert-butyl
3-(3-((2-(4-((4-tert-butylbenzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-y-
l)phenyl)carbamoyl)benzylthio)propanoate as a yellow solid.
Example 1.3
3-((3-((2-(4-((4-(tert-butyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-
-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
[0285] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((4-tert-butylbenzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-y-
l)phenyl)carbamoyl) benzylthio)propanoate (100 mg, 0.14 mmol, 1.00
equiv) in dichloromethane (2 mL), and trifluoroacetic acid (160 mg,
1.40 mmol, 10.00 equiv). The resulting solution was stirred
overnight at 25.degree. C. in an oil bath. The resulting mixture
was concentrated under vacuum. The crude product (95 mg) was
purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 50 mg
(46%) of a white solid. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm):
.delta. 9.03-9.05 (d, J=5.4 Hz, 1H), 8.80-8.83 (d, J=9.3 Hz, 1H),
8.42 (s, 1H), 8.16-8.17 (d, J=2.7 Hz, 1H), 8.00 (s, 1H), 7.90-7.90
(d, J=1.5 Hz, 1H), 7.87-7.89 (m, 2H), 7.71-7.75 (dd, J=9.02 Hz,
J'=2.7 Hz, 1H), 7.60-7.62 (m, 1H), 7.50-7.55 (m, 1H), 7.40-7.42 (m,
2H), 7.31-7.39 (m, 2H), 4.61 (s, 2H), 3.91 (s, 2H), 3.70-3.73 (m,
4H), 2.70 (m, 2H), 2.56-2.51 (m, 2H), 2.06-2.09 (m, 4H), 1.84-1.86
(m, 1H), 1.32-1.33 (m, 9H). MS (ES, m/z): 665 [M+H].sup.+.
Examples 1.4 Through 1.49
[0286] The compounds listed in Table 1 were prepared from
intermediate 1.1j and the requisite amines or amine hydrochloride
salts using the methods described for the preparation of Example
1.1 (Method 1) and Example 1.2 (Method 2). Mass spectral data (ES,
positive ion mode) is provided for each compound.
##STR00013##
TABLE-US-00002 TABLE 1 MS Example No. R Method [M + H] Salt Form
1.4 ##STR00014## 1 609 Not (NA).sup.1 Applicable 1.5 ##STR00015## 1
691 NA 1.6 ##STR00016## 1 617 Trifluoroacetate 1.7 ##STR00017## 2
615 Trifluoroacetate 1.8 ##STR00018## 1 575 Trifluoroacetate 1.9
##STR00019## 1 649 Trifluoroacetate 1.10 ##STR00020## 2 652
Trifluoroacetate 1.11 ##STR00021## 1 624 NA 1.12 ##STR00022## 1 659
NA 1.13 ##STR00023## 2 649 NA 1.14 ##STR00024## 2 692
Trifluoroacetate 1.15 ##STR00025## 1 692 NA 1.16 ##STR00026## 2 708
Trifluoroacetate 1.17 ##STR00027## 1 657 Trifluoroacetate 1.18
##STR00028## 1 613 Trifluoroacetate 1.19 ##STR00029## 2 635
Trifluoroacetate 1.20 ##STR00030## 1 652 Trifluoroacetate 1.21
##STR00031## 1 675 Trifluoroacetate 1.22 ##STR00032## 1 681
Trifluoroacetate 1.23 ##STR00033## 1 653 Trifluoroacetate 1.24
##STR00034## 1 651 NA 1.25 ##STR00035## 1 711 Trifluoroacetate 1.26
##STR00036## 1 711 NA 1.27 ##STR00037## 1 707 Trifluoracetate 1.28
##STR00038## 1 695 Trifluoracetate 1.29 ##STR00039## 1 695 NA 1.30
##STR00040## 1 695 NA 1.31 ##STR00041## 1 695 Trifluoracetate 1.32
##STR00042## 1 745 NA 1.33 ##STR00043## 1 711 Trifluoroacetate 1.34
##STR00044## 1 635 Trifluoroacetate 1.35 ##STR00045## 1 635
Trifluoroacetate 1.36 ##STR00046## 1 685 NA 1.37 ##STR00047## 1 691
NA 1.38 ##STR00048## 1 637 Trifluoroacetate 1.39 ##STR00049## 1 715
NA 1.40 ##STR00050## 1 701 NA 1.41 ##STR00051## 1 685
Trifluoroacetate 1.42 ##STR00052## 1 685 Trifluoroacetate 1.43
##STR00053## 1 693 Trifluoroacetate 1.44 ##STR00054## 1 693
Trifluoroacetate 1.45 ##STR00055## 1 693 Trifluoroacetate 1.46
##STR00056## 1 623 NA 1.47 ##STR00057## 1 677 Trifluoroacetate 1.48
##STR00058## 1 677 NA 1.49 ##STR00059## 1 637 NA .sup.1Not
Applicable (NA): compound isolated as a zwitterion, or free base,
or conjugate acid
Example 2
3,3'-(((((((4,4'-((Dodecane-1,12-diylbis(azanediyl))bis(carbonyl))bis(pyri-
dine-4,2-diyl))bis(4-(piperidin-1-yl)-2,1-phenylene))bis(azanediyl))bis(ca-
rbonyl))bis(3,1-phenylene))bis(methylene))bis(sulfanediyl))dipropanoic
acid
##STR00060##
[0288] A stirred mixture of 27 mg of intermediate 1.1j, 4.8 mg of
1,12-diaminododecane, and 26 .mu.L of diisopropylamine in 0.5 mL of
DMF was treated with 21 mg of HATU. After 20 minutes the solvent
was evaporated at reduced pressure and the residue was partitioned
between ethyl acetate and aqueous sodium bicarbonate solution. The
organic extracts were washed twice with water and once with brine.
The solution was dried (Na.sub.2SO.sub.4) and the solvent was
evaporated. The residue was dissolved in 300 .mu.L of
dichloromethane and treated with 300 .mu.L of TFA. The solvent was
evaporated and the residue was purified by reverse-phase HPLC to
yield 16 mg of
3,3'-(((((((4,4'-((dodecane-1,12-diylbis(azanediyl))bis(carbonyl))bis(pyr-
idine-4,2-diyl))bis(4-(piperidin-1-yl)-2,1-phenylene))bis(azanediyl))bis(c-
arbonyl))bis(3,1-phenylene))bis(methylene))bis-(sulfanediyl))dipropanoic
acid. .sup.1H-NMR (400 MHz, CD.sub.3OD, ppm): .delta. 8.97 (dd,
J=5.2 Hz, J'=0.8 Hz, 2H), 8.79 (d, J=9.0 Hz, 2H), 8.34 (s, 2H),
8.16 (d, J=2.7 Hz, 2H), 7.96 (t, J=1.7 Hz, 2H), 7.84 (dt, J=8.2 Hz,
J'=1.3 Hz, 2H), 7.78 (dd, J=5.3 Hz, J'=1.6 Hz, 2H), 7.70 (dd, J=9.2
Hz, J'=2.8 Hz, 2H), 7.56 (dt, J=8.0 Hz, J'=1.2 Hz, 2H), 7.48 (t,
J=7.6 Hz, 2H), 3.87 (s, 4H), 3.69 (t, J=5.5 Hz, 8H), 3.39 (t, J=7.2
Hz, 4H), 2.71 (dt, J=7.2 Hz, J'=1.0 Hz, 4H), 2.55 (dt, J=7.1 Hz,
J'=1.0 Hz, 4H), 2.05 (m, 8H), 1.81 (m, 4H), 1.62 (m, 4H), 1.40-1.25
(m, 16H). MS (ES, m/z) 1203.6 [M+H].sup.+.
Example 3.1
3-((3-((4-(Piperidin-1-yl)-2-(6-((3-(trifluoromethyl)benzyl)amino)pyrimidi-
n-4-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00061## ##STR00062##
[0289] Intermediate 3.1a: tert-butyl
3-((3-(chlorocarbonyl)benzyl)thio)propanoate
[0290] Into a 100-mL round-bottom flask, was placed a solution of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c (3.00 g,
10.14 mmol, 1.00 equiv) in dichloromethane (50 mL). This was
followed by the addition of oxalyl dichloride (4.50 g, 35.43 mmol,
3.00 equiv) dropwise with stirring at 0.degree. C. To this was
added N,N-dimethylformamide (one drop). The resulting solution was
stirred for 1.5 h at room temperature. The resulting mixture was
concentrated under vacuum. This resulted in 3.18 g (99%) of
tert-butyl 3-(3-(chlorocarbonyl)benzylthio)propanoate as red
oil.
Intermediate 3.1 b.
4-chloro-6-(2-nitro-5-(piperidin-1-yl)phenyl)pyrimidine
[0291] Into a 250-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidi-
ne (5 g, 15.06 mmol, 1.00 equiv) in 1,4-dioxane (150 mL), water (25
mL), 4,6-dichloropyrimidine (5.54 g, 37.69 mmol, 2.50 equiv),
Pd(PPh.sub.3).sub.2Cl.sub.2 (500 mg, 0.75 mmol, 0.05 equiv),
triphenylarsine (460 mg, 1.50 mmol, 0.10 equiv), and
K.sub.3PO.sub.4 (4.79 g, 22.59 mmol, 1.50 equiv). The resulting
solution was stirred overnight at 75.degree. C. The resulting
mixture was concentrated under vacuum. The residue was applied onto
a silica gel column and eluted with ethyl acetate/petroleum ether
(1:10). This resulted in 2.5 g (47%) of
4-chloro-6-(2-nitro-5-(piperidin-1-yl)phenyl)pyrimidine as a yellow
solid.
Intermediate 3.1c:
6-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)
benzyl)-pyrimidin-4-amine
[0292] Into a 50-mL round-bottom flask, was placed a solution of
4-chloro-6-(2-nitro-5-(piperidin-1-yl)phenyl)pyrimidine (191 mg) in
N,N-dimethylformamide (10 mL), and 3-(trifluoromethyl)benzylamine
(210 mg). The resulting solution was stirred overnight at
50.degree. C. The resulting mixture was dissolved in 50 mL of ethyl
acetate and washed with 2.times.50 mL of water. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was purified by silica gel chromatography to give 186
mg of product as yellow oil.
Intermediate 3.1d:
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)
benzyl)-pyrimidin-4-amine
[0293] A mixture of
6-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)
benzyl)pyrimidin-4-amine (184 mg) and 5% Pd/C (35 mg) in ethanol
was stirred for 1 h under an atmosphere of hydrogen. The mixture
was filtered and the solvent was evaporated.
Intermediate 31e: tert-butyl
3-((3-((4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl)
benzyl)amino)pyrimidin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoate
[0294] A solution of
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)
benzyl)pyrimidin-4-amine (122 mg) in 1.0 mL of dichloromethane was
treated with 54 mg of tert-butyl
3-((3-(chlorocarbonyl)benzyl)thio)propanoate. The mixture was
stirred overnight. The solvent was evaporated and the residue was
purified by silica gel chromatography to give 120 mg of product as
a yellow oil.
Example 3.1
3-((3-((4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl)benzyl)
amino)-pyrimidin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoic
acid
[0295] To a solution of tert-butyl
3-((3-((4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl) benzyl)
amino)pyrimidin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoate in 1
mL of dichloroethane was added 1 mL of TFA. The mixture was stirred
1 h, and then the solvent was evaporated. The residue was purified
by chromatography on silica gel to give 100 mg of a yellow solid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.82 (s, 1H), 7.82 (s,
1H), 7.78-7.60 (m, 4H), 7.59-7.50 (m, 4H), 7.45 (t, J=7.6 Hz, 1H),
7.34-7.15 (m, 2H), 6.97 (s, 1H), 4.76 (s, 2H), 3.84 (s, 2H), 3.26
(s, 4H), 2.64-2.54 (m, 2H), 2.53-2.45 (m, 2H), 1.73-1.62 (m, 4H),
1.62-1.50 (m, 2H). MS (ES, m/z): 650.28 [M+H].sup.+.
Example 3.2
3-((3-((4-(Piperidin-1-yl)-2-(6-((3-methylbenzyl)amino)pyrimidin-4-yl)phen-
yl)carbamoyl)benzyl)thio)propanoic acid
##STR00063## ##STR00064##
[0296] Intermediate 3.2a:
N-(3-methylbenzyl)-6-(2-nitro-5-(piperidin-1-yl)phenyl)
pyrimidin-4-amine
[0297] Into a 50-mL round-bottom flask, was placed a solution of
4-chloro-6-(2-nitro-5-(piperidin-1-yl)phenyl)pyrimidine 3.1b (500
mg, 1.57 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL),
m-methylbenzylamine (285 mg, 2.36 mmol, 1.50 equiv), and potassium
carbonate (650 mg, 4.71 mmol, 3.00 equiv). The resulting solution
was stirred overnight at 80.degree. C. The solids were filtered
out. The resulting mixture was concentrated under vacuum. The
residue was dissolved in 50 mL of ethyl acetate. The resulting
mixture was washed with 2.times.50 mL of water. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column and eluted with
ethyl acetate/petroleum ether (1:5). This resulted in 0.5 g (79%)
of N-(3-methylbenzyl)-6-(2-nitro-5-(piperidin-1-yl)phenyl)
pyrimidin-4-amine as yellow oil.
Intermediate 3.2b:
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-methylbenzyl)
pyrimidin-4-amine
[0298] Into a 50-mL round-bottom flask, was placed a solution of
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-methylbenzyl)
pyrimidin-4-amine (400 mg, 0.99 mmol, 1.00 equiv) in acetic acid (5
mL). This was followed by the addition of zinc (630 mg, 9.84 mmol,
10.00 equiv) in several batches at 70.degree. C. The resulting
solution was stirred for 2 h at 60.degree. C. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
The solution was adjusted to pH 8 with aqueous ammonia (1 mol/L).
The resulting solution was extracted with 2.times.50 mL of ethyl
acetate and the organic layers combined, dried over anhydrous
sodium sulfate, and concentrated under vacuum. The residue was
applied onto a silica gel column and eluted with
dichloromethane:methanol (1:50). This resulted in 200 mg (49%) of
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-methylbenzyl)pyrimidin-4-amine
as a black solid.
Intermediate 3.2c: tert-butyl
3-((3-((4-(piperidin-1-yl)-2-(6-((3-methyl
benzyl)amino)-pyrimidin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoate
[0299] Into a 50-mL round-bottom flask, was placed a solution of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (143 mg, 0.48
mmol, 1.00 equiv) in dichloromethane (10 mL), EDC.HCl (139 mg, 0.72
mmol, 1.50 equiv), 4-dimethylaminopyridine (89 mg, 0.69 mmol, 1.50
equiv), and 6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-methylbenzyl)
pyrimidin-4-amine (180 mg, 0.48 mmol, 1.00 equiv). The resulting
solution was stirred overnight at room temperature. The resulting
mixture was concentrated under vacuum. The residue was applied onto
a silica gel column and eluted with petroleum ether/ethyl acetate
(5:1). This resulted in 200 mg (57%) of product as yellow oil.
Example 3.2
3-((3-((2-(6-((3-methylbenzyl)amino)pyrimidin-4-yl)-4-(piperidin-1-yl)-phe-
nyl)carbamoyl)benzyl)thio)propanoic acid
[0300] Into a 100-mL round-bottom flask, was placed a solution of
tert-butyl
3-(3-(2-(6-(3-methylbenzylamino)pyrimidin-4-yl)-4-(piperidin-1-yl)phenylc-
arbamoyl)benzylthio)propanoate (180 mg, 0.28 mmol, 1.00 equiv) in
dichloromethane (5 mL), and 2,2,2-trifluoroacetic acid (2 mL). The
resulting solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum. The crude product
was purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 84 mg
(51%) of a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 9.42 (s, 1H), 8.84 (s, 1H), 7.80 (s, 1H), 7.71 (m, 2H),
7.52 (m, 1H), 7.45 (m, 1H), 7.24 (m, 6H), 6.90 (s, 1H), 5.42 (s,
2H), 4.64 (m, 1H), 3.82 (s, 2H), 3.26 (m, 4H), 2.59 (m, 2H), 1.67
(m, 6H). MS (ES, m/z): 596 [M+H].sup.+.
Example 3.3
3-((3-((4-(Piperidin-1-yl)-2-(6-((3-(trifluoromethyl)phenethyl)amino)pyrim-
idin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00065##
[0302] This compound was prepared using the procedure described for
the preparation of Example 3.2, except that
3-(trifluoromethyl)phenethylamine was used in place of
3-methylbenzylamine. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm):
.delta. 8.67 (s, 1H), 7.86 (s, 1H), 7.76 (m, 2H), 7.47 (m, 9H),
6.82 (s, 1H), 3.85 (s, 4H), 3.38 (m, 4H), 3.01 (m, 2H), 2.66 (m,
2H), 2.56 (m, 2H), 1.83 (m, 4H), 1.72 (m, 2H). MS (ES, m/z): 664
[M+H].sup.+.
Example 3.4
3-((3-((2-(6-((3,4-Dimethylbenzyl)amino)pyrimidin-4-yl)-4-(piperidin-1-yl)-
phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00066##
[0304] This compound was prepared using the procedure described for
the preparation of Example 3.2, except that 3,4-dimethylbenzylamine
was used in place of 3-methylbenzylamine. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6, ppm): .delta. 8.83 (s, 1H), 7.79 (s, 1H), 7.71 (m,
2H), 7.53 (m, 1H), 7.47 (m, 1H), 7.26 (m, 2H), 7.06 (m, 2H), 6.96
(m, 1H), 6.88 (s, 1H), 4.58 (s, 2H), 3.82 (s, 2H), 3.26 (m, 4H),
2.57 (m, 2H), 2.18 (m, 6H), 1.66 (m, 6H). MS (ES, m/z): 610
[M+H].sup.+.
Example 3.5
3-((3-((2-(6-((4-Chloro-3-(trifluoromethyl)benzyl)amino)pyrimidin-4-yl)-4--
(piperidin-1-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00067##
[0306] This compound was prepared using the procedure described for
the preparation of Example 3.2, except that
4-chloro-3-(trifluoromethyl)benzylamine was used in place of
3-methylbenzylamine. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm):
.delta. 8.75 (s, 1H), 7.86 (s, 1H), 7.77 (m, 3H), 7.48 (m, 8H),
6.91 (s, 1H), 4.79 (s, 2H), 3.84 (s, 2H), 3.42 (m, 4H), 2.70 (m,
2H), 2.56 (m, 2H), 1.85 (m, 4H), 1.73 (m, 2H). MS (ES, m/z): 684
[M+H].sup.+.
Example 3.6
3-((3-((2-(6-((3,4-Dimethoxybenzyl)amino)pyrimidin-4-yl)-4-(piperidin-1-yl-
)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00068##
[0308] This compound was prepared using the procedure described for
the preparation of Example 3.2, except that
3,4-dimethoxybenzylamine was used in place of 3-methylbenzylamine.
.sup.1H-NMR (400 MHz, DMSO-d.sub.6, ppm): .delta. 8.85 (s, 1H),
7.79 (s, 1H), 7.73 (m, 2H), 7.54 (m, 1H), 7.44 (m, 1H), 7.25 (m,
1H), 7.23 (m, 1H), 6.88 (m, 2H), 6.83 (m, 1H), 6.76 (m, 1H), 4.58
(s, 2H), 4.39 (s, 1H), 3.82 (s, 2H), 3.72 (m, 3H), 3.68 (s, 3H),
3.25 (m, 4H), 2.58 (m, 2H), 1.66 (m, 4H), 1.58 (m, 2H). MS (ES,
m/z): 642 [M+H].sup.+.
Example 3.7
3-((3-((2-(6-(Benzylamino)pyrimidin-4-yl)-4-(piperidin-1-yl)phenyl)carbamo-
yl)benzyl)thio)propanoic acid
##STR00069##
[0310] This compound was prepared using the procedure described for
the preparation of Example 3.2, except that benzylamine was used in
place of 3-methylbenzylamine. 5 .sup.1H-NMR (400 MHz, DMSO d.sub.6,
ppm): .delta. 9.55 (s, 1H), 8.85 (s, 1H), 7.80 (s, 1H), 7.74 (m,
1H), 7.72 (m, 1H), 7.55 (m, 1H), 7.45 (m, 1H), 7.28 (m, 7H), 6.91
(s, 1H), 4.68 (m, 2H), 4.52 (s, 1H), 3.82 (s, 2H), 3.27 (s, 4H),
2.57 (m, 2H), 1.67 (m, 4H), 1.58 (m, 2H). MS (ES, M/Z): 582
[M+H].sup.+.
Example 3.8
3-((3-((4-(Piperidin-1-yl)-2-(6-((3-(trifluoromethyl)benzyl)oxy)pyrimidin--
4-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00070## ##STR00071##
[0311] Intermediate 3.8a:
4-(2-nitro-5-(piperidin-1-yl)phenyl)-6-((3-(trifluoromethyl)
benzyl)-oxy)pyrimidine
[0312] To a solution of 99 mg of 3-(trifluoromethyl)benzyl alcohol
in 2 mL of DMF was added 27 mg of a 50% dispersion of sodium
hydride in oil. After 15 min the solution was treated with 150 mg
of intermediate 3.1b. After an additional 2 h the reaction mixture
was partitioned between water and ethyl acetate. The organic
extracts were washed with brine and dried (Na.sub.2SO.sub.4). The
solvent was evaporated to give a yellow syrup that was used
directly in the next step.
Intermediate 3.8b: 4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl)
benzyl)oxy)pyrimidin-4-yl)aniline
[0313] All of the product from the preceding step was dissolved in
4 mL of dioxane and a solution of 410 mg of sodium dithionite and
158 mg of sodium bicarbonate in 4 mL of water was added dropwise.
After 3 h a fresh solution of 410 mg of sodium dithionite and 158
mg of sodium bicarbonate in 4 mL of water was added dropwise, and
the mixture was stirred an additional 4 h. It was partitioned
between ethyl acetate and water, and the aqueous phase was
extracted with ethyl acetate. The combined organic extracts were
washed with brine and dried (Na.sub.2SO.sub.4). The solvent was
evaporated and the residue was chromatographed on silica gel to
give 75 mg of a yellow syrup.
Intermediate 3.8c: tert-butyl
3-((3-((4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl) benzyl)
oxy)pyrimidin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoate
[0314] To a 5.degree. C. solution of 75 mg of
4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl)benzyl)oxy)pyrimidin-4-yl)an-
iline in dichloromethane was added 65 mg of intermediate 3.1a. The
mixture was stirred overnight and then the solvent was evaporated.
The residue was purified by chromatography on silica gel to give 75
mg of a yellow syrup.
Example 3.8
3-((3-((4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl)
benzyl)oxy)pyrimidin-4-yl)phenyl)carbamoyl) benzyl)thio)propanoic
acid
[0315] This compound was prepared from intermediate 3.8c using the
same procedure used to prepare Example 1.1 from intermediate 1.1k.
MS (ES, m/z): 651.1 [M+H].sup.+
Example 3.9
3-((3-((4-(Piperidin-1-yl)-2-(6-(3-(trifluoromethyl)phenoxy)pyrimidin-4-yl-
)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00072## ##STR00073##
[0316] Intermediate 3.9a:
4-(2-nitro-5-(piperidin-1-yl)phenyl)-6-(3-(trifluoromethyl)phenoxy)-pyrim-
idine
[0317] To a solution of 160 mg of 3-(trifluoromethyl)phenol in 2 mL
of DMF was added 104 mg of potassium carbonate and 160 mg of
intermediate 3.1b. After stirring overnight at 50.degree. C. the
reaction mixture was partitioned between water and ethyl acetate.
The organic extracts were washed with brine and dried
(Na.sub.2SO.sub.4). The solvent was evaporated to give a yellow
syrup that was used directly in the next step.
Intermediate 3.9b:
4-(piperidin-1-yl)-2-(6-(3-(trifluoromethyl)phenoxy)pyrimidin-4-yl)-anili-
ne
[0318] A solution of
4-(2-nitro-5-(piperidin-1-yl)phenyl)-6-(3-(trifluoromethyl)phenoxy)pyrimi-
dine in a mixture of methanol and ethyl acetate was treated with 35
mg of 5% Pd/C and stirred for 2 h under a hydrogen atmosphere. The
mixture was filtered and the solvent was evaporated. The residue
was purified by chromatography to give the product as 170 mg of a
yellow syrup.
Example 3.9
3-((3-((4-(piperidin-1-yl)-2-(6-(3-(trifluoromethyl)phenoxy)pyrimidin-4-yl-
)-phenyl)carbamoyl)benzyl)thio)propanoic acid
[0319] This compound was prepared from intermediate 3.9 using the
procedure described for the conversion of intermediate 1.1k to
Example 1.1.
Example 3.10
3-((3-((4-(Piperidin-1-yl)-2-(6-((3-(trifluoromethyl)phenyl)amino)pyrimidi-
n-4-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00074##
[0320] Intermediate 3.10a:
6-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)phenyl)-pyrimi-
din-4-amine
[0321] A solution of 15 mg of 3-(trifluoromethyl)aniline and 27 mg
intermediate 3.1b in 1 mL of DMF was treated with 1 drop of
concentrated hydrochloric acid and heated to 90.degree. C. for 1 h.
The solution was cooled and partitioned between ethyl acetate and
water. The organic extracts were washed with brine and dried over
Na.sub.2SO.sub.4. The solvent was evaporated at reduced pressure to
give 28 mg of product.
Intermediate 3.10b:
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)phenyl)-pyrimi-
din-4-amine
[0322] This compound was prepared from intermediate 3.10a using the
procedure used for the preparation of intermediate 3.9b from
intermediate 3.9a.
Example 3.10
3-((3-((4-(piperidin-1-yl)-2-(6-((3-(trifluoromethyl)phenyl)amino)-pyrimid-
in-4-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
[0323] This compound was prepared from intermediate 3.10b using the
procedure described for the preparation of Example 3.8 from
intermediate 3.8b. MS (ES, m/z): 636.3 [M+H].sup.+
Example 4.1
N1-(2-(Diethylamino)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-((3-(trif-
luoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00075## ##STR00076##
[0324] Intermediate 4.1a:
2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinic acid
[0325] Into a 50-mL round-bottom flask, was placed a solution of
methyl 2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinate 1.1g (1 g,
2.93 mmol, 1.00 equiv) in tetrahydrofuran/water (1:1) (20 mL),
lithium hydroxide hydrate (1.26 g, 30.00 mmol, 10.23 equiv). The
resulting solution was stirred overnight at 25.degree. C. in an oil
bath. The resulting mixture was concentrated under vacuum. The
resulting solution was diluted with 10 mL of water. The resulting
solution was extracted with 2.times.20 mL of ethyl acetate and the
aqueous layers combined. The solution was adjusted to pH 5 with
hydrochloric acid. The resulting solution was extracted with
2.times.50 mL of ethyl acetate and the organic layers combined,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
This resulted in 0.8 g (83%) of
2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinic acid as a yellow
solid.
Intermediate 4.1 b:
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(piperidin-1-yl)phenyl)-isonic-
otinamide
[0326] Into a 50-mL round bottom flask, was placed a solution of
2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinic acid (1 g, 3.06
mmol, 1.00 equiv) in dichloromethane (20 mL), EDC.HCl (970 mg, 5.05
mmol, 1.65 equiv), 4-dimethylaminopyridine (620 mg, 5.08 mmol, 1.66
equiv), and (3-(trifluoromethyl)phenyl)methanamine (590 mg, 3.37
mmol, 1.10 equiv). The resulting solution was stirred overnight at
25.degree. C. in an oil bath. The reaction progress was monitored
by LCMS. The mixture was concentrated under vacuum. The residue was
applied onto a silica gel column and eluted with petroleum
ether/ethyl acetate (10:1.about.3:1). This resulted in 800 mg (51%)
of
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(piperidin-1-yl)phenyl)isonico-
tinamide as a yellow solid.
Intermediate 4.1c:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)phenyl)-isonic-
otinamide
[0327] Into a 250 mL round bottom flask, was placed a solution of
1-(2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl)ethanone (1 g,
2.07 mmol, 1.00 equiv) in methanol/ethyl acetate (3:2) (35 mL). The
mixture was treated with Pd/C (10%) (1 g) and stirred under a
hydrogen atmosphere for 1.5 h at room temperature. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
This resulted in 0.9 g (96%) of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)pheny-
l)isonicotinamide as a yellow solid.
Intermediate 4.1d:
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoate
[0328] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)phenyl)-isonic-
otinamide (300 mg, 0.66 mmol, 1.00 equiv) in dichloromethane (15
mL), EDC.HCl (153 mg, 0.80 mmol, 1.21 equiv),
4-dimethylaminopyridine (96.75 mg, 0.79 mmol, 1.20 equiv), and
3-(methoxycarbonyl)benzoic acid (130.8 mg, 0.73 mmol, 1.10 equiv).
The resulting solution was stirred overnight at 25.degree. C. in an
oil bath. The reaction progress was monitored by LCMS. The
resulting solution was diluted with 50 mL of dichloromethane. The
resulting mixture was washed with 2.times.50 mL of NH.sub.4Cl aq.
and 1.times.50 mL of brine. The resulting mixture was concentrated
under vacuum. The residue was applied onto a silica gel column and
eluted with petroleum ether/ethyl acetate (3:1.about.2:1). This
resulted in 360 mg (88%) of methyl
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoate as a yellow solid.
Intermediate 4.1e:
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid
[0329] Into a 50-mL round-bottom flask, was placed a solution of
methyl
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoate (360 mg, 0.58 mmol, 1.00 equiv) in
tetrahydrofuran/water (2:3) (35 mL), and lithium hydroxide hydrate
(251.2 mg, 5.98 mmol, 10.25 equiv). The resulting solution was
stirred overnight at 25.degree. C. in an oil bath. The reaction
progress was monitored by LCMS. The resulting mixture was
concentrated under vacuum. The resulting solution was diluted with
50 mL of water adjusted to pH 2-3 with hydrogen chloride (2 mol/L).
The resulting solution was extracted with 3.times.50 mL of ethyl
acetate and the organic layers combined. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 325 mg (92%) of
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid as a yellow oil.
Example 4.1
N1-(2-(diethylamino)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-((3-(trif-
luoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0330] Into a 10-mL round bottom flask, was placed a solution of
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid (100 mg, 0.17 mmol, 1.00
equiv) in dichloromethane (5 mL), EDC.HCl (63.75 mg, 0.33 mmol,
2.00 equiv), 4-dimethylaminopyridine (40.5 mg, 0.33 mmol, 2.00
equiv), N1,N1-diethyl-N2-methylethane-1,2-diamine (64.8 mg, 0.56
mmol, 3.00 equiv). The resulting solution was stirred overnight at
25.degree. C. in an oil bath. The reaction progress was monitored
by LCMS. The resulting solution was diluted with 50 mL of
dichloromethane. The resulting mixture was washed with 3.times.70
mL of NH.sub.4Cl (aq). The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (150 mg)
was purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 47.8 mg
(34%) of a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 12.36 (s, 1H), 9.57 (t, 1H), 9.28 (s, 1H), 8.90 (d, J=5.1
Hz, 1H), 8.30 (m, 2H), 7.98 (d, J=7.2 Hz, 2H), 7.84 (d, J=4.8 Hz,
1H), 7.65 (m, 7H), 7.28 (d, J=8.4 Hz, 1H), 4.66 (d, J=6.0 Hz, 2H),
3.82 (m, 2H), 3.31 (m, 9H), 2.97 (s, 4H), 1.71 (m, 6H), 1.24 (m,
6H). MS (ES, m/z): 715 [M+H].sup.+.
Example 4.2
N1-(2-(4-((3-(Trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin--
1-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopropyl)-N3-methylisophthalam-
ide
##STR00077##
[0332] Into a 10-mL vial, was placed a solution of
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid 4.1e (80 mg, 0.13 mmol, 1.00
equiv) in dichloromethane (5 mL), EDC.HCl (51.1 mg, 0.27 mmol),
4-dimethylaminopyridine (32.4 mg, 0.27 mmol, 2.00 equiv), and
N-(2-methoxyethyl)-3-(methylamino)propanamide (31.2 mg, 0.20 mmol,
1.47 equiv). The resulting solution was stirred for 6 h at
25.degree. C. in an oil bath. The reaction progress was monitored
by LCMS. The resulting solution was diluted with 50 mL of
dichloromethane. The resulting mixture was washed with 3.times.70
mL of NH.sub.4Cl. The mixture was dried over sodium sulfate and
concentrated under vacuum. The crude product (100 mg) was purified
by reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. This yielded 50.4 mg (44%) of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopropyl)-N3-methylisophthala-
mide as a yellow solid. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6+D.sub.2O, ppm) .delta. 8.89 (d, J=5.1 Hz, 1H), 8.43
(t, 1H), 8.31 (s, 1H), 7.94 (t, J=9.3 Hz, 4H), 7.83 (m, 7H), 4.58
(s, 2H), 3.32-3.65 (m, 7H), 3.07-3.17 (m, 6H), 2.85-2.95 (m, 3H),
2.31 (s, 2H), 1.63-1.85 (m, 6H). MS (ES, m/z): 745 [M+H].sup.+.
Example 4.3
N1-(2-(2-Hydroxyethoxy)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-((3-(t-
rifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00078##
[0334] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid 4.1e using the procedure
described for the preparation of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopropyl)-N3-methylisophthala-
mide 4.2. 2-(2-(Methylamino)-ethoxy)ethanol was used as the amine
component in this coupling. .sup.1H-NMR: (300 MHz,
DMSO-d.sub.6+D.sub.2O, ppm): .delta. 9.58 (s, 1H), 8.91 (d, J=5.1
Hz, 1H), 8.46 (d, J=9 Hz, 1H), 8.36 (s, 1H), 7.87-7.96 (m, 4H),
7.545-7.689 (m, 7H), 4.61 (s, 2H), 3.29-3.49 (m, 12H), 2.97 (d,
J=21.9 Hz, 3H), 1.84 (s, 4H), 1.68 (s, 2H). MS (ES, m/z): 704
[M+H].sup.+.
Example 4.4
N1-(2-Morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)be-
nzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00079##
[0336] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid 4.1e using the procedure
described for the preparation of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopropyl)-N3-methylisophthala-
mide 4.2. 2-Morpholinoethanamine was used as the amine component in
this coupling. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm) .delta.
12.60 (s, 1H), 9.68 (s, 1H), 9.57 (t, 1H), 9.00 (d, J=5.1 Hz, 1H),
8.95 (t, 1H), 8.50 (s, 1H), 8.36 (s, 2H), 8.09 (t, 2H), 7.85 (d,
J=5.1 Hz, 1H), 7.64 (m, 6H), 7.28 (s, 1H), 4.63 (d, J=6.0 Hz, 2H),
4.02 (m, 4H), 3.69 (m, 6H), 3.43 (m, 8H), 1.65 (m, 6H). MS (ES,
m/z): 715 [M+H].sup.+.
Example 4.5
Tert-butyl
4-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl-
)benzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)piperazine-
-1-carboxylate
##STR00080##
[0338] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid 4.1e using the procedure
described for the preparation of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopropyl)-N3-methylisophthala-
mide 4.2. Tert-Butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate was used as the
amine component in this coupling. .sup.1H-NMR (300 MHz, CD.sub.3OD,
ppm): .delta. 8.98 (d, J=5.1 Hz, 1H), 8.75 (d, J=9.0 Hz, 1H), 8.46
(s, 1H), 8.18-8.11 (m, 3H), 7.89-7.53 (m, 8H), 4.72 (s, 2H),
4.00-3.11 (m, 16H), 3.08 (s, 3H), 2.04 (d, J=4.8 Hz, 4H), 1.83 (d,
J=5.7 Hz, 2H), 1.49 (s, 9H). MS (ES, m/z): 828 [M+H].sup.+.
Example 4.6
2-(2-(3-(4-Acetylpiperazine-1-carbonyl)benzamido)-5-(piperidin-1-yl)phenyl-
)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00081##
[0340] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid 4.1e using the procedure
described for the preparation of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopropyl)-N3-methylisophthala-
mide 4.2. N-Acetylpiperazine was used as the amine component in
this coupling. .sup.1H-NMR (400 MHz, DMSO-d.sub.6, ppm): .delta.
12.48 (s, 1H), 9.57 (m, 1H), 8.93 (d, J=5.2 Hz, 1H), 8.39 (d,
J=11.2 Hz, 2H), 7.99.about.7.46 (m, 11H), 4.63 (d, J=6.0 Hz, 2H),
3.55.about.3.42 (m, 12H), 2.21 (s, 3H), 1.79 (s, 4H), 1.62 (s, 2H).
MS (ES, m/z): 713 [M+H].sup.+.
Example 4.7
2-(2-(3-(4-Acetamidopiperidine-1-carbonyl)benzamido)-5-(piperidin-1-yl)phe-
nyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00082##
[0342] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure
described for the preparation of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopropyl)-N3-methylisophthala-
mide 4.2. N-(piperidin-4-yl)acetamide was used as the amine
component in this coupling. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm):
.delta. 8.98 (d, J=3.5 Hz, 1H), 8.85 (d, J=9.0 Hz, 1H), 8.47 (s,
1H), 8.24 (d, J=2.4 Hz, 1H), 8.12.about.8.09 (m, 2H),
7.90.about.7.88 (m, 1H), 7.77.about.7.68 (m, 5H), 6.62.about.7.55
(m, 2H), 4.72 (s, 2H), 4.58 (s, 1H), 3.99.about.3.93 (m, 1H),
3.73.about.3.70 (m, 5H), 3.27.about.3.12 (m, 2H), 2.09.about.2.02
(m, 5H), 1.94 (s, 3H), 1.85 (d, J=4.8 Hz, 1H), 1.60.about.1.35 (m,
2H). MS (ES, m/z): 727 [M+H].sup.+.
Example 4.8
N1-Ethyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluoro-
methyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00083##
[0344] To a mixture of 25 mg of
3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-
-2-yl)phenyl)carbamoyl)benzoic acid 4.1e, 17 mg of
diisopropylethylamine and 9 mg of N-ethyl-2-morpholineethanamine in
1 mL of DMF was added 17 mg of HATU. The mixture was stirred at
25.degree. C. for 1 h. The solution was injected onto a preparative
reverse phase HPLC and the product was eluted with 0.5% TFA in a
gradient of water and acetonitrile. The yield was 11.2 mg of
product. .sup.1H-NMR (400 MHz, DMSO-d.sub.6, ppm) .delta. 12.46 (s,
1H), 9.90 (s, 1H), 9.57 (t, J=6.1 Hz, 1H), 8.90 (d, J=5.1 Hz, 1H),
8.36, (s, 2H), 8.03-7.92 (m, 2H), 7.87 (dd, J=5.1, 1.3 Hz, 1H),
7.75-7.53 (m, 26H), 7.39 (s, 1H), 4.63 (d, J=5.8 Hz, 2H), 4.03 (s,
2H), 3.82 (s, 2H), 3.60 (s, 4H), 3.40 (d, J=23.1 Hz, 6H), 3.24 (s,
4H), 1.77 (s, 4H), 1.61 (s, 2H), 1.08 (t, J=6.5 Hz, 10H). MS (ES,
m/z): 743 [M+H].sup.+.
Example 4.9
(S)-2-(2-(3-(3-Acetamidopyrrolidine-1-carbonyl)benzamido)-5-(piperidin-1-y-
l)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00084##
[0346] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure
described for the preparation of
N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluo-
romethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide 4.8,
except that CH.sub.3CN was substituted for DMF as the reaction
solvent and (S)--N-(pyrrolidin-3-yl)acetamide was used as the amine
component. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 8.88 (d,
J=3.5 Hz, 1H), 8.69.about.8.663 (m, 1H), 8.33 (s, 1H),
8.10.about.8.05 (m, 2H), 8.00.about.7.97 (m, 1H), 7.76 (d, J=5.2
Hz, 1H), 7.71.about.7.66 (m, 1H), 7.60.about.7.43 (m, 6H), 4.60 (s,
2H), 4.40.about.4.16 (m, 1H), 3.71.about.3.21 (m, 8H),
2.22.about.1.71 (m, 11H). MS (ES, m/z): 713 [M+H].sup.+.
Example 4.10
(S)-2-(2-(3-(3-Acetamidopyrrolidine-1-carbonyl)benzamido)-5-(piperidin-1-y-
l)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00085##
[0348] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)-benzoic acid 4.1e using the procedure
described for the preparation of
N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluo-
romethyl)benzyl)carbamoyl)-pyridin-2-yl)phenyl)isophthalamide 4.8,
except that CH.sub.3CN was substituted for DMF as the reaction
solvent and (R)--N-(pyrrolidin-3-yl)acetamide was used as the amine
component. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 8.99 (d,
J=6.0 Hz, 1H), 8.70 (d, J=9.6 Hz, 1H), 8.41 (s, 1H), 8.21 (d, J=6.0
Hz, 1H), 8.12 (d, J=7.8 Hz, 1H), 8.01 (s, 1H), 7.88.about.7.78 (m,
2H), 7.72.about.7.54 (m, 6H), 4.72 (s, 1H), 4.51.about.4.28 (m,
1H), 3.91.about.3.52 (m, 8H), 2.30.about.1.79 (m, 11H). MS (ES,
m/z): 713 [M+H].sup.+.
Example 4.11
N1-Cyclopropyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(tri-
fluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00086##
[0349] Intermediate 4.11a: N-(2-morpholinoethyl)cyclopropanamine,
hydrochloride salt
[0350] A solution of 100 mg of N-(2-chloroethyl)morpholine and 307
mg of cyclopropylamine in 5 mL of CH.sub.3CN was refluxed for 2 h.
The mixture was cooled to 25.degree. C. and treated with excess
K.sub.2CO.sub.3. After stirring for 1 h the suspension was filtered
and the solvent was evaporated. The residual solvent was removed at
high vacuum and the residue was dissolved in a large excess of
methanolic HCl. The solvent was evaporated to give 102 mg of the
product.
Example 4.11
N1-cyclopropyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(tri-
fluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0351] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure
described for the preparation of
N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluo-
romethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide 4.8.
N-(2-morpholinoethyl)cyclopropanamine hydrochloride was used as the
amine component in this coupling. MS (ES, m/z): 755 [M+H].sup.+
Example 4.12
N1-Benzyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00087##
[0352] Intermediate 4.12a: N-benzyl-2-morpholineethanamine,
hydrochloride salt
[0353] A solution of 100 mg of N-(2-chloroethyl)morpholine and 575
mg of benzylamine in 5 mL of CH.sub.3CN was refluxed for 2 h. The
mixture was cooled to 25.degree. C. and partitioned between
dichloromethane and an aqueous sodium bicarbonate solution. The
organic extracts were dried and the solvent was evaporated. The
residual solvent was removed at high vacuum and the residue was
dissolved in a large excess of methanolic HCl. The solvent was
evaporated to give 60 mg of the product.
Example 4.12
N1-benzyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0354] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure
described for the preparation of
N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluo-
romethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide 4.8.
N-benzyl-2-morpholineethanamine was used as the amine component in
this coupling. MS (ES, m/z): 805 [M+H].sup.+
Example 4.13
2-(2-(3-(4-Acetyl-1,4-diazepane-1-carbonyl)benzamido)-5-(piperidin-1-yl)ph-
enyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00088##
[0355] Intermediate 4.13a: tert-butyl
4-(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)-carbamoyl)pyr-
idin-2-yl)phenyl)carbamoyl)benzol)-1,4-diazepane-1-carboxylate
[0356] This compound was prepared from
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e and tert-butyl
1,4-diazepane-1-carboxylate using the procedure used to prepare
N1-(2-(diethylamino)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-((3-(tri-
fluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)-isophthalamide
4.1.
Example 4.13
2-(2-(3-(4-acetyl-1,4-diazepane-1-carbonyl)benzamido)-5-(piperidin-1-yl)ph-
enyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0357] The Boc protecting group was removed from
2-(2-(3-(4-acetyl-1,4-diazepane-1-carbonyl)benzamido)-5-(piperidin-1-yl)p-
henyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide by treatment
with a 1:1 solution of dichloromethane and TFA. The product was
acylated using acetyl chloride and pyridine in dichloromethane as
solvent under standard conditions. .sup.1H-NMR (300 MHz,
CDCl.sub.3, ppm): .delta. 14.26 (s, 1H), 9.55 (s, 1H), 9.31 (s,
1H), 9.15 (d, J=8.4 Hz, 1H), 8.94 (s, 1H), 8.87 (d, J=4.8 Hz, 1H),
8.14.about.8.06 (m, 3H), 7.73 (s, 1H), 7.68.about.7.60 (m, 3H),
7.52.about.7.41 (m, 3H), 4.76 (d, J=5.7 Hz, 2H), 3.93.about.3.47
(m, 10H), 2.19.about.2.13 (m, 10H), 1.73 (s, 3H). MS (ES, m/z): 727
[M+H].sup.+.
Example 4.14
(S)-2-(2-(3-(3-((2-Methoxyethyl)carbamoyl)piperidine-1-carbonyl)benzamido)-
-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00089##
[0358] Intermediate 4.14a:
(S)--N-(2-methoxyethyl)piperidine-3-carboxamide
[0359] A 0.degree. C. solution of 500 mg of
(S)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid, 328 mg of
2-methoxyethylamine, 736 mg of HOBt, and 1.82 mL of triethylamine
in 9 mL of dichloromethane was treated with 836 mg of EDC.HCl. The
mixture was stirred at 25.degree. C. overnight and the solvent was
evaporated at reduced pressure. The residue was dissolved in ethyl
acetate, and the solution was sequentially washed with water, an
aqueous solution of citric acid, an aqueous sodium bicarbonate
solution, and brine. The solution was dried (Na.sub.2SO.sub.4) and
the solvent was evaporated. The residue was dissolved in a 4 M
solution of HCl in dioxane. After 1 h the mixture was evaporated to
give 406 mg of the product.
Example 4.14
(S)-2-(2-(3-(3-((2-methoxyethyl)carbamoyl)piperidine-1-carbonyl)-benzamido-
)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0360] A solution of 31.4 mg of
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e, 31.1 mg of intermediate
4.14a, 68 .mu.L of diisopropylethylamine, and 22.4 mg of HATU in
150 .mu.L of DMF was stirred for 2 h. The product was isolated by
reverse phase chromatography. MS (ES, m/z): 771.8 [M+H].sup.+
Example 4.15
(R)-2-(2-(3-(3-((2-Methoxyethyl)carbamoyl)piperidine-1-carbonyl)benzamido)-
-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00090##
[0362] This compound was prepared using the methods described in
Example 4.14. MS (ES, m/z): 771.8 [M+H].sup.+
Example 4.16
2-(2-(3-(((3-((2-Morpholinoethyl)amino)-3-oxopropyl)thio)methyl)benzamido)-
-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00091##
[0364] A solution of 25 mg of
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)benzylthio)propanoic acid 1.1, 19 mg of
diisopropylethylamine, and 6 mg of 2-morpholinoethylamine in 1 mL
of DMF was treated with 15 mg of HATU and stirred for 24 h. The
product was isolated by reverse phase HPLC eluting with 0.05% TFA
in a water/acetonitrile gradient to give 11.3 mg of product. MS
(ES, m/z): 789 [M+H].sup.+
Example 4.17
2-(2-(3-(((3-((2-Methoxyethyl)amino)-3-oxopropyl)thio)methyl)benzamido)-5--
(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00092##
[0366] This compound was prepared using the procedure described for
the preparation of
2-(2-(3-(((3-((2-morpholinoethyl)amino)-3-oxopropyl)thio)methyl)benzamido-
)-5-(piperidin-1-yl)-phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
4.16, using 2-methoxyethylamine in place of 2-morpholinoethylamine.
MS (ES, m/z): 734 [M+H].sup.+
Example 4.18
2-(3-((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)p-
yridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanamido)acetic
acid
##STR00093##
[0368] Tert-butyl glycinate was coupled to
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)-benzylthio)propanoic acid 1.1 using the
procedure described for the synthesis of
2-(2-(3-(((3-((2-morpholinoethyl)amino)-3-oxopropyl)thio)methyl)benzamido-
)-5-(piperidin-1-yl)-phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
4.16. This material was dissolved in 2 mL of 1:1
dichloromethane/TFA and stirred for 1 h. The solvent was evaporated
to give 4.6 mg of product. MS (ES, m/z): 734 [M+H].sup.+
Example 4.19
2-(2-(3-(29-Hydroxy-5-oxo-9,12,15,18,21,24,27-heptaoxa-2-thia-6-azanonacos-
yl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isoni-
cotinamide
##STR00094##
[0370] A solution of 50 mg of
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)benzylthio)propanoic acid 1.1, 57 mg of
diisopropylethylamine, 27 mg of
23-amino-3,6,9,12,15,18,21-heptaoxatricosan-1-ol, 18 mg of EDCI,
and 19 mg of HOBt in 2 mL of DMF was stirred for 24 h. The product
was isolated by reverse phase HPLC eluting with 0.05% TFA in a
water/acetonitrile gradient to give 5.1 mg of product. MS (ES,
m/z): 1028 [M+H].sup.+
Example 4.20.1
N1-Methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00095##
[0372] This compound was prepared by coupling
N-methyl-2-morpholinoethylamine to
3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-
-2-yl)phenyl)-carbamoyl)benzoic acid 4.1e, using the procedure
described for the preparation of
N1-ethyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)-carbamoyl)pyridin-2-yl)phenyl)isophthalamide 4.8.
MS (ES, m/z): 743 [M+H].sup.+
Example 4.20.2
N1-(2-((2-Methoxyethyl)(methyl)amino)ethyl)-N1-methyl-N3-(4-(piperidin-1-y-
l)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophtha-
lamide
##STR00096##
[0373] Intermediate 4.20a:
N1-(2-chloroethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluorome-
thyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0374] A solution of 50 mg of
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e, 9.3 mg of
N-methyl-N-(2-chloroethyl)amine hydrochloride, 43 .mu.L of
diisopropylethylamine, and 35 mg of HATU in 1000 .mu.L of DMF was
stirred for 1 h. The mixture was diluted with 20 mL of water, and
the resulting precipitate was collected by filtration. It was
dissolved in dichloromethane and the solution was washed with water
and dried (Na.sub.2SO.sub.4). The solvent was evaporated to give 42
mg of product.
Example 4.20.2
N1-(2-((2-methoxyethyl)(methyl)amino)ethyl)-N1-methyl-N3-(4-(piperidin-1-y-
l)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)-isophth-
alamide
[0375] A mixture of 21 mg of
N1-(2-chloroethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluorome-
thyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide 4.20a and
4.1 mg of N-methyl-2-(methoxyethyl)amine in 1 mL of acetonitrile
was refluxed for 2 h. The product was isolated by reverse phase
HPLC, eluting with 0.05% TFA in a water/acetonitrile gradient to
give 18.8 mg. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 12.34 (s,
1H), 9.55 (t, J=6.0 Hz, 1H), 9.40 (s, 1H), 8.90 (d, J=5.0 Hz, 1H),
8.33 (s, 1H), 8.28 (d, J=7.3 Hz, 1H), 8.05-7.93 (m, 2H), 7.84 (d,
J=5.1 Hz, 1H), 7.75-7.54 (m, 6H), 7.25 (s, 1H), 4.63 (d, J=5.9 Hz,
2H), 3.88-3.81 (m, 2H), 3.75-3.66 (m, 2H), 3.64-3.55 (m, 2H),
3.56-3.42 (m, 2H), 3.42-3.22 (m, 7H), 3.01-2.88 (m, 6H), 1.80-1.66
(m, 4H), 1.58 (s, 2H). MS (ES, m/z): 727 [M+H].sup.+.
Example 4.21
N1-(2-((2-Hydroxyethyl)(methyl)amino)ethyl)-N1-methyl-N3-(4-(piperidin-1-y-
l)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophtha-
lamide
##STR00097##
[0377] This compound was prepared by the procedure described for
the preparation of
N1-(2-((2-methoxyethyl)(methyl)amino)ethyl)-N1-methyl-N3-(4-(piperidin-1--
yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophth-
alamide 4.20.2, using 2-(methylamino) ethanol in place of
N-methyl-2-(methoxyethyl)amine. MS (ES, m/z): 717 [M+H].sup.+.
Examples 4.22 Through 4.30
[0378] The compounds in the Table 2 were prepared by the following
procedure: A 60.degree. C. solution of 20 mg of
3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)carbamoyl)benzoic acid 4.1e, 1.2 equivalents of the
requisite amine, 14.4 mg of HATU, and 28.3 mg of
diisopropylethylamine in 150 .mu.L of DMF was stirred for 1 h. The
product was isolated by reverse phase HPLC, eluting with 0.05% TFA
in a gradient of water/acetonitrile.
##STR00098##
TABLE-US-00003 TABLE 2 Example No. RR'NH Mass Spectrum 4.22
##STR00099## 759.45 [M + H] 4.23 ##STR00100## 755.29 [M + H] 4.24
##STR00101## 696.13 [M + H] 4.25 ##STR00102## 710.22 [M + H] 4.26
##STR00103## 710.19 [M + H] 4.27 ##STR00104## 707.26 [M + H] 4.28
##STR00105## 710.16 [M + H] 4.29 ##STR00106## 714.56 [M + H] 4.30
##STR00107## 700.53 [M + H]
Example 4.31
2-(1-(3-(4-(Piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyrid-
in-2-yl)phenylcarbamoyl)benzoyl)piperidin-4-yl)acetic acid
##STR00108##
[0380] To a mixture of 20 mg of
3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)-benzyl)carbamoyl)pyridi-
n-2-yl)phenyl)carbamoyl)benzoic acid 4.1e, 28 mg of
diisopropylethylamine, and 6.5 mg of ethyl
2-(piperidin-4-yl)acetate in 1 mL of DMF was added 17 mg of HATU.
The mixture was stirred at 60.degree. C. for 1 h. The solution was
diluted with water and extracted with ethyl acetate. The organic
phase was washed with water, then brine. It was dried and the
solvent was evaporated at reduced pressure. It was dissolved in 4:1
methanol/water and treated with 19.4 mg of LiOH.H.sub.2O. After
stirring for 20 h the product was isolated by reverse phase HPLC,
eluting with 0.5% TFA in a gradient of water and acetonitrile to
give 10.9 mg of product. MS (ES, m/z): 728.7 [M+H].sup.+.
Example 4.32
3-((N-Methyl-3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)benzamido)methyl)benzoic acid
##STR00109##
[0382] This compound was prepared using the procedure described for
the preparation of Example 4.31, using
3-((methylamino)methyl)benzoic acid methyl ester as the amine
component. MS (ES, m/z): 750.5 [M+H].sup.+.
Examples 5.1 and 6.1
3-((3-((2-(4-(3-Phenylpropanoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)car-
bamoyl)benzyl)thio)propanoic acid and
3-((3-((2-(4-(1-hydroxy-3-phenylpropyl)pyridin-2-yl)-4-(piperidin-1-yl)ph-
enyl)carbamoyl)benzyl)thio)propanoic acid
##STR00110##
[0383] Intermediate 5.1a:
1-(2-bromopyridin-4-yl)-3-phenylpropan-1-one
[0384] 1.0 mL of 1.0 N phenyethylmagnesium chloride in THF was
added dropwise to a -78.degree. C. solution of 200 mg of
2-bromo-N-methoxy-N-methylisonicotinamide in 6 mL of THF. The
solution was allowed to warm to 25.degree. C. After 10 minutes the
solution was cooled back to -78.degree. C. and an additional 1.0 mL
of 1.0 N phenylmagnesium chloride in THF was added. The mixture was
warmed to 25.degree. C. and after 10 minutes 10 mL of 1.0 N
hydrochloric acid was added. The solution was then made basic with
excess aqueous sodium hydroxide solution and the mixture was
partitioned between ethyl acetate and water. The aqueous phase was
washed with ethyl acetate and the combined organic extracts were
dried over sodium sulfate. The solvent was evaporated and the
residue was chromatographed on silica gel to give 168 mg of
product.
Intermediate 5.1b:
1-(2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-phenylpropan-1-one
[0385] A solution of 200 mg of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
phenyl)piperidine 1.1e, 168 mg of
1-(2-bromopyridin-4-yl)-3-phenylpropan-1-one 5.1a, 12 mg of
Pd(OAc).sub.2, 58 mg of PPh.sub.3 in 1.25 mL of 2 N aqueous
Na.sub.2CO.sub.3 solution and 3 mL of dimethoxyethane was refluxed
for 4 h. The mixture was diluted with ethyl acetate and washed with
water twice. The combined organic layer was dried over
Na.sub.2SO.sub.4 and the solvent was evaporated. The residue was
chromatographed on silica gel eluting with a gradient of 0% to 7%
ethyl acetate in dichloromethane to give 196 mg of product.
Intermediates 5.1c:
1-(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-phenylpropan-1-one
and
1-(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-phenylpropan-1-
-ol
[0386] This mixture was prepared using the procedure described for
the conversion of
6-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)
benzyl)pyrimidin-4-amine 3.1c to
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)
benzyl)pyrimidin-4-amine 3.1d. After chromatography on silica gel,
95 mg of a mixture of starting material,
1-(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-phenylpropan-1-one
and
1-(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-phenylpropan-1-
-ol was obtained.
Examples 5.1 and 6.1
3-((3-((2-(4-(3-phenylpropanoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)car-
bamoyl)benzyl)thio)propanoic acid and
3-((3-((2-(4-(1-hydroxy-3-phenylpropyl)pyridin-2-yl)-4-(piperidin-1-yl)ph-
enyl)carbamoyl)benzyl)thio)propanoic acid
[0387] The mixture of products from the previous synthetic step was
converted to a mixture containing
3-((3-((2-(4-(3-phenylpropanoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)-c-
arbamoyl)benzyl)thio)propanoic acid 5 and
3-((3-((2-(4-(1-hydroxy-3-phenylpropyl)pyridin-2-yl)-4-(piperidin-1-yl)ph-
enyl)carbamoyl)benzyl)thio)propanoic acid 6 using intermediate 3.1a
and following procedures described in the preparation of Example
3.1. These two examples were isolated from the mixture by
chromatography on silica gel, eluting with a gradient of 0% to 20%
ethyl acetate in dichloromethane. Each product was then further
purified by reverse phase HPLC. The mass spectrum (ES) of
3-((3-((2-(4-(3-phenylpropanoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)ca-
rbamoyl)benzyl)-thio)propanoic acid 5 exhibited m/z=608.3
[M+H].sup.+. The mass spectrum (ES) of
3-((3-((2-(4-(1-hydroxy-3-phenylpropyl)pyridin-2-yl)-4-(piperidin-1-yl)ph-
enyl)carbamoyl)-benzyl)thio)propanoic acid 6 exhibited m/z=610.3
[M+H].sup.+.
Example 5.2
N1-Benzyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00111## ##STR00112##
[0388] Intermediate 5.2a:
2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinaldehyde
[0389] A mixture of 200 mg of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)
phenyl)piperidine 1e, 85 mg of 2-chloroisonicotinaldehyde, 6.7 mg
of Pd(OAc).sub.2, 31 mg of PPh.sub.3, 1.25 mL of 2 N aqueous
Na.sub.2CO.sub.3 solution, and 3 mL of DME were refluxed 2 h. The
mixture was diluted with ethyl acetate and washed 3.times. with
water. The organic extracts were washed with brine and dried
(Na.sub.2SO.sub.4). The solvent was evaporated and the residue was
chromatographed on silica gel eluting with 10% ethyl acetate in
dichloromethane. This gave 114 mg of product. MS (ES, m/z): 312.0
[M+H].sup.+.
Intermediate 5.2b:
(2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)-ph-
enyl)methanol
[0390] To a -78.degree. solution of 110 mg of
2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinaldehyde in 4 mL of
THF was added 0.82 mL of a 1.0 M solution of
3-(trifluoromethyl)phenylmagnesium chloride in THF. After 5 min the
solution was warmed to 0.degree. C. and treated with 10 mL of a
saturated aqueous solution of NaHCO.sub.3. The mixture was
extracted with ethyl acetate and the organic extracts were washed
with water and then with brine. The solution was dried
(Na.sub.2SO.sub.4) and the solvent was evaporated. The residue was
purified by silica gel chromatography eluting with 1:1 ethyl
acetate/hexanes to give 123 mg of product. MS (ES, m/z) 458.2
[M+H].sup.+.
Intermediate 5.2c:
(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)-ph-
enyl)methanol
[0391] A mixture of 123 mg of
(2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phe-
nyl)methanol 5.2b, 30 mg of moist 10% Pd/C, and 3 mL of methanol
was stirred under a hydrogen atmosphere for 5 h. The mixture was
filtered and the solvent was evaporated to provide 1.05 mg of
product. MS (ES, m/z) 428.2 [M+H].sup.+.
Intermediate 5.2d: tert-butyl
3-((3-((2-(4-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-pyridin-2-yl)-4-(-
piperidin-1-yl)phenyl)carbamoyl)benzyl)thio)propanoate
[0392] A solution of 54 mg of
(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phe-
nyl)-methanol 5.2c, and 41 mg of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c, 67 mg
of diisopropylethylamine in 1.5 mL of DMF was treated with 57 mg of
HATU. After stirring at 60.degree. C. for 2 h the mixture was
diluted with ethyl acetate and washed once with a saturated aqueous
solution of sodium bicarbonate, three times with water, and once
with brine. After drying (Na.sub.2SO.sub.4) the solvent was
evaporated to give 107 mg of product. MS (ES, m/z) 706.2
[M+H].sup.+.
Intermediate 5.2e: tert-butyl
3-((3-((4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzoyl)-pyridin-2-yl-
)phenyl)carbamoyl)benzyl)thio)propanoate
[0393] A -10.degree. C. solution of 23 mg of tert-butyl
3-((3-((2-(4-(hydroxy(3-(trifluoromethyl)phenyl)methyl)pyridin-2-yl)-4-(p-
iperidin-1-yl)phenyl)carbamoyl)benzyl)thio)propanoate 5.2d, 17 mg
of diisopropylethylamine, and 10 mg of DMSO in 0.4 mL of
dichloromethane was treated with 10 mg of pyridine sulfur trioxide
complex. After stirring for 1 h the reaction mixture was applied
directly to a silica gel column and eluted with a gradient of 0% to
10% ethyl acetate in dichloromethane. Evaporation of the solvent
yielded 9.5 mg of product. MS (ES, m/z) 704.2 [M+H].sup.+.
Example 5.2
3-((3-((4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzoyl)pyridin-2-yl)p-
henyl)carbamoyl)benzyl)thio)propanoic acid
[0394] A solution of 9.5 mg of
3-((3-((4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzoyl)pyridin-2-yl)-
phenyl)carbamoyl)benzyl)-thio)propanoate. 5.2e in 600 .mu.L of 1:1
dichloromethane/TFA was stirred 45 minutes and then the solvent was
evaporated. The residue was purified by reverse phase
chromatography eluting with a water/acetonitrile gradient
containing 0.05% TFA to afford 5 mg of product. .sup.1H-NMR (400
MHz, CD.sub.3OD, ppm) .delta. 9.10 (d, J=5 Hz, 1H), 8.75 (d, J 9
Hz, 1H), 8.28 (s, 1H), 8.18 (s, 1H), 8.10-8.05 (m, 2H), 7.99-8.02
(m, 3H), 7.87 (d, J=8 Hz, 1H), 7.76-7.71 (m, 3H), 7.58 (d, J 8 Hz,
1H), 7.49 (d, J=8 Hz, 1H), 3.89 (s, 2H), 3.70-3.60 (m, 4H), 2.70
(t, J=7 Hz, 2H), 2.55 (t, J=7 Hz, 2H), 2.10-2.00 (m, 4H), 1.85-1.75
(m, 2H). .sup.19F-NMR analysis revealed the presence of two peaks
at .delta.-64 and .delta. -77 in a 1:2 ratio, suggesting that the
compound was isolated as a salt containing two equivalents of TFA.
MS (ES, m/z) 648.3 [M+H].sup.+.
Example 6.2
3-((3-((2-(4-(Hydroxy(3-(trifluoromethyl)phen
1)methyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzyl)thio)pro-
panoic acid
##STR00113##
[0396] This compound was prepared from
(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phe-
nyl)methanol 5.2c using the procedures described in Example 5.2,
but omitting the oxidation step (Step 5.2e). MS (ESI, m/z) 650.3
[M+H].sup.+.
Example 7
3-((3-((4-(Piperidin-1-yl)-2-(4-(((3-(trifluoromethyl)benzyl)amino)methyl)-
pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00114##
[0397] Intermediate 7a: tert-butyl
((2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl)methyl)(3-(trifluorome-
thyl)benzyl)carbamate
[0398] A solution of 120 mg of
2-(2-nitro-5-(piperidin-1-yl)phenyl)isonicotinaldehyde 5.2a and 70
mg of 3-(trifluoromethyl)benzylamine in 4 mL of dichloromethane was
treated with 207 mg of NaBH(OAc).sub.3. After 17 h the mixture was
diluted with 10 mL of a saturated aqueous solution of sodium
bicarbonate. The phases were separated and the aqueous phase was
washed 3 times with dichloromethane. The combined organic extracts
were dried (Na.sub.2SO.sub.4), and the solvent was evaporated to
give 220 mg of a product giving MS (ES, m/z) 471.2 [M+H].sup.+. The
product was dissolved in 3 mL of dichloromethane and treated with
109 mg of Boc.sub.2O and stirred for 17 h. The solvent was
evaporated and the product was purified by silica gel
chromatography to give 93 mg of tert-butyl
((2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl)methyl)(3-(trifluorome-
thyl)-benzyl)carbamate 7a.
Intermediate 7b: tert-butyl
((2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)methyl)(3-(trifluorome-
thyl)benzyl)carbamate
[0399] This compound was prepared using the procedure described for
the conversion of
(2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phe-
nyl)methanol 5.2b to
2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phen-
yl)methanol 5.2c. MS (ES, m/z) 541.2 [M+H].sup.+.
Example 7
3-((3-((4-(piperidin-1-yl)-2-(4-(((3-(trifluoromethyl)benzyl)amino)
methyl)-pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic
acid
[0400] This compound was prepared using the procedure described for
the preparation of
3-((3-((4-(piperidin-1-yl)-2-(6-(3-(trifluoromethyl)phenoxy)pyrimidin-4-y-
l)phenyl)carbamoyl)benzyl)thio)propanoic acid 3.9 from
4-(piperidin-1-yl)-2-(6-(3-(trifluoromethyl)phenoxy)pyrimidin-4-yl)anilin-
e 3.9b. MS (ES, m/z) 662.2 [M+H].sup.+.
Example 8.1
3-((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyri-
din-2-yl)phenyl)carbamoyl)benzyl)thio)benzoic acid
##STR00115##
[0401] Intermediate 8.1a.
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)isonicotinamide
[0402] 3-(Chloromethyl)benzoyl chloride was added dropwise to a
0.degree. C. solution of 900 mg of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)phenyl)isonico-
tinamide 4.1c 1.02 g of diisopropylethylamine in 10 mL of a 1:1
mixture of dichloromethane and THF. The mixture was warmed to
25.degree. C. and stirred for 1 h, after which it was washed five
times with aqueous hydrochloric acid, once with a saturated aqueous
solution of sodium bicarbonate, and once with water. The solution
was dried and the solvent was evaporated to give 1.24 g of product
as a yellow solid.
Example 8.1
3-((3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)-pyr-
idin-2-yl)phenyl)carbamoyl)benzyl)thio)benzoic acid
[0403] A mixture of 250 mg of
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)-isonicotinamide 8.1a, 70 mg of 3-mercaptobenzoic
acid, 10 mL of acetone, and 171 mg of K.sub.2CO.sub.3 was stirred
for 16 h and then filtered. The solvent was removed by evaporation.
The residue was dissolved in dichloromethane and the resulting
solution was washed with aqueous hydrochloric acid. The solution
was dried, and the solvent was evaporated. The residue was purified
by silica gel chromatography to give 113 mg of product. MS (ES,
m/z) 725 [M+H].sup.+.
Examples 8.2 Through 8.24
[0404] The compounds presented in Table 3 were prepared as follows:
A mixture of
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)-isonicotinamide 8.1a (0.05 mmol), the requisite
thiol (0.055 mmol), and K.sub.2CO.sub.3 in 500 .mu.L of DMF were
stirred for 18 h under nitrogen. The mixture was filtered, and the
filtrate was purified by reverse-phase HPLC eluting with a
water/acetonitrile gradient containing 0.1% TFA. The purity and
identity of the products was confirmed by LCMS (Table 3) and
.sup.1H NMR (data not shown).
##STR00116##
TABLE-US-00004 TABLE 3 Example Mass No. R Spectrum 8.2
--SCH.sub.2CH.sub.2OH 649.30 [M + H] 8.3
--SCH.sub.2CH.sub.2CH.sub.2OH 663.31 [M + H] 8.4
--SCH.sub.2CH.sub.2CH.sub.2CH.sub.2OH 677.32 [M + H] 8.5
--SCH.sub.2CH.sub.2CH.sub.2COOH 691.33 [M + H] 8.6
--SC(CH.sub.3).sub.2COOH 691.32 [M + H] 8.7
--S(CH.sub.2CH.sub.2O).sub.4CH.sub.2CH.sub.2COOH 853.55 [M + H] 8.8
##STR00117## 753.33 [M + H] 8.9 ##STR00118## 767.35 [M + H] 8.10
##STR00119## 792.14 [M + H] 8.11 ##STR00120## 762.32 [M + H] 8.12
##STR00121## 762.33 [M + H] 8.13 --SCH.sub.2CH.sub.2SO.sub.3Na
713.29 [M + H] 8.14 ##STR00122## 743.25 [M + H] 8.15 ##STR00123##
726.27 [M + H] 8.16 ##STR00124## 760.18 [M + H] 8.17 ##STR00125##
739.32 [M + H] 8.18 ##STR00126## 739.32 [M + H] 8.19 ##STR00127##
767.33 [M + H] 8.20 ##STR00128## 781.40 [M + H] 8.21 ##STR00129##
803.44 [M + H] 8.22
--SCH.sub.2CH.sub.2(OCH.sub.2CH.sub.2).sub.8COOH 1029 [M + H] 8.23
##STR00130## 725 [M + H] 8.24 ##STR00131## 725 [M + H]
Example 8.25
3-(3-(4-Chloro-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)pheny-
lcarbamoyl)benzylthio)benzoic acid
##STR00132##
[0406] A mixture of 173 mg of
2-(5-chloro-2-(3-(chloromethyl)benzamido)phenyl)-N-(3-(trifluoromethyl)be-
nzyl)isonicotinamide, which was made from intermediate 21b in a
similar manner as the synthesis of 8.1a, 52 mg of 3-mercaptobenzoic
acid, and 128 mg of K.sub.2CO.sub.3 in 2 mL of DMF was stirred for
2 h and then poured into 20 mL of water. The solution was acidified
with hydrochloric acid. A precipitate formed and was collected by
filtration and dried. The resulting solid was dissolved in acetone
and filtered. Evaporation of the solvent gave 92 mg of product. MS
(ES, m/z) 676 [M+H].sup.+.
Example 8.26
3-((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyri-
din-2-yl)phenyl)carbamoyl)benzyl)sulfonyl)benzoic acid
##STR00133##
[0408] A solution of 25 mg of
3-((3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyr-
idin-2-yl)phenyl)carbamoyl)benzyl)thio)benzoic acid 8.25 in 2 mL of
a 2:1:1 mixture of THF, methanol, and water was treated with 110 mg
of Oxone.RTM.. The mixture was stirred for 2 h and then it was
diluted with ethyl acetate. The organic phase was washed with
water, which caused a precipitate to form. The precipitate was
redissolved by adding methanol. The organic phase was separated and
filtered. Evaporation of the solvent gave a white solid. This solid
was dissolved in methanol and treated with 5 mg of 5% Pd/C. The
mixture was stirred under a hydrogen atmosphere for 15 minutes, and
then it was filtered. The solvent was evaporated and the residue
was purified by reverse phase HPLC, eluting with 0.05% TFA in a
water/acetonitrile gradient. The process yielded 8.6 mg of product.
MS (ES, m/z) 757 [M+H].sup.+.
Example 8.27
3-((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyri-
din-2-yl)phenyl)carbamoyl)benzyl)thio)benzoic acid
##STR00134##
[0410] A mixture of 20 mg of
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)isonicotinamide 8.1a, 4.6 mg of
4-(hydroxymethyl)piperidine, and 9.1 mg of K.sub.2CO.sub.3 in 2 mL
of DMF was stirred for 12 h. The product (12 mg) was isolated by
reverse phase chromatography eluting with 0.05% TFA in a
water/acetonitrile gradient. MS (ES, m/z) 686.3 [M+H].sup.+.
Example 8.28
2-(2-(3-((4-(2-Hydroxyethyl)piperidin-1-yl)methyl)benzamido)-5-(piperidin--
1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00135##
[0412] A mixture of 20 mg of
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)isonicotinamide 8.1a, 5.2 mg of
2-(piperidin-4-yl)ethanol, and 9.1 mg of K.sub.2CO.sub.3 in 2 mL of
DMF was stirred for 12 h. The product was isolated by reverse phase
chromatography eluting with 0.05% TFA in a water/acetonitrile
gradient. MS (ES, m/z) 700.27 [M+H].sup.+.
Example 9.1
1-(3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyrid-
in-2-yl)phenyl)carbamoyl)benzyl)-1H-indole-4-carboxylic acid
##STR00136##
[0414] A mixture of 10.5 mg of methyl 1H-indole-4-carboxylate, 18.2
mg of
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)-isonicotinamide 8.1a, and excess potassium
carbonate in 300 .mu.L of DMF was stirred for 24 h. The solvent was
evaporated and the residue was purified by silica gel
chromatography. The product was dissolved in 1 mL of 4:1 THF/water
and treated with 10 mg of LiOH.H.sub.2O. After stirring 4 days at
70.degree. C. the reaction mixture was acidified with 3.0 N
hydrochloric acid and then extracted with ethyl acetate. The
aqueous phase was washed with ethyl acetate, and the combined
organic extracts washed with brine and dried (NaSO.sub.4). The
residue was purified by reverse phase HPLC eluting with 0.1% TFA in
a water/acetonitrile gradient to give 10.6 mg of product. MS (ES,
m/z) 732.4 [M+H].sup.+.
Example 9.2
1-Oxo-1-(1-(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbam-
oyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)-1H-indol-4-yl)-5,8,11-trioxa-2-a-
zatetradecan-14-oic acid
##STR00137##
[0416] A mixture of 3 mg of
1-(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)-benzyl)carbamoyl)pyr-
idin-2-yl)phenyl)carbamoyl)benzyl)-1H-indole-4-carboxylic acid 9.1,
1.7 mg of 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoic acid, and
2.5 mg of HATU in 300 .mu.L of DMF was treated with 1.5 .mu.L of
diisopropylethylamine. After 2 h the solvent was evaporated and the
residue was partitioned between ethyl acetate and water. The
aqueous phase was washed with ethyl acetate, and the combined
organic extracts were washed with brine and dried
(Na.sub.2SO.sub.4). The solvent was evaporated and a fraction of
the product was dissolved in 1:1 dichloromethane/TFA. After
stirring for 1 h the solvent was evaporated and the residue was
purified by reverse phase HPLC eluting with 0.05% TFA in a
water/acetonitrile gradient to yield 1.4 mg of the title compound.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 12.62 (s, 1H), 9.57 (t,
J=5.7 Hz, 1H), 8.98 (d, J=5.1 Hz, 1H), 8.51 (d, J=8.7 Hz, 1H), 8.40
(s, 1H), 7.93 (s, 1H), 7.89 (d, J=5.1 Hz, 1H), 7.78 (d, J=7.4 Hz,
1H), 7.72 (s, 1H), 7.65 (m, 2H), 7.60-7.52 (m, 3H), 7.48 (t, J=7.7
Hz, 1H), 7.24-7.14 (m, 3H), 7.03-6.94 (m, 1H), 4.64 (d, J=5.8 Hz,
2H), 4.36 (s, 2H), 3.47 (s, 4H), 2.15 (t, J=7.3 Hz, 2H), 1.83 (br,
4H), 1.81-1.67 (m, 2H), 1.64 (br, 2H). MS (ES, m/z) 935.32
[M+H].sup.+
Example 9.3
3-(((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyr-
idin-2-yl)phenyl)carbamoyl)benzyl)thio)methyl)benzoic acid
##STR00138##
[0417] Intermediate 9.3a: 3,3'-(thiobis(methylene))dibenzoic
acid
[0418] A mixture of 284 .mu.L of 3-(chloromethyl)benzoyl chloride,
78 mg of Na.sub.2S, 36 .mu.L of water, and 276 mg K.sub.2CO.sub.3
in DMF was stirred 18 h at RT The mixture was filtered and the
solvent was evaporated at reduced pressure. The residue was
triturated with dichloromethane to give 100 mg of product.
Example 9.3
3-(((3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)-py-
ridin-2-yl)phenyl)carbamoyl)benzyl)thio)methyl)benzoic acid
[0419] A solution of 15 mg of thiobis(methylene))dibenzoic acid
9.3a, 7.5 mg of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)phenyl)i-
sonicotinamide. 4.1c, and 17 mg of HATU in DMF was treated with 26
.mu.L of diisopropylethylamine. After 18 h the product was isolated
by reverse phase HPLC, eluting with 0.05% TFA in a
water/acetonitrile gradient. The procedure gave 7.5 mg of product.
MS (ES, m/z) 739.3 [M+H].sup.+.
Example 10.1
1-Oxo-1-(3-(((3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carb-
amoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)methyl)phenyl)-5,8,11-trio-
xa-2-azatetradecan-14-oic acid
##STR00139## ##STR00140##
[0420] Intermediate 10.1b: tert-butyl
1-oxo-1-(3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)-benzylcarbamo-
yl)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-5,8,11-trioxa-2-azatetr-
adecan-14-oate
[0421] A solution of 25 mg of
3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)-benzylcarbamoyl)pyridi-
n-2-yl)phenylcarbamoyl)benzylthio)benzoic acid 8.1, 12 mg of
tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate, and
17.8 mg of diisopropylethylamine in 1 mL of DMF was treated with 15
mg of HATU. The mixture was stirred for 1 h and then the product
was isolated by reverse phase HPLC eluting with 0.05% TFA in a
water/acetonitrile gradient.
Example 10.1
1-oxo-1-(3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzyl-carbamoy-
l)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-5,8,11-trioxa-2-azatetra-
decan-14-oic acid
[0422] tert-Butyl
1-oxo-1-(3-(((3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)-ca-
rbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)methyl)-phenyl)-5,8,11-t-
rioxa-2-azatetradecan-14-oate 10.1b from the previous step was
dissolved in 1 mL of 1:1 dichloromethane/TFA. After 45 minutes the
solvent was evaporated in a stream of nitrogen and the residue was
dissolved in 1:1 acetonitrile/water. Lyophilization gave 18 mg of
product. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.94 (d, J=5.2
Hz, 1H), 8.81 (d, J=9.2 Hz, 1H), 8.43 (s, 1H), 8.15 (s, 1H), 7.96
(s, 1H), 7.88-7.83 (m, 2H), 7.82 (t, J=1.8 Hz, 1H), 7.73-7.70 (m,
2H), 7.67 (d, J=7.4 Hz, 1H), 7.64-7.60 (m, 1H), 7.60-7.54 (m, 3H),
7.52-7.44 (m, 2H), 7.34 (t, J=7.8 Hz, 1H), 4.72 (d, J=4.2 Hz, 2H),
4.34 (s, 2H), 3.72-3.68 (m, 4H), 3.65 (t, J=6.3 Hz, 2H), 3.61-3.55
(m, 8H), 3.54-3.48 (m, 4H), 2.47 (t, J=6.3 Hz, 2H), 2.10-2.02 (m,
4H), 1.82 (s, 2H). MS (ES, m/z) 928 [M+H].sup.+
Examples 10.2 Through 10.8
[0423] The compounds presented in Table 4 were prepared using the
procedure described for the preparation of intermediate 10.1a
##STR00141##
TABLE-US-00005 TABLE 4 Example No. R Mass Spectrum 10.2
##STR00142## 835 [M + H] 10.3 ##STR00143## 807 [M + H] 10.4
##STR00144## 821 [M + H] 10.5 ##STR00145## 782 [M + H] 10.6
##STR00146## 837 [M + H] 10.7 ##STR00147## 851 [M + H] 10.8
##STR00148## 837 [M + H]
Examples 10.9 Through 10.12
[0424] The compounds presented in Table 5 were prepared using the
method described for the synthesis of
1-oxo-1-(3-(((3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)-ca-
rbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)methyl)phenyl)-5,8,11-tr-
ioxa-2-azatetradecan-14-oic acid 10.1 from
3-(((3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)py-
ridin-2-yl)phenyl)carbamoyl)benzyl)thio) methyl)-benzoic acid 9.3.
The products were assayed by NMR and LCMS to confirm identity and
purity.
##STR00149##
TABLE-US-00006 TABLE 5 Example No. R Mass Spectrum 10.9
--NHCH.sub.2COOH 782 [M + H] 10.10 ##STR00150## 836 [M + H] 10.11
--NH(CH.sub.2).sub.3COOH 810 [M + H] 10.12 --NH(CH.sub.2).sub.2COOH
796 [M + H]
Example 11.1
N2-Methyl-N2-(2-morpholinoethyl)-N6-(4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)pyridine-2,6-dicarboxamide
##STR00151##
[0426] A solution of 25 mg of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)phenyl)isonico-
tinamide 4.1c, 28 mg of pyridine-2,6-dicarboxylic acid, and 4.3 mg
of diisopropylethylamine in 1 mL of DMF was treated with 21 mg of
HATU. After 2 h the mixture was separated by reverse phase HPLC,
eluting with 0.05% TFA in a water/acetonitrile gradient. The
isolated monoamide adduct of pyridine-2,6-dicarboxylic acid and
4.1c was dissolved in 2 mL of DMF and treated with 10 mg of
N-methyl-2-morpholineethanamine, 28 mg of diisopropylethylamine,
and 23 mg of HATU. After 2 h the product was isolated by reverse
phase HPLC. MS (ES, m/z) 730 [M+H].sup.+
Example 11.2
N1,5-Dimethyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trif-
luoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00152##
[0428] This compound was prepared using the method described for
the preparation of Example 11.2, using 5-methyl-isophthalic acid in
place of pyridine-2,6-dicarboxylic acid. MS (ES, m/z) 743
[M+H].sup.+
Example 11.3
2-Methoxy-N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-
-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00153##
[0430] This compound was prepared using the method described for
the preparation of Example 11.2, using 2-methoxy-isophthalic acid
in place of pyridine-2,6-dicarboxylic acid. MS (ES, m/z) 759
[M+H].sup.+
Example 11.4
5-Methoxy-N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-
-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00154##
[0432] This compound was prepared using the method described for
the preparation of Example 11.2, using 5-methoxy-isophthalic acid
in place of pyridine-2,6-dicarboxylic acid. MS (ES, m/z) 759
[M+H].sup.+
Example 12.1
(S)-2-(2-(3-((3-((2-Methoxyethyl)carbamoyl)piperidin-1-yl)methyl)benzamido-
)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00155##
[0434] A mixture of 20 mg of
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)isonicotinamide 8.1a, 8.8 mg of
(S)--N-(2-methoxyethyl)piperidine-3-carboxamide and 13.7 mg of
K.sub.2CO.sub.3 in 0.33 mL of DMF was stirred for 2 h. The product
was isolate by preparative reverse phase HPLC eluting with 0.05%
TFA in a water/acetonitrile gradient to give 23 mg of product. MS
(ES, m/z) 757.3 [M+H].sup.+
Example 12.2
(R)-2-(2-(3-((3-((2-Methoxyethyl)carbamoyl)piperidin-1-yl)methyl)benzamido-
)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00156##
[0436] This compound was prepared by the procedure described for
the preparation of its enantiomer. MS (ES, m/z) 757.3
[M+H].sup.+
Example 14
3-((3-((4-Morpholino-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2--
yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00157## ##STR00158##
[0437] Intermediate 14a:
N-(3-(trifluoromethyl)benzyl)-2-chloroisonicotinamide
[0438] Into a 500-mL round bottom flask, was placed a solution of
2-chloroisonicotinic acid (18 g, 113.92 mmol, 2.00 equiv) in
dichloromethane (200 mL), 3-(trifluoromethyl)benzylamine (10 g,
57.14 mmol, 1.00 equiv), EDC.HCl (22 g, 115.18 mmol, 2.00 equiv),
and 4-dimethylaminopyridine (14 g, 114.75 mmol, 2.00 equiv). The
resulting solution was stirred for 3 h at 25.degree. C. The
resulting solution was diluted with 500 mL of dichloromethane. The
resulting mixture was washed with 2.times.50 mL of aqueous
NH.sub.4Cl, 1.times.50 mL of 10% sodium bicarbonate, and 1.times.50
mL of brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column and eluted with petroleum ether/ethyl acetate
(5:1). The product was obtained as 11.8 g (63%) of a white
solid.
Intermediate 14b: 5-fluoro-2-nitrophenyl
trifluoromethanesulfonate
[0439] Into a 250-mL round bottom flask, was placed a solution of
5-fluoro-2-nitrophenol (5 g, 31.85 mmol, 1.00 equiv) in pyridine
(25 mL). This was followed by the addition of
trifluoromethanesulfonic anhydride (9.6 g, 34.04 mmol, 1.07 equiv)
dropwise with stirring at 0.degree. C. The resulting solution was
stirred for 1 h at 0.degree. C., overnight at room temperature. The
resulting solution was diluted with 100 mL of water. The resulting
solution was extracted with 3.times.100 mL of dichloromethane and
the organic layers combined. The resulting mixture was washed with
3.times.100 mL of water. The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. The product was
obtained as 5 g (54%) of a yellow oil.
Intermediate 14c:
2-(5-fluoro-2-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
[0440] Into a 250-mL round bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
5-fluoro-2-nitrophenyl trifluoromethanesulfonate (18 g, 62.28 mmol,
1.00 equiv) in 1,4-dioxane (150 mL),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (24 g,
94.49 mmol, 1.50 equiv), Pd(dppf)Cl.sub.2 (1.5 mg, 0.03 equiv), and
potassium acetate (12.6 g, 128.44 mmol, 2.00 equiv). The resulting
solution was stirred overnight at 80.degree. C. The mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with petroleum ether/ethyl acetate (1:5-ethyl
acetate). The product was obtained as 10 g (60%) of a yellow
solid.
Intermediate 14d:
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)-isonicotinamide
[0441] Into a 500-mL round bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
2-(5-fluoro-2-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(11.8 g, 44.19 mmol, 3.00 equiv) in 330 mL of 10:1 DME/H.sub.2O,
N-(3-(trifluoromethyl)benzyl)-2-chloroisonicotinamide (5 g, 15.92
mmol, 1.00 equiv), Pd(PPh3).sub.2Cl.sub.2 (2.54 g, 3.62 mmol, 0.20
equiv), X-PHOS (2.5 g, 6.36 mmol, 0.20 equiv), and K.sub.3PO.sub.4
(20 g, 59.17 mmol, 4.00 equiv). The resulting solution was stirred
overnight at 80.degree. C. The resulting mixture was concentrated
under vacuum. The residue was applied onto a silica gel column and
eluted with ethyl acetate/petroleum ether (1:5.about.1). The
product was obtained as 2 g (27%) of a brown oil.
Intermediate 14e:
N-(3-(trifluoromethyl)benzyl)-2-(5-morpholino-2-nitrophenyl)-isonicotinam-
ide
[0442] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
14d (200 mg, 0.48 mmol, 1.00 equiv) in N,N-dimethylformamide (2
mL), morpholine (80 mg, 0.90 mmol, 1.70 equiv), and potassium
carbonate (0.2 g, 3.00 equiv). The resulting solution was stirred
overnight at 80.degree. C. The solids were filtered out. The
resulting mixture was concentrated under vacuum to yield 0.1 g of
crude product as a yellow oil.
Intermediate 14f:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-morpholinophenyl)-isonicotinam-
ide
[0443] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-morpholino-2-nitrophenyl)isonicotinami-
de (100 mg, 0.21 mmol, 1.00 equiv) in methanol (5 mL). The solution
was treated with Pd/C (100 mg), and stirred under an atmosphere of
hydrogen overnight at room temperature. The solids were filtered
out. The resulting mixture was concentrated under vacuum to yield
50 mg (53%) of product as a yellow oil.
Intermediate 14g: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-morphol-
inophenyl)carbamoyl)benzylthio)propanoate
[0444] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-morpholinophenyl)isonicotinami-
de (200 mg, 0.44 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL),
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c (200 mg,
0.68 mmol, 1.50 equiv), EDC.HCl (160 mg, 0.84 mmol, 2.00 equiv),
and 4-dimethylaminopyridine (60 mg, 0.49 mmol, 1.00 equiv). The
resulting solution was stirred for 2 h at room temperature. After a
conventional aqueous/organic workup, the resulting mixture was
concentrated under vacuum to yield 100 mg of crude product as a
yellow oil.
Example 14
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-morpholi-
nophenyl)carbamoyl)benzylthio)propanoic acid
[0445] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-morphol-
inophenyl)carbamoyl)benzylthio)propanoate (100 mg, 0.14 mmol, 1.00
equiv) in dichloromethane (5 mL), and trifluoroacetic acid (0.1
mL). The resulting solution was stirred overnight at room
temperature. The reaction progress was monitored by LCMS. The
resulting mixture was concentrated under vacuum. The crude product
(100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 14 mg (15%) of a yellow solid. .sup.1H-NMR (300 MHz,
CDCl.sub.3, ppm): .delta. 13.55 (s, 1H), 9.09 (s, 1H), 8.96-8.78
(m, 2H), 8.72 (s, 1H), 8.65 (s, 1H), 8.25-8.09 (m, 3H), 8.05-7.90
(m, 8H), 4.73 (d, J=5.4 Hz, 2H), 4.13 (s, 4H), 3.82 (s, 2H), 3.47
(s, 4H), 2.75-2.57 (m, 4H). MS (ES, m/z): 679 [M+H].sup.+.
Example 15
3-((3-((4-Isopropoxy-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2--
yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00159## ##STR00160##
[0446] Intermediate 15a:
N-(3-(trifluoromethyl)benzyl)-2-(5-isopropoxy-2-nitrophenyl)-isonicotinam-
ide
[0447] Into a 50-mL round bottom flask, was placed a solution of
propan-2-ol (2 mL) in N,N-dimethylformamide (5 mL), sodium hydride
(72 mg, 3.00 mmol, 5.00 equiv), and
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
14d (250 mg, 0.58 mmol, 1.00 equiv, 98%). The resulting solution
was stirred for 3 h at 60.degree. C. in an oil bath. The resulting
solution was diluted with 200 mL of ethyl acetate and washed with
3.times.30 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum to yield 280 mg (99%) of
product as a brown oil.
Intermediate 15b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-isopropoxyphenyl)-isonicotinam-
ide
[0448] Into a 100-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-isopropoxy-2-nitrophenyl)isonicotinami-
de (270 mg, 0.53 mmol, 1.00 equiv, 90%) in dichloromethane/methanol
(3/6 mL). The solution was treated with Pd/C (270 mg), and stirred
under an atmosphere of hydrogen for 2 h at room temperature. The
solids were filtered out. The filtrate was concentrated under
vacuum to yield 230 mg (91%) of product as a brown oil.
Intermediate 15c: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-isoprop-
oxyphenyl)carbamoyl)benzylthio)propanoate
[0449] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-isopropoxyphenyl)isonicotinami-
de (230 mg, 0.48 mmol, 1.00 equiv, 90%) in dichloromethane (8 mL),
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c (317 mg,
0.86 mmol, 2.00 equiv, 80%), EDC.HCl (206 mg, 1.07 mmol, 2.00
equiv), and 4-dimethylaminopyridine (131 mg, 1.07 mmol, 2.00
equiv). The resulting solution was stirred for 2 h at 25.degree. C.
The resulting solution was diluted with 100 mL of ethyl acetate and
washed with 1.times.20 mL of aqueous NH.sub.4Cl, 1.times.20 mL of
10% sodium bicarbonate, and 1.times.20 mL of brine. The mixture was
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:2). The product was obtained as 240 mg
(60%) of a brown oil.
Example 15
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-isopropo-
xyphenyl)carbamoyl)benzylthio)propanoic acid
[0450] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-isoprop-
oxyphenyl)carbamoyl)-benzylthio)propanoate (230 mg, 0.28 mmol, 1.00
equiv, 85%) in dichloromethane (5 mL), and trifluoroacetic acid (1
mL). The resulting solution was stirred for 2 h at room
temperature. The resulting mixture was concentrated under vacuum.
The crude product (180 mg) was purified by reverse phase HPLC
eluting with a water/CH.sub.3CN gradient containing 0.05% TFA. The
product was obtained as 139.8 mg (76%) of a white solid.
.sup.1H-NMR (400 MHz, DMSO-d.sub.6, ppm): .delta. 12.52 (s, 1H),
12.23 (s, 1H), 9.57 (t, J=8 Hz, 1H), 8.96 (d, J=4 Hz, 1H),
8.41-8.36 (m, 2H), 7.88-7.84 (m, 2H), 7.79-7.63 (m, 2H), 7.60-7.52
(m, 2H), 7.50-7.48 (m, 4H), 7.16-7.13 (d, J=12 Hz, 1H), 4.76-4.70
(m, 1H), 4.62 (d, J=6 Hz, 2H), 3.88 (s, 2H), 2.63-2.53 (m, 4H),
1.30 (s, 6H). MS (ES, m/z): 652 [M+H].sup.+.
Example 16
3-((3-((4-((tetrahydro-2H-pyran-4-yl)oxy)-2-(4-((3-(trifluoromethyl)benzyl-
)-carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic
acid
##STR00161## ##STR00162##
[0451] Intermediate 16a: tetrahydro-2H-pyran-4-ol
[0452] Into a 250-mL 3-necked round bottom flask, was placed a
solution of tetrahydropyran-4-one (5 g, 50.00 mmol, 1.00 equiv) in
tetrahydrofuran (25 mL). This was followed by dropwise addition of
a solution of LiAlH.sub.4 (3.8 g, 102.70 mmol, 2.00 equiv) in
tetrahydrofuran (25 mL) with stirring at 0-5.degree. C. The
resulting solution was stirred for 3 h at 0-5.degree. C. in a
water/ice bath. The reaction was then quenched by the addition of
3.8 mL of water, 3.8 mL of 15% NaOH, and 11.4 mL of water. The
mixture was dried over anhydrous sodium sulfate. The solids were
filtered out. The resulting mixture was concentrated under vacuum
to yield 5 g (96%) of product as a yellow oil.
Intermediate 16b:
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(tetrahydro-2H-pyran-4-yloxy)p-
henyl)isonicotinamide
[0453] Into a 50-mL round bottom flask, was placed a solution of
tetrahydro-2H-pyran-4-ol (220 mg, 2.11 mmol, 3.00 equiv, 98%) in
N,N-dimethylformamide (5 mL). This was followed by the addition of
sodium hydride (86 mg, 3.58 mmol, 5.00 equiv), in portions at room
temperature. The resulting solution was stirred for 10 min at room
temperature. To this was added
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
(300 mg, 0.70 mmol, 1.00 equiv, 98%). Then the resulting solution
was stirred for an additional 2 h at 80.degree. C. in an oil bath.
The resulting solution was diluted with 200 mL of ethyl acetate,
and washed with 2.times.30 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column and eluted with ethyl
acetate/methanol (20/1). The product was obtained as 400 mg (97%)
of a brown oil.
Intermediate 16c:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(tetrahydro-2H-pyran-4-yloxy)p-
henyl)isonicotinamide
[0454] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(tetrahydro-2H-pyran-4-yloxy)p-
henyl)isonicotinamide (400 mg, 0.76 mmol, 1.00 equiv, 95%) in
methanol/dichloromethane (10/5 mL). The solution was treated with
Pd/C (400 mg), and stirred under an atmosphere of hydrogen for 2 h
at room temperature. The solids were filtered out. The resulting
mixture was concentrated under vacuum to yield 270 mg (68%) of
product as a brown oil.
Intermediate 16d: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(tetrah-
ydro-2H-pyran-4-yloxy)phenyl)carbamoyl)benzylthio)propanoate
[0455] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(tetrahydro-2H-pyran-4-yloxy)p-
henyl)isonicotinamide (270 mg, 0.52 mmol, 1.00 equiv, 90%) in
dichloromethane (10 mL),
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (339 mg, 0.92
mmol, 2.00 equiv, 80%), EDC.HCl (220 mg, 1.15 mmol, 2.00 equiv),
and 4-dimethylaminopyridine (140 mg, 1.15 mmol, 2.00 equiv). The
resulting solution was stirred for 3 h at 25.degree. C. The
resulting solution was diluted with 150 mL of dichloromethane and
was washed with 1.times.20 mL of aqueous NH.sub.4Cl, 1.times.20 mL
of 10% sodium bicarbonate, and 1.times.20 mL of brine. The mixture
was dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:1).about.dichloromethane:methanol
(20:1). The product was obtained as 190 mg (42%) of a brown
oil.
Example 16
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(tetrahy-
dro-2H-pyran-4-yloxy)phenyl)carbamoyl)benzylthio)propanoic acid
[0456] Into a 50-10 mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(tetrah-
ydro-2H-pyran-4-yloxy)phenyl)-carbamoyl)benzylthio)propanoate (190
mg, 0.20 mmol, 1.00 equiv, 80%) in dichloromethane (5 mL), and
trifluoroacetic acid (1 mL). The resulting solution was stirred for
3 h at room temperature. The resulting mixture was concentrated
under vacuum. The crude product (100 mg) was purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 82.4 mg (57%) of as a yellow
solid. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 8.94 (d, J=3
Hz, 1H), 8.30 (s, 1H), 8.22 (d, J=9 Hz, 1H), 7.89-7.85 (m, 2H),
7.77 (d, J=9 Hz, 1H), 7.70 (s, 1H), 7.66-7.52 (m, 4H), 7.48-7.43
(m, 2H), 7.19-7.15 (q, J=9 Hz, 1H), 4.69 (s, 3H), 4.01-3.95 (m,
2H), 3.86 (s, 2H), 3.66-3.58 (m, 2H), 2.73-2.68 (m, 2H), 2.59-2.54
(m, 2H), 2.06 (m, 2H), 1.80-1.76 (m, 2H). MS (ES, m/z): 694
[M+H].sup.+.
Example 17
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(bis(2-m-
ethoxyethyl)amino)phenyl)carbamoyl)benzylthio)propanoic acid
##STR00163## ##STR00164##
[0457] Intermediate 17a:
N-(3-(trifluoromethyl)benzyl)-2-(5-(bis(2-methoxyethyl)amino)-2-nitrophen-
yl)isonicotinamide
[0458] Into a 10-mL vial, was placed a solution of
bis(2-methoxyethyl)amine (285.6 mg, 2.15 mmol, 3.00 equiv) in
N,N-dimethylformamide (3 mL), and N,N-diisopropylethylamine (277
mg, 2.14 mmol, 2.99 equiv). This was followed by the addition of a
solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
(300 mg, 0.72 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL).
The resulting solution was stirred for 48 h at 80.degree. C. in an
oil bath. The reaction progress was monitored by LCMS. The
resulting solution was diluted with 50 mL of water. The resulting
solution was extracted with 3.times.50 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
2.times.70 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column and eluted with ethyl acetate/petroleum ether
(1:5.about.1). The product was obtained as 270 mg (71%) of a yellow
to green oil.
Intermediate 17b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(bis(2-methoxyethyl)-amino)phe-
nyl)isonicotinamide
[0459] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-(bis(2-methoxyethyl)amino)-2-nitrophen-
yl)-isonicotinamide (270 mg, 0.51 mmol, 1.00 equiv) in methanol (10
mL). The solution was treated with Pd/C (300 mg), and stirred under
an atmosphere of hydrogen for 2 h at room temperature in a water
bath. The solids were filtered out. The resulting mixture was
concentrated under vacuum to yield 180 mg (71%) of product as a
yellow to green oil.
Intermediate 17c: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(bis(2--
methoxyethyl)amino)phenyl)carbamoyl)benzylthio)propanoate
[0460] Into a 10-mL vial, was placed a solution of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (188.64 mg,
0.64 mmol, 2.00 equiv) in dichloromethane (5 mL), EDC.HCl (120.8
mg, 0.63 mmol, 1.98 equiv), 4-dimethylaminopyridine (77.6 mg, 0.64
mmol, 2.00 equiv), and
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(bis(2-methoxyethyl)amino)phen-
yl)-isonicotinamide (160 mg, 0.32 mmol, 1.00 equiv). The resulting
solution was stirred for 2 h at 25.degree. C. in an oil bath. The
reaction progress was monitored by LCMS. The resulting solution was
diluted with 50 mL of dichloromethane, and washed with 3.times.50
mL of aqueous NH.sub.4Cl. The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:5.about.1). The product was obtained as
160 mg (64%) of a yellow solid.
Example 17
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(bis(2-m-
ethoxyethyl)amino)phenyl)carbamoyl)benzylthio)propanoic acid
[0461] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(bis(2--
methoxyethyl)amino)phenyl)-carbamoyl)benzylthio)propanoate (160 mg,
0.21 mmol, 1.00 equiv) in dichloromethane (8 mL), and
trifluoroacetic acid (2 mL). The resulting solution was stirred for
4 h at 25.degree. C. in an oil bath. The reaction progress was
monitored by LCMS. The resulting mixture was concentrated under
vacuum. The crude product (125 mg) was purified by reverse phase
HPLC eluting with a water/CH.sub.3CN gradient containing 0.05% TFA.
The product was obtained as 81.1 mg (41%) of as a yellow solid.
.sup.1H-NMR (300 MHz, DMSO, ppm): .delta. 11.86 (s, 1H), 9.49 (t,
J=5.7 Hz, 1H), 8.94 (d, J=5.1 Hz, 1H), 8.25 (s, 1H), 8.12 (d, J=6.5
Hz, 1H), 7.82 (s, 2H), 7.71 (m, 2H), 7.62 (m, 5H), 7.15 (d, J=2.4
Hz, 1H), 6.90 (m, 1H), 4.61 (d, J=6.0 Hz, 2H), 3.87 (s, 2H), 3.56
(m, 8H), 3.27 (s, 6H), 2.63 (m, 2H), 2.51 (m, 2H). MS (ES, m/z):
725 [M+H].sup.+.
Example 18
3-((3-((4-Fluoro-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)p-
henyl)carbamoyl)benzyl)thio)propanoic acid
##STR00165##
[0462] Intermediate 18a:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-fluorophenyl)-isonicotinamide
[0463] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
14d (200 mg, 0.48 mmol, 1.00 equiv) in methanol (5 mL). The
solution was treated with Pd/C (0.2 g), and stirred under an
atmosphere of hydrogen for 2 h at room temperature. The reaction
progress was monitored by LCMS. The solids were filtered out. The
resulting mixture was concentrated under vacuum to yield 200 mg of
crude product as a yellow oil.
Intermediate 18b: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-fluorop-
henyl)carbamoyl)benzylthio)propanoate
[0464] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-fluoro-phenyl)isonicotinamide
(200 mg, 0.51 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL),
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (200 mg, 0.68
mmol, 1.50 equiv), EDC.HCl (0.18 g, 0.94 mmol, 2.00 equiv), and
4-dimethylaminopyridine (58 mg, 0.48 mmol, 1.00 equiv). The
resulting solution was stirred for 2 h at room temperature. The
reaction progress was monitored by LCMS. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with ethyl acetate/petroleum ether (1:5-ethyl
acetate). The product was obtained as 100 mg (29%) of a yellow
solid.
Example 18
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-fluoro-p-
henyl)carbamoyl)benzylthio)propanoic acid
[0465] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-
-fluorophenyl)carbamoyl)benzylthio)propanoate (100 mg, 0.15 mmol,
1.00 equiv) in dichloromethane (5 mL), and trifluoroacetic acid (1
mL). The resulting solution was stirred overnight at room
temperature. The resulting mixture was concentrated under vacuum.
The crude product (100 mg) was purified by reverse phase HPLC
eluting with a water/CH.sub.3CN gradient containing 0.05% TFA. The
product was obtained as 22.7 mg (25%) of a yellow solid.
.sup.1H-NMR (300 MHz, DMSO, ppm): .delta. 12.78 (s, 1H), 9.55-9.54
(m, 1H), 9.00-8.99 (m, 1H), 8.58-8.53 (m, 1H), 8.43 (s, 1H),
7.94-7.39 (m, 11H), 4.65-4.63 (t, J=3 Hz, 2H), 3.89 (s, 2H),
2.63-2.59 (m, 2H). MS (ES, m/z): 612 [M+H].sup.+.
Example 19
3-((3-((4-(Dipropylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyrid-
in-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00166##
[0466] Intermediate 19a:
N-(3-(trifluoromethyl)benzyl)-2-(5-(dipropylamino)-2-nitrophenyl)-isonico-
tinamide
[0467] Into a 10-mL vial, was placed a solution of dipropylamine
(216.9 mg, 2.15 mmol, 3.00 equiv) in N,N-dimethylformamide (3 mL),
N,N-diisopropylethylamine (277 mg, 2.15 mmol, 3.00 equiv), and a
solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamid-
e 14d (300 mg, 0.72 mmol, 1.00 equiv) in N,N-dimethylformamide (2
mL). The resulting solution was stirred for 8 h at 90.degree. C. to
100.degree. C. in an oil bath. The resulting solution was diluted
with 50 mL of water. The resulting solution was extracted with
3.times.50 mL of ethyl acetate and the organic layers combined. The
resulting mixture was washed with 2.times.70 mL of brine, dried
over sodium sulfate, and concentrated under vacuum. The crude
product was obtained as 400 mg of a yellow to green oil.
Intermediate 19b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(dipropylamino)phenyl)-isonico-
tinamide
[0468] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-(dipropylamino)-2-nitrophenyl)isonicot-
inamide (400 mg, 0.80 mmol, -1.00 equiv) in methanol (20 mL). The
solution was treated with Pd/C (400 mg, 10%), and stirred under an
atmosphere of hydrogen for 4 h at room temperature. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
The product was obtained as 300 mg (80%) of a yellow to green
oil.
Intermediate 19c: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(diprop-
ylamino)phenyl)carbamoyl)benzylthio)propanoate
[0469] Into a 10-mL vial, was placed a solution of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (355.2 mg,
1.20 mmol, 2.00 equiv) in dichloromethane (5 mL), EDC.HCl (228 mg,
1.19 mmol, 2.00 equiv), 4-dimethylaminopyridine (146.4 mg, 2.00
mmol), and
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(dipropylamino)phenyl)isonicot-
inamide (300 mg, 0.64 mmol, 1.00 equiv). The resulting solution was
stirred for 2 h at 25.degree. C. in an oil bath. The resulting
solution was diluted with 50 mL of dichloromethane and washed with
3.times.50 mL of aqueous NH.sub.4Cl. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:5-1:3). The product was obtained as 320
mg (67%) of a yellow to green oil.
Example 19
3-((3-((4-(dipropylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)-pyri-
din-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
[0470] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)-benzyl)carbamoyl)pyridin-2-yl)-4-(dipro-
pylamino)phenyl)carbamoyl)benzylthio)-propanoate (320 mg, 0.43
mmol, 1.00 equiv) in dichloromethane (10 mL), and trifluoroacetic
acid (1 mL). The resulting solution was stirred overnight at
25.degree. C. in an oil bath. The reaction progress was monitored
by LCMS. The resulting mixture was concentrated under vacuum. The
crude product (200 mg) was purified by reverse phase HPLC eluting
with a water/CH.sub.3CN gradient containing 0.05% TFA. The product
was obtained as 108 mg (30%) of a yellow solid. .sup.1H-NMR (300
MHz, DMSO, ppm): .delta. 9.52 (t, J=6 Hz, 1H), 8.96 (d, J=5.1 Hz,
1H), 8.27 (s, 2H), 7.85 (s, 2H), 7.74 (m, 2H), 7.53 (m, 5H), 7.02
(s, 2H), 4.61 (d, J=5.7 Hz, 2H), 3.87 (s, 2H), 3.39 (s, 4H), 2.61
(m, 2H), 2.50 (m, 2H), 1.53 (t, J=9.3 Hz, 4H), 0.89 (t, J=7.2 Hz,
6H). MS (ES, m/z): 693 [M+H].sup.+.
Example 20
3-((3-((4-(Pyrrolidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyr-
idin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00167##
[0471] Intermediate 20a:
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(pyrrolidin-1-yl)phenyl)-isoni-
cotinamide
[0472] Into a 10-mL vial, was placed a solution of pyrrolidine
(152.5 mg, 2.15 mmol, 3.00 equiv) in N,N-dimethylformamide (5 mL),
potassium carbonate (296.2 mg, 2.15 mmol, 3.00 equiv), and
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
14d (300 mg, 0.72 mmol, 1.00 equiv). The resulting solution was
stirred for 4 h at 90.degree. C. in an oil bath. The resulting
solution was diluted with 50 mL of water. The resulting solution
was extracted with 3.times.50 mL of ethyl acetate and the organic
layers combined. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum to yield 400 mg of crude
product as a yellow to green oil.
Intermediate 20b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(pyrrolidin-1-yl)phenyl)-isoni-
cotinamide
[0473] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(pyrrolidin-1-yl)phenyl)isonic-
otinamide (400 mg, 0.85 mmol, 1.00 equiv) in methanol (20 mL). The
solution was treated with Pd/C (400 mg) and stirred under an
atmosphere of hydrogen for 3.5 h at room temperature. The solids
were filtered out. The resulting mixture was concentrated under
vacuum. The product was obtained as 300 mg (80%) of a yellow to
green solid.
Intermediate 20c: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(pyrrol-
idin-1-yl)phenyl)carbamoyl)benzylthio)propanoate
[0474] Into a 10-mL vial, was placed a solution of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (402.6 mg,
1.36 mmol, 2.00 equiv) in dichloromethane (5 mL), EDC.HCl (258.5
mg, 1.35 mmol, 2.00 equiv), 4-dimethylaminopyridine (165.9 mg, 1.36
mmol, 2.00 equiv), and
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(pyrrolidin-1-yl)phenyl)isonic-
otinamide (300 mg, 0.68 mmol, 1.00 equiv). The resulting solution
was stirred for 5 h at 25.degree. C. in an oil bath. The resulting
solution was diluted with 50 mL of dichloromethane and washed with
2.times.70 mL of aqueous NH.sub.4Cl. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:10-1:3). The crude product was obtained
as 600 mg of a yellow solid.
Example 20
3-((3-((4-(pyrrolidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)-py-
ridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
[0475] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(pyrrol-
idin-1-yl)phenyl)carbamoyl)-benzylthio)propanoate (600 mg, 0.84
mmol, 1.00 equiv) in dichloromethane (20 mL), and trifluoroacetic
acid (2 mL). The resulting solution was stirred for 2.5 h at
25.degree. C. in an oil bath. The reaction progress was monitored
by LCMS. The resulting mixture was concentrated under vacuum. The
crude product (120 mg) was purified by reverse phase HPLC eluting
with a water/CH.sub.3CN gradient containing 0.05% TFA. The product
was obtained as 96.2 mg (15%) of a yellow solid. .sup.1H-NMR (300
MHz, DMSO, ppm): .delta. 11.92 (s, 1H), 9.51 (t, J=11.7 Hz, 1H),
8.95 (d, J=5.4 Hz, 1H), 8.28 (s, 1H), 8.15 (d, J=8.7 Hz, 1H), 7.82
(d, J=5.4 Hz, 2H), 7.73 (t, J=12.3 Hz, 2H), 7.55 (m, 5H), 6.96 (d,
J=2.4 Hz, 1H), 6.76 (m, 1H), 4.62 (d, J=5.7 Hz, 2H), 3.87 (s, 2H),
3.33 (s, 4H), 2.62 (m, 2H), 2.50 (m, 2H), 1.99 (s, 4H). MS (ES,
m/z): 663 [M+H].sup.+.
Example 21
3-((3-((4-Chloro-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)p-
henyl)carbamoyl)benzyl)thio)propanoic acid
##STR00168##
[0476] Intermediate 21a:
N-(3-(trifluoromethyl)benzyl)-2-bromoisonicotinamide
[0477] Into a 250-mL round bottom flask, was placed a solution of
2-bromoisonicotinic acid (1.4 g, 6.93 mmol, 1.20 equiv) in
dichloromethane (50 mL), EDC.HCl (1.64 g, 8.56 mmol, 1.50 equiv),
4-dimethylaminopyridine (1.04 g, 8.51 mmol, 1.50 equiv), and
3-(trifluoromethyl)benzylamine (1.0 g, 5.71 mmol, 1.00 equiv). The
resulting solution was stirred overnight at 25.degree. C. in an oil
bath. The resulting solution was diluted with 100 mL of
dichloromethane. The resulting mixture was washed with 2.times.50
mL of sat. NH.sub.4Cl, 2.times.50 mL of sat. Na.sub.2CO.sub.3, and
2.times.50 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column and eluted with ethyl acetate/petroleum ether
(1:10-1:5). The product was obtained as 1.2 g (59%) of a white
solid.
Intermediate 21b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-chlorophenyl)-isonicotinamide
[0478] Into a 50-mL round bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
4-chloro-2-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)benzenamine (300
mg, 1.17 mmol, 1.00 equiv) in ethylene glycol dimethyl ether (15
mL), N-(3-(trifluoromethyl)benzyl)-2-bromoisonicotinamide (432 mg,
1.20 mmol, 1.00 equiv), a solution of sodium carbonate (636 mg,
6.00 mmol, 5.00 equiv) in water (3.0 mL), and Pd(PPh.sub.3).sub.4
(138 mg, 0.12 mmol, 0.10 equiv). The resulting solution was stirred
for 2 h at 85.degree. C. in an oil bath. The resulting mixture was
concentrated under vacuum. The resulting solution was diluted with
10 mL of water. The resulting solution was extracted with
3.times.10 mL of ethyl acetate and the organic layers combined, and
washed with brine. The mixture was dried over sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with petroleum ether/ethyl acetate
(10:1-5:1). The product was obtained as 260 mg (55%) of a yellow
solid.
Intermediate 21c: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-chlorop-
henyl)carbamoyl)benzylthio)propanoate
[0479] Into a 100-mL round bottom flask, was placed a solution of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (210 mg, 0.71
mmol, 1.20 equiv) in dichloromethane (35 mL), EDC.HCl (170.6 mg,
0.89 mmol, 1.50 equiv), 4-dimethylaminopyridine (108.8 mg, 0.89
mmol, 1.50 equiv), and
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-chlorophenyl)isonicotinami-
de (240 mg, 0.59 mmol, 1.00 equiv). The resulting solution was
stirred for 6 h at 25.degree. C. in an oil bath. The resulting
solution was diluted with 100 mL of dichloromethane and washed with
2.times.50 mL of aqueous NH.sub.4Cl and brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum
to yield 350 mg (86%) of product as a yellow solid.
Example 21
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-chloroph-
enyl)carbamoyl)benzylthio)propanoic acid
[0480] Into a 50-mL round bottom flask, was placed a solution of
tert-butyl(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-
-chlorophenyl)carbamoyl) benzylthio)propanoate (350 mg, 0.51 mmol,
1.00 equiv) in dichloromethane (5.0 mL), and trifluoroacetic acid
(581.4 mg, 5.10 mmol, 10.00 equiv). The resulting solution was
stirred overnight at 15.degree. C. The resulting mixture was
concentrated under vacuum. The crude product (340 mg) was purified
by reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. The product was obtained 250 mg (78%) of a
white solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm): .delta.
12.988 (s, 1H), 12.228 (s, 1H), 9.595-9.560 (m, 1H), 9.020-9.003
(d, J=5.1 Hz, 1H), 8.631-8.601 (d, J=9.0 Hz, 1H), 8.448 (s, 1H),
8.118-8.126 (d, J=2.4 Hz, 1H), 7.917-7.899 (d, J=5.4 Hz, 2H),
7.837-7.812 (d, J=7.5 Hz, 1H), 7.727-7.510 (m, 6H), 4.662-4.643 (d,
J=5.7 Hz, 2H), 3.904 (s, 2H), 2.637-2.594 (m, 2H), 2.538 (m, 2H).
MS (ES, m/z): 628 [M+H].sup.+.
Example 22
3-((3-((2-(4-((3-(Trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)car-
bamoyl)benzyl)thio)propanoic acid
##STR00169## ##STR00170##
[0481] Intermediate 22a:
N-(3-(trifluoromethyl)benzyl)-2-(2-nitrophenyl) isonicotinamide
[0482] Into a 250-mL 3-necked round bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of 2-nitrophenylboronic acid (500 mg, 2.99 mmol, 1.00
equiv) in ethylene glycol dimethyl ether (30 mL),
N-(3-(trifluoromethyl)benzyl)-2-bromoisonicotinamide 21a (1.08 g,
3.01 mmol, 1.00 equiv), Pd(PPh.sub.3).sub.4 (334.7 mg, 0.30 mmol,
0.10 equiv), and a solution of sodium carbonate (1.6 g, 15.09 mmol,
5.00 equiv) in water (4 mL). The resulting solution was stirred for
1.5 h at 80.degree. C. The reaction progress was monitored by TLC
(ethyl acetate/petroleum ether=1:1). The resulting solution was
diluted with 50 mL of water. The resulting solution was extracted
with 2.times.100 mL of ethyl acetate and the organic layers
combined and dried over magnesium sulfate. The solids were filtered
out. The resulting mixture was concentrated under vacuum. The
residue was applied onto a silica gel column and eluted with
petroleum ether/EtOAc (20:1-5:1). The product was obtained as 1.0 g
(83%) of a light yellow solid.
Intermediate 22b:
N-(3-(trifluoromethyl)benzyl)-2-(2-aminophenyl)isonicotinamide
[0483] Into a 100-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-nitrophenyl)isonicotinamide (350
mg, 0.87 mmol, 1.00 equiv) in ethanol/H.sub.2O (1/1) (30 mL), iron
(489 mg, 8.73 mmol, 10.00 equiv), and acetic acid (0.1 mL). The
resulting solution was heated to reflux for 0.5 h. The solids were
filtered out. The resulting solution was extracted with of ethyl
acetate and the organic layers combined and dried over magnesium
sulfate. The solids were filtered out. The resulting mixture was
concentrated under vacuum. The product was obtained as 260 mg (80%)
of a yellow solid.
Intermediate 22c: 3-((3-methoxy-3-oxopropylthio)methyl)benzoic
acid
[0484] To a solution of 3-(mercaptomethyl)benzoic acid (500 mg,
2.97 mmol, 1.00 equiv) in acetonitrile (10.0 mL) was added methyl
acrylate (10.0 mL) and 1,8-Diazabicyclo[5.4.0]undec-7-ene (1.0 g,
6.57 mmol, 2.00 equiv) and the resulting solution was heated to
reflux overnight. The reaction was concentrated under vacuum and
the residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (0.about.1:6) to afford 220 mg (28%) of
3-((3-methoxy-3-oxopropylthio)methyl)benzoic acid as light-red
oil.
Intermediate 22d: methyl
3-(3-(chlorocarbonyl)benzylthio)propanoate
[0485] To a solution of
3-((3-methoxy-3-oxopropylthio)methyl)benzoic acid (61.6 mg, 0.24
mmol, 1.00 equiv) in dichloromethane (5 mL) was added dropwise
oxalyl dichloride (121.76 mg, 0.96 mmol, 4.00 equiv) followed by a
few drops of N,N-dimethylformamide. The resulting solution was
heated to reflux for 30 min, then concentrated under vacuum to
afford 60 mg (crude) of methyl
3-(3-(chlorocarbonyl)benzylthio)propanoate as a yellow oil.
Intermediate 22e: methyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)car-
bamoyl)benzylthio)propanoate
[0486] Into a 100-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-aminophenyl)isonicotinamide (240
mg, 0.65 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), and pyridine
(77 mg, 0.97 mmol, 1.50 equiv). This was followed by dropwise
addition of a solution of methyl
3-(3-(chlorocarbonyl)benzylthio)propanoate (194 mg, 0.71 mmol, 1.10
equiv) in tetrahydrofuran (5 mL) with stirring. The resulting
solution was stirred for 2 h at room temperature. The reaction was
then quenched with 30 mL of water. The resulting solution was
extracted with 3.times.10 mL of ethyl acetate and the organic
layers combined and dried over magnesium sulfate. The resulting
mixture was concentrated under vacuum to yield 250 mg (64%) of
product as a light yellow solid.
Example 22
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)-car-
bamoyl)benzylthio) propanoic acid
[0487] Into a 100-mL 3-necked round bottom flask, was placed a
solution of methyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phe-
nyl)carbamoyl)benzylthio)propanoate (250 mg, 0.41 mmol, 1.00 equiv)
in tetrahydrofuran (8 mL), and a solution of LiOH (98 mg, 4.08
mmol, 10.00 equiv) in water (2 mL). The resulting solution was
stirred for 2 h at room temperature. The reaction progress was
monitored by LCMS. The reaction was then quenched with 50 mL of
water. The solution was adjusted to pH 3 with hydrochloric acid.
The resulting solution was extracted with of ethyl acetate and the
organic layers combined and dried over anhydrous sodium sulfate.
The solids were filtered out. The resulting mixture was
concentrated under vacuum. The crude product (120 mg) was purified
by reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. The product was obtained 50 mg (20%) of a
white solid. .sup.1H-NMR (400 MHz, DMSO-d.sub.6, ppm): .delta.
13.02 (s, 1H), 9.60-9.56 (t, 1H), 9.01-8.99 (d, 1H), 8.60-8.57 (d,
1H), 8.42 (s, 1H), 8.05-8.03 (d, 1H), 7.93-7.82 (m, 3H), 7.72-7.51
(m, 7H), 7.35-7.30 (t, 1H), 4.65-4.63 (d, 2H), 3.91 (s, 2H),
2.64-2.59 (m, 3H). MS (ES, m/z): 594 [M+H].sup.+.
Example 24
N1-(2-(4-(1-Benzyl-1H-1,2,3-triazol-4-yl)pyridin-2-yl)-4-(piperidin-1-yl)p-
henyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00171## ##STR00172##
[0488] Intermediate 24a:
2-chloro-4-((trimethylsilyl)ethynyl)pyridine
[0489] A solution 0.835 mL of triethylamine in 10 mL of THF was
degassed and treated with 16 mg of Ph.sub.3P, 70 mg of
(Ph.sub.3P).sub.2PdCl.sub.2, and 479 mg of 2-chloro-4-iodopyridine.
The solution was stirred 1 h then treated with 236 mg of
TMSC.ident.CH and 11.4 mg of CuI. After stirring overnight the
solvent was evaporated and the residue was dissolved in
dichloromethane. The solution was washed with water and then with
brine. The solution was dried (Na.sub.2SO.sub.4) and then the
solvent was evaporated at reduced pressure. The residue was
chromatographed on silica gel eluting with a gradient of 0% to 20%
ethyl acetate in hexanes to give 516 mg of product. MS (ESI, m/z)
210.1 [M+H].sup.+.
Intermediate 24b:
4-ethynyl-2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridine
[0490] A degassed mixture of
2-chloro-4-((trimethylsilyl)ethynyl)pyridine 24a, boronic ester
1.1e, 4.9 mL of 2 M aqueous Na.sub.2CO.sub.3, and 12 mL of DME was
treated with 45 mg of XPHOS and 11 mg of Pd(OAc).sub.2. The mixture
was stirred at 75.degree. C. for 1.5 h. The solvent was evaporated
at reduced pressure and the residue was dissolved in 100 mL of
dichloromethane. The solution was washed with water and dried over
Na.sub.2SO.sub.4. The solvent was evaporated and the residue was
purified by silica gel chromatography eluting with a 0-20% gradient
of EtOAc in CH.sub.2Cl.sub.2 to give 275 mg of product. MS (ESI,
m/z) 308.1 [M+H].sup.+.
Intermediate 24c:
4-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(2-nitro-5-(piperidin-1-yl)phenyl)-p-
yridine
[0491] A solution of 50 mg of
4-ethynyl-2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridine, 20 .mu.L of
benzyl azide, 16.3 .mu.L of 1 M aqueous sodium ascorbate solution,
5.4 .mu.L of 0.3 M CuSO.sub.4 solution, 326 .mu.L of tert-butanol,
and 326 .mu.L of water was stirred for 2 days and then the solvent
was evaporated at reduced pressure. The residue was dissolved in
dichloromethane. The solution was washed with water and dried. The
solvent was evaporated at reduced pressure and the residue was
chromatographed on silica gel eluting with a 0% to 4% gradient of
methanol in dichloromethane. The process yielded 22 mg of
product.
Intermediate 24d:
2-(4-(1-benzyl-1H-1,2,3-triazol-4-yl)pyridin-2-yl)-4-(piperidin-1-yl)-ani-
line
[0492] A solution of 22 mg of
4-(1-benzyl-1H-1,2,3-triazol-4-yl)-2-(2-nitro-5-(piperidin-1-yl)phenyl)py-
ridine 24c in 1 mL of methanol was treated with 10 mg of Pd/C and
stirred under a hydrogen atmosphere for 1 h. The mixture was
filtered through celite and the solvent was evaporated to give 22
mg of product.
Example 24
N1-(2-(4-(1-benzyl-1H-1,2,3-triazol-4-yl)pyridin-2-yl)-4-(piperidin-1-yl)--
phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
[0493] A solution of 22 mg of
2-(4-(1-benzyl-1H-1,2,3-triazol-4-yl)pyridin-2-yl)-4-(piperidin-1-yl)anil-
ine 24d, 15.2 mg of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic
acid, 22.6 mg of HATU, and 27.9 mg of diisopropylethylamine in 0.3
mL of DMF was stirred for 1 h. The solution was filtered and the
product was isolated from the filtrate by reverse phase
chromatography eluting with 0.05% TFA in a water/acetonitrile
gradient. This procedure gave 13.4 mg of product. .sup.1H NMR (400
MHz, DMSO-d.sub.6, ppm): .delta. 8.97 (s, 1H), 8.78 (d, J=5.0 Hz,
1H), 8.35 (s, 1H), 8.32-8.26 (m, 1H), 8.03-7.94 (m, 2H), 7.91 (d,
J=5.2 Hz, 1H), 7.70-7.50 (m, 3H), 7.35 (mj, 4H), 7.28-7.19 (m, 1H),
5.69 (s, 2H), 4.09-3.90 (m, 3H), 3.85-3.76 (m, 2H), 3.71-3.53 (m,
4H), 2.91 (s, 3H), 1.69 (s, 4H), 1.55 (s, 2H). MS (ESI, m/z) 685.3
[M+H].sup.+.
Example 25
N1-(4-(Diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2--
yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00173##
[0494] Intermediate 25a:
N-(3-(trifluoromethyl)benzyl)-2-(5-(diethylamino)-2-nitrophenyl)-isonicot-
inamide
[0495] A 25.degree. C. mixture of 500 mg of
2-(5-fluoro-2-nitrophenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
14d, 131 mg of diethylamine, and 329 mg of K.sub.2CO.sub.3 in 4 mL
of DMF was stirred for 16 h and then stirred for an additional 24 h
at 60.degree. C. The mixture was diluted with ethyl acetate, and
the resulting solution was washed with water, and then with brine.
The solution was dried (Na.sub.2SO.sub.4) and the solvent was
removed at reduced pressure. The residue was purified by
chromatography on silica gel to give 500 mg of a yellow solid.
Intermediate 25b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(diethylamino)phenyl)-isonicot-
inamide
[0496] A mixture of 500 mg of
N-(3-(trifluoromethyl)benzyl)-2-(5-(diethylamino)-2-nitrophenyl)isonicoti-
namide, 120 mg of 10% Pd/C, and 30 mL of methanol was stirred for 2
h under a hydrogen atmosphere. The mixture was filtered and
concentrated to give 0.42 g of product.
Example 25
N1-(4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2--
yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
[0497] A mixture of 80 mg of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(diethylamino)phenyl)isonicoti-
namide, 64 mg of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic
acid, 83 mg of HATU, and 190 .mu.L of diisopropylethylamine in 0.5
mL of DMF was stirred at 60.degree. C. for 2 h. The product was
isolated by reverse phase chromatography eluting with 0.05% TFA in
a water/acetonitrile gradient. This procedure gave 17.6 mg of
product. .sup.1H NMR (400 MHz, CD.sub.3OD, ppm): .delta. 9.54 (t,
J=5.9 Hz, 1H), 8.98 (dd, J=5.2, 0.6 Hz, 1H), 8.88 (d, J=9.0 Hz,
1H), 8.49 (s, 1H), 8.26 (d, J=2.6 Hz, 1H), 8.20 (s, 1H), 8.16-8.10
(m, 1H), 7.90 (dd, J=5.2, 1.5 Hz, 1H), 7.80 (d, J=7.8 Hz, 1H),
7.75-7.63 (m, 4H), 7.63-7.50 (m, 2H), 4.74-4.67 (m, 2H), 4.21-4.03
(m, 2H), 3.99 (t, J=5.7 Hz, 2H), 3.90-3.69 (m, 4H), 3.76 (q, J=7.2
Hz, 4H), 3.54 (t, J=5.9 Hz, 2H), 3.34-3.18 (m, 2H), 3.10 (s, 3H),
1.22 (t, J=7.2 Hz, 6H). MS (ESI, m/z) 717.24 [M+H].sup.+.
Example 26
N1-(4-Cyclobutoxy-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00174##
[0498] Intermediate 26a:
2-(5-cyclobutoxy-2-nitrophenyl)-N-(3-(trifluoromethyl)benzyl)-isonicotina-
mide
[0499] A 25.degree. C. solution of 26 mg of cyclobutanol in 0.5 mL
of DMF was treated with 10 mg of 60% NaH in oil. After stirring for
15 minutes, 75 mg of
2-(5-fluoro-2-nitrophenyl)-N-(3-(trifluoromethyl)benzyl)isonicot-
inamide 14d was added. The mixture was stirred overnight and then
it was quenched with water. It was diluted with ethyl acetate, and
the resulting solution was washed with water, then with brine. The
solution was dried (Na.sub.2SO.sub.4) and the solvent was removed
at reduced pressure. The residue was purified by chromatography on
silica gel to give 62 mg of a syrup.
Intermediate 26b:
2-(2-amino-5-cyclobutoxyphenyl)-N-(3-(trifluoromethyl)benzyl)-isonicotina-
mide
[0500] A mixture of 62 mg of
2-(5-cyclobutoxy-2-nitrophenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinam-
ide, 10 mg of 10% Pd/C, and 4 mL of methanol was stirred for 2 h
under a hydrogen atmosphere. The mixture was filtered and
concentrated to give 46 mg of product.
Example 26
N1-(4-cyclobutoxy-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
[0501] A mixture of 26 mg of
2-(2-amino-5-cyclobutoxyphenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinam-
ide, 21 mg of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid,
27 mg of HATU, and 63 .mu.L of DIEA in 0.2 mL of DMF was stirred at
60.degree. C. for 2 h. The product was isolated by reverse phase
chromatography eluting with 0.05% TFA in a water/acetonitrile
gradient. This procedure gave 24 mg of a yellow solid. .sup.1H NMR
(400 MHz, CD.sub.3OD, ppm): .delta. 9.46 (t, J=5.8 Hz, 1H), 8.85
(d, J=5.3 Hz, 1H), 8.26 (s, 1H), 8.15 (d, J=9.0 Hz, 1H), 8.05 (s,
1H), 8.01 (d, J=7.8 Hz, 1H), 7.85-7.80 (m, 1H), 7.80-7.47 (m, 6H),
7.31 (d, J=2.7 Hz, 1H), 7.00 (dd, J=8.9, 2.6 Hz, 1H), 4.83-4.71 (m,
1H), 4.67 (s, 2H), 4.09 (s, 2H), 3.96 (m, 2H), 3.77 (m, 4H), 3.52
(t, J=4.9 Hz, 2H), 3.24 (s, 2H), 3.07 (s, 3H), 2.59-2.39 (m, 2H),
2.25-2.04 (m, 2H), 1.93-1.60 (m, 2H). MS (ESI, m/z) 716.26
[M+H].sup.+.
Example 27
3-((3-((4-Thiomorpholino-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridi-
n-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00175##
[0503] This compound was prepared according to the procedure
described for the synthesis of
3-((3-((4-morpholino-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 14, using
thiomorpholine in place of morpholine. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6, ppm): .delta. 12.22 (s, 1H), 9.54 (t, 1H), 8.32 (d,
J=3 Hz, 1H), 8.27 (m, 2H), 7.85 (m, 2H), 7.75 (m, 2H), 7.50 (m,
6H), 7.15 (m, 1H), 4.62 (d, J=6 Hz, 2H), 3.87 (s, 2H), 3.58 (m,
4H), 2.74 (m, 4H), 2.62 (m, 2H), 2.50 (m, 1H). MS (ES, m/z): 695
[M+H].sup.+.
Example 28
3-((3-((4-(Hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-2-(4-((3-(trifluoromethy-
l)-benzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic
acid
##STR00176##
[0505] This compound was prepared according to the procedure
described for the synthesis of
3-((3-((4-morpholino-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)-carbamoyl)benzyl)thio)propanoic acid 14, using
octahydrocyclopenta[c]pyrrole in place of morpholine. .sup.1H-NMR
(300 MHz, DMSO-d.sub.6+D.sub.2O, ppm): .delta. 9.54 (s, 1H), 8.92
(d, J=3 Hz, 1H), 8.25 (s, 1H), 8.11 (d, J=9 Hz, 1H), 7.73 (m, 2H),
7.58 (m, 2H), 7.49 (m, 2H), 7.45 (m, 2H), 7.02 (s, 1H), 6.80 (d,
J=9 Hz, 1H), 4.60 (s, 2H), 3.84 (s, 2H), 3.05 (d, J=6 Hz, 2H), 2.77
(m, 2H), 2.56 (m, 3H), 1.80 (m, 2H), 1.52 (m, 3H). MS (ES, m/z):
703 [M+H].sup.+.
Example 29
3-((3-((4-Ethoxy-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)p-
henyl)carbamoyl)benzyl)thio)propanoic acid
##STR00177##
[0507] This compound was prepared according to the procedure
described for the synthesis of
3-((3-((4-morpholino-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 14, using ethanol
in place of morpholine. .sup.1H-NMR (300 MHz, DMSO, ppm): .delta.
12.49 (s, 1H), 9.57 (m, 1H), 8.98-8.96 (m, 1H), 8.41-8.38 (m, 2H),
7.88-7.54 (m, 10H), 7.16-7.10 (m, 2H), 4.63 (m, 2H), 4.14-4.12 (m,
2H), 3.88 (s, 2H), 2.60-2.58 (m, 2H), 1.37-1.35 (t, J=3 Hz, 3H). MS
(ES, m/z): 638 [M+H].sup.+.
Example 30
3-((3-((4-Methoxy-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00178##
[0509] This compound was prepared according to the procedure
described for the synthesis of
3-((3-((4-morpholino-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 14, using methanol
in place of morpholine. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 12.40 (s, 1H), 9.55 (m, 1H), 8.98-8.96 (m, 1H), 8.39-8.36
(m, 2H), 7.87-7.47 (m, 10H), 7.16-7.14 (m, 1H), 4.62-4.61 (m, 2H),
3.88 (s, 1H), 3.86 (s, 3H), 2.62-2.58 (m, 2H). MS (ES, m/z): 624
[M+H].sup.+.
Example 31
3-((3-((4-(4-Methoxypiperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carba-
moyl)-pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00179##
[0511] This compound was prepared according to the procedure
described for the synthesis of
3-((3-((4-morpholino-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)-carbamoyl)benzyl)thio)propanoic acid 14, using
4-methoxypiperidine in place of morpholine and using triethylamine
in place of potassium carbonate in the nucleophilic aromatic
substitution step. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm) .delta.
8.98 (d, J=4.1 Hz, 1H), 8.47 (d, J=9 Hz, 1H) 8.33 (s, 1H), 7.94 (s,
1H), 7.84 (m, 2H), 7.72-7.46 (m, 7H), 7.38 (d, J=7.5 Hz, 1H), 4.71
(s, 3H), 3.89 (s, 2H), 3.72 (m, 2H), 3.55 (m, 1H), 3.33 (s, 3H),
3.26 (m, 2H), 2.74 (t, 2H), 2.56 (t, 2H), 2.20 (m, 2H), 1.88 (m,
2H). MS (ES, m/z): 707 [M+H].sup.+.
Example 32
3-((3-((4-((2,2,2-Trifluoroethoxy)-2-(4-((3-(trifluoromethyl)benzyl)carbam-
oyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00180##
[0512] Intermediate 32a:
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(2,2,2-trifluoroethoxy)-phenyl-
)isonicotinamide
[0513] Into a 50-mL round-bottom flask, was placed a solution of
2,2,2-trifluoroethanol (150 mg, 1.50 mmol, 2.00 equiv) in
tetrahydrofuran (10 mL). This was followed by the addition of
sodium hydride (180 mg, 7.50 mmol, 10.00 equiv), in portions at
0.degree. C. The resulting solution was stirred for 20 min at
0.degree. C. in an ice/salt bath. To this was added
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
14d (300 mg, 0.72 mmol, 1.00 equiv). The resulting solution was
stirred overnight at room temperature. The resulting solution was
diluted with 20 mL of water. The resulting solution was extracted
with 3.times.20 mL of dichloromethane and the organic layers
combined and dried over sodium sulfate and concentrated under
vacuum. This resulted in 200 mg (crude) of
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(2,2,2-trifluoroethoxy)phenyl)-
isonicotinamide as a yellow solid.
Intermediate 32b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(2,2,2-trifluoroethoxy)-phenyl-
)isonicotinamide
[0514] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(2,2,2-trifluoroethoxy)phenyl)-
isonicotinamide (200 mg, 0.40 mmol, 1.00 equiv) in methanol (5 mL).
The solution was treated with Pd/C (0.2 g), and stirred under an
atmosphere of hydrogen for 2 h at room temperature. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
This resulted in 200 mg (crude) of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(2,2,2-trifluoroethoxy)phenyl)-
isonicotinamide as a yellow solid.
Intermediate 32c: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2--
trifluoroethoxy)phenyl)carbamoyl)benzylthio)propanoate
[0515] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(2,2,2-trifluoroethoxy)phenyl)-
isonicotinamide (200 mg, 0.43 mmol, 1.00 equiv) in
N,N-dimethylformamide (3 mL),
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (200 mg, 0.74
mmol, 1.50 equiv), EDC.HCl (190 mg, 0.99 mmol, 2.00 equiv), and
4-dimethylaminopyridine (60 mg, 0.49 mmol, 1.00 equiv). The
resulting solution was stirred for 2 h at room temperature. This
resulted in 300 mg (crude) of tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2--
trifluoroethoxy)phenyl)-carbamoyl)benzylthio)propanoate as a yellow
solid.
Example 32
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2-t-
rifluoroethoxy)phenyl)carbamoyl)benzylthio)propanoic acid
[0516] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2--
trifluoroethoxy)phenyl)-carbamoyl)benzylthio)propanoate (200 mg,
0.27 mmol, 1.00 equiv) in dichloromethane (5 mL), and
trifluoroacetic acid (2 mL). The resulting solution was stirred
overnight at room temperature. The reaction progress was monitored
by LCMS. The resulting mixture was concentrated under vacuum. The
crude product (200 mg) was purified by reverse phase HPLC eluting
with a water/CH.sub.3CN gradient containing 0.05% TFA. The product
was obtained as 68 mg (37%) of a light yellow solid. .sup.1H-NMR
(300 MHz, DMSO-d.sub.6, ppm): .delta. 12.61 (s, 1H), 9.57-9.54 (m,
1H), 8.99-8.98 (m, 1H), 8.49-8.41 (m, 2H), 7.89-7.79 (m, 10H),
7.30-7.26 (m, 1H), 4.92-4.84 (dd, J=18 Hz, 9 Hz, 2H), 4.65-4.63 (d,
J=5.4 Hz, 2H), 3.89 (s, 2H), 2.63-2.59 (m, 4H). MS (ES, m/z): 692
[M+H].sup.+.
Example 33
3-((3-((4-Methoxy-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00181##
[0518] This compound was prepared according to the procedure
described for the synthesis of
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2--
trifluoroethoxy)-phenyl)carbamoyl)benzylthio)propanoic acid 32,
using isobutanol in place of trifluoroethanol. .sup.1H-NMR (300
MHz, DMSO-d.sub.6, ppm): .delta. 12.44 (s, 1H), 9.56 (m, 1H), 8.97
(m, 1H), 8.36 (m, 2H), 7.87-7.52 (m, 10H), 7.16 (m, 1H), 4.63 (d,
2H), 3.87 (m, 4H), 2.59 (m, 2H), 2.06 (m, 2H), 1.03 (m, 6H). MS
(ES, m/z): 666 [M+H].sup.+.
Example 34
3-((3-((4-(2-Methoxyethoxy)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyr-
idin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00182##
[0520] This compound was prepared according to the procedure
described for the synthesis of
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2--
trifluoroethoxy)phenyl)carbamoyl)benzylthio)propanoic acid 32 using
2-methoxyethanol in place of trifluoroethanol. .sup.1H-NMR (400
MHz, DMSO-d.sub.6, ppm): .delta. 12.55 (s, 1H), 9.60-9.58 (m, 1H),
8.99-8.97 (m, 1H), 8.43-8.39 (m, 2H), 7.89-7.49 (m, 11H), 7.18-7.15
(m, 1H), 4.64-4.63 (m, 2H), 4.22-4.20 (t, J=6 Hz, J=3 Hz, 2H), 3.89
(s, 2H), 3.71-3.69 (t, J=6 Hz, J=3 Hz, 2H), 3.33 (s, 3H), 2.63-2.59
(m, 2H). MS (ES, m/z): 668 [M+H].sup.+.
Example 35
3-((3-((4-(Ethylthio)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00183##
[0521] Intermediate 35a:
N-(3-(trifluoromethyl)benzyl)-2-(5-(ethylthio)-2-nitrophenyl)-isonicotina-
mide
[0522] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicotinamide
14d (300 mg, 0.72 mmol, 1.00 equiv) in DMSO (5 mL), and sodium
ethanethiolate (100 mg, 1.19 mmol, 1.70 equiv). The resulting
solution was stirred for overnight at 90.degree. C. in an oil bath.
The mixture was concentrated under vacuum. The residue was diluted
with 20 mL of water. The resulting solution was extracted with
3.times.20 mL of dichloromethane and the organic layers combined.
The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. This resulted in 300 mg (crude) of
N-(3-(trifluoromethyl)benzyl)-2-(5-(ethylthio)-2-nitrophenyl)isonicotinam-
ide as a yellow solid.
Intermediate 35b:
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(ethylthio)phenyl)-isonicotina-
mide
[0523] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-(ethylthio)-2-nitrophenyl)isonicotinam-
ide (300 mg, 0.65 mmol, 1.00 equiv) in methanol (5 mL). The
solution was treated with Pd/C (300 mg), and stirred under an
atmosphere of hydrogen for 2 h at room temperature. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
This resulted in 200 mg (71%) of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(ethylthio)phenyl)isonicotinam-
ide as a yellow solid.
Intermediate 35c: tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(ethylt-
hio)phenyl)carbamoyl)benzylthio)propanoate
[0524] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(ethylthio)phenyl)isonicotinam-
ide (200 mg, 0.46 mmol, 1.00 equiv) in N,N-dimethylformamide (5
mL), 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (200 mg,
0.68 mmol, 1.50 equiv), EDC.HCl (190 mg, 0.99 mmol, 2.00 equiv),
and 4-dimethylaminopyridine (60 mg, 0.49 mmol, 1.00 equiv). The
resulting solution was stirred for 2 h at room temperature. The
resulting mixture was concentrated under vacuum. This resulted in
300 mg (crude) of tert-butyl
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(ethylt-
hio)phenyl)carbamoyl)-benzylthio)propanoate as a yellow solid.
Example 35
3-(3-(4-(ethylthio)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)-
phenylcarbamoyl)benzylthio)propanoic acid
[0525] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
3-(3-(4-(ethylthio)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl-
)phenylcarbamoyl)benzylthio)propanoate (200 mg, 0.28 mmol, 1.00
equiv) in dichloromethane (5 mL), and trifluoroacetic acid (2 mL).
The resulting solution was stirred overnight at room temperature.
The reaction progress was monitored by LCMS. The resulting mixture
was concentrated under vacuum. The crude product (0.2 g) was
purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained 40.4 mg
(21%) of a light yellow solid. .sup.1H-NMR (400 MHz, DMSO-d.sub.6,
ppm): .delta. 12.85 (s, 1H), 12.28 (s, 1H), 9.60-9.57 (m, 1H),
9.01-8.99 (m, 1H), 8.55-8.53 (m, 1H), 8.39 (s, 1H), 7.96-7.51 (m,
11H), 4.65-4.64 (d, J=5.2 Hz, 2H), 3.90 (s, 2H), 3.08-3.03 (m, 2H),
2.63-2.59 (t, J=5.1 Hz, 2H), 1.28-1.24 (t, J=5.7 Hz, 3H). MS (ES,
m/z): 654 [M+H].sup.+.
Example 36
3-((3-((4-Phenoxy-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00184##
[0527] This compound was prepared according to the procedure
described for the synthesis of
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2--
trifluoroethoxy)phenyl)carbamoyl)benzylthio)propanoic acid 32 using
phenol in place of trifluoroethanol. .sup.1H-NMR- (300 MHz,
CD.sub.3OD, ppm): .delta. 8.97 (m, 1H), 8.47-8.50 (d, 1H), 8.24 (s,
1H), 7.96 (s, 1H), 7.81-7.86 (m, 2H), 7.36-7.69 (m, 6H), 7.36-7.40
(m, 2H), 7.05-7.15 (m, 4H), 4.66 (s, 2H), 3.89 (s, 2H), 2.70-2.74
(m, 2H), 2.56-2.61 (m, 2H). MS (ES, m/z): 686 [M+H].sup.+.
Example 37
(S)--N1-Methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((1,2,3,-
4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00185##
[0528] Intermediate 37a: methyl
2-(2-(3-(methyl(2-morpholinoethyl)carbamoyl)benzamido)-5-(piperidin-1-yl)-
phenyl)isonicotinate
[0529] A solution of 150 mg of methyl
2-(2-amino-5-(piperidin-1-yl)phenyl)isonicotinate 1.1h, 169 mg of
3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid, and 249 mg of
diisopropylethylamine in 3 mL of DMF was treated with 202 mg of
HATU. The mixture was stirred for 2 h and then it was diluted with
20 mL of water. The resulting precipitate was collected by
filtration and dissolved in dichloromethane. The solution was
washed with water and then dried over Na.sub.2SO.sub.4. The solvent
was evaporated to give the product as 231 mg of an orange oil.
Intermediate 37b:
2-(2-(3-(methyl(2-morpholinoethyl)carbamoyl)benzamido)-5-(piperidin-1-yl)-
phenyl)isonicotinic acid
[0530] A solution of 231 mg of methyl
2-(2-(3-(methyl(2-morpholinoethyl)carbamoyl)benzamido)-5-(piperidin-1-yl)-
phenyl)isonicotinate in 9 mL of 2:1 dioxane/water was treated with
33 mg of lithium hydroxide hydrate. After stirring for 1 h the
solvent was evaporated and the residue was partitioned between
dichloromethane and 3 N hydrochloric acid. The aqueous phase was
evaporated to give the product as 280 mg of a yellow solid.
Example 37c
(S)--N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((1,2,3,-
4-tetrahydronaphthale
1-yl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0531] A solution of 550 mg of
2-(2-(3-(methyl(2-morpholinoethyl)carbamoyl)benzamido)-5-(piperidin-1-yl)-
phenyl)isonicotinic acid, 142 mg of
(S)-1,2,3,4-tetrahydronaphthalen-1-amine, and 497 mg of
diisopropylethylamine in 6 mL of DMF was treated with 366 mg of
HATU. After stirring for 2 h the product was isolated by reverse
phase HPLC, eluting with 0.05% TFA in a water/acetonitrile
gradient. The procedure gave 220 mg of product.
Example 37
S)--N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4--
tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
trihydrochloride
[0532] Into a 100-mL round-bottom flask, was placed a solution of
(S)--N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,-
4-tetrahydronaphthalen-1-yl-carbamoyl)pyridin-2-yl)phenyl)isophthalamide
(1.02 g, 1.46 mmol, 1.00 equiv) in methanol (30 mL). Hydrogen
chloride gas was bubbled through the reaction mixture for 15
minutes. The resulting solution was stirred for 2 min at 5.degree.
C. in a water/ice bath. The resulting mixture was concentrated
under vacuum. The resulting mixture was washed with 2.times.20 mL
of diethyl ether. This resulted in 1.12 g (93%) of
(S)--N1-methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,-
4-tetrahydronaphthalen-1-yl-carbamoyl)pyridin-2-yl)phenyl)isophthalamide
trihydrochloride as a yellow solid. .sup.1H-NMR (300 MHz,
CD.sub.3OD, ppm): .delta. 9.00 (d, J=5.4 Hz, 1H), 8.60.about.8.58
(m, 2H), 8.51 (s, 1H), 8.34 (s, 1H), 8.20.about.7.91 (m, 3H), 7.84
(d, J=7.2 Hz, 1H), 7.72.about.7.67 (m, 1H), 7.25.about.7.16 (m,
4H), 5.39.about.5.37 (m, 1H), 4.14.about.3.88 (m, 6H),
3.84.about.3.76 (m, 6H), 3.56.about.3.55 (m, 2H), 3.28.about.3.24
(m, 2H), 3.12 (s, 3H), 2.91.about.2.83 (m, 2H), 2.14.about.1.86 (m,
10H). MS (ES, m/z): 701 [M+H].sup.+.
Example 38
Tert-butyl
4-(2-(methyl(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)b-
enzyl)-carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)amino)ethyl)piperazi-
ne-1-carboxylate
##STR00186##
[0533] Intermediate 38a: tert-butyl
4-(2-chloroethyl)piperazine-1-carboxylate
[0534] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate (2.31 g,
10.03 mmol, 1.00 equiv) in dichloromethane (20 mL) and a solution
of thionyl chloride (1.5 mL, 2.00 equiv) in dichloromethane (3 mL)
was added dropwise at 0.degree. C. The resulting solution was
stirred overnight at 25.degree. C. The resulting mixture was
concentrated under vacuum. The resulting solution was diluted with
10 mL of water. The resulting solution was extracted with
2.times.25 mL of ethyl acetate and the organic layers combined. The
resulting mixture was washed with 2.times.15 mL of sodium
bicarbonate aq. and 2.times.10 mL of brine. The mixture was dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:5). This resulted in 1.16 g (46%) of
tert-butyl 4-(2-chloroethyl)piperazine-1-carboxylate as a off-white
solid.
Intermediate 38b: tert-butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate
[0535] Into a 50-mL sealed tube, was placed tert-butyl
4-(2-chloroethyl)piperazine-1-carboxylate (300 mg, 1.21 mmol, 1.00
equiv), methylamine (in ethanol) (10 mL), and NaI (100 mg). The
resulting solution was stirred for 12 h at 70.degree. C. in an oil
bath. The resulting mixture was concentrated under vacuum. The
resulting solution was diluted with 3 mL of water and adjusted to
pH 7-8 with sodium bicarbonate (5%). The resulting solution was
extracted with 2.times.5 mL of dichloromethane and the organic
layers combined. The resulting mixture was washed with 1.times.3 mL
of water and 1.times.3 mL of brine. The resulting mixture was
concentrated under vacuum. This resulted in 180 mg (crude) of
tert-butyl 4-(2-(methylamino)ethyl)piperazine-1-carboxylate as
brown oil.
Example 38
tert-butyl
4-(2-(methyl(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)b-
enzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)amino)ethyl)-piperazi-
ne-1-carboxylate
[0536] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(chloromethyl)benzamido)-5-(piperid-
in-1-yl)phenyl)-isonicotinamide (100 mg, 0.17 mmol, 1.00 equiv) in
N,N-dimethylformamide (2.5 mL), acetone (2.5 mL), tert-butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate (48 mg, 0.20 mmol,
1.20 equiv), potassium carbonate (68 mg, 0.49 mmol, 3.00 equiv),
and potassium iodide (6 mg, 0.04 mmol, 0.20 equiv). The resulting
solution was stirred for 2.5 h at 70.degree. C. in an oil bath. The
resulting mixture was concentrated under vacuum. The crude product
(100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 75.5 mg (49%) of a yellow solid. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6, ppm): .delta. 12.28 (s, 1H), 9.58-9.54 (m, 1H),
8.94-8.92 (d, J=5.1 Hz, 1H), 8.33-8.27 (m, 2H), 8.04 (s, 1H),
7.96-7.93 (d, J=7.8 Hz, 1H), 7.85-7.84 (d, J=4.2 Hz, 1H), 7.71-7.55
(m, 7H), 7.31-7.28 (d, J=8.1 Hz, 1H), 4.64-4.62 (d, J=5.7 Hz, 2H),
4.29 (s, 2H), 3.44-3.31 (m, 8H), 3.20 (s, 2H), 3.06 (s, 2H),
3.27-3.26 (m, 6H), 1.73 (s, 4H), 1.60 (s, 2H), 1.39 (s, 9H). MS
(ES, m/z): 814 [M+H].sup.+.
Example 39
2-(2-(3-((Methyl(2-(4-methylpiperazin-1-yl)ethyl)amino)methyl)benzamido)-5-
-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00187##
[0538] Into a 25-mL round-bottom flask, was placed 160 mg of
tert-butyl
4-(2-(methyl(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carb-
amoyl)pyridin-2-yl)phenyl)-carbamoyl)benzyl)amino)ethyl)piperazine-1-carbo-
xylate Example 38 and 10 mL of 1:1 dichloromethane/TFA. After
stirring for 2 hours, the solvent was evaporated. The residue was
partitioned between ethyl acetate and aqueous sodium bicarbonate
solution. The organic phase was dried and the solvent was
evaporated. The residue was treated with triethylamine (78 mg, 0.77
mmol, 6.00 equiv), and dichloromethane (2 mL). This was followed by
dropwise addition of a solution of methanesulfonyl chloride (21.9
mg, 0.19 mmol, 1.50 equiv) in dichloromethane (1 mL) with stirring
at 0.degree. C. The resulting solution was stirred for 4 h at
25.degree. C. The resulting mixture was concentrated under vacuum.
The crude product (200 mg) was purified by reverse phase HPLC
eluting with a water/CH.sub.3CN gradient containing 0.05% TFA. The
product was obtained as 45 mg (28%) of a yellow solid. .sup.1H-NMR
(300 MHz, DMSO-d.sub.6, ppm): .delta. 12.31 (s, 1H), 9.55-9.59 (t,
J=6.6 Hz, 1H), 8.93-8.94 (d, J=3 Hz, 1H), 8.35 (s, 1H), 8.27-8.30
(d, J=9 Hz, 1H), 8.09 (s, 1H), 7.96-7.98 (d, J=6 Hz, 1H), 7.85-7.86
(d, J=3 Hz, 1H), 7.56-7.76 (m, 7H), 7.31-7.34 (d, J=9 Hz, 1H),
4.62-4.64 (d, J=6 Hz, 2H), 4.39 (s, 2H), 3.34 (s, 4H), 3.22-3.24
(d, J=6 Hz, 6H), 2.90 (s, 5H), 2.74 (s, 3H), 2.69 (s, 4H), 1.75 (s,
4H), 1.60-1.61 (d, J=3 Hz, 2H). MS (ES, m/z): 792 [M+H].sup.+.
Example 40
2-(2-(3-((Methyl(2-(4-methylpiperazin-1-yl)ethyl)amino)methyl)benzamido)-5-
-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00188##
[0540] Into a 25-mL round-bottom flask, was placed 190 mg of
tert-butyl
4-(2-(methyl(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carb-
amoyl)pyridin-2-yl)phenyl)-carbamoyl)benzyl)amino)ethyl)piperazine-1-carbo-
xylate and 10 mL of 1:1 dichloromethane/TFA. After stirring for 2
hours, the solvent was evaporated. The residue was dissolved in 10
mL of aqueous sodium bicarbonate solution. The mixture was stirred
for 20 minutes at room temperature. The resulting solution was
extracted with 3.times.10 mL of ethyl acetate and the organic
layers combined. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. This resulted in 150 mg of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-((methyl(2-(piperazin-1-yl)ethyl)am-
ino)methyl)-benzamido)-5-(piperidin-1-yl)phenyl)isonicotinamide.
Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-((methyl(2-(piperazin-1-yl)ethyl)am-
ino)methyl)benzamido)-5-(piperidin-1-yl)-phenyl)isonicotinamide
(150 mg, 0.21 mmol, 1.00 equiv) in formaldehyde solution (5 mL),
sodium cyanoborohydride (16 mg, 0.25 mmol, 1.20 equiv), and acetic
acid (cat.). The resulting solution was stirred for 2 h at room
temperature. The resulting solution was diluted with 2 mL of water.
The resulting solution was extracted with 2.times.5 mL of ethyl
acetate and the organic layers combined and dried over sodium
sulfate and concentrated under vacuum. The crude product (150 mg)
was purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 21.3 mg
(8%) of a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 12.18 (s, 1H), 9.57 (s, 1H), 9.56-9.54 (d, J=6.0 Hz, 1H),
8.93-8.91 (d, J=5.1 Hz, 1H), 8.32 (s, 1H), 8.23-8.20 (d, J=9.0 Hz,
1H), 8.08 (s, 1H), 7.98-7.96 (d, J=7.8 Hz, 1H), 7.84-7.82 (m, 6H),
7.50 (s, 1H), 7.22 (s, 1H), 4.81-4.80 (m, 1H), 4.68-4.60 (m, 3H),
4.44 (s, 3H), 3.41-3.38 (d, J=10.5 Hz, 2H), 3.28-3.20 (m, 6H),
2.98-2.94 (d, J=12 Hz, 4H), 2.78-2.73 (m, 7H), 2.51-2.49 (m, 2H),
1.76 (s, 4H), 1.59-1.57 (d, J=4.5 Hz, 2H). MS (ES, m/z): 728
[M+H].sup.+.
Example 41
2-(2-(3-(((2-(4-Acetylpiperazin-1-yl)ethyl)(methyl)amino)methyl)benzamido)-
-5-(piperidin-1-yl)phenyl)-N-benzylisonicotinamide
##STR00189##
[0542] The free base of
N-benzyl-2-(2-(3-((methyl(2-(piperazin-1-yl)ethyl)amino)methyl)benzamido)-
-5-(piperidin-1-yl)phenyl)isonicotinamide was prepared as described
in the preparation of
2-(2-(3-((methyl(2-(4-methylpiperazin-1-yl)ethyl)amino)methyl)benzamido)--
5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)-benzyl)isonicotinamide
40. Into a 50-mL round-bottom flask, was placed a solution of this
free base (150 mg, 0.21 mmol, 1.00 equiv) in tetrahydrofuran (5
mL), acetyl acetate (26 mg, 0.25 mmol, 1.20 equiv), and pyridine
(33 mg, 0.42 mmol, 2.00 equiv). The resulting solution was stirred
for 2 h at room temperature. The resulting mixture was concentrated
under vacuum. The crude product (200 mg) was purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 44 mg (17%) of a yellow
solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm): .delta. 12.25 (s,
1H), 9.56-9.52 (m, 1H), 8.93-8.91 (d, J=5.1 Hz, 1H), 8.33-8.26 (m,
2H), 8.04 (s, 1H), 7.96-7.93 (d, J=7.8 Hz, 1H), 7.85-7.83 (d, J=6.3
Hz, 1H), 7.70-7.55 (m, 6H), 7.29-7.26 (d, J=8.7 Hz, 1H), 4.64-4.62
(d, J=5.7 Hz, 2H), 4.29 (s, 2H), 3.54 (s, 4H), 3.30-3.21 (m, 6H),
3.03 (s, 2H), 2.80-2.73 (m, 3H), 2.66 (s, 3H), 1.99 (s, 3H), 1.73
(s, 4H), 1.60-1.59 (d, J=4.8 Hz, 1H). MS (ES, m/z): 756
[M+H].sup.+.
Example 42
2-(2-(3-((N-Methyl-2-morpholinoacetamido)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00190##
[0543] Intermediate 42a:
2-(2-(3-(bromomethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoro-
methyl)benzyl)isonicotinamide
[0544] This compound was prepared from 3-(bromomethyl)benzoyl
chloride and Intermediate 4.1c using the procedure described for
the synthesis of
2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluor-
omethyl)benzyl)isonicotinamide 8.1a.
Intermediate 42b:
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-((methylamino)methyl)-benzamido)-5--
(piperidin-1-yl)phenyl)isonicotinamide
[0545] Into a 100-mL round-bottom flask, was placed a solution of
methylamine in methanol (126 mg, 1.22 mmol, 4.00 equiv, 30%),
potassium carbonate (124 mg, 0.90 mmol, 3.00 equiv), potassium
iodide (10 mg, 0.06 mmol, 0.20 equiv), and a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (200 mg, 0.31 mmol, 1.00 equiv) in
N,N-dimethylformamide (15 mL). The resulting solution was stirred
for 3 h at 70.degree. C. in an oil bath. The resulting solution was
diluted with 250 mL of water. The resulting solution was extracted
with 4.times.20 mL of ethyl acetate and the organic layers
combined. The resulting mixture was washed with 2.times.50 mL of
brine, dried over sodium sulfate, and concentrated under vacuum.
This resulted in 200 mg (crude) of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-((methylamino)methyl)benzamido)-5-(-
piperidin-1-yl)phenyl)isonicotinamide as a yellow solid.
Example 42
2-(2-(3-((N-methyl-2-morpholinoacetamido)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0546] Into a 50-mL round-bottom flask, was placed a solution of
2-morpholinoacetic acid (25.0 mg, 0.17 mmol, 1.00 equiv) in
dichloromethane (10 mL), EDC.HCl (50.0 mg, 0.26 mmol, 1.50 equiv),
4-dimethylaminopyridine (32.0 mg, 0.26 mmol, 1.50 equiv), and
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-((methylamino)methyl)benzamido)-5-(-
piperidin-1-yl)phenyl)isonicotinamide (1000 mg, 1.66 mmol, 1.00
equiv). The resulting solution was stirred for 6 h at 25.degree. C.
in an oil bath. The resulting solution was diluted with 50 mL of
dichloromethane. The resulting mixture was washed with 2.times.30
mL of aqueous NH.sub.4Cl. The resulting mixture was washed with
brine. The mixture was dried over sodium sulfate and concentrated
under vacuum. The crude product (120 mg) was purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 47.4 mg (26%) of a
pale-yellow solid. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta.
8.90-8.98 (m, 1H), 8.57-8.64 (m, 1H), 8.40 (s, 1H), 7.84-8.00 (m,
4H), 7.54-7.72 (m, 7H), 4.72-4.76 (m, 4H), 4.36-4.38 (m, 2H), 3.96
(m, 4H), 3.58-3.61 (m, 4H), 3.01 (s, 3H), 1.99-2.00 (m, 4H), 1.75
(m, 2H). MS (ES, m/z) 729 [M+H].sup.+.
Example 43
2-Methyl-1-(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbam-
oyl)
pyridin-2-yl)phenyl)carbamoyl)phenyl)-5,8,11-trioxa-2-azatetradecan-1-
4-oic acid
##STR00191##
[0547] Intermediate 43a: tert-butyl
3-(2-(2-(2-((3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)-pyridin-2-yl-
)-4-(piperidin-1-yl)phenyl)carbamoyl)-benzyl)(methyl)amino)ethoxy)ethoxy)--
ethoxy)propanoate
[0548] Into a 8-mL round-bottom flask, was placed a solution of
tert-butyl 3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate
(89.3 mg, 0.31 mmol, 1.00 equiv) in N,N-dimethylformamide (6 mL),
potassium carbonate (84.7 mg, 0.61 mmol, 1.99 equiv), potassium
iodide (10.2 mg, 0.06 mmol, 0.20 equiv), and
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (200 mg, 0.31 mmol, 1.00 equiv). The
resulting solution was stirred overnight at 70.degree. C. The
solids were filtered out. The resulting mixture was concentrated
under vacuum. The residue was dissolved in 20 mL of
dichloromethane. The resulting mixture was washed with 2.times.20
mL of water. The resulting mixture was washed with 1.times.20 mL of
brine, dried over sodium sulfate, and concentrated under vacuum.
This resulted in 264 mg (crude) of product as yellow oil.
Example 43
2-methyl-1-(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)-carba-
moyl)pyridin-2-yl)phenyl)carbamoyl)phenyl)-5,8,11-trioxa-2-azatetradecan-1-
4-oic acid
[0549] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
3-(2-(2-(2-((3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
-4-(piperidin-1-yl)phenyl)-carbamoyl)benzyl)(methyl)amino)ethoxy)ethoxy)et-
hoxy)propanoate (264 mg, 0.31 mmol, 1.00 equiv) in dichloromethane
(2 mL), and trifluoroacetic acid (1 mL). The resulting solution was
stirred for 2 h at room temperature. The resulting mixture was
concentrated under vacuum. The crude product (200 mg) was purified
by reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. The product was obtained as 46 mg (13%) of as
a yellow solid. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta.
8.941-8.924 (d, J=5.1 Hz, 1H), 8.665-8.635 (d, J=9.0 Hz, 1H), 8.436
(s, 1H), 8.159-8.081 (m, 3H), 7.888-7.863 (m, 1H), 7.792-7.563 (m,
7H), 4.720 (s, 2H), 4.533 (s, 2H), 3.895-3.862 (m, 6H), 3.685-3.560
(m, 14H), 3.410 (s, 2H), 2.910 (s, 3H), 2.509-2.468 (m, 2H),
2.020-2.004 (s, 4H), 1.816-1.799 (s, 2H). MS (ES, m/z): 806
[M+H].sup.+.
Example 44
tert-Butyl
4-(3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)
carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)-1,4-diazepane-1-carboxyla-
te
##STR00192##
[0550] Example 44
tert-butyl
4-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
-4-(piperidin-1-yl)phenyl)carbamoyl)benzyl)-1,4-diazepane-1-carboxylate
[0551] Into a 100-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (400 mg, 0.61 mmol, 1.00 equiv) in
N,N-dimethylformamide (20 mL), potassium carbonate (248 mg, 1.79
mmol, 2.92 equiv), potassium iodide (20 mg, 0.12 mmol, 0.20 equiv),
and tert-butyl 1,4-diazepane-1-carboxylate (240 mg, 1.20 mmol, 1.95
equiv). The resulting solution was stirred for 3 h at 70.degree. C.
in an oil bath. The resulting solution was diluted with 300 mL of
water. The resulting solution was extracted with 4.times.200 mL of
ethyl acetate and the organic layers combined. The resulting
mixture was washed with 2.times.200 mL of brine. The mixture was
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with
dichloromethane:methanol (20:1.about.10:1). The product was
obtained as 400 mg (85%) of a yellow solid. .sup.1H-NMR (300 MHz,
CD.sub.3OD, ppm): .delta. 8.875-8.887 (d, J=3.6 Hz, 1H),
8.287-8.298 (d, J=3.3 Hz, 1H), 8.253 (s, 1H), 7.936 (s, 1H),
7.772-7.936 (m, 2H), 7.433-7.711 (m, 7H), 7.106-7.146 (dd, J=2.7
Hz, J=9.0 Hz, 1H), 4.689 (s, 2H), 3.740 (s, 2H), 3.482 (m, 4H),
3.197-3.232 (m, 4H), 2.656-2.693 (m, 4H), 1.720-1.847 (m, 6H),
1.614-1.649 (m, 2H), 1.420-1.459 (m, 9H). MS (ES, m/z):
771[M+H].sup.+; 793 [M+Na].sup.+.
Example 45
2-(2-(3-((4-Methyl-1,4-diazepan-1-yl)methyl)benzamido)-5-(piperidin-1-yl)p-
henyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00193##
[0553] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in
N,N-dimethylformamide (2 mL), 1-methyl-1,4-diazepane (65.4 mg, 0.57
mmol, 3.74 equiv), KI (12.7 mg, 0.08 mmol, 0.50 equiv), and
potassium carbonate (42.4 mg, 0.31 mmol, 2.00 equiv). The resulting
solution was stirred for 3 h at 70.degree. C. in an oil bath. The
reaction progress was monitored by LCMS. The resulting solution was
diluted with 20 mL of water. The resulting solution was extracted
with 3.times.20 mL of ethyl acetate and the organic layers
combined. The resulting mixture was washed with 3.times.20 mL of
brine, dried over anhydrous sodium sulfate, and concentrated under
vacuum. The crude product was purified by reverse phase HPLC
eluting with a water/CH.sub.3CN gradient containing 0.05% TFA. The
product was obtained as 40 mg (23%) of a yellow solid. .sup.1H-NMR
(400 MHz, CD.sub.3OD, ppm): .delta. 8.95-8.93 (d, J=4.2 Hz, 1H),
8.75-8.73 (d, J=6.6 Hz, 1H), 8.46 (s, 1H), 8.18-8.17 (d, J=4.2 Hz,
1H), 8.09 (s, 1H), 8.02-8.00 (d, J=8 Hz, 1H), 7.90-7.88 (m, 1H),
7.75-7.55 (m, 1H), 4.72 (s, 2H), 4.19 (s, 2H), 3.70-3.67 (t, J=5.6
Hz, 4H), 3.55-3.49 (m, 4H), 3.18-3.16 (t, J=5.6 Hz, 2H), 2.95 (s,
3H), 2.22-2.18 (m, 2H), 2.07-2.05 (t, J=5.2 Hz, 4H), 1.84-1.83 (d,
J=5.2 Hz, 1H). MS (ES, m/z): 685 [M+H].sup.+.
Example 46
2-(2-(3-((4-Acetamidopiperidin-1-yl)methyl)benzamido)-5-(piperidin-1-yl)ph-
enyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00194##
[0555] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in
N,N-dimethylformamide (2 mL), N-(piperidin-4-yl)acetamide (52.5 mg,
0.37 mmol, 2.41 equiv), potassium iodide (12.7 mg, 0.08 mmol, 0.50
equiv), and potassium carbonate (42.4 mg, 0.31 mmol, 2.00 equiv).
The resulting solution was stirred for 3 h at 70.degree. C. in an
oil bath. The reaction progress was monitored by LCMS. The
resulting solution was diluted with 20 mL of water. The resulting
solution was extracted with 3.times.20 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
3.times.20 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product was
purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 80.4 mg
(50%) of a yellow solid. .sup.1H-NMR (400 MHz, CD.sub.3OD, ppm):
.delta. 8.93-8.92 (d, J=5.2 Hz, 1H), 8.67-8.65 (d, J=8.8 Hz, 1H),
8.44 (s, 1H), 8.13-8.09 (m, 3H), 7.88-7.87 (m, 1H), 7.78-7.67 (m,
5H), 7.62-7.54 (m, 1H), 4.72 (s, 2H), 4.44 (s, 2H), 3.91 (s, 1H),
3.66-3.63 (t, J=5.2 Hz, 4H), 3.57-3.54 (m, 2H), 3.20-3.14 (m, 2H),
2.17-2.13 (m, 2H), 2.05-2.00 (m, 4H), 1.93 (s, 3H), 1.82-1.70 (m,
4H). MS (ES, m/z): 713 [M+H].sup.+.
Example 47
(S)-2-(2-(3-((3-Acetamidopyrrolidin-1-yl)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00195##
[0557] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in
N,N-dimethylformamide (10 mL), potassium carbonate (62 mg, 0.45
mmol, 2.92 equiv), potassium iodide (5 mg, 0.03 mmol, 0.20 equiv),
and (S)--N-(pyrrolidin-3-yl)acetamide (38.5 mg, 0.30 mmol, 1.96
equiv). The resulting solution was stirred for 3 h at 70.degree. C.
in an oil bath. The resulting solution was diluted with 150 mL of
water. The resulting solution was extracted with 4.times.100 mL of
ethyl acetate and the organic layers combined. The resulting
mixture was washed with 2.times.200 mL of brine. The mixture was
dried over sodium sulfate and concentrated under vacuum. The crude
product (100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 38.7 mg (24%) of a light yellow solid. .sup.1H-NMR (300
MHz, CD.sub.3OD, ppm): .delta. 8.921-8.938 (d, J=5.1 Hz, 1H),
8.623-8.653 (d, J=9.0 Hz, 1H), 8.429 (s, 1H), 8.070-8.138 (m, 3H),
7.859-7.881 (m, 1H), 7.536-7.799 (m, 7H), 4.719 (s, 2H),
4.526-4.593 (m, 2H), 4.377-7.420 (m, 1H), 3.612-3.648 (t, J=5.4 Hz,
4H), 2.500 (m, 1H), 2.007-2.022 (m, 5H), 1.946 (s, 3H), 1.803-1.818
(m, 2H). MS (ES, m/z): 699 [M+H].sup.+.
Example 48
(S)-2-(2-(3-((3-Acetamidopyrrolidin-1-yl)methyl)benzamido)-5-(piperidin-1--
yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00196##
[0559] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in
N,N-dimethylformamide (10 mL), potassium carbonate (62 mg, 0.45
mmol, 2.92 equiv), potassium iodide (5 mg, 0.03 mmol, 0.20 equiv),
and (R)--N-(pyrrolidin-3-yl)acetamide (38.5 mg, 0.30 mmol, 1.96
equiv). The resulting solution was stirred for 3 h at 70.degree. C.
in an oil bath. The resulting solution was diluted with 150 mL of
water. The resulting solution was extracted with 4.times.100 mL of
ethyl acetate and the organic layers combined. The resulting
mixture was washed with 2.times.200 mL of brine. The mixture was
dried over sodium sulfate and concentrated under vacuum. The crude
product (100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 48 mg (30%) of a light yellow solid. .sup.1H-NMR (300
MHz, CD.sub.3OD, ppm): .delta. 8.925-8.942 (d, J=5.1 Hz, 1H),
8.642-8.672 (d, J=9.0 Hz, 1H), 8.435 (s, 1H), 8.075-8.141 (m, 3H),
7.863-7.880 (m, 1H), 7.537-7.801 (m, 7H), 4.720 (s, 2H),
4.524-4.594 (m, 2H), 4.374-4.418 (m, 1H), 3.628-3.663 (m, 4H),
2.501 (m, 1H), 2.016-2.031 (m, 5H), 1.947 (m, 3H), 1.810-1.826 (m,
2H). MS (ES, m/z): 699 [M+H].sup.+.
Example 49
2-(2-(3-((4-Acetyl-1,4-diazepan-1-yl)methyl)benzamido)-5-(piperidin-1-yl)p-
henyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00197##
[0560] Intermediate 49:
2-(2-(3-((1,4-diazepan-1-yl)methyl)benzamido)-5-(piperidin-1-yl)-phenyl)--
N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0561] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
4-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)benzyl)-1,4-diazepane-1-carboxylate (100
mg, 0.13 mmol, 1.00 equiv) in dichloromethane (15 mL), and
trifluoroacetic acid (147.9 mg, 1.30 mmol, 10.00 equiv). The
resulting solution was stirred for 3 h at 15.degree. C. The
resulting mixture was concentrated under vacuum to yield 130 mg of
crude product as a red solid.
Example 49
2-(2-(3-((4-acetyl-14-diazepan-1-yl)methyl)benzamido)-5-(piperidin-1-yl)-p-
henyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0562] Into a 50-mL round-bottom flask, was placed a solution of
PH-RDX-002-1161-1 (149 mg, 0.19 mmol, 1.00 equiv) in
tetrahydrofuran (15 mL), pyridine (31 mg, 0.39 mmol, 2.00 equiv),
and acetyl acetate (33 mg, 0.23 mmol, 1.20 equiv). The resulting
solution was stirred for 3 h at room temperature. The resulting
mixture was concentrated under vacuum. The resulting solution was
diluted with 20 mL of water. The resulting solution was extracted
with 2.times.20 mL of ethyl acetate and the organic layers
combined. The resulting mixture was washed with brine. The mixture
was dried over sodium sulfate and concentrated under vacuum. The
crude product (160 mg) was purified by reverse phase HPLC eluting
with a water/CH.sub.3CN gradient containing 0.05% TFA. The product
was obtained as 92.2 mg (46%) of a pale-yellow solid. .sup.1H-NMR
(300 MHz, CD.sub.3OD, ppm): .delta. 8.907-8.924 (d, J=5.1 Hz, 1H),
8.562-8.592 (d, J=9.0 Hz, 1H), 8.402 (s, 1H), 8.082-8.146 (m, 2H),
7.986-7.994 (d, J=2.4 Hz, 1H), 7.854-7.877 (m, 1H), 7.662-7.791 (m,
4H), 7.536-7.601 (m, 3H), 4.717 (s, 2H), 4.508-4.519 (d, J=3.3 Hz,
2H), 3.656-3.698 (t, J=6.3 Hz, 2H), 3.569-3.604 (t, J=5.3 Hz, 4H),
3.466-3.480 (m, 2H), 2.249-2.265 (m, 2H), 2.152 (s, 3H), 1.993 (m,
4H), 1.784-1.802 (m, 2H). MS (ES, m/z): 713 [M+H].sup.+; 357
[(M+2H)/2].sup.+.
Example 50
2-(2-(3-((4-Acetylpiperazin-1-yl)methyl)benzamido)-5-(piperidin-1-yl)pheny-
l)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00198##
[0564] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in
N,N-dimethylformamide (2 mL), 1-(piperazin-1-yl)ethanone (59 mg,
0.46 mmol, 3.00 equiv), potassium iodide (12.7 mg, 0.08 mmol, 0.50
equiv), and potassium carbonate (42.4 mg, 0.31 mmol, 2.00 equiv).
The resulting solution was stirred for 3 h at 70.degree. C. in an
oil bath. The reaction progress was monitored by LCMS. The
resulting solution was diluted with 20 mL of water. The resulting
solution was extracted with 3.times.20 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
3.times.20 mL of brine, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The crude product was purified by
reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. The product was obtained as 54.8 mg (34%) of
a yellow solid. .sup.1H-NMR (400 MHz, CD.sub.3OD, ppm): 8.94-8.92
(d, J=4.2 Hz, 1H), 8.66-8.64 (d, J=6.6 Hz, 1H), 8.43 (s, 1H),
8.14-8.09 (m, 3H), 7.88-7.87 (m, 1H), 7.79-7.54 (m, 7H), 4.72 (s,
2H), 4.47 (s, 2H), 3.82 (s, 3H), 3.65-3.62 (t, J=4.2 Hz, 1H),
3.33-3.29 (m, 5H), 2.15 (s, 3H), 2.04-2.01 (t, J=5.2 Hz, 4H),
1.82-1.81 (d, J=5.2 Hz, 1H). MS (ES, m/z): 699 [M+H].sup.+.
Example 51
2-(2-(3-(((3-((2-Methoxyethyl)amino)-3-oxopropyl)(methyl)amino)methyl)benz-
amido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinam-
ide
##STR00199##
[0565] 3-(benzyl(methyl)amino)-N-(2-methoxyethyl)propanamide
[0566] To methyl 3-(benzyl(methyl)amino)propanoate (1.5 g, 7.24
mmol, 1.00 equiv) was added 2-methoxyethanamine (11 g, 146.45 mmol,
20.00 equiv) and the mixture was stirred for 2 days at 100.degree.
C. in sealed tube. The resulting mixture was concentrated under
vacuum and purified via silica gel chromatography
(dichloromethane/methanol 30:1) to afford 1.1 g (61%) of the
product as a yellow oil.
N-(2-methoxyethyl)-3-(methylamino)propanamide
[0567] To a solution of
3-(benzyl(methyl)amino)-N-(2-methoxyethyl)propanamide (1.1 g, 4.39
mmol, 1.00 equiv) in methanol (50 mL) was added 5%
palladium-on-carbon (50 mg) and the suspension stirred under a
hydrogen atmosphere for 2 h. The solids were filtered out and the
mixture was concentrated under vacuum to afford 200 mg (28%) of the
product as a white solid.
Example 51
2-(2-(3-(((3-((2-methoxyethyl)amino)-3-oxopropyl)(methyl)amino)-methyl)ben-
zamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)-isonicotin-
amide
[0568] Into a 8-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)-isonicotinamide 42a (250 mg, 0.31 mmol, 1.00 equiv,
80%) in N,N-dimethylformamide (6 mL),
N-(2-methoxyethyl)-3-(methylamino)propanamide (185 mg, 1.04 mmol,
3.00 equiv, 90%), potassium carbonate (106 mg, 0.77 mmol, 2.00
equiv), and potassium iodide (32 mg, 0.19 mmol, 0.50 equiv). The
resulting solution was stirred for 5 h at 60.degree. C. The
resulting solution was diluted with 100 mL of ethyl acetate. The
resulting mixture was washed with 1.times.20 mL of 10% sodium
bicarbonate. The resulting mixture was washed with 1.times.20 mL of
brine, dried over sodium sulfate, and concentrated under vacuum.
The crude product was purified by Flash-Prep-HPLC with
water:methanol (0.05% TFA) (10:90). The product was obtained as
63.7 mg (23%) of a yellow solid. .sup.1H-NMR (300 MHz, CD.sub.3OD,
ppm): .delta. 8.87 (d, J=6 Hz, 1H), 8.29 (m, 2H), 8.06 (m, 2H),
7.70 (m, 8H), 7.31 (d, J=9 Hz, 1H), 4.70 (s, 2H), 4.50 (m, 2H),
3.43 (m, 2H), 3.39 (m, 6H), 2.89 (s, 3H), 2.76 (m, 2H), 1.86 (m,
4H), 1.73 (m, 2H). MS (ES, m/z): 731 [M+H].sup.+.
Example 52
tert-Butyl
4-(2-(methyl((6-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)-
benzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)pyridin-2-yl)methyl)amino)e-
thyl)piperazine-1-carboxylate
##STR00200##
[0569] Intermediate 52a:
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido)-5-(pipe-
ridin-1-yl)phenyl)isonicotinamide
[0570] Into a 50-mL 1-neck bottle, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)phenyl)isonico-
tinamide (1.83 g, 4.03 mmol, 1.00 equiv) in dichloromethane (30
mL), 6-(chloromethyl)picolinic acid (1.04 g, 6.05 mmol, 1.50
equiv), EDC.HCl (1.54 g, 8.06 mmol, 2.00 equiv), and
4-dimethylaminopyridine (490 mg, 4.02 mmol, 1.00 equiv). The
resulting solution was stirred for 4 h at 25.degree. C. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column and eluted with
dichloromethane:methanol (100:1). The product was obtained as 2 g
(82%) of a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 13.01 (s, 1H), 9.54 (t, J=8.7 Hz, 1H), 9.09 (d, J=5.1 Hz,
1H), 8.51 (d, J=9.0 Hz, 1H), 8.25 (s, 1H), 8.12-8.04 (m, 2H),
7.87-7.37 (m, 6H), 7.36 (s, 1H), 7.14 (dd, J=9.0 Hz, 1H), 4.95 (s,
2H), 4.65 (t, J=4.8 Hz, 2H), 3.34-3.20 (m, 4H), 1.67-1.55 (m, 6H).
MS (ES, m/z): 608 [M+H].sup.+.
Example 52
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido)-5-(piper-
idin-1-yl)phenyl)isonicotinamide
[0571] Into a 8-mL sealed tube, was placed a solution of
6-(chloromethyl)-N-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcar-
bamoyl)pyridin-2-yl)phenyl)picolinamide (166 mg, 0.27 mmol, 1.00
equiv) in N,N-dimethylformamide (5 mL), tert-butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate (100 mg, 0.41
mmol, 1.50 equiv), potassium carbonate (114 mg, 0.82 mmol, 3.00
equiv), and potassium iodide (9 mg, 0.05 mmol, 0.20 equiv). The
resulting solution was stirred for 3 h at 65.degree. C. The
resulting solution was diluted with 10 mL of water. The resulting
solution was extracted with 3.times.30 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
3.times.30 mL of brine. The mixture was dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with dichloromethane:methanol (100:1-40:1). This
resulted in 180 mg (81%) of tert-butyl
4-(2-(methyl((6-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbam-
oyl)pyridin-2-yl)-phenylcarbamoyl)pyridin-2-yl)methyl)amino)ethyl)piperazi-
ne-1-carboxylate as a yellow solid. .sup.1H-NMR (400 MHz,
DMSO-d.sub.6, ppm): .delta. 12.88 (s, 1H), 9.54 (t, J=6.0 Hz, 1H),
9.04 (d, J=4.8 Hz, 1H), 8.51 (d, J=9.2 Hz, 1H), 8.24 (s, 1H), 8.01
(d, J=4.0 Hz, 2H), 7.88 (dd, J=4.8 Hz, 1H), 7.56-7.72 (m, 5H), 7.34
(d, J=3.6 Hz, 1H), 7.14 (dd, J=9.2 Hz, 1H), 4.64 (d, J=5.6 Hz, 2H),
3.78 (s, 2H), 3.20-3.78 (m, 8H), 1.67-2.56 (m, 11H), 1.57-1.66 (m,
6H), 1.35 (s, 9H). MS (ES, m/z): 815 [M+H].
Example 53
6-((N-Methyl-2-morpholinoacetamido)methyl)-N-(4-(piperidin-1-yl)-2-(4-((3--
(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picolinamide
##STR00201##
[0572] Intermediate 53a:
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-((methylamino)methyl)-picolinamido)-
-5-(piperidin-1-yl)phenyl)isonicotinamide
[0573] Into a 10-mL vial, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido)-5-(pipe-
ridin-1-yl)phenyl)isonicotinamide (150 mg, 0.25 mmol, 1.00 equiv)
in dichloromethane (5 mL), methylamine (2 mL). The resulting
solution was stirred for 48 h at 25.degree. C. in an oil bath. The
reaction progress was monitored by LCMS. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with ethyl acetate/petroleum ether
(1:10-1:5). The product was obtained as 110 mg (74%) of a yellow
solid.
Example 53
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-((N-methyl-2-morpholinoacetamido)-me-
thyl)picolinamido)-5-(piperidin-1-yl)phenyl)isonicotinamide
[0574] Into a 50-mL vial, was placed
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-((methylamino)methyl)picolinamido)--
5-(piperidin-1-yl)phenyl)isonicotinamide (100 mg, 0.17 mmol, 1.00
equiv) in dichloromethane (10 mL), 2-morpholinoacetic acid (28.9
mg, 0.20 mmol, 1.20 equiv), EDC.HCl (47.4 mg, 0.25 mmol, 1.50
equiv), and 4-dimethylaminopyridine (30.4 mg, 0.25 mmol, 1.50
equiv). The resulting solution was stirred for 4 h at 25.degree. C.
in an oil bath. The reaction progress was monitored by LCMS. The
resulting solution was diluted with 50 mL of dichloromethane. The
resulting mixture was washed with 3.times.50 mL of aqueous
NH.sub.4Cl, dried over anhydrous sodium sulfate, and concentrated
under vacuum. The crude product (200 mg) was purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 116 mg (59%) of a yellow
solid. .sup.1H-NMR (400 MHz, CD.sub.3OD, ppm): .delta. 9.12 (m,
1H), 8.86 (d, J=9.2 Hz, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.17 (m, 1H),
8.12 (m, 1H), 8.01 (m, 1H), 7.95 (m, 1H), 7.80 (m, 3H), 7.60 (m,
3H), 4.96 (m, 2H), 4.72 (s, 2H), 4.50 (m, 2H), 3.98 (m, 4H), 3.70
(m, 4H), 3.1 (s, 3H), 2.10 (m, 4H), 1.98 (s, 2H). MS (ES, m/z): 730
[M+H].sup.+.
Example 54
2-Methyl-1-(6-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbam-
oyl)pyridin-2-yl)phenyl)carbamoyl)pyridin-2-yl)-5,8,11-trioxa-2-azatetrade-
can-14-oic acid
##STR00202##
[0575] Intermediate 54a: tert-butyl
3-(2-(2-(2-(((6-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)-pyridin-2-y-
l)-4-(piperidin-1-yl)phenyl)carbamoyl)pyridin-2-yl)methyl)(methyl)amino)-e-
thoxy)ethoxy)ethoxy)propanoate
[0576] Into a 10-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido)-5-(pipe-
ridin-1-yl)phenyl)isonicotinamide (200 mg, 0.33 mmol, 1.00 equiv)
in N,N-dimethylformamide (10 mL), tert-butyl
3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate (191.7 mg,
0.66 mmol, 2.00 equiv), potassium carbonate (90.9 mg, 0.66 mmol,
2.00 equiv), and potassium iodide (109.4 mg, 0.66 mmol, 2.00
equiv). The resulting solution was stirred overnight at 60.degree.
C. in an oil bath. The resulting solution was diluted with 50 mL of
water. The resulting solution was extracted with 2.times.50 mL of
dichloromethane and the organic layers combined. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The crude product was obtained as 300 mg of a yellow oil.
Example 54
3-(2-(2-(2-(((6-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-
-4-(piperidin-1-yl)phenyl)carbamoyl)pyridin-2-yl)methyl)(methyl)amino)etho-
xy)ethoxy)-ethoxy)propanoic acid
[0577] Into a 50-mL vial, was placed a solution of tert-butyl
3-(2-(2-(2-(((6-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl-
)-4-(piperidin-1-yl)phenyl)carbamoyl)pyridin-2-yl)methyl)(methyl)amino)eth-
oxy)ethoxy)ethoxy)-propanoate (200 mg, 0.23 mmol, 1.00 equiv) in
dichloromethane (10 mL), and 2,2,2-trifluoroacetic acid (2 mL). The
resulting solution was stirred for 3 h at 25.degree. C. in an oil
bath. The reaction progress was monitored by LCMS. The resulting
mixture was concentrated under vacuum. The residue was dissolved in
50 mL of ethyl acetate. The resulting mixture was washed with
4.times.30 mL of brine, dried over sodium sulfate, and concentrated
under vacuum. The crude product (200 mg) was purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 84.9 mg (31%) of a yellow
solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm): .delta. 12.34 (s,
1H), 9.89 (s, 1H), 9.54 (m, 1H), 9.02 (m, 1H), 8.19 (m, 4H), 7.84
(m, 2H), 7.57 (m, 5H), 7.29 (s, 1H), 4.60 (t, J=5.7 Hz, 6H), 3.77
(t, J=4.8 Hz, 2H), 3.48 (m, 16H), 2.84 (s, 3H), 2.51 (m, 2H), 1.9
(s, 4H), 1.7 (s, 2H). MS (ES, m/z): 807 [M+H].sup.+.
Example 55
(R)-6-((3-Acetamidopyrrolidin-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-((3--
(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picolinamide
2,2,2-trifluoroacetate
##STR00203##
[0579] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido)-5-(pipe-
ridin-1-yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv,
90%) in N,N-dimethylformamide (3 mL),
(R)--N-(pyrrolidin-3-yl)acetamide (42 mg, 0.33 mmol, 2.00 equiv),
potassium carbonate (45 mg, 0.33 mmol, 2.00 equiv), and potassium
iodide (14 mg, 0.08 mmol, 0.50 equiv). The resulting solution was
stirred for 3 h at 60.degree. C. in an oil bath. The resulting
solution was diluted with 100 mL of ethyl acetate. The resulting
mixture was washed with 3.times.20 mL of brine, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The crude
product (100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 33.4 mg (27%) of a yellow solid. .sup.1H-NMR (300 MHz,
CD.sub.3OD, ppm): .delta. 8.90 (d, J=6 Hz, 1H), 8.40 (s, 1H), 8.26
(m, 1H), 8.21-8.09 (m, 2H), 7.98 (d, J=3 Hz, 1H), 7.82 (d, J=6 Hz,
1H), 7.71-7.50 (m, 6H), 4.65 (m, 4H), 4.20 (m, 1H), 3.85 (m, 1H),
3.66-3.63 (m, 4H), 2.50 (m, 1H), 2.00 (m, 4H), 1.80 (m, 3H), 1.68
(m, 3H). MS (ES, m/z): 700 [M+H].sup.+.
Example 56
(S)-6-((3-Acetamidopyrrolidin-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-((3--
(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picolinamide
##STR00204##
[0581] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido)-5-(pipe-
ridin-1-yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv,
90%) in N,N-dimethylformamide (3 mL),
(S)--N-(pyrrolidin-3-yl)acetamide (42 mg, 0.33 mmol, 2.00 equiv),
potassium carbonate (45 mg, 0.33 mmol, 2.00 equiv), and potassium
iodide (14 mg, 0.08 mmol, 0.50 equiv). The resulting solution was
stirred for 3 h at 60.degree. C. in an oil bath. The resulting
solution was diluted with 100 mL of ethyl acetate. The resulting
mixture was washed with 2.times.20 mL of brine, dried over
anhydrous sodium sulfate, and concentrated under vacuum. The crude
product (100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 47.8 mg (39%) of a yellow solid. .sup.1H-NMR (300 MHz,
CD.sub.3OD, ppm): .delta. 8.92 (d, J=6 Hz, 1H), 8.42 (s, 1H), 8.19
(m, 1H), 8.15 (m, 1H), 8.10 (m, 1H), 8.04 (m, 1H), 7.83 (d, J=6 Hz,
1H), 7.74 (m, 3H), 7.61 (m, 2H), 7.52 (m, 1H), 4.65 (m, 4H), 4.22
(m, 1H), 3.80 (m, 1H), 3.69-3.54 (m, 5H), 3.44 (m, 1H), 2.49 (m,
1H), 2.05-2.00 (m, 5H), 1.83-1.66 (m, 5H). MS (ES, m/z): 700
[M+H].sup.+.
Example 57
6-((4-Acetamidopiperidin-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-((3-(trif-
luoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picolinamide
##STR00205##
[0583] Into a 50-mL round-bottom flask, was placed a solution of
6-(chloromethyl)-N-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcar-
bamoyl)pyridin-2-yl)phenyl)picolinamide (100 mg, 0.16 mmol, 1.00
equiv) in N,N-dimethylformamide (2 mL), N-(piperidin-4-yl)acetamide
(35 mg, 0.25 mmol, 1.50 equiv), potassium carbonate (70 mg, 0.51
mmol, 3.00 equiv), and potassium iodide (6 mg, 0.04 mmol, 0.20
equiv). The resulting solution was stirred overnight at 60.degree.
C. The reaction progress was monitored by LCMS. The solids were
filtered out. The mixture was concentrated under vacuum. The crude
product (200 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 70.8 mg (51%) of a yellow solid. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6, ppm): .delta. 12.49 (s, 1H), 9.86 (m, 1H), 9.54 (m,
1H), 9.06 (m, 1H), 8.37-8.19 (d, J=9 Hz, 1H), 8.24-8.19 (m, 3H),
7.97-7.95 (d, J=6 Hz, 1H), 7.86-7.83 (m, 2H), 7.70-7.49 (m, 5H),
7.26 (m, 1H), 4.64-4.51 (m, 4H), 3.82 (m, 1H), 3.54-3.24 (m, 8H),
1.95-1.58 (m, 13H). MS (ES, m/z): 714 [M+H].sup.+.
Example 58
6-((4-Acetylpiperazin-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-((3-(trifluo-
romethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picolinamide
##STR00206##
[0585] Into a 8-mL sealed tube, was placed a solution of
6-(chloromethyl)-N-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcar-
bamoyl)pyridin-2-yl)phenyl)picolinamide (120 mg, 0.20 mmol, 1.00
equiv) in N,N-dimethylformamide (5 mL), 1-(piperazin-1-yl)ethanone
(37.9 mg, 0.30 mmol, 1.50 equiv), potassium carbonate (82 mg, 0.59
mmol, 3.00 equiv), and potassium iodide (7 mg, 0.04 mmol, 0.20
equiv). The resulting solution was stirred for 3 h at 65.degree. C.
The reaction was then quenched with 10 mL of water. The resulting
solution was extracted with 3.times.30 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
3.times.30 mL of brine, dried over sodium sulfate, and concentrated
under vacuum. The crude product (100 mg) was purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 89.2 mg (56%) of a yellow
solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm): .delta. 12.56 (s,
1H), 9.54 (t, J=6.0 Hz, 1H), 9.08 (d, J=5.1 Hz, 1H), 8.38 (d, J=8.7
Hz, 1H), 8.25-8.17 (m, 3H), 7.84 (d, J=3.9 Hz, 2H), 7.71-7.58 (m,
5H), 7.51 (s, 1H), 4.63 (d, J=5.7 Hz, 2H), 4.49 (s, 2H), 3.31-3.21
(m, 10H), 2.01 (s, 3H), 1.72-1.59 (m, 6H). MS (ES, m/z): 700
[M+H].sup.+.
Example 59
6-((4-Acetyl-1,4-diazepan-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-((3-(tri-
fluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picolinamide
##STR00207## ##STR00208##
[0586] Intermediate 59a: tert-butyl
4-((6-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)-carbamoyl)py-
ridin-2-yl)phenyl)carbamoyl)pyridin-2-yl)methyl)-1,4-diazepane-1-carboxyla-
te
[0587] This compound was prepared using the procedure described for
the preparation of
6-((4-acetylpiperazin-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-((3-(triflu-
oromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picolinamide 58,
substituting tert-butyl 1,4-diazepane-1-carboxylate for
-(piperazin-1-yl)ethanone.
Intermediate 59b:
6-((1,4-diazepan-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromet-
hyl)benzylcarbamoyl)pyridin-2-yl)phenyl)picolinamide
[0588] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
4-((6-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridi-
n-2-yl)phenylcarbamoyl)pyridin-2-yl)methyl)-1,4-diazepane-1-carboxylate
(150 mg, 0.18 mmol, 1.00 equiv, 95%) in dichloromethane (5 mL), and
trifluoroacetic acid (1 mL). The resulting solution was stirred
overnight at room temperature. The resulting solution was diluted
with 50 mL of dichloromethane. The solution was adjusted to pH 9
with aqueous sodium bicarbonate. The resulting solution was
extracted with 3.times.50 mL of dichloromethane and the organic
layers combined, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The product was obtained as 120 mg (97%)
of a yellow solid.
Example 59
6-((4-acetyl-1,4-diazepan-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-(3-(trif-
luoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)picolinamide
[0589] Into a 50-mL round-bottom flask, was placed a solution of
6-((1,4-diazepan-1-yl)methyl)-N-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromet-
hyl)benzylcarbamoyl)pyridin-2-yl)phenyl)picolinamide (135 mg, 0.19
mmol, 1.00 equiv, 95%) in dichloromethane (5 mL), triethylamine (40
mg, 0.39 mmol, 2.00 equiv, 99%), and acetyl chloride (18 mg, 0.23
mmol, 1.20 equiv, 99%). The resulting solution was stirred for 3 h
at room temperature. The resulting solution was diluted with 50 mL
of dichloromethane. The resulting mixture was washed with
1.times.50 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The resulting mixture was
washed with 2.times.10 mL of hexane. The product was obtained as
120 mg (87%) of a yellow solid. .sup.1H-NMR (400 MHz, DMSO-d.sub.6,
ppm): .delta. 12.86 (s, 1H), 9.54-9.51 (t, 1H), 9.00 (s, 1H),
8.51-8.49 (d, J=6 Hz, 1H), 8.23 (s, 1H), 8.00 (s, 2H), 7.88-7.86
(d, 1H), 7.72-7.55 (m 5H), 7.33 (s, 1H), 7.14-7.11 (d, J=9 Hz, 1H),
4.63 (s, 2H), 3.91-3.88 (s, J=9 Hz, 2H), 3.52-3.50 (m, 4H),
3.21-3.19 (m, 4H), 2.78-2.63 (m, 4H), 2.01-1.98 (d, J=9 Hz, 3H),
1.79-1.55 (m, 8H). MS (ES, m/z): 714 [M+H].sup.+.
Example 60
6-(((2-(4-Acetylpiperazin-1-yl)ethyl)(methyl)amino)methyl)-N-(4-(piperidin-
-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)pico-
linamide
##STR00209##
[0591] The tert-butoxycarbonyl group of tert-butyl
4-(2-(methyl((6-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)car-
bamoyl)pyridin-2-yl)phenyl)carbamoyl)pyridin-2-yl)-methyl)amino)ethyl)pipe-
razine-1-carboxylate 52 was cleaved by stirring for 1 hour in 1:1
dichloromethane/TFA and the resultant amine converted to the free
base by partitioning between ethyl acetate and aqueous sodium
bicarbonate solution. Into a 50-mL round-bottom flask, was placed a
solution of this amine (110 mg, 0.15 mmol, 1.00 equiv) in
dichloromethane (5 mL), and N,N-diisopropylethylamine (30 mg, 0.23
mmol, 1.50 equiv). This was followed by dropwise addition of a
solution of acetyl chloride (14.4 mg, 0.18 mmol, 1.20 equiv) in
dichloromethane (1 mL) with stirring at 0.degree. C. The resulting
solution was stirred for 3 h at room temperature. The resulting
mixture was concentrated under vacuum. The crude product (200 mg)
was purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 90.3 mg
(44%) of as a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6,
ppm): .delta. 12.77 (s, 1H), 9.56 (t, J=5.7 Hz, 1H), 9.06 (d, J=5.1
Hz, 1H), 8.49 (d, J=8.7 Hz, 1H), 8.28 (s, 1H), 8.15-8.09 (m, 2H),
7.90-7.79 (m, 2H), 7.72-7.56 (m, 5H), 7.34 (s, 1H), 4.64 (d, J=5.7
Hz, 2H), 4.20 (s, 2H), 3.56 (s, 4H), 3.34 (s, 4H), 3.18-2.95 (m,
7H), 2.56-2.49 (m, 4H), 1.96 (s, 3H), 1.74 (s, 4H), 1.60 (d, J=4.2
Hz, 2H). MS (ES, m/z): 757 [M+H].sup.+.
Example 61
6-((Methyl(2-(4-methylpiperazin-1-yl)ethyl)amino)methyl)-N-(4-(piperidin-1-
-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picoli-
namide
##STR00210##
[0593] The tert-butoxycarbonyl group of tert-butyl
4-(2-(methyl((6-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)car-
bamoyl)pyridin-2-yl)phenyl)carbamoyl)pyridin-2-yl)methyl)amino)ethyl)piper-
azine-1-carboxylate 52 was cleaved by stirring for 1 hour in 1:1
dichloromethane/TFA and the resultant amine converted to the free
base by partitioning between ethyl acetate and aqueous sodium
bicarbonate solution. Into a 8-mL sealed tube, was placed a
solution of
6-((methyl(2-(piperazin-1-yl)ethyl)amino)methyl)-N-(4-(piperidin-1-yl)-2--
(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)picolinamide
(100 mg, 0.14 mmol, 1.00 equiv) in tetrahydrofuran (3 mL),
NaBH(OAc).sub.3 (90 mg, 0.42 mmol, 3.00 equiv), and formaldehyde (2
mL). The resulting solution was stirred for overnight at 40.degree.
C. The resulting mixture was concentrated under vacuum. The crude
product (100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 53.7 mg (27%) of as a yellow solid. .sup.1H-NMR (300
MHz, DMSO-d.sub.6, ppm): .delta. 12.44 (s, 1H), 9.82 (s, 1H), 9.58
(t, J=5.4 Hz, 1H), 9.06 (d, J=5.1 Hz, 1H), 8.33 (d, J=9.0 Hz, 1H),
8.26 (s, 1H), 8.21-8.15 (m, 2H), 7.90-7.84 (m, 2H), 7.71-7.55 (m,
4H), 7.47 (s, 1H), 7.25 (d, J=8.1 Hz, 1H), 4.64-4.58 (m, 4H),
3.36-3.29 (m, 8H), 2.97 (s, 4H), 2.86 (s, 3H), 2.76 (s, 5H),
2.33-2.27 (m, 2H), 1.71-1.58 (m, 6H). MS (ES, m/z): 729
[M+H].sup.+.
Example 62
6-((Methyl(2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)amino)methyl)-N-(4-(p-
iperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phe-
nyl)picolinamide
##STR00211##
[0595] The tert-butoxycarbonyl group of tert-butyl
4-(2-(methyl((6-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)car-
bamoyl)pyridin-2-yl)phenyl)carbamoyl)pyridin-2-yl)methyl)amino)ethyl)piper-
azine-1-carboxylate 52 was cleaved by stirring for 1 hour in 1:1
dichloromethane/TFA and the resultant amine converted to the free
base by partitioning between ethyl acetate and aqueous sodium
bicarbonate solution. Into a 50-mL round-bottom flask, was placed a
solution of
6-((methyl(2-(piperazin-1-yl)ethyl)amino)methyl)-N-(4-(piperidin-1-yl)-2--
(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)-picolinamide
(110 mg, 0.15 mmol, 1.00 equiv) in dichloromethane (5 mL). To this
was added triethylamine (23.3 mg, 0.23 mmol, 1.50 equiv). This was
followed by dropwise addition of a solution of methanesulfonyl
chloride (21.2 mg, 0.18 mmol, 1.20 equiv) in dichloromethane (2 mL)
with stirring at 0.degree. C. The resulting solution was stirred
for 3 h at room temperature. The resulting mixture was concentrated
under vacuum. The crude product (100 mg) was purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 58.1 mg (28%) of a yellow
solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm): .delta. 12.62 (s,
1H), 9.56 (t, J=6.0 Hz, 1H), 9.05 (d, J=5.4 Hz, 1H), 8.42 (d, J=9.0
Hz, 1H), 8.27 (s, 1H), 8.16 (dd, J=4.8 Hz, 2H), 7.88-7.81 (m, 2H),
7.71 (s, 1H), 7.67-7.54 (m, 4H), 7.30 (d, J=7.8 Hz, 1H), 4.63 (d,
J=5.7 Hz, 2H), 4.35 (s, 2H), 3.32 (s, 4H), 3.18 (s, 6H), 2.99 (s,
2H), 2.88-2.84 (m, 7H), 2.68 (s, 3H), 1.73-1.59 (m, 6H). MS (ES,
m/z): 793 [M+H].sup.+.
Example 63
N-(2-Methoxyethyl)-4-(2-(methyl((6-((4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)pyridin-2-yl)methyl-
)amino)ethyl)piperazine-1-carboxamide
##STR00212##
[0596] Intermediate 63a: 4-nitrophenyl
4-(2-(methyl((6-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbam-
oyl)pyridin-2-yl)phenylcarbamoyl)pyridin-2-yl)methyl)-amino)ethyl)piperazi-
ne-1-carboxylate
[0597] The tert-butoxycarbonyl group of tert-butyl
4-(2-(methyl((6-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)car-
bamoyl)pyridin-2-yl)-phenyl)carbamoyl)pyridin-2-yl)methyl)amino)ethyl)pipe-
razine-1-carboxylate 52 was cleaved by stirring for 1 hour in 1:1
dichloromethane/TFA and the resultant amine converted to the free
base by partitioning between ethyl acetate and aqueous sodium
bicarbonate solution. Into a 50-mL round-bottom flask, was placed a
solution of
6-((methyl(2-(piperazin-1-yl)ethyl)amino)methyl)-N-(4-(piperidin-1-yl)-2--
(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)picolinamide
(100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (2 mL), and
4-nitrophenyl chloroformate (28 mg, 0.14 mmol, 1.00 equiv). The
resulting solution was stirred for 2 h at room temperature. The
mixture was concentrated under vacuum. The crude product was
obtained as 0.1 g of a yellow solid.
Example 63
N-(2-methoxyethyl)-4-(2-(methyl((6-(4-(piperidin-1-yl)-2-(4-(3-(trifluorom-
ethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)pyridin-2-yl)methyl)ami-
no)ethyl)piperazine-1-carboxamide
[0598] Into a 50-mL round-bottom flask, was placed a solution of
4-nitrophenyl
4-(2-(methyl((6-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbam-
oyl)pyridin-2-yl)phenylcarbamoyl)pyridin-2-yl)methyl)-amino)ethyl)piperazi-
ne-1-carboxylate (100 mg, 0.11 mmol, 1.00 equiv) in
N,N-dimethylformamide (5 mL), 2-methoxyethanamine (10 mg, 0.13
mmol, 1.00 equiv), and N,N-diisopropylethylamine (45 mg, 0.35 mmol,
3.00 equiv). The resulting solution was stirred overnight at room
temperature. The mixture was concentrated under vacuum. The crude
product (0.1 g) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 23.2 mg (18%) of a yellow solid. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6, ppm): .delta. 12.76 (s, 1H), 9.54-9.52 (m, 1H),
9.05-9.03 (m, 1H), 8.48-8.45 (m, 1H), 8.26 (m, 1H), 8.14-8.12 (m,
2H), 7.88-7.86 (m, 1H), 7.79-7.24 (m, 7H), 6.71 (m, 1H), 4.65-4.63
(d, J=5.7 Hz, 2H), 4.09 (m, 3H), 3.69-3.01 (m, 23H), 1.71-1.59 (m,
6H). MS (ES, m/z): 816 [M+H].sup.+.
Example 64
N1-(2-(2-Hydroxyethoxy)ethyl)-N3-(4-(piperidin-1-yl)-2-(6-((3-(trifluorome-
thyl)benzyl)amino)pyrimidin-4-yl)phenyl)isophthalamide
##STR00213##
[0599] Intermediate 64a: methyl
3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoate
[0600] Into a 1000-mL round bottom flask, was placed a solution of
3-(methoxycarbonyl)benzoic acid (20 g, 111.11 mmol, 1.00 equiv) in
N,N-dimethylformamide (500 mL), HATU (63.2 g, 166.32 mmol, 1.50
equiv), N,N-diisopropylethylamine (21.5 g, 166.67 mmol, 1.50
equiv), 2-(2-aminoethoxy)ethanol (23.3 g, 221.90 mmol, 2.00 equiv).
The resulting solution was stirred for overnight at 25.degree. C.
The resulting mixture was concentrated under vacuum. The resulting
solution was dissolved in 200 mL of ethyl acetate. The resulting
mixture was washed with 10.times.200 mL of brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with
dichloromethane:methanol (100:1). This resulted in 15 g (51%) of
methyl 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoate as red
oil.
Intermediate 64b: 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoic
acid
[0601] Into a 500-mL round bottom flask, was placed a solution of
methyl 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoate (10 g, 37.45
mmol, 1.00 equiv) in tetrahydrofuran (40 mL), and a solution of
lithium hydroxide hydrate (23.4 g, 558.33 mmol, 15.00 equiv) in
water (30 mL). The resulting solution was stirred for overnight at
room temperature. The resulting mixture was concentrated under
vacuum. The solution was adjusted to pH 3-4 with hydrochloric acid
(2 mol/L). The resulting solution was extracted with 3.times.10 mL
of ethyl acetate and the organic layers combined. The resulting
mixture was washed with 2.times.10 mL of brine, dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column and eluted with
dichloromethane:methanol (50:1). This resulted in 5 g (53%) of
3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoic acid as a yellowish
solid. .sup.1H-NMR (300 MHz DMSO-d.sub.6, ppm): .delta. 13.25 (s,
1H), 8.71 (m, 1H), 8.48 (d, J=8.5 Hz 1H), 8.06 (m, 2H), 7.62 (m,
1H), 4.59 (s, 1H), 3.41.about.3.60 (m, 8H). MS (ES, m/z): 254
[M+H].sup.+.
Example 64
N1-(2-(2-hydroxyethoxy)ethyl)-N3-(4-(piperidin-1-yl)-2-(6-((3-(trifluorome-
thyl)benzyl)amino)pyrimidin-4-yl)phenyl)isophthalamide
[0602] Into a 100-mL round bottom flask, was placed a solution of
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)pyrimid-
in-4-amine (300 mg, 0.70 mmol, 1.00 equiv) in N,N-dimethylformamide
(6 mL). This was followed by the addition of
3-(2-(2-hydroxyethoxy)ethylcarbamoyl)benzoic acid (302.2 mg, 1.19
mmol, 1.70 equiv) at room temperature. To this was added
triethylamine (156 mg, 1.54 mmol, 2.20 equiv). To the mixture was
added EDC.HCl (148.2 mg, 0.78 mmol, 1.10 equiv) at room
temperature, followed by HOBT (104.4 mg, 0.77 mmol, 1.10 equiv) at
room temperature. The resulting solution was stirred overnight at
room temperature. The resulting mixture was concentrated under
vacuum. The crude product was purified by reverse phase HPLC
eluting with a water/CH.sub.3CN gradient containing 0.05% TFA. The
product was obtained as 83.6 mg (15%) of a yellow solid.
.sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 8.76 (s, 1H), 8.40
(s, 1H), 8.039 (t, J=8.1 Hz, 2H), 7.74 (s, 1H), 7.63.about.7.57 (m,
3H), 7.53.about.7.50 (m, 2H), 7.47.about.7.40 (m, 2H), 6.93 (s,
1H), 4.81 (s, 2H), 3.71.about.3.58 (m, 8H), 3.43.about.3.39 (m,
4H), 1.84.about.1.81 (m, 6H). MS (ES, m/z): 663 [M+H].sup.+.
Example 65
N1-(4-Chloro-2-(6-((3-(trifluoromethyl)benzyl)amino)pyrimidin-4-Y)phenyl)--
N3-(2-(2-hydroxyethoxy)ethyl)isophthalamide
##STR00214## ##STR00215##
[0603] Intermediate 65a:
4-chloro-2-(6-chloropyrimidin-4-yl)aniline
[0604] Into a 250-mL round bottom flask, was placed a solution of
4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine
(3 g, 11.83 mmol, 1.00 equiv) in dioxane (120 mL), water (20 mL),
4,6-dichloropyrimidine (4.4 g, 29.53 mmol, 2.50 equiv),
triphenylarsine (360 mg, 1.18 mmol, 0.10 equiv), K.sub.3PO.sub.4
(3.8 g, 17.90 mmol, 1.50 equiv), Pd(PPh.sub.3).sub.2Cl.sub.2 (390
mg, 0.56 mmol, 0.05 equiv). The resulting solution was stirred for
3 h at 75.degree. C. in an oil bath. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:50.about.1:10).
This resulted in 1.5 g (53%) of
4-chloro-2-(6-chloropyrimidin-4-yl)benzenamine as a yellow
solid.
Intermediate 65b:
6-(2-amino-5-chlorophenyl)-N-(3-(trifluoromethyl)benzyl)pyrimidin-4-amine
[0605] Into a 50-mL round bottom flask, was placed a solution of
4-chloro-2-(6-chloropyrimidin-4-yl)benzenamine (1.5 g, 6.25 mmol,
1.00 equiv) in N,N-dimethylformamide (30 mL), potassium carbonate
(2.7 g, 19.54 mmol, 3.00 equiv), 3-(trifluoromethyl)benzylamine
(1.7 g, 9.70 mmol, 1.50 equiv). The resulting solution was stirred
overnight at 80.degree. C. in an oil bath. The resulting mixture
was concentrated under vacuum. The resulting solution was diluted
with 20 mL of ethyl acetate. The resulting mixture was washed with
2.times.20 mL of water. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:2). This
resulted in 1 g (42%) of
N-(3-(trifluoromethyl)benzyl)-6-(2-amino-5-chlorophenyl)pyrimidin-4-amine
as yellow oil
Intermediate 65c: methyl
3-((2-(6-(3-(trifluoromethyl)benzalamino)pyrimidin-4-yl)-4-chlorophenyl)c-
arbamoyl)benzoate
[0606] Into a 100-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-6-(2-amino-5-chlorophenyl)pyrimidin-4-amine
(500 mg, 1.32 mmol, 1.00 equiv) in dichloromethane (30 mL), EDC.HCl
(380 mg, 1.98 mmol, 1.50 equiv), N,N-dimethylpyridin-4-amine (242
mg, 1.98 mmol, 1.50 equiv), and 3-(methoxycarbonyl)benzoic acid
(357 mg, 1.98 mmol, 1.50 equiv). The resulting solution was stirred
for 2 h at 30.degree. C. in an oil bath. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with petroleum ether/ethyl acetate (2:1). The
product was obtained as 400 mg (56%) of a yellow solid.
Intermediate 65d:
3-((2-(6-(3-(trifluoromethyl)benzylamino)pyrimidin-4-yl)-4-chlorophenyl)c-
arbamoyl)benzoic acid
[0607] Into a 100-mL round bottom flask, was placed a solution of
methyl
3-((2-(6-(3-(trifluoromethyl)benzylamino)pyrimidin-4-yl)-4-chlorophenyl)c-
arbamoyl)benzoate (400 mg, 0.74 mmol, 1.00 equiv) in
tetrahydrofuran (30 mL), water (30 mL), and lithium hydroxide
hydrate (317 mg, 7.55 mmol, 10.00 equiv). The resulting solution
was stirred for 4 h at 30.degree. C. in an oil bath. The solution
was adjusted to pH 1 with hydrochloric acid (1 mol/L). The
resulting solution was extracted with 20 mL of ethyl acetate and
the organic layers combined, dried over anhydrous sodium sulfate,
and concentrated under vacuum. The product was obtained as 350 mg
(90%) of a white solid.
Example 65
N1-(2-(6-(3-(trifluoromethyl)benzylamino)pyrimidin-4-yl)-4-chlorophenyl)-N-
3-(2-(2-hydroxyethoxy)ethyl)isophthalamide
[0608] Into a 50-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-6-(2-amino-5-chlorophenyl)pyrimidin-4-amine
(200 mg, 0.53 mmol, 1.00 equiv) in N,N-dimethylformamide (20 mL),
HATU (290 mg, 0.76 mmol, 2.00 equiv), N,N-diisopropylethylamine
(200 mg, 1.55 mmol, 4.00 equiv), and
N1-(2-(6-(3-(trifluoromethyl)benzylamino)pyrimidin-4-yl)-4-chlorophenyl)--
N3-(2-(2-hydroxyethoxy)ethyl)isophthalamide (60 mg, 0.10 mmol, 1.50
equiv). The resulting solution was stirred overnight at 30.degree.
C. in an oil bath. The reaction progress was monitored by LCMS. The
resulting mixture was concentrated under vacuum. The crude product
was purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 105.9 mg
(33%) of a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 8.87 (s, 1H), 8.71 (t, J=4.8 Hz, 9.9 Hz, 1H), 8.49 (s, 1H),
8.07 (t, J=7.5 Hz, 15.3 Hz, 2H), 7.83 (s, 1H), 7.58 (m, 6H), 7.07
(s, 1H), 4.75 (s, 2H), 3.57 (m, 2H), 3.49 (m, 6H). MS (ES, m/z):
614 [M+H].sup.+.
Example 66
3-((3-((4-Chloro-2-(6-((3-(trifluoromethyl)benzyl)amino)pyrimidin-4-yl)phe-
nyl)carbamoyl)benzyl)thio)propanoic acid
##STR00216##
[0610] This compound was prepared from
6-(2-amino-5-chlorophenyl)-N-(3-(trifluoromethyl)benzyl)pyrimidin-4-amine
65b using the procedure described for the preparation of
3-((3-((4-(piperidin-1-yl)-2-(6-((3-methylbenzyl)amino)pyrimidin-4-yl)phe-
nyl)carbamoyl)benzyl)thio)propanoic acid 3.2 from
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3-methylbenzyl)
pyrimidin-4-amine 3.2b. .sup.1H-NMR (400 MHz, DMSO-d.sub.6, ppm):
.delta. 8.79 (s, 1H), 8.48 (s, 1H), 7.91 (s, 1H), 7.81 (d, J=5.7
Hz, 2H), 7.63 (s, 1H), 7.56 (m, 6H), 7.09 (s, 1H), 4.74 (s, 2H),
3.88 (s, 2H), 2.57 (d, J=4.8 Hz, 2H). MS (ES, m/z): 601
[M+H].sup.+.
Example 67
N-(4-Chloro-2-(6-(3-(trifluoromethyl)benzylamino)pyrimidin-4-yl)phenyl)-3--
(4-(dimethylamino)but-1-ynyl)benzamide 2,2,2-trifluoroacetate
##STR00217## ##STR00218##
[0611] Intermediate 67a: 3-(4-hydroxybut-1-yn-1-yl)benzoic acid
[0612] Into a 500-mL round bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
3-bromobenzoic acid (10 g, 49.75 mmol, 1.00 equiv) in
triethylamine/N,N-dimethylformamide (100/20 mL), but-3-yn-1-ol
(6.98 g, 99.57 mmol, 2.00 equiv), copper(I) iodide (1.90 g, 9.97
mmol, 0.20 equiv), Pd(PPh.sub.3).sub.2Cl.sub.2 (6.98 g, 9.94 mmol,
0.20 equiv). The resulting solution was stirred overnight at
80.degree. C. The resulting mixture was concentrated under vacuum.
The resulting solution was diluted with 100 mL of water. The pH
value of the solution was adjusted to 11-12 with sodium hydroxide
(1 mol/L). The resulting solution was extracted with 3.times.300 mL
of dichloromethane and the aqueous layers combined. The solution
was adjusted to pH 1-2 with hydrochloric acid (1 mol/L). The
resulting solution was extracted with 5.times.300 mL of
dichloromethane and the organic layers combined, dried over sodium
sulfate, and concentrated under vacuum. This resulted in 10 g crude
product as brown oil.
Intermediate 67b: 3-(4-((methylsulfonyl)oxy)but-1-yn-1-yl)benzoic
acid
[0613] Into a 250-mL round bottom flask, was placed a solution of
3-(4-hydroxybut-1-ynyl)benzoic acid (2 g, 10.52 mmol, 1.00 equiv)
in dichloromethane (100 mL), triethylamine (3200 mg, 31.68 mmol,
3.00 equiv), and methanesulfonic anhydride (3700 mg, 21.24 mmol,
2.00 equiv). The resulting solution was stirred for 5 h at room
temperature. The resulting mixture was concentrated under vacuum.
The residue was applied onto a silica gel column and eluted with
dichloromethane/methanol (100:1). This resulted in 3 g crude
product as a brown oil.
Example 67c
3-(4-(dimethylamino)but-1-yn-1-yl)benzoic acid trifluoroacetic acid
salt
[0614] Into a 250-mL round bottom flask, was placed a solution of
3-(4-(methylsulfonyloxy)but-1-ynyl)benzoic acid (8.23 g, 30.67
mmol, 1.00 equiv) in ethanol (50 mL), dimethylamine 33% water
solution (50 mL). The resulting solution was stirred overnight at
30.degree. C. in an oil bath. The resulting mixture was
concentrated under vacuum. The crude product (10 g) was purified by
reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. 3-(4-(dimethylamino)but-1-ynyl)benzoic acid
trifluoroacetic acid salt was obtained as 2.68 g (40%) of as yellow
oil
Example 67
N-(4-chloro-2-(6-(3-(trifluoromethyl)benzylamino)pyrimidin-4-yl)phenyl)-3--
(4-(dimethylamino)but-1-ynyl)benzamide 2,2,2-trifluoroacetate
[0615] Into a 50-mL round bottom flask, was placed a solution of
6-(2-amino-5-chlorophenyl)-N-(3-(trifluoromethyl)benzyl)pyrimidin-4-amine
57b (100 mg, 0.26 mmol, 1.00 equiv) in dichloromethane (2 mL),
3-(4-(dimethylamino)but-1-ynyl)benzoic acid (57 mg, 0.26 mmol, 1.00
equiv), EDC.HCl (76 mg, 0.40 mmol, 1.50 equiv), and
4-dimethylaminopyridine (48 mg, 0.39 mmol, 1.50 equiv). The
resulting solution was stirred overnight at 25.degree. C. The crude
product (100 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 7.4 mg (4%) of a light yellow solid. .sup.1H-NMR (300
MHz, DMSO-d.sub.6, ppm): .delta. 8.666 (s, 1H), 8.5385 (d, J=2.9
Hz, 1H), 8.430 (s, 1H), 8.1125 (d, J=6.9 Hz, 1H), 8.008 (s, 1H),
7.866 (s, 1H), 7.819 (m, 2H), 7.769 (m, 1H), 7.623 (m, 4H), 7.120
(s, 1H), 6.491 (s, 1H), 4.7285 (d, J=5.7 Hz, 2H), 4.090 (t, J=6.9
Hz, 2H), 3.169 (m, 6H), 2.930 (m, 2H). MS (ES, m/z): 578
[M+H].sup.+.
Example 68
N-(4-Chloro-2-(6-((3-(trifluoromethyl)benzyl)amino)pyrimidin-4-yl)phenyl)--
3-(((2-(diethylamino)ethyl)(methyl)amino)methyl)benzamide
##STR00219##
[0616] Intermediate 68a:
3-(((2-(diethylamino)ethyl)(methyl)amino)methyl)benzoic acid
[0617] Into a 1000-mL round bottom flask, was placed a solution of
N1,N1-diethyl-N2-methylethane-1,2-diamine (9.1 g, 63.00 mmol, 1.50
equiv, 90%) in N,N-dimethylformamide (500 mL),
3-(bromomethyl)benzoic acid (10 g, 46.51 mmol, 1.00 equiv),
potassium carbonate (7.8 g, 56.12 mmol, 1.20 equiv), and potassium
iodide (1.55 g, 9.34 mmol, 0.20 equiv). The resulting solution was
stirred for 2 h at 90.degree. C. in an oil bath. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
The crude product (10 g) was purified by reverse phase HPLC eluting
with 0.05% TFA in a water/CH.sub.3CN gradient. The product was
obtained as 6 g (46%) of a white solid. .sup.1H-NMR (300 MHz,
CDCl.sub.3, ppm): .delta. 8.01 (m, 1H), 7.89-7.87 (m, 1H),
7.28-7.22 (m, 2H), 3.99 (s, 2H), 2.97-2.72 (m, 8H), 2.28 (s, 3H),
1.13-1.01 (m, 6H). MS (ES, m/z): 265 [M+H].sup.+.
Example 68
N-(4-chloro-2-(6-((3-(trifluoromethyl)benzyl)amino)pyrimidin-4-yl)phenyl)--
3-(((2-(diethylamino)ethyl)(methyl)amino)methyl)benzamide
[0618] Into a 50-mL round bottom flask, was placed a solution of
6-(2-amino-5-chlorophenyl)-N-(3-(trifluoromethyl)benzyl)pyrimidin-4-amine
65b (200 mg, 0.53 mmol, 1.00 equiv) in N,N-dimethylformamide (5
mL), 3-(((2-(diethylamino)ethyl)(methyl)amino)methyl)benzoic acid
(130 mg, 0.49 mmol, 1.00 equiv), HATU (300 mg, 0.79 mmol, 1.50
equiv), and N,N-diisopropylethylamine (270 mg, 2.09 mmol, 5.00
equiv). The resulting solution was stirred for 2 days at 25.degree.
C. in an oil bath. The reaction was then quenched with 50 mL of
water. The resulting solution was extracted with 2.times.100 mL of
ethyl acetate and the organic layers combined. The resulting
mixture was washed with 2.times.50 mL of saturated NH.sub.4Cl,
dried over anhydrous sodium sulfate, and concentrated under vacuum.
The crude product (200 mg) was purified by reverse phase HPLC
eluting with a water/CH.sub.3CN gradient containing 0.05% TFA. The
product was obtained as 36.1 mg (9%) of a yellow solid. .sup.1H-NMR
(300 MHz, DMSO-d.sub.6, ppm): .delta. 8.73 (s, 1H), 8.60 (d, J=9.3
Hz, 1H), 8.41 (s, 1H), 8.19 (m, 1H), 7.92 (m, 3H), 7.64 (m, 7H),
7.14 (s, 1H), 4.73 (d, J=5.7 Hz, 2H), 3.35 (s, 2H), 3.14 (d, J=6.9
Hz, 4H), 1.18 (t, J=7.2 Hz, 6H). MS (ES, m/z): 625 [M+H].sup.+.
Example 69
3-((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)amino)pyridin--
2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00220## ##STR00221## ##STR00222##
[0619] Intermediate 69a:
4-fluoro-2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridine
[0620] Into a 500-mL 3-necked round bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)
piperidine (15 g, 45.18 mmol, 1.00 equiv) in DME/H.sub.2O (100/5
mL), 2-chloro-4-fluoropyridine (7.80 g, 60.00 mmol, 1.20 equiv),
K.sub.3PO.sub.4 (31 g, 146.23 mmol, 3.00 equiv),
2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) (2.00 g,
4.88 mmol, 0.10 equiv), and Pd(PPh.sub.3).sub.4 (2800 mg, 2.42
mmol, 0.05 equiv). The resu lting solution was stirred for 1
overnight at 80.degree. C. in an oil bath. The reaction progress
was monitored by LCMS. The resulting mixture was conentrated under
vacuum. The resulting solution was diluted with 200 mL of H.sub.2O,
extracted with 3.times.300 mL of dichloromethane, and the organic
layers combined. The resulting mixture was washed with 1.times.20
mL of brine, dried over anhydrous sodium sulfate, and concentrated
under vacuum. The residue was applied onto a silica gel column and
eluted with ethyl acetate/petroleum ether (10:1). The product was
obtained as 8 g of a yellow solid.
Intermediate 69b:
2-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)-pyridi-
n-4-amine
[0621] Into a 30-mL round bottom flask, was placed a solution of
4-fluoro-2-(2-nitro-5-(piperidin-1-yl) phenyl)pyridine (500 mg,
1.66 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL),
(3-(trifluoromethyl)benzylamine (581 mg, 3.32 mmol, 2.00 equiv),
and potassium carbonate (985 mg, 7.14 mmol, 4.00 equiv). The
resulting solution was stirred overnight at 100.degree. C. in an
oil bath. The resulting solution was diluted with 30 mL of water.
The resulting solution was extracted with 3.times.30 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 2.times.20 mL of brine and concentrated under vacuum.
The residue was applied onto a silica gel column and eluted with
ethyl acetate/hexane (1:1). The product was obtained as 500 mg
(66%) of a yellow oil.
Intermediate 69c: tert-butyl
2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl(3-(trifluoro-methyl)benz-
yl)carbamate
[0622] Into a 100-mL round bottom flask, was placed a solution of
2-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)pyridin-
-4-amine (670 mg, 1.47 mmol, 1.00 equiv) in dichloromethane (40
mL), (Boc).sub.2O (960 mg, 4.40 mmol, 3.00 equiv), and
4-dimethylaminopyridine (268 mg, 2.20 mmol, 1.50 equiv). The
resulting solution was stirred overnight at 35.degree. C. in an oil
bath. The resulting mixture was concentrated under vacuum. The
resulting solution was diluted with 30/30 mL of H.sub.2O/DCM, and
adjusted to pH 7 with sulfuric acid (1 N). The resulting solution
was extracted with 3.times.50 mL of dichloromethane and the organic
layers combined, dried over sodium sulfate, and concentrated under
vacuum. The product was obtained as 760 mg (93%) of a yellow
solid.
Intermediate 69d: tert-butyl
2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl(3-(trifluoro-methyl)benz-
yl)carbamate
[0623] Into a 100-mL 3-necked round bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of tert-butyl
2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-yl(3-(trifluoromethyl)benzy-
l)carbamate (760 mg, 1.37 mmol, 1.00 equiv) in dichloromethane (10
mL), and Zn (500 mg). This was followed by dropwise addition of
acetic acid (0.7 mL) with stirring. The resulting solution was
stirred for 3 h at room temperature. The reaction progress was
monitored by LCMS. The solids were removed by filtration. The
solution was adjusted to pH 8-9 with NaHCO.sub.3 (aq). The
resulting solution was extracted with 3.times.50 mL of
dichloromethane and the organic layers combined. The resulting
mixture was washed with 1.times.50 mL of brine, dried over sodium
sulfate, and concentrated under vacuum. The product was obtained as
600 mg (83%) of a black solid.
Intermediate 69e: methyl
3-(3-(2-(4-(tert-butoxycarbonyl(3-(trifluoromethyl)benzyl)-amino)pyridin--
2-yl)-4-(piperidin-1-yl)phenylcarbamoyl)benzylthio)propanoate
[0624] Into a 50-mL round bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
tert-butyl
2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl(3-(trifluoromethyl)benzy-
l) carbamate (600 mg, 1.14 mmol, 1.00 equiv) in DCM/THF (5/20 mL),
methyl 3-(3-(chlorocarbonyl) benzylthio)propanoate (580 mg, 2.13
mmol, 1.40 equiv), and pyridine (750 mg, 9.49 mmol, 3.00 equiv).
The resulting solution was stirred for 3 h at room temperature. The
reaction progress was monitored by LCMS. The resulting solution was
diluted with 30 mL of H.sub.2O and adjusted to pH 6-7 with
H.sub.2SO.sub.4 (1 N). The resulting solution was extracted with
3.times.40 mL of dichloromethane and the organic layers combined.
The resulting mixture was washed with 1.times.30 mL of brine. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum to yield 800 mg (92%) of product as a yellow oil.
Intermediate 69f: methyl
3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylamino)-pyridin-2--
yl)phenylcarbamoyl)benzylthio)propanoate
[0625] Into a 50-mL round bottom flask, was placed a solution of
methyl
3-(3-(2-(4-(tert-butoxycarbonyl(3-(trifluoromethyl)benzyl)amino)pyridin-2-
-yl)-4-(piperidin-1-yl)phenylcarbamoyl)-benzylthio)propanoate (800
mg, 1.05 mmol, 1.00 equiv) in dichloromethane (2 mL), and
2,2,2-trifluoroacetic acid (5 mL). The resulting solution was
stirred for 3 h at room temperature. The reaction progress was
monitored by LCMS. The resulting solution was diluted with 20 mL of
NaHCO.sub.3 (aq), extracted with 3.times.50 mL of dichloromethane,
and the organic layers combined. The resulting mixture was washed
with 1.times.50 mL of brine. The resulting mixture was concentrated
under vacuum. The residue was applied onto a silica gel column and
eluted with petroleum ether:ethyl acetate (5:1). The product was
obtained as 200 mg (29%) of a yellow solid.
Example 69
3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylamino)
pyridin-2-yl)phenylcarbamoyl)benzylthio)propanoic acid
[0626] Into a 50-mL round bottom flask, was placed a solution of
methyl
3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)-benzylamino)pyridin-2--
yl)phenylcarbamoyl)benzylthio)propanoate (300 mg, 0.35 mmol, 1.00
equiv, 78%) in tetrahydrofuran/H.sub.2O (20/5 mL), and LiOH (150
mg, 10.00 equiv, 40%). The resulting solution was stirred for 2 h
at room temperature. The reaction progress was monitored by LCMS.
The solution was adjusted to pH 6-7 with hydrochloric acid (1 N).
The resulting solution was extracted with 3.times.50 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 1.times.20 mL of ethoxyethane. The resulting mixture
was concentrated under vacuum. The crude product (250 mg) was
purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA to afford the product (27 mg, 10%) as
a yellow oil. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm) .delta.
13.49 (s, 1H), 10.05 (m, 1H), 8.89 (m, 1H), 8.02 (m, 1H), 7.68 (m,
4H), 7.37 (m, 5H), 7.08 (m, 1H), 6.91 (m, 2H), 6.28 (m, 1H), 3.80
(s, 2H), 3.23 (s, 4H), 2.27 (m, 2H), 1.63 (s, 6H). MS (ES, m/z):
649 [M+H].sup.+.
Example 70
3-((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)phenethyl)amino)pyrid-
in-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00223##
[0628] This compound was prepared by the route used to prepare
3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylamino)
pyridin-2-yl)phenylcarbamoyl)benzylthio)propanoic acid 69,
substituting 3-(trifluromethyl)phenethylamine for
3-(trifluoromethyl)benzylamine. .sup.1H-NMR (300 MHz, DMSO-d.sub.6,
ppm): .delta. 13.37 (s, 1H), 12.23 (s, 1H), 8.22 (s, 1H), 7.82-7.74
(m, 2H), 7.64-7.50 (m, 6H), 7.12 (m, 3H), 6.99 (s, 1H), 6.70 (s,
1H), 3.82 (s, 2H), 3.47 (s, 2H), 3.21 (t, 4H), 2.92 (t, 2H),
2.58-2.50 (m, 4H), 1.66 (m, 4H), 1.58 (m, 2H). MS (ES, m/z): 663
[M+H].sup.+.
Example 71
3-((3-((2-(4-((3,4-Dimethylphenyl)amino)pyridin-2-yl)-4-(piperidin-1-yl)ph-
enyl)carbamoyl)benzyl)thio)propanoic acid
##STR00224## ##STR00225##
[0629] Intermediate 71a:
N-(3,4-dimethylphenyl)-2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-amin-
e
[0630] Into a 100-mL 3-necked round bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of 3,4-dimethylbenzenamine (2 g, 16.53 mmol, 4.98 equiv)
in N,N-dimethylformamide (50 mL), and sodium hydride (660 mg, 16.50
mmol, 4.97 equiv, 60%). The resulting solution was stirred for 1 h
at room temperature. To this was added
4-fluoro-2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridine (1 g, 3.32
mmol, 1.00 equiv). The resulting solution stirred for an additional
1 h at 50-80.degree. C. in an oil bath. The reaction mixture was
cooled. The reaction was then quenched with 150 mL of H.sub.2O. The
resulting solution was extracted with 3.times.60 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 1.times.60 mL of brine, dried over sodium sulfate, and
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with ethyl acetate:petroleum ether (1:1). The
product was obtained as 500 mg (37%) of a yellow solid.
Intermediate 71b:
2-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3,4-dimethylphenyl)pyridin-4-amin-
e
[0631] Into a 50-mL 3-necked round bottom flask, was placed a
solution of
N-(3,4-dimethylphenyl)-2-(2-nitro-5-(piperidin-1-yl)phenyl)pyridin-4-amin-
e (300 mg, 0.75 mmol, 1.00 equiv) in tetrahydrofuran/EtOH (10/1
mL), Zn (485 mg, 7.46 mmol, 10.00 equiv), and acetic acid (1 mL).
The resulting solution was stirred for 30 min at room temperature.
The solids were filtered out. The solution was adjusted to pH 7-8
with sodium bicarbonate (aq). The resulting solution was extracted
with 3.times.25 mL of dichloromethane and the organic layers
combined. The resulting mixture was washed with 1.times.25 mL of
brine, dried over sodium sulfate, and concentrated under vacuum.
The product was obtained as 270 mg (97%) of a yellow solid.
Intermediate 71c: methyl
3-(3-((2-(4-(3,4-dimethylphenylamino)pyridin-2-yl)-4-(piperidin-1-yl)phen-
yl)carbamoyl)benzylthio)propanoate
[0632] Into a 50-mL 3-necked round bottom flask, was placed a
solution of
2-(2-amino-5-(piperidin-1-yl)phenyl)-N-(3,4-dimethylphenyl)pyridin-4-amin-
e (270 mg, 0.72 mmol, 1.00 equiv) in tetrahydrofuran (10 mL),
pyridine (170 mg, 2.15 mmol, 2.97 equiv), and methyl
3-(3-(chlorocarbonyl)benzylthio)propanoate (197.6 mg, 0.72 mmol,
1.00 equiv). The resulting solution was stirred for 1.5 h at room
temperature. This reaction was used directly in next step without
workup.
Example 71
3-(3-((2-(4-(3,4-dimethylphenylamino)pyridin-2-yl)-4-(piperidin-1-yl)-phen-
yl)carbamoyl) benzylthio)propanoic acid
[0633] Into a 50-mL 3-necked round bottom flask, was placed a
solution of methyl
3-(3-((2-(4-(3,4-dimethylphenylamino)pyridin-2-yl)-4-(piperidin-1--
yl)phenyl)carbamoyl)benzylthio)propanoate (440 mg, 0.72 mmol, 1.00
equiv) in tetrahydrofuran (10 mL), and a solution of LiOH H.sub.2O
(300 mg, 7.14 mmol, 9.89 equiv) in water (2 mL). The resulting
solution was stirred for 18 h at room temperature. The reaction was
then quenched with 30 mL of water. The solution was adjusted to pH
6-7 with hydrochloric acid (1 N). The resulting solution was
extracted with 3.times.30 mL of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 1.times.30
mL of brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. The crude product (250 mg) was
purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 237.2 mg
(55%) of as a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6,
ppm): .delta. 13.76 (s, 1H), 10.22 (s, 1H), 10.11 (s, 1H), 8.21 (d,
J=6 Hz, 1H), 7.71 (s, 1H), 7.61 (d, J=6.6 Hz, 1H), 7.51 (d, J=7.5
Hz, 1H), 7.42 (m, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.16 (d, J=9 Hz,
1H), 7.08 (s, 2H), 6.94 (m, 3H), 6.81 (s, 1H), 3.80 (s, 2H), 3.24
(s, 4H), 2.55 (m, 3H), 2.17 (d, 6H), 1.63 (s, 6H). MS (ES, m/z):
595 [M+H].sup.+.
Example 72
3-((3-((4-(Piperidin-1-yl)-2-(4-((3-(trifluoromethyl)phenyl)amino)pyridin--
2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00226##
[0635] This compound was prepared by the route used to prepare
3-((3-((2-(4-((3,4-dimethylphenyl)amino)pyridin-2-yl)-4-(piperidin-1-yl)p-
henyl)carbamoyl)benzyl)thio)-propanoic acid 71, substituting
3-(trifluoromethyl)aniline for 3,4-dimethylaniline. .sup.1H-NMR
(300 MHz, DMSO-d.sub.6, ppm) .delta. 13.08 (s, 1H), 9.36 (s, 1H),
8.54-8.52 (d, 1H), 8.43-8.40 (d, 1H), 7.89 (s, 1H), 7.81-7.78 (d,
1H), 7.56-7.39 (m, 7H), 7.24-7.23 (d, 1H), 7.10-7.04 (m, 2H), 3.89
(s, 2H), 3.17-3.15 (d, 4H), 2.62-2.58 (m, 2H), 1.66-1.56 (d, 6H).
MS (ES, m/z): 635 [M+H].sup.+.
Example 73
3-((3-((4-(Piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzamido)pyridin-2-yl-
)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00227## ##STR00228##
[0636] Intermediate 73a:
4-(piperidin-1-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-anilin-
e
[0637] Into a 50-mL round-bottom flask, was placed a solution of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidi-
ne (600.0 mg, 1.81 mmol, 1.00 equiv) in ethyl acetate (30.0 mL),
then Palladium carbon (10%) (150 mg) was added next. The gas of
H.sub.2 was introduced in. The resulting solution was stirred for 1
h at 0.about.5.degree. C. The Pd/C was filtered out and the
filtrate was collected and concentrated under vacuum. This resulted
in 545.8 mg (99%) of
4-(piperidin-1-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz-
enamine as a green to yellow solid. The target product was
unstable, it was used to the next reaction step rapidly
Intermediate 73b:
N-(2-chloropyridin-4-yl)-3-(trifluoromethyl)benzamide
[0638] Into a 100-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
2-chloropyridin-4-amine (1.0 g, 7.78 mmol, 1.00 equiv) and
N,N-Diisopropylethylamine (1.0 mL) in dichloromethane (30.0 mL).
This was followed by the addition of a solution of
3-(trifluoromethyl)benzoyl chloride (2.6 g, crude) in
dichloromethane (5.0 mL) dropwise with stirring at 0.degree. C. The
resulting solution was stirred for 2 h at room temperature. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(0.about.1:2). This resulted in 2.2 g (92%) of
N-(2-chloropyridin-4-yl)-3-(trifluoromethyl)benzamide as a
light-yellow syrup
Intermediate 73c:
N-(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-(trifluoromethyl)b-
enzamide
[0639] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
N-(2-chloropyridin-4-yl)-3-(trifluoromethyl)benzamide (350 mg, 1.16
mmol, 1.00 equiv),
4-(piperidin-1-yl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzena-
mine (430 mg, 1.42 mmol, 1.20 equiv), Pd(PPh.sub.3).sub.2Cl.sub.2
(81.7 mg, 0.12 mmol, 0.10 equiv), K.sub.3PO.sub.4.7H.sub.2O (790
mg, 2.33 mmol, 2.00 equiv), X-PHOS (91.6 mg, 0.23 mmol, 0.20 equiv)
in DME/H.sub.2O (10:1) (30/3 mL). The resulting solution was
stirred for 2 h at 80.degree. C. The reaction progress was
monitored by LCMS. The resulting mixture was concentrated under
vacuum. The residual solution was diluted with 50 mL of water. The
resulting solution was extracted with 2.times.50 mL of
dichloromethane and the organic layers combined and dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(100.about.100:1.about.40:1). This resulted in 350 mg (67%) of
N-(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-(trifluoromethyl)b-
enzamide as a yellow solid
Intermediate 73d: methyl
3-(3-((4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzamido)-pyridin-2-y-
l)phenyl)carbamoyl)benzylthio)propanoate
[0640] Into a 50-mL round bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
N-(2-(2-amino-5-(piperidin-1-yl)phenyl)pyridin-4-yl)-3-(trifluoromethyl)b-
enzamide (100.0 mg, 0.23 mmol, 1.00 equiv) and
N,N-diisopropylethylamine (0.2 mL) in dichloromethane (20 mL). This
was followed by dropwise addition of a solution of methyl
3-(3-(chlorocarbonyl)benzylthio)propanoate 22d (74.0 mg, 0.27 mmol,
1.20 equiv) in dichloromethane (2.0 mL) with stirring at 0.degree.
C. The resulting solution was stirred for 2 h at room temperature.
The resulting mixture was combined with the solution of the
previous batch and then concentrated under vacuum. The residue was
applied onto a silica gel column and eluted with
dichloromethane:methanol (100.about.100:1.about.50:1). The product
was obtained as 170 mg (70%) of a yellow solid.
Example 73
3-((3-((4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzamido)pyridin-2-yl-
)-phenyl)carbamoyl)benzyl)thio)propanoic acid
[0641] Into a 50-mL round bottom flask, was placed a solution of
methyl
3-(3-((4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzamido)pyridin-2-yl-
)phenyl)carbamoyl)benzylthio)propanoate (100 mg, 0.15 mmol, 1.00
equiv) and lithium hydroxide hydrate (62.0 mg, 1.48 mmol, 10.00
equiv) in tetrahydrofuran/water (1:1) (10/10 mL). The resulting
solution was stirred for 2 h at room temperature. The resulting
mixture was combined with the solution of the previous batch and
then concentrated under vacuum. The residual solution was adjusted
to pH 5.about.6 with 1 N acetic acid. The resulting solution was
extracted with 2.times.30 mL of dichloromethane and the organic
layers combined and dried over anhydrous sodium sulfate. The
solvent was removed under vacuum. The crude product (140 mg) was
purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The fractions were collected and
lyophilized to yield 100 mg (58%) of product as an off-white solid.
.sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm): .delta. 11.29 (br, 1H),
8.79 (d, J=6.0 Hz, 1H), 8.42 (s, 1H), 8.31-8.27 (m, 2H), 8.07-7.97
(m, 2H), 7.87-7.74 (m, 3H), 7.53-7.44 (m, 3H), 7.38-7.37 (m, 1H),
3.83 (s, 2H), 3.35 (s, 4H), 2.56 (t, J=6.3 Hz, 2H), 1.74-1.61 (m,
6H). MS (ES, m/z): 663 [M+H].sup.+.
Example 74
3-((3-((2-(4-(3,4-Dimethylbenzamido)pyridin-2-yl)-4-(piperidin-1-yl)phenyl-
)carbamoyl)benzyl)thio)propanoic acid
##STR00229##
[0643] This compound was prepared by the route used to prepare
3-((3-((4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzamido)pyridin-2-y-
l)phenyl)carbamoyl)benzyl)thio)propanoic acid 73, substituting
3,4-dimethylbenzoyl chloride for 3-(trifluoromethyl)benzoyl
chloride. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 8.71-8.65
(m, 2H), 7.96-7.84 (m, 3H), 7.77-7.70 (m, 3H), 7.55-7.41 (m, 4H),
7.33 (d, J=8.1 Hz, 1H), 2.63 (s, 2H), 2.60 (d, J=6.9 Hz, 4H),
2.63-2.58 (m, 2H), 2.52-2.46 (m, 2H), 2.38 (s, 6H), 1.90-1.74 (m,
6H). MS (ES, m/z): 623 [M+H].sup.+.
Example 75
2-(2-(3-((4-(2-Hydroxyethyl)-1H-1,2,3-triazol-1-yl)methyl)benzamido)-5-(pi-
peridin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00230##
[0644] Intermediate 75a:
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(azidomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide
[0645] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (200 mg, 0.18 mmol, 1.00 equiv, 60%)
in N,N-dimethylformamide (5 mL), and NaN.sub.3 (70 mg, 1.08 mmol,
5.00 equiv). The resulting solution was stirred for 2 h at
80.degree. C. in an oil bath. The resulting solution was diluted
with 25 mL of water. The resulting solution was extracted with
3.times.50 mL of ethyl acetate and the organic layers combined. The
resulting mixture was washed with 1.times.50 mL of brine, dried
over anhydrous sodium sulfate, and concentrated under vacuum. The
residue was applied onto a silica gel column and eluted with ethyl
acetate/petroleum ether (1:2). The product was obtained as 55 mg
(49%) a yellow solid.
Example 75
2-(2-(3-((4-(2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)methyl)benzamido)-5-(pi-
peridin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0646] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(azidomethyl)benzamido)-5-(piperidi-
n-1-yl)phenyl)isonicotinamide (55 mg, 0.09 mmol, 1.00 equiv, 95%)
in DMSO (3 mL), but-3-yn-1-ol (19 mg, 0.27 mmol, 3.00 equiv), and
copper(I) iodide (0.84 mg, 0.05 equiv). The resulting solution was
stirred overnight at room temperature. The resulting solution was
diluted with 10 mL of 10% NH.sub.3.H.sub.2O. The resulting solution
was extracted with 5.times.30 mL of ethyl acetate and the organic
layers combined, dried over anhydrous sodium sulfate, and
concentrated under vacuum. The crude product (60 mg) was purified
by reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. The product was obtained as 10 mg (14%) of a
yellow to green solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 12.48 (s, 1H), 9.55-9.58 (t, J=6 Hz, 1H), 8.93 (s, 1H),
8.36 (s, 2H), 7.96 (s, 1H), 7.85-7.96 (s, 1H), 7.71-7.77 (m, 3H)
7.64 (s, 1H), 7.55-7.60 (m, 5H), 7.44 (s, 1H), 5.67 (s, 2H), 4.63
(t, 2H), 3.58-3.61 (t, 2H), 3.40 (s, 4H), 2.75-2.77 (t, J=9 Hz,
2H), 1.61-1.78 (d, 6H). MS (ES, m/z): 684 [M+H].sup.+.
Example 76
3-((3-((4-(Piperidin-1-yl)-2-(6-((1-(3-(trifluoromethyl)phenyl)ethyl)amino-
)pyrimidin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid
##STR00231## ##STR00232##
[0647] Intermediate 76a:
1-(3-(trifluoromethyl)phenyl)ethanamine
[0648] Into a 150 mL 3-necked round bottom flask, was placed
ethanol (25 mL). NH.sub.3 gas was added at 0.degree. C. The mixture
was stirred for 1 h at 0.degree. C. Into a 150-mL sealed tube, was
placed a solution of 1-(3-(trifluoromethyl)phenyl)ethanone (2 g,
10.64 mmol, 1.00 equiv) in ethanol (5 mL), and
Ti[OCH(CH.sub.3).sub.2].sub.4 (6.04 g, 21.13 mmol, 2.00 equiv).
This was followed by the addition of the above solution of NH.sub.3
(gas) in ethanol (25 mL). The mixture was stirred overnight at
48.degree. C. To this was added NaBH.sub.4 (600 mg, 15.79 mmol,
1.48 equiv). The resulting solution was stirred for 3 h at room
temperature. The resulting solution was diluted with 10 mL of
ammonia and the solids were filtered out. The resulting mixture was
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with dichloromethane/methanol (50:1). The
product was obtained as 1 g (50%) of a yellow oil.
Intermediate 76b:
6-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(1-(3-(trifluoromethyl)phenyl)-eth-
yl)pyrimidin-4-amine
[0649] Into a 100 mL round bottom flask, was placed a solution of
4-chloro-6-(2-nitro-5-(piperidin-1-yl)phenyl)pyrimidine (100 mg,
0.31 mmol, 1.00 equiv) in toluene (10 mL),
1-(3-(trifluoromethyl)phenyl)ethanamine (71 mg, 0.38 mmol, 1.20
equiv), BINAP (9 mg, 0.01 mmol, 0.05 equiv), Cs.sub.2CO.sub.3 (144
mg, 0.44 mmol, 1.40 equiv), and Pd(dba).sub.3 CHCl.sub.3 (6.5 mg,
0.01 mmol, 0.02 equiv). The resulting solution was stirred for 3 h
at 120.degree. C. The resulting mixture was concentrated under
vacuum. The residue was applied onto a silica gel column and eluted
with ethyl acetate/petroleum ether (1:5). The product was obtained
as 80 mg (54%) of a yellow oil.
Intermediate 76c:
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(1-(3-(trifluoromethyl)phenyl)-eth-
yl)pyrimidin-4-amine
[0650] Into a 100-mL round-bottom flask, was placed a solution of
6-(2-nitro-5-(piperidin-1-yl)phenyl)-N-(1-(3-(trifluoromethyl)phenyl)ethy-
l)pyrimidin-4-amine (400 mg, 0.85 mmol, 1.00 equiv) in acetic acid
(5 mL). To this was added zinc (552 mg, 8.62 mmol, 10.00 equiv) in
several batches at 70.degree. C. The resulting solution was stirred
for 1 h at 70.degree. C. The solids were filtered out. The
resulting mixture was concentrated under vacuum. The solution was
adjusted to pH 8 with ammonia (1 mol/L). The resulting solution was
extracted with 4.times.50 ml of ethyl acetate and the organic
layers combined, dried over sodium sulfate, and concentrated under
vacuum. The residue was applied onto a silica gel column and eluted
with methanol:dichloromethane (1:50). The product was obtained as
200 mg (53%) of a black solid.
Intermediate 76d: tert-butyl
3-(3-(4-(piperidin-1-yl)-2-(6-(1-(3-(trifluoromethyl)phenyl)-ethylamino)p-
yrimidin-4-yl)phenylcarbamoyl)benzylthio)propanoate
[0651] Into a 100-mL round-bottom flask, was placed a solution of
3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (147 mg, 0.50
mmol, 1.10 equiv) in dichloromethane (5 mL), EDC.HCl (143 mg, 0.74
mmol, 1.50 equiv), 4-dimethylaminopyridine (92 mg, 0.71 mmol, 1.50
equiv), and
6-(2-amino-5-(piperidin-1-yl)phenyl)-N-(1-(3-(trifluoromethyl)phenyl)ethy-
l)pyrimidin-4-amine (200 mg, 0.45 mmol, 1.00 equiv). The resulting
solution was stirred for 3 h at 30.degree. C. The resulting mixture
was concentrated under vacuum. The residue was applied onto a
silica gel column and eluted with petroleum ether/ethyl acetate
(5:1). The product was obtained as 100 mg (31%) of a yellow
oil.
Example 76
3-(3-(4-(piperidin-1-yl)-2-(6-(1-(3-(trifluoromethyl)phenyl)ethylamino)-py-
rimidin-4-yl)phenylcarbamoyl)benzylthio)propanoic acid
[0652] Into a 100-mL round-bottom flask, was placed a solution of
tert-butyl
3-(3-(4-(piperidin-1-yl)-2-(6-(1-(3-(trifluoromethyl)phenyl)ethylamino)py-
rimidin-4-yl)phenylcarbamoyl)benzylthio)-propanoate (90 mg, 0.13
mmol, 1.00 equiv) in dichloromethane (4 mL), and
2,2,2-trifluoroacetic acid (2 mL). The resulting solution was
stirred for 2 h at 30.degree. C. The resulting mixture was
concentrated under vacuum. The crude product (80 mg) was purified
by reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. The product was obtained as 46.1 mg (55%) of
as a yellow solid. .sup.1H-NMR (300 MHz, DMSO-d.sub.6, ppm):
.delta. 8.78 (s, 1H), 7.71 (m, 4H), 7.53 (m, 6H), 7.27 (m, 2H),
6.93 (s, 1H), 5.40 (s, 1H), 3.92 (s, 2H), 3.48 (m, 4H), 2.61 (m,
4H), 1.59 (m, 10H). MS (ES, m/z): 663 [M+H].sup.+.
Example 77
3-(3-(4-(piperidin-1-yl)-2-(4-(1-(3-(trifluoromethyl)phenyl)ethylcarbamoyl-
)pyridin-2-yl)phenylcarbamoyl)benzylthio)propanoic acid
##STR00233##
[0654] This compound was prepared using the procedure used to
prepare
3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)-benzylthio)propanoic acid 1.1, using
1-(3-(trifluoromethyl)phenyl)ethanamine in place of
3-(trifluoromethyl)benzylamine. .sup.1H-NMR (300 MHz, CD.sub.3OD,
ppm): .delta. 9.044-9.062 (d, J=5.4 Hz, 1H), 8.786-8.816 (d, J=9.0
Hz, 1H), 8.378 (s, 1H), 8.125-8.133 (d, J=2.4 Hz, 1H), 8.003 (s,
1H), 7.875-7.905 (m, 2H), 7.707-7.754 (m, 3H), 7.499-7.623 (m, 4H),
5.324-5.393 (m, 1H), 3.913 (s, 2H), 3.678-3.714 (m, 4H),
2.709-2.754 (m, 2H), 2.574-2.618 (m, 2H), 2.043-2.060 (m, 4H),
1.831-1.846 (m, 2H), 1.641-1.664 (d, J=6.9 Hz, 3H). MS (ES, m/z):
692 [M+H].sup.+.
Example 78
3-(3-(2-(4-(4-Morpholinobenzylcarbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)-p-
henylcarbamoyl)benzylthio) propanoic acid
##STR00234## ##STR00235##
[0655] Intermediate 78a: 4-morpholinobenzonitrile
[0656] Into a 50-mL 3-necked round-bottom flask, was placed a
solution of 4-fluorobenzonitrile (500 mg, 4.13 mmol, 1.00 equiv) in
DMSO (5 mL), and morpholine (1070 mg, 12.30 mmol, 3.00 equiv). The
resulting solution was stirred for 4 h at 120.degree. C. in an oil
bath. The resulting solution was diluted with 100 mL of H.sub.2O.
The solids were collected by filtration. The product was obtained
as 617 mg (79%) of a yellow solid.
Intermediate 78b: (4-morpholinophenyl)methanamine
[0657] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
4-morpholinobenzonitrile (200 mg, 1.06 mmol, 1.00 equiv) in
tetrahydrofuran (10 mL), and LiAlH.sub.4 (400 mg, 10.53 mmol, 10.00
equiv). The resulting solution was stirred for 3 h at 60.degree. C.
The reaction was then quenched with 1 N NaOH. The solids were
removed by filtration. The resulting solution was extracted with
3.times.20 mL of dichloromethane and the organic layers combined,
dried over NaSO.sub.4, and concentrated under vacuum. The product
was obtained as 120 mg (58%) of a yellow solid. .sup.1H-NMR (300
MHz, CDCl.sub.3, ppm): .delta. 7.26 (m, 2H). 6.91 (m, 2H), 3.87 (m,
6H), 3.16 (m, 4H).
Intermediate 78c: tert-butyl
3-(3-(2-(4-(chlorocarbonyl)pyridin-2-yl)-4-(piperidin-1-yl)phenylcarbamoy-
l)benzylthio)propanoate
[0658] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperidin-1--
yl)phenyl) isonicotinic acid (170 mg, 0.30 mmol, 1.00 equiv) in
dichloromethane (10 mL), and oxalyl dichloride (112 mg, 0.88 mmol,
3.00 equiv). The resulting solution was stirred for 4 h at room
temperature. The resulting mixture was concentrated under vacuum to
yield 200 mg of crude product a yellow solid.
Intermediate 78d: tert-butyl
3-(3-(2-(4-(4-morpholinobenzylcarbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)p-
henylcarbamoyl)benzylthio)propanoate
[0659] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
tert-butyl
3-(3-(2-(4-(chlorocarbonyl)pyridin-2-yl)-4-(piperidin-1-yl)phenylcarbamoy-
l)-benzylthio)-propanoate (120 mg, 0.20 mmol, 1.00 equiv) in
tetrahydrofuran (10 mL), (4-morpholinophenyl)methanamine (68 mg,
0.35 mmol, 1.50 equiv), and DIPEA (32 mg, 0.25 mmol, 3.00 equiv).
The resulting solution was stirred for 4 h at room temperature. An
additional 68 mg of 4-morpholinophenyl)methanamine was added. The
resulting solution was stirred for an additional 2 h at room
temperature. The resulting solution was diluted with 10 mL of
H.sub.2O. The resulting solution was extracted with 3.times.50 mL
of dichloromethane and the organic layers combined. The resulting
mixture was washed with 1.times.50 mL of brine, dried over
anhydrous sodium sulfate, and concentrated under vacuum. This
resulted in 200 mg of crude product as a yellow oil.
Example 78
3-(3-(2-(4-(4-morpholinobenzylcarbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)-p-
henylcarbamoyl)benzylthio) propanoic acid
[0660] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
tert-butyl
3-(3-(2-(4-(4-morpholinobenzylcarbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)p-
henylcarbamoyl)-benzylthio)propanoate (170 mg, 0.20 mmol, 1.00
equiv, 86%) in dichloromethane (20 mL), and trifluoroacetic acid (2
mL). The resulting solution was stirred overnight at room
temperature. The reaction progress was monitored by LCMS. The
solution was adjusted to pH 7-8 with NaHCO.sub.3 (aq). The
resulting solution was extracted with 3.times.30 mL of
dichloromethane and the organic layers combined. The resulting
mixture was washed with 1.times.30 mL of brine, dried over
NaSO.sub.4 and concentrated under vacuum. The crude product (120
mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 17 mg (13%) of a yellow solid. .sup.1H-NMR (300 MHz,
DMSO-d.sub.6, ppm): .delta. 8.96 (s, 1H), 8.49 (m, 1H), 8.34 (s,
1H), 7.79 (m, 4H), 7.54 (m, 3H), 7.16 (m, 2H), 6.89 (m, 2H), 4.42
(s, 2H), 3.86 (s, 2H), 3.70 (m, 5H), 3.49 (s, 4H), 3.04 (m, 4H),
2.60 (m, 2H), 1.78 (m, 6H). MS (ES, m/z): 694 [M+H].sup.+.
Example 79
3-(3-((2-(4-((4-(1H-Pyrazol-1-yl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperid-
in-1-yl) phenyl)carbamoyl)benzylthio)propanoic acid
##STR00236##
[0661] Intermediate 79a: 4-(1H-pyrazol-1-yl)benzonitrile
[0662] Into a 50-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed
1H-pyrazole (422 mg, 6.21 mmol, 1.50 equiv), sodium hydroxide (248
mg, 6.20 mmol, 1.50 equiv), and N,N-dimethylformamide (20 mL). The
mixture was stirred and heated 15 to 80.degree. C. for 30 min, then
to this was added 4-fluorobenzonitrile (500 mg, 4.13 mmol, 1.00
equiv). The resulting solution was stirred for 3 h at 110.degree.
C. in an oil bath. The resulting solution was diluted with 50 mL of
H.sub.2O. The solids were collected by filtration and dried in an
oven. The product was obtained as 0.43 g (62%) of a white
solid.
Intermediate 79b: (4-(1H-pyrazol-1-yl)phenyl)methanamine
[0663] Into a 50-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed
tetrahydrofuran (15 mL). This was followed by dropwise addition of
a 4-(1H-pyrazol-1-yl)benzonitrile (250 mg, 1.48 mmol, 1.00 equiv)
in tetrahydrofuran (5 mL) with stirring at 0.degree. C. To this was
added LiAlH.sub.4 (337 mg, 8.87 mmol, 6.00 equiv). The resulting
solution was stirred for 3 h at room temperature. The reaction was
then quenched by the addition of NaOH (15%, aq). The resulting
solution was extracted with 3.times.50 mL of dichloromethane and
the organic layers were combined, dried over anhydrous sodium
sulfate, and concentrated under vacuum. The product was obtained as
0.251 mg of a white crude solid.
Intermediate 79c: tert-butyl
3-(3-((2-(4-((4-(1H-pyrazol-1-yl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)benzylthio)propanoate
[0664] Into a 50-mL 3-necked round-bottom flask, was placed
2-(2-(3-((3-tert-butoxy-3-oxopropylthio)
methyl)benzamido)-5-(piperidin-1-yl)phenyl)isonicotinic acid (125
mg, 0.22 mmol, 1.00 equiv), (4-(1H-pyrazol-1-yl)phenyl)methanamine
(41 mg, 0.24 mmol, 1.10 equiv), EDC.HCl (62 mg, 0.32 mmol, 1.50
equiv), 4-dimethylaminopyridine (40 mg, 0.33 mmol, 1.51 equiv), and
dichloromethane (15 mL). The resulting solution was stirred
overnight at room temperature. The resulting solution was extracted
with 40 mL of dichloromethane and the organic layers combined. The
resulting mixture was washed with 2.times.15 mL of H.sub.2O. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. The product was obtained as 0.132 g (83%) of a yellow
crude solid.
Example 79
3-(3-((2-(4-((4-(1H-pyrazol-1-yl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperid-
in-1-yl)phenyl)carbamoyl)benzylthio)propanoic acid
[0665] Into a 50-mL 3-necked round bottom flask, was placed
tert-butyl
3-(3-((2-(4-((4-(1H-pyrazol-1-yl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi-
din-1-yl)phenyl)carbamoyl)benzylthio)-propanoate (130 mg, 0.18
mmol, 1.00 equiv), and dichloromethane (2 mL). This was followed by
dropwise addition of trifluoroacetic acid (3 mL) with stirring. The
resulting solution was stirred for 60 min at room temperature. The
solution was adjusted to pH 7 with sodium bicarbonate (aq). The
resulting solution was diluted with 30 mL of dichloromethane and
washed with 2.times.10 mL of H.sub.2O. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (300 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 86.9 mg (72%) of a yellow solid. .sup.1H-NMR: (300 MHz,
DMSO-d.sub.6+D.sub.2O, ppm): .delta. 1.63 (m, 2H), 1.82 (m, 4H),
2.58-2.62 (m, 4H), 3.47 (t, 4H), 3.87 (s, 2H), 4.56 (d, 2H), 6.53
(s, 1H), 7.44-7.54 (m, 4H), 7.72-7.79 (m, 3H), 7.87-7.89 (m, 2H),
8.36 (s, 1H), 8.42 (s, 1H), 8.99 (d, 1H), 9.53 (s, 1H), 11.97 (s,
1H). MS (ES, m/z): 675 [M+H].sup.+.
Example 80
N1-Methyl-N1-(2-morpholinoethyl)-N3-(4-(piperidin-1-yl)-2-(4-((3-(trifluor-
omethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00237## ##STR00238##
[0666] Intermediate 80a: methyl 3-(chlorocarbonyl)benzoate
[0667] Into a 250-mL round-bottom flask, was placed a solution of
3-(methoxycarbonyl)benzoic acid (6.2 g, 34.44 mmol, 1.00 equiv) in
dichloromethane (50 mL), oxalyl dichloride (8.74 g, 69.37 mmol,
2.00 equiv), and N,N-dimethylformamide (cat.). The resulting
solution was stirred for 1 h at 40.degree. C. in an oil bath. The
resulting mixture was concentrated under vacuum. This resulted in
6.6 g (87%) of methyl 3-(chlorocarbonyl)benzoate as brown oil
Intermediate 80b: tert-butyl (2-morpholinoethyl)carbamate
[0668] Into a 250-mL round-bottom flask, was placed a solution of
2-morpholineethanamine (10 g, 76.92 mmol, 1.00 equiv) in
dichloromethane (50 mL). To this was added triethylamine (5.83 g,
57.72 mmol, 0.50 equiv). This was followed by the addition of
di-tert-butyl dicarbonate (18.44 g, 84.59 mmol, 1.10 equiv) at
0-5.degree. C. The resulting solution was stirred overnight at
25.degree. C. The resulting solution was diluted with 200 mL of
dichloromethane. The resulting mixture was washed with 1.times.30
mL of 10% sodium bicarbonate and 1.times.30 mL of brine. The
mixture was dried over sodium sulfate and concentrated under
vacuum. This resulted in 16 g (81%) of tert-butyl
2-morpholinoethylcarbamate as an off-white solid.
Intermediate 80c: N-methyl-2-morpholinoethanamine
[0669] Into a 250-mL 3-necked round-bottom flask, was placed a
solution of LiAlH.sub.4 (7.72 g, 208.65 mmol, 3.00 equiv) in
tetrahydrofuran (60 mL). This was followed by the addition of a
solution of tert-butyl 2-morpholinoethylcarbamate (16 g, 62.61
mmol, 1.00 equiv, 90%) in tetrahydrofuran (40 mL) dropwise with
stirring at 0-5.degree. C. The resulting solution was stirred for 2
h at 70.degree. C. in a oil bath. The reaction was then quenched by
the addition of 7.7 mL of water, 7.7 mL of 15% sodium hydroxide,
and 23.1 mL of water. The solids were filtered out. The mixture was
dried over sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column and eluted with
dichloromethane:methanol (0.5% triethylamine) (20:1). This resulted
in 4.2 g (42%) of N-methyl-2-morpholinoethanamine as brown oil.
Intermediate 80d: methyl
3-(methyl(2-morpholinoethyl)carbamoyl)benzoate
[0670] Into a 100-mL round-bottom flask, was placed a solution of
N-methyl-2-morpholinoethanamine (2.1 g, 13.12 mmol, 1.00 equiv,
90%) in dichloromethane (20 mL), and triethylamine (1.47 g, 14.55
mmol, 1.00 equiv). This was followed by the addition of a solution
of methyl 3-(chlorocarbonyl)benzoate (3.3 g, 15.00 mmol, 1.20
equiv, 90%) in dichloromethane (10 mL) dropwise with stirring at
0-5.degree. C. The resulting solution was stirred for 3 h at room
temperature. The resulting solution was diluted with 100 mL of
dichloromethane. The resulting mixture was washed with 1.times.30
mL of 10% sodium bicarbonate. The resulting mixture was washed with
1.times.30 mL of brine. The mixture was dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with dichloromethane:methanol (20:1). This
resulted in 4.4 g (99%) of methyl
3-(methyl(2-morpholinoethyl)carbamoyl)benzoate as a brown
solid.
Intermediate 80e: 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic
acid
[0671] Into a 100-mL round-bottom flask, was placed a solution of
methyl 3-(methyl(2-morpholinoethyl)carbamoyl)benzoate (4.4 g, 13.66
mmol, 1.00 equiv, 95%) in tetrahydrofuran/water (15/10 mL), and
lithium hydroxide hydrate (1.77 g, 43.17 mmol, 3.00 equiv). The
resulting solution was stirred for 1 h at 25.degree. C. The
resulting mixture was concentrated under vacuum. The resulting
solution was diluted with 10 mL of water and adjusted to pH 2-3
with hydrochloric acid. The resulting mixture was washed with
2.times.30 mL of ethyl acetate. The aqueous layers were
concentrated under vacuum. The residue was applied onto a silica
gel column and eluted with ethyl acetate:methanol (4:1). This
resulted in 2.7 g (65%) of
3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid as a white
solid. .sup.1H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 8.17 (m,
2H), 7.78 (m, 1H), 7.61 (m, 1H), 3.98 (m, 6H), 3.56 (m, 5H), 3.47
(m, 1H), 3.10 (s, 3H). MS (ES, m/z): 293 [M+H].sup.+.
Example 80
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin--
1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
hydrochloride
[0672] Into a 250-mL round bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-1-yl)phenyl)isonico-
tinamide (1 g, 2.09 mmol, 1.00 equiv, 95%) in dichloromethane (30
mL), 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid (960 mg,
3.12 mmol, 1.50 equiv, 95%), EDC.HCl (840 mg, 4.38 mmol, 2.00
equiv), and 4-dimethylaminopyridine (540 mg, 4.43 mmol, 2.00
equiv). The resulting solution was stirred for 3 h at 25.degree. C.
The resulting solution was diluted with 200 mL of ethyl acetate.
The resulting mixture was washed with 2.times.30 mL of NH.sub.4Cl
(aq), 1.times.30 mL of 10% sodium bicarbonate, and 1.times.30 mL of
brine. The mixture was dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column and
eluted with ethyl acetate:methanol (20:1). This resulted in 1.30 g
of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide as a
brown oil. The brown oil was dissolved in 40 mL of methanol. HCl
gas was added at 0.degree. C. The mixture was stirred for 20 min at
0.degree. C. The mixture was concentrated under vacuum. The product
was obtained as 1.40 g (86%) of a yellow solid. .sup.1H-NMR (300
MHz, DMSO-d.sub.6+D.sub.2O, ppm): .delta. 9.96 (m, 1H), 8.94 (d,
J=6 Hz, 1H), 8.59 (m, 2H), 8.49 (s, 1H), 7.93-8.07 (m, 2H),
7.87-8.03 (m, 2H), 7.54-7.80 (m, 7H), 4.59 (s, 2H), 4.12 (m, 1H),
3.99-4.03 (m, 2H), 3.88 (m, 2H), 3.76-3.79 (m, 2H), 3.58 (m, 2H),
3.43 (m, 2H), 3.15-3.17 (m, 3H), 2.96 (s, 3H), 1.97 (m, 4H), 1.71
(m, 2H). MS (ES, m/z): 729 [M+H].sup.+.
Example 81
N1-(2-(4-Acetylpiperazin-1-yl)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-
-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00239## ##STR00240##
[0673] Intermediate 81a: tert-butyl
4-(2-chloroethyl)piperazine-1-carboxylate
[0674] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate (2.31 g,
10.03 mmol, 1.00 equiv) in dichloromethane (20 mL) and a solution
of thionyl chloride (1.5 mL, 2.00 equiv) in dichloromethane (3 mL)
was added dropwise under ice-bath. The resulting solution was
stirred overnight at 25.degree. C. The resulting mixture was
concentrated under vacuum. The resulting solution was diluted with
10 mL of water. The resulting solution was extracted with
2.times.25 mL of ethyl acetate and the organic layers combined. The
resulting mixture was washed with 2.times.15 mL of sodium
bicarbonate aq. and 2.times.10 mL of brine. The mixture was dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:5). This resulted in 1.16 g (46%) of
tert-butyl 4-(2-chloroethyl)piperazine-1-carboxylate as a off-white
solid
Intermediate 81b: tert-butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate
[0675] Into a 50-mL sealed tube, was placed tert-butyl
4-(2-chloroethyl)piperazine-1-carboxylate (300 mg, 1.21 mmol, 1.00
equiv), methanamine (in ethanol) (10 mL), NaI (100 mg). The
resulting solution was stirred for 12 h at 70.degree. C. in an oil
bath. The resulting mixture was concentrated under vacuum. The
resulting solution was diluted with 3 mL of water. The pH value of
the solution was adjusted to 7-8 with sodium bicarbonate (5%). The
resulting solution was extracted with 2.times.5 mL of
dichloromethane and the organic layers combined. The resulting
mixture was washed with 1.times.3 mL of water and 1.times.3 mL of
brine. The resulting mixture was concentrated under vacuum. This
resulted in 180 mg (crude) of tert-butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate as brown oil
Intermediate 81c: tert-butyl
4-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-((3-(trifluoromethyl)benzyl)ca-
rbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)-piperazine-1-carbox-
ylate
[0676] Into a 50-mL round-bottom flask, was placed a solution of
3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)-benzoic acid (100 mg, 0.17 mmol, 1.00 equiv) in
dichloromethane (5 mL), EDC.HCl (48 mg, 0.25 mmol, 1.50 equiv),
4-dimethylaminopyridine (31 mg, 0.25 mmol, 1.50 equiv). The mixture
was stirred for 5 min at room temperature. To the above was added
tert-butyl 4-(2-(methylamino)ethyl)piperazine-1-carboxylate (53 mg,
0.22 mmol, 1.30 equiv). The resulting solution was stirred for 2 h
at 25.degree. C. The resulting solution was diluted with 5 mL of
water. The resulting solution was extracted with 2.times.5 mL of
dichloromethane and the organic layers combined. The resulting
mixture was washed with 1.times.5 mL of water and 2.times.5 mL of
brine. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude product (100 mg) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, WATER WITH
0.05% TFA and CH.sub.3CN (25% CH.sub.3CN up to 45% in 6 min);
Detector, Waters2545 UvDector 254&220 nm. 33.6 mg product was
obtained. This resulted in 33.6 mg (21%) of PH-RDX-002-1129-0 as a
light yellow solid. MS (ES, m/z): 828 [M-+H].sup.+. H-NMR (300 MHz,
CD.sub.3OD, ppm) 8.98 (d, J=5.1 Hz, 1H), 8.75 (d, J=9.0 Hz, 1H),
8.46 (s, 1H), 8.18.about.8.11 (m, 3H), 7.89.about.7.53 (m, 8H),
4.72 (s, 2H), 4.00.about.3.11 (m, 16H), 3.08 (s, 3H), 2.04 (d,
J=4.8 Hz, 4H), 1.83 (d, J=5.7 Hz, 2H), 1.49 (s, 9H)
Intermediate 81 d:
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthalamide
[0677] Compound 81c was dissolved in 1:1 dichloromethane/TFA and
stirred for 1 hour. The solvent was evaporated and 250 mg of the
residue was placed into a 50-mL round bottom flask with a saturated
aqueous solution of sodium bicarbonate aq. (10 mL). The mixture was
stirred for 20 minutes at room temperature. The resulting solution
was extracted with 3.times.10 mL of ethyl acetate and the organic
layers combined. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum to yield 150 mg of
product.
Example 81
N1-(2-(4-acetylpiperazin-1-yl)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-
-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0678] Into a 50-mL round-bottom flask, was placed a solution of
N1-methyl-N1-(2-(piperazin-1-yl)ethyl)-N3-(4-(piperidin-1-yl)-2-(4-(3-(tr-
ifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)-isophthalamide
(150 mg, 0.21 mmol, 1.00 equiv) in dichloromethane (3 mL), and
triethylamine (63 mg, 0.62 mmol, 3.00 equiv). This was followed by
dropwise addition of acetyl chloride (25 mg, 0.32 mmol, 1.50 equiv)
with stirring at 0.degree. C. The resulting solution was stirred
for 2 h at 25.degree. C. The reaction was then quenched with 3 mL
of water. The resulting solution was extracted with 2.times.5 mL of
dichloromethane and the organic layers combined. The resulting
mixture was washed with 1.times.5 mL of sodium bicarbonate and
2.times.5 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (130 mg)
was purified by reverse phase HPLC eluting with a water/CH.sub.3CN
gradient containing 0.05% TFA. The product was obtained as 56.5 mg
(38%) of a light yellow solid. .sup.1H-NMR (300 MHz, CD.sub.3OD,
ppm): .delta. 8.96 (d, J=5.1 Hz, 1H), 8.70 (d, J=9.0 Hz, 1H), 8.43
(s, 1H), 8.16.about.8.08 (m, 3H), 7.87.about.7.86 (m, 1H),
7.79.about.7.56 (m, 7H), 4.71 (s, 2H), 4.00.about.3.89 (m, 5H),
3.63.about.3.52 (m, 11H), 3.23 (s, 3H), 2.17 (s, 3H), 2.01 (s, 1H),
1.81 (d, J=4.8 Hz, 1H). MS (ES, m/z): 770 [M+H].sup.+.
Example 82
N1-Methyl-N1-(2-(4-methylpiperazin-1-yl)ethyl)-N3-(4-(piperidin-1-yl)-2-(4-
-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00241##
[0680] Into a 50-mL round bottom flask, was placed a solution of
N1-methyl-N1-(2-(piperazin-1-yl)ethyl)-N3-(4-(piperidin-1-yl)-2-(4-(3-(tr-
ifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(150 mg, 0.21 mmol, 1.00 equiv) in HCHO (in water) (6 mL),
NaBH.sub.3CN (15 mg, 1.10 equiv), and acetic acid (5 drops). The
resulting solution was stirred for 2 h at 25.degree. C. The
resulting solution was diluted with 5 mL of sodium bicarbonate,
extracted with 2.times.5 mL of dichloromethane, and the organic
layers combined. The resulting mixture was washed with 1.times.5 mL
of water and 1.times.5 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (80 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 13.3 mg (9%) of a light yellow solid. .sup.1H-NMR (300
MHz, CD.sub.3OD, ppm): .delta. 8.96 (d, J=5.1 Hz, 1H), 8.76 (d,
J=9.3 Hz, 1H), 8.45 (s, 1H), 8.15 (s, 1H), 8.05 (s, 2H),
7.89.about.7.87 (m, 1H), 7.71.about.7.62 (m, 5H), 7.59.about.7.56
(m, 2H), 4.72 (s, 2H), 3.79 (s, 2H), 3.66 (d, J=5.1 Hz, 4H),
3.50.about.3.34 (m, 2H), 3.15.about.3.04 (m, 6H), 2.89.about.2.85
(m, 6H), 2.80.about.2.60 (m, 2H), 2.04 (d, J=4.5 Hz, 4H), 1.83 (d,
J=5.4 Hz, 2H). MS (ES, m/z): 742 [M+H].sup.+.
Example 83
N1-methyl-N1-(2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)-N3-(4-(piperidin--
1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isophth-
alamide
##STR00242##
[0682] Into a 50-mL round-bottom flask, was placed a solution of
N1-methyl-N1-(2-(piperazin-1-yl)ethyl)-N3-(4-(piperidin-1-yl)-2-(4-(3-(tr-
ifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (3 mL),
triethylamine (42 mg, 0.42 mmol, 3.00 equiv), and methanesulfonyl
chloride (17 mg, 0.15 mmol, 1.05 equiv). The resulting solution was
stirred for 40 min at 25.degree. C. The reaction was then quenched
by the addition of 3 mL of water. The resulting solution was
extracted with 2.times.5 mL of dichloromethane and the organic
layers combined. The resulting mixture was washed with 1.times.5 mL
of water and 1.times.5 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (90 mg) was purified by reverse phase HPLC eluting with a
water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 55.8 mg (50%) of a light yellow solid. .sup.1H-NMR (300
MHz, CD.sub.3OD, ppm): .delta. 8.97 (d, J=5.1 Hz, 1H), 8.764 (d,
J=9.0 Hz, 1H), 8.45 (s, 1H), 8.16.about.8.10 (m, 3H),
7.89.about.7.87 (m, 1H), 7.80 (d, J=7.5 Hz, 1H), 7.72.about.7.67
(m, 4H), 7.62.about.7.53 (m, 2H), 4.72 (s, 2H), 4.00 (s, 2H),
3.68.about.3.55 (m, 14H), 3.11 (s, 3H), 2.96 (s, 3H), 2.04 (d,
J=4.8 Hz, 1H), 1.83 (d, J=5.1 Hz, 1H). MS (ES, m/z): 806
[M+H].sup.+.
Examples 84 Through 119
[0683] The compounds listed in Table 6 were prepared by the
procedures disclosed above as typified in Example 1.1 (Method 1),
Example 8.1 (Method 2), Example 5.1 (Method 3), Example 71 (Method
4), Example 25 (Method 5), Example 37 (Method 6), Example 26
(Method 7), Example 4.22 (Method 8) or Example 8.25 (Method 9).
Mass spectral data (ES, positive ion mode) is provided for each
compound.
TABLE-US-00007 TABLE 6 Example Mass Method No. Structure Spectrum 1
84 ##STR00243## 663.3 [M + H] 1 85 ##STR00244## 691.32 [M + H] 1 86
##STR00245## 711.28 [M + H] 1 87 ##STR00246## 678.26 [M + H] 1 88
##STR00247## 695.29 [M + H] 1 89 ##STR00248## 659.28 [M + H] 1 90
##STR00249## 711.35 [M + H] 2 91 ##STR00250## 727.30 [M + H] 2 92
##STR00251## 691.32 [M + H] 3 (treating the ketone product with
deoxo-fluor (Bis-(2- methoxy- ethyl) aminosulfur - trifluoride) to
install the fluorines) 93 ##STR00252## 670.23 [M + H] 4 94
##STR00253## 636.28 [M + H] 5 95 ##STR00254## 759.24 [M + H] 5 96
##STR00255## 808.21 [M + H] 6 97 ##STR00256## 701 [M + H] 4 98
##STR00257## 650.29 [M + H] 4 99 ##STR00258## 702.26 [M + H] 7 101
##STR00259## 748.29 [M + H] 5 102 ##STR00260## 759.21 [M + H] 5 103
##STR00261## 759.21 [M + H] 4 104 ##STR00262## 701.27 [M + H] 5 105
##STR00263## 743.21 [M + H] 3 (treating the ketone product with
deoxo-fluor (Bis-(2- methoxy- ethyl) aminosulfur- trifluoride) to
install the fluorines) 106 ##STR00264## 682.2 [M + H] 5 108
##STR00265## 757.26 [M + H] 4 109 ##STR00266## 650.28 [M + H] 8 110
##STR00267## 721.23 [M + H] 5 111 ##STR00268## 783.23 [M + H] 8 112
##STR00269## 756.64 [M + H] 8 113 ##STR00270## 909.91 [M + H] 5 114
##STR00271## 783.23 [M + H] 8 115 ##STR00272## 632.42 [M + H] 5 116
##STR00273## 745.26 [M + H] 5 117 ##STR00274## 836.35 [M + H] 5 118
##STR00275## 747.19 [M + H] 9 119 ##STR00276## 690 [M + H]
Example 120
3-(3-(4-(dimethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)benzylthio)propanoic acid
##STR00277##
[0685] This compound was prepared according to the procedure
described for the synthesis of
3-((3-((4-(Dipropylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyri-
din-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid Example 19,
using dimethylamine in place of dipropylamine. (ES, m/z): 637
[M+H].sup.+(300 MHz, DMSO, ppm): 12.10 (s, 1H), 9.53 (t, J=6.0 Hz,
1H), 8.97 (d, J=5.1 Hz, 1H), 8.33 (s, 1H), 8.26 (d, J=8.7 Hz, 1H),
7.85-7.87 (m, 2H), 7.72-7.77 (m, 2H), 7.45-7.69 (m, 5H), 7.35 (s,
1H), 7.09 (d, J=7.8 Hz, 1H), 4.63 (d, J=5.7 Hz, 2H), 3.87 (s, 2H),
3.04 (s, 6H), 2.53-2.64 (m, 4H).
Example 121
N1-(2-(4-((2-methoxy-4-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(-
piperidin-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00278##
[0687] Into a 50-mL round-bottom flask, was placed a solution of
2-(2-(3-(carbamoyl)benzamido)-5-(piperidin-1-yl)phenyl)isonicotinic
acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (6
mL), (2-methoxy-4-(trifluoromethyl)phenyl)methanamine (36 mg, 0.17
mmol, 1.00 equiv), EDC.HCl (67 mg, 0.35 mmol, 2.00 equiv),
4-dimethylaminopyridine (43 mg, 0.35 mmol, 2.00 equiv). The
resulting solution was stirred for 2 h at 25.degree. C. The
resulting solution was diluted with 100 mL of ethyl acetate. The
resulting mixture was washed with 2.times.20 mL of NH.sub.4Cl aq.
and 1.times.20 mL of 10% sodium bicarbonate. The resulting mixture
was washed with 1.times.20 mL of Brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (120 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (28%
CH.sub.3CN up to 39% in 5.5 min); Detector, Waters2545 UvDector
254&270 nm. 79.9 mg product was obtained. This resulted in 79.9
mg (48%) of
N1-(2-(4-((2-methoxy-4-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4--
(piperidin-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
as a yellow solid. (ES, m/z): 759 [M+H].sup.+ H.sup.1-NMR (300 MHz,
DMSO d.sub.6, ppm): 12.41 (s, 1H), 9.74 (s, 1H), 9.39-9.43 (t, J=12
Hz, 1H), 8.91 (d, J=6 Hz, 1H), 8.30-8.35 (m, 2H), 7.48-8.03 (m,
2H), 7.85 (d, J=6 Hz, 1H), 7.57-7.71 (m, 3H), 7.24-7.42 (m, 3H),
4.53 (s, 2H), 4.17-4.21 (m, 3H), 3.85-3.93 (m, 6H), 3.67 (m, 4H),
3.46 (m, 2H), 3.32 (m, 4H), 3.19 (m, 2H), 2.96 (s, 3H), 1.73 (m,
4H), 1.59 (m, 2H).
Example 122
N1-(2-(4-((4-tert-butylbenzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)ph-
enyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00279##
[0689] Into a 8-mL round-bottom flask, was placed a solution of
2-(2-(3-(carbamoyl)benzamido)-5-(piperidin-1-yl)phenyl)isonicotinic
acid (125 mg, 0.19 mmol, 1.00 equiv, 85%) in dichloromethane (2
mL), (4-tert-butylphenyl)methanamine (36 mg, 0.22 mmol, 1.00
equiv), EDC.HCl (84 mg, 0.44 mmol, 2.00 equiv),
4-dimethylaminopyridine (54 mg, 0.44 mmol, 2.00 equiv). The
resulting solution was stirred for 2 h at 25.degree. C. The
resulting solution was diluted with 100 mL of ethyl acetate. The
resulting mixture was washed with 2.times.20 mL of NH.sub.4Cl aq.
and 1.times.20 mL of 10% sodium bicarbonate. The resulting mixture
was washed with 1.times.20 mL of Brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (130 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (28%
CH.sub.3CN up to 39% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 85.8 mg product was obtained. This resulted in 85.8
mg (44%) of
N1-(2-(4-((4-tert-butylbenzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)p-
henyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide as a yellow
solid. (ES, m/z): 717 [M+H].sup.+; H-NMR (300 MHz, DMSO, ppm):
12.39 (s, 1H), 9.71 (s, 1H), 9.41 (t, J=12 Hz, 1H), 8.89 (d, J=3
Hz, 1H), 8.28 (m, 2H), 7.98-8.02 (m, 2H), 7.83 (d, J=6 Hz, 1H),
7.62-7.69 (m, 3H), 7.24-7.36 (m, 5H), 4.48 (s, 2H), 3.46 (m, 3H),
3.31 (m, 4H), 3.20 (m, 3H), 2.96 (s, 3H), 1.73 (m, 4H), 1.58 (m,
2H), 1.26 (s, 9H).
Example 123
N1-(2-(4-((2-(trifluoromethoxy)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00280##
[0691] Into a 8-mL round-bottom flask, was placed a solution of
2-(2-(3-(carbamoyl)benzamido)-5-(piperidin-1-yl)phenyl)isonicotinic
acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (2
mL), (2-(trifluoromethoxy)phenyl)methanamine (33.45 mg, 0.17 mmol,
1.00 equiv), EDC.HCl (67.25 mg, 0.35 mmol, 2.00 equiv),
4-dimethylaminopyridine (42.73 mg, 0.35 mmol, 2.00 equiv). The
resulting solution was stirred for 2 h at 25.degree. C. The
resulting solution was diluted with 100 mL of ethyl acetate. The
resulting mixture was washed with 2.times.20 mL of NH.sub.4Cl aq.
and 1.times.20 mL of 10% sodium bicarbonate. The resulting mixture
was washed with 1.times.20 mL of Brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (120 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (22%
CH.sub.3CN up to 40% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 62.2 mg product was obtained. This resulted in 62.2
mg (38%) of
N1-(2-(4-((2-(trifluoromethoxy)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidi-
n-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide as a
yellow solid. (ES, m/z): 745 [M+H].sup.+; H-NMR (300 MHz, DMSO,
ppm): 12.37 (s, 1H), 9.65 (s, 1H), 9.47 (t, J=12 Hz, 1H), 8.90 (d,
J=6 Hz, 1H), 8.28-8.30 (m, 2H), 7.83-8.00 (m, 2H), 7.96 (d, J=6 Hz,
1H), 7.57-7.71 (m, 3H), 7.34-7.48 (m, 4H), 7.27 (m, 1H), 4.59 (s,
2H), 3.66 (m, 3H), 3.46 (m, 4H), 3.30 (m, 2H), 2.96 (s, 3H), 1.72
(m, 4H), 1.58-1.60 (m, 2H).
Example 124
N1-(2-(4-((2-methoxybenzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)pheny-
l)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00281##
[0693] Into a 8-mL round-bottom flask, was placed a solution of
2-(2-(3-(carbamoyl)benzamido)-5-(piperidin-1-yl)phenyl)isonicotinic
acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (2
mL), (2-methoxyphenyl)methanamine (30 mg, 0.22 mmol, 1.00 equiv),
EDC.HCl (67.25 mg, 0.35 mmol, 2.00 equiv), 4-dimethylaminopyridine
(42.73 mg, 0.35 mmol, 2.00 equiv). The resulting solution was
stirred for 2 h at 25.degree. C. The resulting solution was diluted
with 100 mL of ethyl acetate. The resulting mixture was washed with
2.times.20 mL of NH.sub.4Cl aq. and 1.times.20 mL of 10% sodium
bicarbonate. The resulting mixture was washed with 1.times.20 mL of
Brine. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude product (120 mg) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with
0.05% TFA and CH.sub.3CN (20% CH.sub.3CN up to 33% in 6 min);
Detector, Waters2545 UvDector 254&270 nm. 85.8 mg product was
obtained. This resulted in 85.8 mg (55%) of
N1-(2-(4-((2-methoxybenzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phen-
yl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide as a yellow
solid. LC-MS (ES, m/z): 691 [M+H].sup.+; H-NMR (300 MHz,
CD.sub.3OD, ppm): 12.48 (s, 1H), 9.81 (s, 1H), 9.29 (t, J=12 Hz,
1H), 8.90 (d, J=6 Hz, 1H), 8.35 (m, 2H), 8.03-7.99 (m, 2H), 7.86
(d, J=3 Hz, 1H), 7.72-7.63 (m, 2H), 7.34-7.19 (m, 3H), 7.00 (m,
1H), 6.92-6.87 (t, J=15 Hz, 1H), 4.49 (m, 4H), 4.36 (m, 5H), 4.24
(m, 3H), 4.03 (m, 5H), 3.66 (m, 4H), 3.34 (m, 6H), 3.20 (m, 2H),
2.96 (s, 3H), 1.74 (m, 6H).
Example 125
N1-(2-(4-((2-methoxy-5-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(-
piperidin-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00282##
[0694] Intermediate 125a
[0695] Into a 50-mL round-bottom flask, was placed a solution of
2-(bromomethyl)-1-methoxy-4-(trifluoromethyl)benzene (230 mg, 0.86
mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), sodiumazide (167
mg, 2.57 mmol, 3.00 equiv). The resulting solution was stirred for
3 h at 75.degree. C. in an oil bath. The resulting solution was
diluted with 100 mL of ethyl acetate. The resulting mixture was
washed with 4.times.20 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 160 mg (73%) of
2-(azidomethyl)-1-methoxy-4-(trifluoromethyl)benzene as brown
oil.
Intermediate 125b
[0696] Into a 50-mL round-bottom flask, was placed a solution of
2-(azidomethyl)-1-methoxy-4-(trifluoromethyl)benzene (160 mg, 0.62
mmol, 1.00 equiv, 90%) in tetrahydrofuran/water (4/0.5 mL),
triphenylphosphine (399 mg, 1.52 mmol, 2.20 equiv). The resulting
solution was stirred for 3 h at 40.degree. C. in an oil bath. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with ethylacetate:methanol (10:1).
This resulted in 180 mg (70%) of
(2-methoxy-5-(trifluoromethyl)phenyl)methanamine as a off-white
solid.
Example 125
N1-(2-(4-((2-methoxy-5-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(-
piperidin-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
[0697] A solution of
2-(2-(3-(carbamoyl)benzamido)-5-(piperidin-1-yl)phenyl)isonicotinic
acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (6
mL), (2-methoxy-5-(trifluoromethyl)phenyl)methanamine (120 mg, 0.29
mmol, 1.00 equiv, 50%), EDC.HCl (67 mg, 0.35 mmol, 2.00 equiv),
4-dimethylaminopyridine (43 mg, 0.35 mmol, 2.00 equiv). The
resulting solution was stirred for 2 h at 25.degree. C. The
resulting solution was diluted with 100 mL of ethyl acetate. The
resulting mixture was washed with 2.times.20 mL of NH.sub.4Cl and
1.times.20 mL of 10% sodium bicarbonate. The resulting mixture was
washed with 1.times.20 mL of Brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (120 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (26%
CH.sub.3CN up to 36% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 80.6 mg product was obtained. This resulted in 80.6
mg (48%) of
N1-(2-(4-((2-methoxy-5-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4--
(piperidin-1-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
Example 125 as a yellow solid. LC-MS (ES, m/z): 759 [M+H].sup.+;
H-NMR (300 MHz, DMSO, ppm): 12.48 (s, 1H), 9.70 (s, 1H), 9.38 (t,
J=12 Hz, 1H), 8.90 (d, J=6 Hz, 1H), 8.32 (m, 2H), 7.98-8.03 (m,
2H), 7.84 (d, J=6 Hz, 1H), 7.59-7.71 (m, 4H), 7.27 (m, 1H), 4.54
(s, 2H), 3.31-3.86 (m, 10H), 3.19 (m, 2H), 3.97 (s, 3H), 1.59-1.72
(m, 6H).
Example 126
(S)--N1-methyl-N1-(3-morpholinopropyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,-
4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00283## ##STR00284##
[0698] Intermediate 126a
[0699] Into a 100-mL round-bottom flask, was placed a solution of
3-morpholinopropan-1-amine (5 g, 34.67 mmol, 1.00 equiv) in
dichloromethane (50 mL), di-tert-butyl dicarbonate (7.56 g, 34.67
mmol, 1.00 equiv.), triethylamine (7 g, 70.00 mmol, 2.00 equiv).
The resulting solution was stirred overnight at 25.degree. C. The
resulting mixture was concentrated under vacuum. This resulted in
6.8 g (80%) of tert-butyl 3-morpholinopropylcarbamate as light
yellow oil.
Intermediate 126b
[0700] Into a 100-mL round-bottom flask, was placed a solution of
tert-butyl 3-morpholinopropylcarbamate (3 g, 12.28 mmol, 1.00
equiv) in tetrahydrofuran (50 mL). This was followed by the
addition of LiAlH.sub.4 (0.93 g, 24.60 mmol, 2.00 equiv) in several
batches. The resulting solution was stirred for 1 h at 75.degree.
C. in an oil bath. The reaction was then quenched by the addition
of 8 mL of water. The solids were filtered out. The resulting
mixture was concentrated under vacuum. This resulted in 1.3 g (67%)
of N-methyl-3-morpholinopropan-1-amine as light yellow oil.
Intermediate 126c
[0701] Into a 250-mL round-bottom flask, was placed a solution of
2-bromoisonicotinic acid (10 g, 49.50 mmol, 1.10 equiv) in
dichloromethane (60 mL), (S)-1,2,3,4-tetrahydronaphthalen-1-amine
(6.6 g, 44.90 mmol, 1.00 equiv), EDC.HCl (12.9 g, 67.29 mmol, 1.50
equiv), 4-dimethylaminopyridine (8.3 g, 68.03 mmol, 1.50 equiv).
The resulting solution was stirred for 3 h at room temperature. The
resulting solution was diluted with 20 mL of water. The resulting
solution was extracted with 2.times.20 ml of dichloromethane and
the organic layers combined. The resulting mixture was washed with
1.times.10 mL of hydrogen chloride (10%) and 1.times.20 ml of
water. The resulting mixture was washed with 1.times.20 mL of
brine. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. This resulted in 13.2 g (89%) of
(S)-2-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide as
a off-white solid.
Intermediate 126d
[0702] Into a 250-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
1-(4-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidi-
ne (6.5 g, 19.58 mmol, 1.00 equiv) in ethylene glycol dimethyl
ether (100 mL),
(S)-2-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
(6.5 g, 19.64 mmol, 1.00 equiv), Pd(PPh.sub.3).sub.4 (1.13 g, 0.98
mmol, 0.05 equiv), a solution of sodium carbonate (6.2 g, 58.49
mmol, 3.00 equiv) in water (20 mL). The resulting solution was
stirred for 3 h at 80.degree. C. in an oil bath. The resulting
solution was extracted with 2.times.30 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
1.times.20 mL of water and 1.times.20 ml of Brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (2:5.about.2:1). This resulted in 7.6 g
(85%) of
2-(2-nitro-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide as a yellow solid.
Intermediate 126e
[0703] Into a 250-mL round-bottom flask, was placed a solution of
2-(2-nitro-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide (7.6 g, 16.67 mmol, 1.00 equiv) in methanol
(120 mL), Palladium carbon (0.76 g). Hydrogen gas was introduced
into the reaction vessel. The resulting solution was stirred
overnight at room temperature. The solids were filtered out. The
resulting mixture was concentrated under vacuum. This resulted in
5.3 g (75%) of
2-(2-amino-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide as a brown solid. (ES, m/z): 427 [M+H].sup.+
(300 MHz, CD.sub.3OD, ppm): 8.726.about.8.745 (m, 1H), 8.072 (s,
1H), 7.630.about.7.682 (m, 2H), 7.266.about.7.306 (m, 2H),
7.145.about.7.198 (m, 3H), 6.984.about.7.022 (m, 1H),
6.831.about.6.86 (d, J=8.7 Hz, 1H), 5.378 (m, 1H),
3.014.about.3.049 (m, 4H), 2.837.about.2.885 (m, 2H),
1.915.about.2.033 (m, 4H), 1.721.about.1.796 (m, 4H).
Intermediate 126f
[0704] Into a 250-mL round-bottom flask, was placed a solution of
2-(2-amino-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide (4.3 g, 10.09 mmol, 1.00 equiv) in
dichloromethane (100 mL), 3-(methoxycarbonyl)benzoic acid (2.08 g,
11.56 mmol, 1.10 equiv), EDCI (2.87 g, 14.97 mmol, 1.50 equiv),
4-dimethylaminopyridine (1.83 g, 14.98 mmol, 1.50 equiv). The
resulting solution was stirred for 2 h at room temperature. The
resulting solution was diluted with 10 mL of water. The resulting
solution was extracted with 2.times.20 ml of dichloromethane and
the organic layers combined. The resulting mixture was washed with
1.times.20 mL of water and 1.times.20 ml of Brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
This resulted in 5.8 g (98%) of methyl
3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(piperidin-1-yl)phenyl)carbamoyl)benzoate as a brown solid.
Intermediate 126g
[0705] Into a 250-mL round-bottom flask, was placed a solution of
methyl
3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(piperidin-1-yl)phenyl)carbamoyl)benzoate (5.8 g, 9.86 mmol, 1.00
equiv) in tetrahydrofuran (50 mL), a solution of lithium hydroxide
hydrate (1.2 g, 28.57 mmol, 5.00 equiv) in water (20 mL). The
resulting solution was stirred for 16 h at 70.degree. C. in an oil
bath. The resulting mixture was concentrated under vacuum. The pH
value of the solution was adjusted to 3.about.4 with hydrogen
chloride (10%). The solids were collected by filtration. The solid
was dried in an oven under reduced pressure. This resulted in 5 g
(88%) of
3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(piperidin-1-yl)phenyl)carbamoyl)benzoic acid as a brown solid.
LC-MS (ES, m/z): 575 [M+H].sup.+; H-NMR (300 MHz, CDCl.sub.3, ppm):
13.36 (s, 1H), 8.85 (s, 1H), 8.59 (s, 2H), 8.31 (s, 1H), 8.11 (s,
2H), 7.81.about.7.46 (m, 4H), 7.08 (d, J=13.5 Hz, 4H), 5.38 (s,
1H), 3.23 (s, 4H), 2.74 (s, 2H), 2.10.about.1.60 (m, 10H).
Example 126
(S)--N1-methyl-N1-(3-morpholinopropyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,-
4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0706] A solution of
3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(piperidin-1-yl)phenyl)carbamoyl)benzoic acid (150 mg, 0.26 mmol,
1.00 equiv) in dichloromethane (3 mL),
N-methyl-3-morpholinopropan-1-amine (42 mg, 0.27 mmol, 1.00 equiv),
EDC.HCl (75 mg, 0.39 mmol, 1.50 equiv), 4-dimethylaminopyridine (48
mg, 0.39 mmol, 1.50 equiv). The resulting solution was stirred for
2 h at 25.degree. C. The resulting solution was diluted with 3 mL
of water. The resulting solution was extracted with 2.times.5 mL of
dichloromethane and the organic layers combined. The resulting
mixture was washed with 1.times.5 mL of water and 2.times.5 mL of
Brine. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude product (120 mg) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with
0.05% TFA and CH.sub.3CN (24% CH.sub.3CN up to 34% in 6 min);
Detector, Waters2545 UvDector 254&220 nm. 97 mg product was
obtained. This resulted in 97 mg (35%) of
(S)--N1-methyl-N1-(3-morpholinopropyl)-N3-(4-(piperidin-1-yl)-2--
(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophth-
alamide. Example 126 as a yellow solid. (ES, m/z): 715
[M+H].sup.+(400 MHz, CD.sub.3OD, ppm): 8.91 (s, 1H), 8.73 (d, J=8.8
Hz, 1H), 8.41 (s, 1H), 8.14.about.8.09 (m, 3H), 7.873.about.7.857
(m, 1H), 7.753.about.7.69 (m, 3H), 7.27 (d, J=7.2 Hz, 1H),
7.19.about.7.13 (m, 3H), 5.40 (d, J=6.4 Hz, 1H), 4.18 (s, 2H),
3.90.about.3.50 (m, 9H), 3.46.about.3.17 (m, 5H), 3.07 (s, 3H),
2.89.about.2.78 (s, 2H), 2.26.about.2.03 (m, 8H), 1.98.about.1.81
(m, 4H).
Example 127
N1-(4-(butyl(methyl)amino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridi-
n-2-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00285##
[0708] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(butyl(methyl)amino)phenyl)iso-
nicotinamide (250 mg, 0.55 mmol, 1.00 equiv) in dichloromethane (10
mL), 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid (190 mg,
0.65 mmol, 1.19 equiv), 4-dimethylaminopyridine (133 mg, 1.09 mmol,
1.99 equiv), EDC.HCl (210 mg, 1.09 mmol, 2.00 equiv). The resulting
solution was stirred overnight at room temperature. The reaction
progress was monitored by LCMS. The resulting solution was diluted
with 100 mL of dichloromethane. The resulting mixture was washed
with 2.times.50 mL of NH.sub.4Cl aq. and 2.times.50 mL of brine.
The mixture was dried over sodium sulfate and concentrated under
vacuum. The crude product was purified by Prep-HPLC with the
following conditions (1#-Waters 2767-3): Column, SunFire Prep C18,
5 um, 19*150 mm; mobile phase, water with 0.05% TFA and CH.sub.3CN
(30% CH.sub.3CN up to 42% in 6 min); Detector, UV 220&254 nm.
This resulted in 87.2 mg (15%) of
N1-(4-(butyl(methyl)amino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyrid-
in-2-yl)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide as a
yellow solid. LC-MS (ES, m/z): 731 [M+H].sup.+ H-NMR (300 MHz,
DMSO, ppm): 11.95 (s, 1H), 9.75 (s, 1H), 9.52 (s, 1H), 8.88 (d,
J=5.1 Hz, 1H), 8.27 (s, 1H), 8.10 (d, J=9.3 Hz, 1H), 7.97-7.83 (m,
2H), 7.82 (d, J=5.1 Hz, 1H), 7.70-7.54 (m, 6H), 7.17 (s, 1H), 6.95
(d, J=7.5 Hz, 1H), 4.61 (d, J=5.7 Hz, 2H), 4.02 (s, 2H), 3.90 (s,
2H), 3.65 (s, 4H), 3.45-3.39 (m, 4H), 3.20 (s, 2H), 3.0 (d, J=12.3
Hz, 6H), 1.55-1.50 (m, 2H), 1.35-1.30 (m, 2H), 0.93-0.88 (m,
3H).
Example 128
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(ethyl(prop-
yl)amino)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
##STR00286##
[0710] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(ethyl(propyl)amino)phenyl)iso-
nicotinamide (150 mg, 0.30 mmol, 1.00 equiv, 90%) in
dichloromethane (8 mL),
3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid (144 mg, 0.44
mmol, 1.50 equiv, 90%), EDC.HCl (126 mg, 0.66 mmol, 2.00 equiv),
4-dimethylaminopyridine (80 mg, 0.66 mmol, 2.00 equiv). The
resulting solution was stirred overnight at room temperature. The
resulting solution was diluted with 100 mL of ethyl acetate. The
resulting mixture was washed with 2.times.20 mL of NH.sub.4Cl aq.
and 1.times.20 mL of sodium bicarbonate (10%). The resulting
mixture was washed with 1.times.20 mL of brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The crude product (250 mg) was purified by Prep-HPLC with the
following conditions (1#-Waters 2767-3): Column, SunFire Prep C18,
19*150 mm 5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN
(25% CH.sub.3CN up to 39% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 183.7 mg product was obtained. This resulted in
183.7 mg (56%) of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(ethyl(pro-
pyl)amino)phenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide as
a yellow solid. LC-MS (ES, m/z): 731 [M+H].sup.+; H-NMR (300 MHz,
DMSO, ppm): 9.83 (s, 1H), 9.52 (t, J=18 Hz, 1H), 8.89 (d, J=3 Hz,
1H), 8.26 (s, 1H), 8.13 (s, 1H), 7.99 (m, 2H), 7.82 (d, 1H),
7.54-7.69 (m, 6H), 6.95-7.54 (m, 2H), 4.60 (s, 2H), 3.85-4.02 (m,
4H), 3.64 (m, 4H), 3.36-3.47 (m, 6H), 3.18 (m, 2H), 2.95 (s, 3H),
1.60 (m, 2H), 1.09-1.13 (m, 3H), 0.87-0.92 (m, 3H).
Example 129
N.sup.1-methyl-N.sup.3-(4-(methyl(propyl)amino)-2-(4-((3-(trifluoromethyl)-
benzyl)
carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-(2-morpholinoethyl)isophtha-
lamide
##STR00287##
[0712] This compound was prepared according to the procedure
described for the synthesis of
N.sup.1-(4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyri-
din-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-morpholinoethyl)isophthalamide
25, using N-methylpropan-1-amine in place of diethylamine. MS (ES,
m/z): 717.3 [M+H].sup.+.
Example 130
(S)--N1-methyl-N1-(2-morpholinoethyl)-N3-(2-(4-(1,2,3,4-tetrahydronaphthal-
en-1-ylcarbamoyl)pyridin-2-yl)-4-(trifluoromethyl)phenyl)isophthalamide
##STR00288##
[0713] Intermediate 130a
[0714] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
2-bromo-4-(trifluoromethyl)benzenamine (1 g, 4.17 mmol, 1.00 equiv)
in DMSO (20 mL),
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-
-dioxaborolane (1.58 g, 6.22 mmol, 1.50 equiv), PdCl.sub.2(dppf)
(91 mg, 0.12 mmol, 0.03 equiv), potassium acetate (1 g, 10.40 mmol,
2.57 equiv). The resulting solution was stirred overnight at
80.degree. C. in an oil bath. The resulting mixture was combined
with the solution of the previous batch and then diluted with 100
mL of ethyl acetate. The resulting mixture was washed with
2.times.100 mL of brine. The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:100). This resulted in 1.2 g of
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)benzen-
amine as a yellow solid.
Intermediate 130b
[0715] Into a 100-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of
2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)benzen-
amine (1.2 g, 4.18 mmol, 1.00 equiv) in ethylene glycol dimethyl
ether (40 mL),
(S)-2-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
(1.38 g, 4.17 mmol, 1.00 equiv), Pd(PPh.sub.3).sub.4 (480 mg, 0.42
mmol, 0.10 equiv), a solution of sodium carbonate (2.22 g, 20.94
mmol, 5.00 equiv) in water (20 mL). The resulting solution was
stirred for 1 h at 80.degree. C. in an oil bath. The resulting
solution was diluted with 100 mL of ethyl acetate. The resulting
mixture was washed with 2.times.100 mL of brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The residue was applied onto a silica gel column with petroleum
ether/ethyl acetate (5:1). This resulted in 900 mg (65%) of
(S)-2-(2-amino-5-(trifluoromethyl)phenyl)-N-(1,2,3,4-tetrahydron-
aphthalen-1-yl)isonicotinamide as a yellow solid.
Example 130
[0716] Into a 25-mL round-bottom flask, was placed a solution of
(S)-2-(2-amino-5-(trifluoromethyl)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide (200 mg, 0.49 mmol, 1.00 equiv) in
dichloromethane (6 mL), pyridine (3 mL). This was followed by the
addition of a solution of
3-(methyl(2-morpholinoethyl)carbamoyl)benzoyl chloride (230 mg,
0.74 mmol, 1.50 equiv) in dichloromethane (1 mL) dropwise with
stirring. The resulting solution was stirred for 3 h at room
temperature. The pH value of the solution was adjusted to 7 with
10% hydrochloric acid. The resulting solution was extracted with
2.times.100 mL of ethyl acetate and the organic layers combined and
concentrated under vacuum. The crude product (200 mg) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with
0.05% TFA and CH.sub.3CN (40% CH.sub.3CN up to 54% in 6 min);
Detector, Waters2545 UvDector 254&270 nm. 93.7 mg product was
obtained. This resulted in 93.7 mg (21%) of
(S)--N1-methyl-N1-(2-morpholinoethyl)-N3-(2-(4-(1,2,3,4-tetrahydronaphtha-
len-1-ylcarbamoyl)pyridin-2-yl)-4-(trifluoromethyl)phenyl)isophthalamide
as a light yellow solid. LC-MS (ES, m/z): 686 [M+H].sup.+; H-NMR
(300 MHz, DMSO, ppm): 13.29 (s, 1H), 9.28 (d, J=8.7 Hz, 1H), 8.96
(d, J=5.1 Hz, 1H), 8.77 (d, J=8.7 Hz, 1H), 8.46 (s, 1H), 8.34 (s,
1H), 8.10 (m, 2H), 7.97 (m, 2H), 7.78 (m, 2H), 7.18 (m, 4H), 5.29
(d, J=5.7 Hz, 1H), 3.69 (m, 10H), 3.21 (s, 2H), 2.98 (s, 4H), 2.82
(m, 2H), 2.03 (m, 4H).
Example 131
(S)--N.sup.1-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)ca-
rbamoyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-morpholinoethyl)iso-
phthalamide
##STR00289## ##STR00290##
[0717] Intermediate 131a
[0718] Into a 1000-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of
2-(5-fluoro-2-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(10.7 g, 40.07 mmol, 1.20 equiv) in ethylene glycol dimethyl ether
(300 mL),
(S)-2-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
(11.05 g, 33.38 mmol, 1.00 equiv), Pd(PPh.sub.3).sub.4 (3.86 g,
3.34 mmol, 0.10 equiv), a solution of sodium carbonate (17.69 g,
166.89 mmol, 5.00 equiv) in water (150 mL). The resulting solution
was stirred for 18 h at 80.degree. C. in an oil bath. The resulting
solution was diluted with 100 mL of water. The resulting solution
was extracted with 2.times.100 mL of ethyl acetate and the organic
layers combined and dried over sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
petroleum ether/ethyl acetate (10:1-1:1). This resulted in 5.0014 g
(32%) of
(S)-2-(5-fluoro-2-nitrophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isoni-
cotinamide as a yellow solid. LC-MS (ES, m/z): 392 [M+H].sup.+
H-NMR (400 MHz, CDCl.sub.3, ppm): 8.73 (d, J=3.9 Hz, 1H), 8.02-7.98
(m, 1H), 7.83 (s, 1H), 7.60-7.58 (m, 1H), 7.32-7.13 (m, 6H), 6.45
(d, J=9.0 Hz, 1H), 5.42-5.38 (m, 1H), 2.89-2.77 (m, 2H), 2.20-2.13
(m, 1H), 2.01-1.90 (m, 3H).
Intermediate 131b:
(S)-2-(5-(diethylamino)-2-nitrophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1--
yl)isonicotinamide
[0719] A mixture of
(S)-2-(5-fluoro-2-nitrophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isoni-
cotinamide (12.77 mmol, 5 g), diethylamine (25.55 mmol, 1.87 g),
and K.sub.2CO.sub.3 (31.93 mmol, 4.41 g) in DMF (30 mL) was stirred
at 60.degree. C. overnight. The mixture was diluted with ethyl
acetate, and the resulting solution was washed with water
(2.times.), and then with brine. The solution was dried
(Na.sub.2SO.sub.4) and the solvent was removed at reduced pressure.
The residue was purified by chromatography on silica gel to give a
yellow solid. (4.73 g, 83%).
Intermediate 131c:
(S)-2-(2-amino-5-(diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1--
yl)isonicotinamide
[0720] A mixture of
(S)-2-(5-(diethylamino)-2-nitrophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1--
yl)isonicotinamide (4.73 g) and 10% Pd/C (1.3 g) in methanol (20
mL) was stirred under a hydrogen atmosphere for 2 h. The mixture
was filtered and concentrated to give a brown solid (4 g, 91%).
Intermediate 131d: (S)-tert-butyl
3-((4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)p-
yridin-2-yl)phenyl)carbamoyl)benzoate
[0721] To a mixture of
(S)-2-(2-amino-5-(diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1--
yl)isonicotinamide (7.1 mmol, 2.94 g),
3-(tert-butoxycarbonyl)benzoic acid (8.52 mmol, 1.89 g) and DIEA
(35.5 mmol, 4.59 g) in DMF (16 mL) was added HATU (8.52 mmol, 3.24
g). The mixture was stirred at 60.degree. C. for 1 h. The reaction
mixture was diluted with ethyl acetate, washed with water
(2.times.), brine (1.times.), dried and concentrated. The residue
was purified by column to give a yellow solid (4.31 g, 98%).
Intermediate 131e:
(S)-3-((4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamo-
yl) pyridin-2-yl)phenyl)carbamoyl)benzoic acid
[0722] To ((S)-tert-butyl
3-((4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)p-
yridin-2-yl)phenyl)carbamoyl)benzoate (4.31 g) was added 4M HCl in
dioxane (20 mL). The mixture was stirred at room temperature for 5
h, concentrated to give a yellow solid which was used without
further purification.
Example 131
(S)--N-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoy-
l)
pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-morpholinoethyl)isophtha-
lamide
[0723] To a mixture of
(S)-3-((4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamo-
yl)pyridin-2-yl)phenyl)carbamoyl)benzoic acid (1.81 mmol, 1.15 g),
N-methyl-2-morpholinoethanamine (2.17 mmol, 0.313 g) and DIEA
(12.67 mmol, 1.64 g) in DMF (5 mL) was added HATU (2.17 mmol, 0.826
g), and the mixture was stirred at 60.degree. C. for 2 h. The
reaction mixture was diluted with ethyl acetate, washed with water
(2.times.), brine (1.times.), dried and concentrated. The residue
was purified by column to give a yellow solid (0.98 g, 79%). MS
(ESI, m/z) 689.28 [M+H].sup.+.
Example 132
##STR00291##
[0724] Intermediate 132a
[0725] To a suspension of sodium hydride (100 mg, 4.17 mmol, 2.04
equiv, 100%) in N,N-dimethylformamide (25 mL) under an inert
atmosphere of nitrogen, was added cyclobutanol (200 mg, 2.77 mmol,
1.36 equiv, 100%) dropwise with stirring at 0.degree. C. over 5
min. To the resulting solution was added
2-(5-fluoro-2-nitrophenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-1-yl)ison-
icotinamide (800 mg, 2.04 mmol, 1.00 equiv, 100%) at 0.degree. C.
The resulting solution was stirred for 3 h at room temperature. The
reaction was then quenched by the addition of 15 mL of water. The
resulting solution was extracted with 3.times.20 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 1.times.20 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 0.92 g (95%) of
2-(5-cyclobutoxy-2-nitrophenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-1-yl-
)isonicotinamide as yellow oil.
Intermediate 132b
[0726] Into a 100-mL round-bottom flask, was placed a solution of
2-(5-cyclobutoxy-2-nitrophenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-1-yl-
)isonicotinamide (920 mg, 2.07 mmol, 1.00 equiv, 100%) in methanol
(30 mL), Palladium carbon (800 mg, 10%). Hydrogen gas was
introduced to the reaction vessel The resulting solution was
stirred overnight at room temperature. The solids were filtered
out. The resulting mixture was concentrated under vacuum. The
residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:5). This resulted in 0.42 g (48%) of
2-(2-amino-5-cyclobutoxyphenyl)-N--((S)-1,2,3,4-tetrahydronaphth-
alen-1-yl)isonicotinamide as light yellow oil. LC-MS (ES, m/z): 414
[M+H].sup.+ H-NMR (300 MHz, CDCl3, ppm): 8.71 (d, J=5.1 Hz, 1H),
7.69 (s, 1H), 7.52 (d, J=1.5 Hz, 1H), 7.51.about.7.16 (m, 4H), 7.09
(d, J=2.7 Hz, 1H), 6.86.about.6.76 (m, 2H), 6.47 (d, J=8.1 Hz, 1H),
5.44 (d, J=7.2 Hz, 1H), 4.65.about.4.60 (m, 1H), 2.91.about.2.84
(m, 2H), 2.49.about.2.39 (m, 4H), 2.23.about.2.14 (m, 5H)
2.06.about.1.88 (m, 1H).
Example 132
[0727] Into a 100-mL round-bottom flask, was placed a solution of
2-(2-amino-5-cyclobutoxyphenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-1-yl-
)isonicotinamide (100 mg, 0.24 mmol, 1.00 equiv, 100%) in
dichloromethane (20 mL),
3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid (80 mg, 0.27
mmol, 1.13 equiv, 100%), 4-dimethylaminopyridine (44 mg, 0.36 mmol,
1.49 equiv, 100%), EDCI (69 mg, 0.36 mmol, 1.49 equiv, 100%). The
resulting solution was stirred overnight at room temperature. The
reaction progress was monitored by LCMS. The resulting mixture was
washed with 2.times.10 mL of water. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (0.15 g) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (36%
CH.sub.3CN up to 52% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 84 mg product was obtained. This resulted in 108.4
mg (65%) of
N1-(2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-cyclobutoxyphenyl)-N3-methyl-N3-(2-morpholinoethyl)isophthalamide
as a light yellow solid. LC-MS (ES, m/z): 688 [M+H].sup.+ H-NMR
(300 MHz, DMSO, ppm): 12.52 (s, 1H), 9.27 (d, J=8.7 Hz, 1H), 8.89
(d, J=5.1 Hz, 1H), 8.32 (d, J=8.7 Hz, 2H), 8.04.about.8.00 (m, 2H),
7.89.about.7.87 (m, 2H), 7.69.about.7.64 (m, 1H), 7.58 (d, J=3.0
Hz, 1H), 7.22.about.7.12 (m, 4H), 7.05.about.7.02 (m, 1H), 5.26 (d,
J=6.0 Hz, 1H), 4.78.about.4.76 (t, 1H), 4.03 (s, 2H), 3.87 (s, 2H),
3.21 (s, 2H), 2.97 (s, 4H), 2.80 (d, J=5.1 Hz, 2H), 2.08 (d. J=7.5
Hz, 4H), 2.04.about.1.99 (m, 4H).
Example 133
(S)--N-(4-(cyclopentyloxy)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbam-
oyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-morpholinoethyl)isophth-
alamide
##STR00292##
[0728] Intermediate 133a
(S)-2-(2-amino-5-(cyclopentyloxy)phenyl)-N-(1,2,3,4-tetrahydronaphthalen--
1-yl)isonicotinamide
[0729] This intermediate was prepared according to the procedure
described for the synthesis of
(S)-2-(2-amino-5-cyclobutoxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-
isonicotinamide Example 132, using cyclopentanol in place of
cyclobutanol.
Example 133
(S)--N.sup.1-(4-(cyclopentyloxy)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)-
carbamoyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-morpholinoethyl)i-
sophthalamide
[0730] To a mixture of
(S)-2-(2-amino-5-(cyclopentyloxy)phenyl)-N-(1,2,3,4-tetrahydronaphthalen--
1-yl)isonicotinamide (0.076 mmol, 32 mg),
3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid (0.083 mmol, 24
mg) and DIEA (0.38 mmol, 49 mg) in DMF (0.25 mL) was added HATU
(0.083 mmol, 32 mg). The mixture was stirred at 60.degree. C.
overnight and purified by prep. HPLC to give Example 133 as a
yellow solid (36 mg, 51%). MS (ES, m/z): 703.3[M+H].sup.+.
Example 134
2-(3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyrid-
in-2-yl)phenylcarbamoyl)benzylthio)phenoxy)acetic acid
##STR00293##
[0731] Intermediate 134a:
2-(2-(3-((3-hydroxyphenylthio)methyl)benzamido)-5-(piperidin-1-yl)phenyl)-
-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0732] A mixture of 8.1a (300 mg, 0.49 mmol), 3-mercaptophenol (66
.mu.L, 0.59 mmol), and K.sub.2CO.sub.3 (75 mg, 1.5 mmol) in dry DMF
(3 mL) was stirred at for 1 h and then filtered. The filtrate was
poured into H.sub.2O (50 mL), forming a yellow precipitate. The
solid was filtered, then dissolved in DCM and washed with aqueous
HCl, saturated aqueous NaHCO.sub.3, and H.sub.2O. The solvent was
then removed to give 298 mg (87%) of the product 134a as a yellow
solid.
Example 134
2-(3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyrid-
in-2-yl)phenylcarbamoyl)benzylthio)phenoxy)acetic acid
[0733] A mixture of 134a (74 mg, 0.11 mmol), ethyl 2-bromoacetate
(21 mg, 0.13 mmol), sodium iodide (1 mg, 0.05 mmol), and
K.sub.2CO.sub.3 (37 mg, 0.27 mmol) were combined in dry DMF and the
suspension heated to 100.degree. C. and stirred for 1 h. The
suspension was poured into H.sub.2O (100 mL), resulting in the
formation of a yellow precipitate, which was filtered. The solid
was dissolved in DCM and washed with aqueous HCl, saturated aqueous
NaHCO.sub.3, and H.sub.2O, then dried over Na.sub.2SO.sub.4 and the
solvent removed to give intermediate 134b. The residue was
dissolved in dioxane (2 mL) and H.sub.2O (1 mL), to which
LiOH.H.sub.2O (7 mg, 0.16 mmol) was added the solution stirred for
1 h. The solution was then acidified and purified by reverse-phase
HPLC eluting with a water/acetonitrile gradient containing 0.1%
TFA. The process resulted in 62 mg (60%) of the product Example 134
as the di-TFA salt. MS (ES, m/z) 755 [M+H].sup.+.
Example 135
3-(2-(2-(2-(N-methyl-3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)ben-
zylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzylthio)benzamido)ethoxy)etho-
xy)ethoxy)propanoic acid
##STR00294## ##STR00295##
[0735] Into a 1000-mL round-bottom flask, was placed a solution of
2,2'-(2,2'-oxybis(ethane-2,1-diyl)bis,2-diylbis(oxy))diethanol (82
g, 546.05 mmol, 3.50 equiv) in tetrahydrofuran (300 mL), sodium
(110 mg, 4.78 mmol, 0.03 equiv). This was followed by the addition
of tert-butyl acrylate (20 g, 156.04 mmol, 1.00 equiv) dropwise
with stirring at room temperature. The resulting solution was
stirred overnight at room temperature. The pH value of the solution
was adjusted to 7 with 1M hydrochloric acid. The resulting solution
was extracted with 3.times.100 mL of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 3.times.100
mL of brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. This resulted in 36.6 g (84%) of
tert-butyl 3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propanoate as
yellow oil.
[0736] Into a 250-mL round-bottom flask, was placed a solution of
tert-butyl 3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propanoate (10 g,
35.97 mmol, 1.00 equiv) in pyridine (40 mL). This was followed by
the addition of 4-methylbenzene-1-sulfonyl chloride (6.8 g, 35.79
mmol, 1.00 equiv), in portions at 0.degree. C. The resulting
solution was stirred for 4 h at 0.degree. C. The resulting mixture
was concentrated under vacuum. The residue was dissolved in 30 ml
of dichloromethane. The resulting mixture was washed with
3.times.20 mL of 3% hydrochloric acid (aq). The resulting mixture
was washed with 20 mL of sodium chloride (aq). The mixture was
dried over sodium sulfate and concentrated under vacuum. This
resulted in 14 g (90%) of tert-butyl
3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propanoate as yellow
oil.
[0737] Into a 250-mL sealed bottle, was placed a solution of
tert-butyl 3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (14
g, 32.41 mmol, 1.00 equiv) in tetrahydrofuran (5 mL),
CH.sub.3NH.sub.2 (66.9 g, 712.16 mmol, 21.98 equiv, 33% in
ethanol). The resulting solution was stirred overnight at
50.degree. C. The resulting mixture was concentrated under vacuum.
The residue was dissolved in 150 ml of dichloromethane. The
resulting mixture was washed with 2.times.150 mL of water. The
resulting mixture was washed with 1.times.150 mL of sodium chloride
(aq). The mixture was dried over sodium sulfate and concentrated
under vacuum. This resulted in 8.2 g (87%) of tert-butyl
3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate as yellow
oil.
[0738] The following intermediates were prepared as depicted in
scheme 64 by substituting appropriate alcohols in place of 135a
then displacing the sulfonate in step 3 with amines, amides or
potassium thioacetate with or without the addition of a suitable
base.
TABLE-US-00008 TABLE 7 Intermediate Alcohol Nucleophile
Intermediate 135c.1 ##STR00296## Methylamine ##STR00297## 135c.2
##STR00298## 2-methoxy- ethanamine ##STR00299## 135c.3 ##STR00300##
KSAc ##STR00301## 135c.4 ##STR00302## 2-methoxy- ethanamine
##STR00303## 135c.5* ##STR00304## tert-butyl oxopiperazine-
1-carboxylate ##STR00305## 135c.6** ##STR00306## NaN.sub.3
##STR00307## *For intermediate 135c.5 the product was obtained
after acidic deprotection of the displacement product. **For
intermediate 135c.6 the product was obtained after catalytic
hydrogenation of the displacement product.
##STR00308##
[0739] This compound was prepared using the method described for
the preparation of Example 10.1, using tert-butyl
3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate 135c in
place of tert-butyl
3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate. MS (ES, m/z) 942
[M+H].sup.+
Example 136
2-(2-(3-((3-(2-(methyl(2-morpholinoethyl)amino)-2-oxoethyl)phenylthio)meth-
yl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isoni-
cotinamide
##STR00309##
[0741] This compound was prepared using the method described for
the preparation of Example 10.1a, using 8.18 in place of 8.1 and
N-methyl-2-morpholinoethanamine in place of tert-butyl
3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate. MS (ES, m/z) 865
[M+H].sup.+.
Examples 137-141
[0742] The compounds presented in Table 8 were prepared using the
procedure described for the preparation of intermediate 10.1, using
8.18 in place of 8.1.
##STR00310##
TABLE-US-00009 TABLE 8 Example No. R Mass Spectrum 137
--NH(CH.sub.2CH.sub.2O).sub.3CH.sub.2CH.sub.2COOH 942 [M + H] 138
--N(Me)(CH.sub.2CH.sub.2O).sub.3CH.sub.2CH.sub.2COOH 956 [M + H]
139 --NHCH.sub.2COOH 796 [M + H] 140 --NHCH.sub.2CH.sub.2COOH 810
[M + H] 141 --NHCH.sub.2CH.sub.2CH.sub.2COOH 824 [M + H]
Example 142
1-(3-{[4-(piperidin-1-yl)-2-(4-{[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]ca-
rbamoyl}pyridin-2-yl)phenyl]carbamoyl}phenyl)-5,8,11,14-tetraoxa-2-thiahep-
tadecan-17-oic acid
##STR00311##
[0743] Intermediate 142a:
(S)-2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(1,2,3,4-
-tetrahydronaphthalen-1-yl)isonicotinamide
[0744] To a stirring mixture of 126e (4.00 g, 9.38 mmol) and
diisopropylethylamine (6.52 mL, 37.5 mmol) in DCM (50 mL) cooled to
0.degree. C. was slowly added dropwise 3-(chloromethyl)benzoyl
chloride (1.46 mL, 10.3 mmol). The solution was then allowed to
warm to room temperature and stirred for 1 h, at which time it was
washed with aqueous HCl, saturated aqueous NaHCO.sub.3, and
H.sub.2O. The organic layer was dried over Na.sub.2SO.sub.4 and
then the solvent removed to give 4.64 g of the product (85%) as a
yellow solid.
Example 142
(S)-1-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbam-
oyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-5,8,11,14-tetraoxa-2-thiaheptadec-
an-17-oic acid
[0745] A mixture of 142a (600 mg, 1.04 mmol),
1-mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid (322 mg, 1.14
mmol), and K.sub.2CO.sub.3 (431 mg, 3.12 mmol) in dry DMF was
stirred for 3 h. The mixture was then poured into H.sub.2O (150 mL)
and the resulting suspension acidified with HCl and filtered. The
solid was further purified by reverse-phase HPLC eluting with a
water/acetonitrile gradient containing 0.1% TFA. The process
resulted in 560 mg (51%) of Example 142 as the di-TFA salt. MS (ES,
m/z) 825 [M+H].sup.+.
Example 143
2-(3-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)benzylthio)phenyl)acetic acid
##STR00312##
[0746] Intermediate 143a:
2-(2-(3-(chloromethyl)benzamido)-5-(diethylamino)phenyl)-N-(3-(trifluorom-
ethyl)benzyl)isonicotinamide
[0747] This compound was prepared using the method described for
the preparation of Example 142a, using 25b in place of 126e. MS
(ES, m/z) 886 [M+H].sup.+.
Example 143
2-(3-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)benzylthio)phenyl)acetic acid
[0748] A mixture of 143a (1.56 g, 2.62 mmol),
2-(3-mercaptophenyl)acetic acid (463 mg, 2.75 mmol), and
K.sub.2CO.sub.3 (1.09 g, 7.86 mmol) in DMF (15 mL) was stirred for
16 h under an atmosphere of N.sub.2. The mixture was poured into
aqueous HCl and the resulting precipitate was filtered. The solid
was dissolved in DCM and washed with H.sub.2O and dried over
Na.sub.2SO.sub.4. The solvent was removed, yielding 1.26 g (66%) of
the product as a yellow solid. MS (ES, m/z) 727 [M+H].sup.+. 1H NMR
(400 MHz, cdcl3) .delta. 8.70 (d, J=5.2 Hz, 1H), 8.20 (d, J=9.2 Hz,
1H), 8.08 (s, 1H), 7.69 (s, 1H), 7.62 (d, J=7.6 Hz, 2H), 7.61-7.55
(m, 2H), 7.55-7.48 (m, 3H), 7.46-7.40 (m, 1H), 7.34 (t, J=7.6 Hz,
2H), 7.28 (s, 1H), 7.16-7.10 (m, 2H), 7.01-6.94 (m, 1H), 6.78 (dd,
J=8.7, 2.6 Hz, 1H), 4.63 (d, J=5.9 Hz, 2H), 4.13 (s, 2H), 3.48 (s,
2H), 3.29 (q, J=7.0 Hz, 4H), 1.10 (t, J=7.1 Hz, 6H).
Example 144
3-(2-(2-(2-(2-(3-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-N-methylacetamido)eth-
oxy)ethoxy)propanoic acid
##STR00313##
[0749] Example 144
3-(2-(2-(2-(2-(3-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-N-methylacetamido)eth-
oxy)ethoxy)propanoic acid
[0750] To a mixture of 142 (1.72 g, 2.37 mmol), tert-butyl
3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate (827 mg,
2.84 mmol), and diisopropylethylamine (1.65 mL, 9.48 mmol) in dry
DMF (5 mL) was added HATU (991 mg, 2.61 mmol) and the solution
stirred for 2 h. The solution was then poured into aqueous HCl and
the resulting precipitate 144a was filtered. The solid was washed
with H.sub.2O, then dissolved in EtOAc and washed with saturated
aqueous NaHCO.sub.3, H.sub.2O, and brine, then dried over
Na.sub.2SO.sub.4 and the solvent removed. The residue was purified
by silica gel chromatography, using a gradient of 30% to 100% EtOAc
in hexanes as eluent and the solvent removed to furnish
intermediate 144a. The purified 144a was dissolved in DCM/TFA
(1:1). After 1 h. the solvent was removed with a stream of N.sub.2
and the resulting residue dissolved in a mixture of H.sub.2O/MeCN
(1:1) and lyophilized to give 2.70 g (96%) of Example 144 as this
di-TFA salt. MS (ES, m/z) 944 [M+H].sup.+. 1H NMR (400 MHz, dmso)
.delta. 8.97 (s, 1H), 7.90 (s, 3H), 7.80 (s, 2H), 7.72 (s, 2H),
7.68-7.55 (m, 5H), 7.54-7.43 (m, 1H), 7.24-7.18 (m, 4H), 7.04-6.96
(m, 1H), 4.62 (d, J=5.7 Hz, 2H), 4.36 (s, 2H), 3.65 (d, J=14.7 Hz,
2H), 3.59-3.53 (m, 4H), 3.50-3.41 (m, 14H), 2.95 (s, 2H), 2.79 (s,
1H), 2.41 (q, J=5.6 Hz, 2H), 1.10 (t, J=7.0 Hz, 6H).
Example 145
18-(2-(2-hydroxyethoxy)ethyl)-17-oxo-1-(3-(4-(piperidin-1-yl)-2-(4-(3-(tri-
fluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-5,8,11,1-
4-tetraoxa-2-thia-18-azaicosan-20-oic acid
##STR00314##
[0751] Intermediate 145a: tert-butyl
2-(2-(2-hydroxyethoxy)ethylamino)acetate
[0752] 2-(2-aminoethoxy)ethanol (11 g, 104.62 mmol, 1.00 equiv) was
dissolved in THF (300 mL) and cooled to 0.degree. C. To the
stirring solution was added dropwise tert-butyl 2-bromoacetate (20
g, 102.54 mmol, 1.00 equiv) and then triethylamine (15.5 g, 153.18
mmol, 1.50 equiv) dropwise The solution was then stirred for 16 h
at room temperature. The solvent was removed and the residue then
dissolved in DCM and washed twice with brine, then dried over
anhydrous sodium sulfate and solvent removed. The residue was
applied onto a silica gel column with dichloromethane/methanol
(20:1) as eluent. This resulted in 5.25 g (16%) of the product as a
yellow oil. MS (ES, m/z) 220 [M+H].sup.+
Example 145
18-(2-(2-hydroxyethoxy)ethyl)-17-oxo-1-(3-(4-(piperidin-1-yl)-2-(4-(3-(tri-
fluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-5,8,11,1-
4-tetraoxa-2-thia-18-azaicosan-20-oic acid
[0753] To a mixture of 8.7 (25 mg, 0.023 mmol), 145a (6 mg, 0.029
mmol), and diisopropylethylamine (16 .mu.L, 0.092 mmol) was added
HATU (10 mg, 0.025 mmol). The solution was stirred for 2 h, the
acidified with TFA and purified by reverse-phase HPLC eluting with
a water/acetonitrile gradient containing 0.1% TFA and lyophilized
to give intermediate 145b. The residue was dissolved in DCM/TFA
(1:1). After 1 h, the solvent was removed under a stream of N.sub.2
and the resulting residue dissolved in a mixture of H.sub.2O/MeCN
(1:1) and lyophilized to give 20 mg (82%) of Example 145 as the
di-TFA salt. MS (ES, m/z) 998 [M+H].sup.+
Example 146
2-(2-(3-(20-morpholino-17-oxo-5,8,11,14-tetraoxa-2-thia-18-azaicosyl)benza-
mido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinami-
de
##STR00315##
[0755] This compound was prepared using the method described for
the preparation of Example 145b, using 2-morpholinoethanamine in
place of tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS
(ES, m/z) 965 [M+H].sup.+
Example 147
2-(2-(3-(17-(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)-17-oxo-5,8,11,14--
tetraoxa-2-thiaheptadecyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifl-
uoromethyl)benzyl)isonicotinamide
##STR00316##
[0757] This compound was prepared using the method described for
the preparation of Example 145b, using
2-(2-(piperazin-1-yl)ethoxy)ethanol in place of tert-butyl
2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 1009
[M+H].sup.+.
Example 148
2-(2-(3-(27-oxo-2,5,8,11,14,17,20,23,30,33,36,39-dodecaoxa-42-thia-26-azat-
ritetracontan-43-yl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluorome-
thyl)benzyl)isonicotinamide
##STR00317##
[0759] This compound was prepared using the method described for
the preparation of Example 145b, using
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine in place of
tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z)
1218 [M+H].sup.+
Example 149
2-(2-(3-(41-hydroxy-17-oxo-5,8,11,14,21,24,27,30,33,36,39-undecaoxa-2-thia-
-18-azahentetracontyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoro-
methyl)benzyl)isonicotinamide
##STR00318##
[0761] This compound was prepared using the method described for
the preparation of Example 145b, using
23-amino-3,6,9,12,15,18,21-heptaoxatricosan-1-ol in place of
tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z)
1204 [M+H].sup.+.
Example 150
2-(2-(3-(18-methyl-20-morpholino-17-oxo-5,8,11,14-tetraoxa-2-thia-18-azaic-
osyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)iso-
nicotinamide
##STR00319##
[0763] This compound was prepared using the method described for
the preparation of Example 145b, using
N-methyl-2-morpholinoethanamine in place of tert-butyl
2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 979
[M+H].sup.+
Example 151
2-(2-(3-(20-hydroxy-18-(2-hydroxyethyl)-17-oxo-5,8,11,14-tetraoxa-2-thia-1-
8-azaicosyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)ben-
zyl)isonicotinamide
##STR00320##
[0765] This compound was prepared using the method described for
the preparation of Example 145b, using diethanolamine in place of
tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z)
940 [M+H].sup.+.
Example 152
2-(2-(3-(21-ethyl-18-methyl-17-oxo-5,8,11,14-tetraoxa-2-thia-18,21-diazatr-
icosyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)i-
sonicotinamide
##STR00321##
[0767] This compound was prepared using the method described for
the preparation of Example 145b, using
N1,N1-diethyl-N2-methylethane-1,2-diamine in place of tert-butyl
2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 965
[M+H].sup.+.
Example 153
2-(2-(3-(17-(4-acetyl-1,4-diazepan-1-yl)-17-oxo-5,8,11,14-tetraoxa-2-thiah-
eptadecyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzy-
l)isonicotinamide
##STR00322##
[0769] This compound was prepared using the method described for
the preparation of Example 145b, using
1-(1,4-diazepan-1-yl)ethanone in place of tert-butyl
2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 977
[M+H].sup.+
Example 154
2-(2-(3-(17-(4-morpholinopiperidin-1-vi)-17-oxo-5,8,11,14-tetraoxa-2-thiah-
eptadecyl)benzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl)benzy-
l)isonicotinamide
##STR00323##
[0771] This compound was prepared using the method described for
the preparation of Example 145b, using 4-(piperidin-4-yl)morpholine
in place of tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS
(ES, m/z) 1005 [M+H].sup.+
Example 155
17-oxo-1-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)-5,8,11,14,21,24,27-heptaoxa-2-thia-18--
azatriacontan-30-oic acid
##STR00324##
[0773] This compound was prepared using the method described for
the preparation of Example 145, using tert-butyl
3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate in place of
tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z)
1056 [M+H].sup.+
Example 157
(S)-1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)phenyl)-5,8,11,14-tetraoxa-2-thiaheptadecan-
-17-oic acid
##STR00325##
[0774] Intermediate 157a:
(S)-2-(2-amino-5-(diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1--
yl)isonicotinamide
[0775] To a stirring mixture of 131c (970 mg, 2.34 mmol) and
diisopropylethylamine (1.63 mL, 9.36 mmol) in DCM (25 mL) cooled to
0.degree. C. was slowly added dropwise 3-(chloromethyl)benzoyl
chloride (365 .mu.L, 2.57 mmol). The solution was then allowed to
warm to room temperature and stirred for 1 h, then the solvent was
removed. The resulting residue was dissolved in EtOAc and washed
with aqueous HCl, saturated aqueous NaHCO.sub.3, and brine, then
dried over Na.sub.2SO.sub.4. The solvent was removed and the
residue purified by silica gel chromatography, using a gradient of
30% to 70% EtOAc in hexanes as eluent and the solvent removed. This
gave 1.22 g (92%) of the product as a yellow solid.
Example 157
(S)-1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)phenyl)-5,8,11,14-tetraoxa-2-thiaheptadecan-
-17-oic acid
[0776] A stirring mixture of 157a (1.22 g, 2.15 mmol),
1-mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid (668 mg, 2.37
mmol), and K.sub.2CO.sub.3 (891 mg, 6.45 mmol) in dry DMF (15 mL)
was stirred for 2 h, then poured into H.sub.2O (100 mL). The
solution was acidified with aqueous HCl and extracted twice with
DCM. The combined organic layers were washed thrice with H.sub.2O
and then dried over Na.sub.2SO.sub.4. Removal of the solvent gave
1.61 g (92%) of the product Example 157 as a yellow foam. MS (ES,
m/z) 813 [M+H].sup.+
Example 157.1
(S)-2-(5-(diethylamino)-2-(3-(27-oxo-2,5,8,11,14,17,20,23,30,33,36,39-dode-
caoxa-42-thia-26-azatritetracontan-43-yl)benzamido)phenyl)-N-(1,2,3,4-tetr-
ahydronaphthalen-1-yl)isonicotinamide
##STR00326##
[0778] To a mixture of 157 (390 mg, 1.14 mmol),
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine (482 mg, 1.26
mmol), and diisopropylethylamine (793 .mu.L, 4.56 mmol) was added
HATU (479 mg, 1.26 mmol). The solution was stirred for 2 h, the
acidified with TFA and purified by reverse-phase HPLC eluting with
a water/acetonitrile gradient containing 0.1% TFA and lyophilized
to give 1.40 g (87%) of the product Example 157.1 as the di-TFA
salt. MS (ES, m/z) 1178 [M+H].sup.+
Example 158
(S)-2-(5-(diethylamino)-2-(3-(20-hydroxy-19,19-bis(hydroxymethyl)-17-oxo-5-
,8,11,14-tetraoxa-2-thia-18-azaicosyl)benzamido)phenyl)-N-(1,2,3,4-tetrahy-
dronaphthalen-1-yl)isonicotinamide
##STR00327##
[0780] This compound was prepared using the method described for
the preparation of Example 157.1, using
tris(hydroxymethyl)aminomethane.HCl in place of
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine. MS (ES, m/z) 916
[M+H].sup.+
Example 159
(S)-2-(5-(diethylamino)-2-(3-(20-hydroxy-19-(hydroxymethyl)-17-oxo-5,8,11,-
14-tetraoxa-2-thia-18-azaicosyl)benzamido)phenyl)-N-(1,2,3,4-tetrahydronap-
hthalen-1-yl)isonicotinamide
##STR00328##
[0782] This compound was prepared using the method described for
the preparation of Example 157.1, using 2-aminopropane-1,3-diol.HCl
in place of 2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine. MS
(ES, m/z) 886 [M+H].sup.+
Example 160
(S)-2-(5-(diethylamino)-2-(3-(20-hydroxy-18-(2-hydroxyethyl)-17-oxo-5,8,11-
,14-tetraoxa-2-thia-18-azaicosyl)benzamido)phenyl)-N-(1,2,3,4-tetrahydrona-
phthalen-1-yl)isonicotinamide
##STR00329##
[0784] This compound was prepared using the method described for
the preparation of Example 157.1, using diethanolamine in place of
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine. MS (ES, m/z) 900
[M+H].sup.+
Example 161
(S)-1-(3-(4-(diethylamino)-2-(4-(12,34-tetrahydronaphthalen-1-ylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)phenyl)-5,8,11,14,17,20,23,26-octaoxa-2-thian-
onacosan-29-oic acid
##STR00330##
[0786] This compound was prepared using the method described for
the preparation of Example 157, using
1-mercapto-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid in
place of 1-mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid. MS
(ES, m/z) 989 [M+H].sup.+
Example 162
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-5,8,11,14-tetraoxa-2-thiaheptadecan-17-oic
acid
##STR00331##
[0787] Example 162
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-5,8,11,14-tetraoxa-2-thiaheptadecan-17-oic
acid
[0788] A mixture of 143a (1.1 g, 1.8 mmol),
1-mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid (0.5 g (1.8
mmol), and K.sub.2CO.sub.3 (250 mg) in DMF (18 mL) was stirred for
16 h. The mixture was acidified with TFA and purified by
reverse-phase HPLC eluting with a water/acetonitrile gradient
containing 0.1% TFA and lyophilized to give 1.05 g (55%) of the
product Example 162 as the di-TFA salt. MS (ES, m/z) 841
[M+H].sup.+. 1H NMR (400 MHz, dmso) .delta. 9.83 (s, 1H), 9.02 (d,
J=5.2 Hz, 1H), 8.74-8.58 (m, 1H), 8.52 (s, 1H), 7.92 (d, J=5.0 Hz,
2H), 7.82 (d, J=7.6 Hz, 1H), 7.73 (s, 1H), 7.70-7.48 (m, 7H), 4.62
(d, J=5.9 Hz, 2H), 3.92 (s, 2H), 3.55 (q, J=6.4 Hz, 4H), 3.50-3.43
(m, 16H), 2.59 (t, J=6.6 Hz, 2H), 2.41 (t, J=6.4 Hz, 2H), 1.10 (t,
J=7.1 Hz, 6H).
Example 163
2-(5-(diethylamino)-2-(3-(20-hydroxy-19,19-bis(hydroxymethyl)-17-oxo-5,8,1-
1,14-tetraoxa-2-thia-18-azaicosyl)benzamido)phenyl)-N-(3-(trifluoromethyl)-
benzyl)isonicotinamide
##STR00332##
[0789] Example 163
2-(5-(diethylamino)-2-(3-(20-hydroxy-19,19-bis(hydroxymethyl)-17-oxo-5,8,1-
1,14-tetraoxa-2-thia-18-azaicosyl)benzamido)phenyl)-N-(3-(trifluoromethyl)-
benzyl)isonicotinamide
[0790] To a mixture of Example 162 (1.02 g, 1.12 mmol),
tris(hydroxymethyl)aminomethane.HCl (223 mg, 1.40 mmol), and
diisopropylethylamine (0.97 mL, 5.6 mmol) in dry DMF (10 mL) was
added HATU (468 mg, 1.23 mmol). The solution was stirred for 2 h,
the acidified with TFA and purified by reverse-phase HPLC eluting
with a water/acetonitrile gradient containing 0.1% TFA and
lyophilized to give 880 mg (67%) of the product as the di-TFA salt.
MS (ES, m/z) 944 [M+H].sup.+.
Example 164
2-(5-(diethylamino)-2-(3-(20-hydroxy-18-(2-hydroxyethyl)-17-oxo-5,8,11,14--
tetraoxa-2-thia-18-azaicosyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzy-
l)isonicotinamide
##STR00333##
[0792]
2-(5-(diethylamino)-2-(3-(20-hydroxy-18-(2-hydroxyethyl)-17-oxo-5,8-
,11,14-tetraoxa-2-thia-18-azaicosyl)benzamido)phenyl)-N-(3-(trifluoromethy-
l)benzyl)isonicotinamide. This compound was prepared using the
method described for the preparation of Example 163, using
diethanolamine in place of tris(hydroxymethyl)aminomethane.HCl. MS
(ES, m/z) 928 [M+H].sup.+.
Example 165
2-(5-(diethylamino)-2-(3-(27-oxo-2,5,8,11,14,17,20,23,30,33,36,39-dodecaox-
a-42-thia-26-azatritetracontan-43-yl)benzamido)phenyl)-N-(3-(trifluorometh-
yl)benzyl)isonicotinamide
##STR00334##
[0794]
2-(5-(diethylamino)-2-(3-(27-oxo-2,5,8,11,14,17,20,23,30,33,36,39-d-
odecaoxa-42-thia-26-azatritetracontan-43-yl)benzamido)phenyl)-N-(3-(triflu-
oromethyl)benzyl)isonicotinamide. This compound was prepared using
the method described for the preparation of Example 163, using
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine in place of
tris(hydroxymethyl)aminomethane.HCl. MS (ES, m/z) 1206
[M+H].sup.+.
Example 166
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-5,8,11,14,17,20,23,26-octaoxa-2-thianonacosan-2-
9-oic acid
##STR00335##
[0796] This compound was prepared using the method described for
the preparation of Example 162, using
1-mercapto-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid in
place of 1-mercapto-3,6,9,12-tetraoxapentadecan-15-oic. MS (ES,
m/z) 1017 [M+H].sup.+. 1H NMR (400 MHz, dmso) .delta. 12.24-12.06
(m, 1H), 11.82 (s, 1H), 9.49 (t, J=5.9 Hz, 1H), 8.95 (d, J=5.1 Hz,
1H), 8.23 (s, 1H), 8.13 (d, J=9.3 Hz, 1H), 7.85-7.77 (m, 2H),
7.75-7.67 (m, 2H), 7.64 (t, J=7.3 Hz, 2H), 7.58 (d, J=8.0 Hz, 1H),
7.53-7.41 (m, 3H), 7.06 (d, J=2.6 Hz, 1H), 6.87 (dd, J=9.2, 3.0 Hz,
1H), 4.61 (d, J=6.0 Hz, 2H), 3.88 (s, 2H), 3.58 (t, J=6.3 Hz, 2H),
3.54 (t, J=6.6 Hz, 2H), 3.50-3.36 (m, 36H), 2.58 (t, J=6.4 Hz, 2H),
2.43 (t, J=6.3 Hz, 2H), 1.13 (t, J=6.9 Hz, 6H).
Example 167
1-(((3-((4-(diethylamino)-2-[4-(((3-(trifluoromethyl)phenyl]methyl)carbamo-
yl)pyridin-2-yl)phenyl)carbamoyl)phenyl)methane)sulfonyl)-3,6,9,12-tetraox-
apentadecan-15-oic acid
##STR00336##
[0798] A mixture of Example 162 (25 mg, 0.023 mmol) and Oxone.RTM.
(71 mg, 0.12 mmol) in THF/MeOH/H.sub.2O (1 mL: 0.5 mL: 0.5 mL) was
stirred for 18 h and then filtered and the solid washed with EtOAc.
The combined organic layers were washed with H.sub.2O and brine,
then dried over Na.sub.2SO.sub.4 and the solvent removed. The
resulting residue was dissolved in MeOH, then 10 mol % Pd/C (5 mg)
was added and the suspension stirred under an atmosphere of H.sub.2
for 0.5 h. The suspension was filtered through celite and the
solvent removed then purified by reverse-phase HPLC eluting with a
water/acetonitrile gradient containing 0.1% TFA and lyophilized to
give 12 mg (47%) of the product as the di-TFA salt. MS (ES, m/z)
873 [M+H].sup.+
Example 168
2-(5-(diethylamino)-2-(3-(19-hydroxy-2,5,8,11,14,17-hexaoxanonadecyl)benza-
mido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00337##
[0799] Example 168
2-(5-(diethylamino)-2-(3-(19-hydroxy-2,5,8,11,14,17-hexaoxanonadecyl)benza-
mido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0800] To a mixture of 143a (500 mg, 0.840 mmol) and
3,6,9,12,15-pentaoxaheptadecane-1,17-diol (1.06 mL, 4.20 mmol) in
dry THF (8 mL) was added a 60% sodium hydride dispersion in mineral
oil (101 mg) and the mixture stirred at 50.degree. C. for 1 h. The
solution was then diluted with DCM and washed with aqueous HCl and
H.sub.2O, then dried over Na.sub.2SO.sub.4 and the solvent removed
to give 634 mg (90%) of the product as a yellow oil. MS (ES, m/z)
841 [M+H].sup.+.
Example 169
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11,14,17-hexaoxanonadecan-19-yl
2-morpholinoethylcarbamate
##STR00338##
[0801] Example 169
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11,14,17-hexaoxanonadecan-19-yl
2-morpholinoethylcarbamate
[0802] To a mixture of Example 168 (50 mg, 0.060 mmol) and
diisopropylethylamine (31 .mu.L, 0.18 mmol) in DCM (1 mL) was added
4-nitrophenylchloroformate (52 mg, 0.26 mmol) and the solution
stirred for 1 h. 2-Morpholinoethanamine (46 .mu.L, 0.36 mmol) was
then added and the solution stirred for 1 h, then the solvent
removed and the residue purified by reverse-phase HPLC eluting with
a water/acetonitrile gradient containing 0.1% TFA and lyophilized
to give 20 mg (25%) of the product as the tri-TFA salt. MS (ES,
m/z) 997 [M+H].sup.+. 1H NMR (400 MHz, CDCl.sub.3) .delta. 9.54 (t,
J=6.0 Hz, 1H), 9.25 (d, J=2.6 Hz, 1H), 9.17 (d, J=9.1 Hz, 1H),
8.92-8.83 (m, 2H), 8.08 (s, 1H), 8.03 (dd, J=5.1, 1.4 Hz, 1H), 7.98
(dt, J=7.0, 1.9 Hz, 1H), 7.69 (s, 1H), 7.62 (d, J=7.6 Hz, 1H),
7.58-7.46 (m, 3H), 7.46-7.35 (m, 2H), 6.27 (s, 1H), 4.74 (d, J=6.0
Hz, 2H), 4.68 (s, 2H), 4.23-4.12 (m, 2H), 4.02-3.82 (m, 4H),
3.74-3.50 (m, 22H), 3.25 (t, J=5.6 Hz, 2H), 2.93 (t, J=12.0 Hz,
2H), 1.27 (t, J=7.2 Hz, 6H).
Example 170
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11,14,17-hexaoxanonadecan-19-yl
methyl(2-morpholinoethyl)carbamate
##STR00339##
[0804] This compound was prepared using the method described for
the preparation of Example 169, using
N-methyl-2-morpholinoethanamine in place of morpholinoethanamine.
MS (ES, m/z) 1011 [M+H].sup.+
Example 171
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11,14,17-hexaoxanonadecan-19-yl
4-(2-(2-hydroxyethoxy)ethyl)piperidine-1-carboxylate
##STR00340##
[0806] This compound was prepared using the method described for
the preparation of Example 169, using
2-(2-(piperidin-4-yl)ethoxy)ethanol in place of
morpholinoethanamine. MS (ES, m/z) 1041 [M+H].sup.+
Example 172
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11,14,17-hexaoxanonadecan-19-yl
bis(2-hydroxyethyl)carbamate
##STR00341##
[0808] This compound was prepared using the method described for
the preparation of Example 169, using diethanolamine in place of
morpholinoethanamine. MS (ES, m/z) 972 [M+H].sup.+. 1H NMR (400
MHz, cdcl3) .delta. 9.53 (t, J=5.9 Hz, 1H), 9.33 (d, J=2.6 Hz, 1H),
9.20 (d, J=9.2 Hz, 1H), 8.94 (s, 1H), 8.88 (d, J=5.2 Hz, 1H),
8.13-8.08 (m, 1H), 8.04 (dd, J=5.1, 1.4 Hz, 1H), 8.00 (dt, J=7.3,
1.7 Hz, 1H), 7.71 (s, 1H), 7.63 (d, J=7.5 Hz, 1H), 7.60-7.32 (m,
5H), 4.74 (d, J=6.0 Hz, 2H), 4.69 (s, 2H), 4.29-4.22 (m, 2H), 3.82
(s, 4H), 3.76-3.54 (m, 26H), 3.47 (s, 4H), 1.27 (t, J=7.2 Hz,
6H).
Example 173
2-(2-(3-2,5,8,11,14,17,20,23,26-nonaoxaheptacosylbenzamido)-5-(diethylamin-
o)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00342##
[0810] This compound can be prepared using the method described for
the preparation of Example 169, using
2,5,8,11,14,17,20,23-octaoxapentacosan-25-ol in place of
3,6,9,12,15-pentaoxaheptadecane-1,17-diol. MS (ES, m/z) 943
[M+H].sup.+
Example 174
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11,14,17-hexaoxanonadecan-19-yl
2,5,8,11,14,17,20-heptaoxadocosan-22-ylcarbamate
##STR00343##
[0812] This compound was prepared using the method described for
the preparation of Example 169, using
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine 135c.6 in place of
morpholinoethanamine. MS (ES, m/z) 972 [M+H].sup.+
Example 175
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11-tetraoxatridecan-13-yl
2,5,8,11,14,17,20-heptaoxadocosan-22-ylcarbamate
##STR00344##
[0813] Intermediate 175a:
2-(5-(diethylamino)-2-(3-(13-hydroxy-2,5,8,11-tetraoxatridecyl)benzamido)-
phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0814] This compound was prepared using the method described for
the preparation of Example 168, using
2,2'-(2,2'-oxybis(ethane-2,1-diyl)bis(oxy))diethanol in place of
3,6,9,12,15-pentaoxaheptadecane-1,17-diol.
Intermediate 175b:
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-2,5,8,11-tetraoxatridecan-13-yl
4-nitrophenyl carbonate
[0815] To a mixture of 175a (196 mg, 0.329 mmol) and
diispropylethylamine (286 .mu.L, 1.65 mmol) was added
4-nitrophenylchloroformate (266 mg, 1.32 mmol) and the mixture
stirred for 2 h. The solution was diluted with DCM and washed with
H.sub.2O, then dried over Na.sub.2SO.sub.4 and the solvent removed.
The resulting residue was purified by silica gel chromatography,
using a gradient of 50% to 100% EtOAc in hexanes as eluent and the
solvent removed. This gave 80 mg (26%) of the product as a viscous,
yellow oil.
Example 175
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11-tetraoxatridecan-13-yl
2,5,8,11,14,17,20-heptaoxadocosan-22-ylcarbamate
[0816] A mixture of 175b (20 mg, 0.022 mmol),
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine (15 mg, 0.436 mmol)
and catalytic DMAP in MeCN was stirred at 80.degree. C. for 2 h.
The solution was acidified with acetic acid and purified by
reverse-phase HPLC eluting with a water/acetonitrile gradient
containing 0.1% TFA and lyophilized to give 15 mg (51%) of the
product as the di-TFA salt. MS (ES, m/z) 1118 [M+H].sup.+
Example 176
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11-tetraoxatridecan-13-yl
bis(2-hydroxyethyl)carbamate
##STR00345##
[0818] This compound was prepared using the method described for
the preparation of Example 175, using diethanolamine in place of
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine. MS (ES, m/z) 884
[M+H].sup.+
Example 177
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)phenyl)-2,5,8,11-tetraoxatridecan-13-yl
1,3-dihydroxy-2-(hydroxymethyl)propan-2-ylcarbamate
##STR00346##
[0820] This compound was prepared using the method described for
the preparation of Example 175, using
tris(hydroxymethyl)aminomethane.HCl in place of
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine. MS (ES, m/z) 900
[M+H].sup.+
Example 178
2-(5-(diethylamino)-2-(3-(22-hydroxy-20-(2-hydroxyethyl)-2,5,8,11,14,17-he-
xaoxa-20-azadocosyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonico-
tinamide
##STR00347##
[0821] Intermediate 178a:
1-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-2,5,8,11,14,17-hexaoxanonadecan-19-yl
4-methylbenzenesulfonate
[0822] To a mixture of Example 168 (500 mg, 0.595 mmol) and
triethylamine (167 .mu.L, 1.19 mmol) in DCM (3 mL) was added
p-toluenesulfonyl chloride (136 mg, 0.714 mmol) in several portions
and the solution stirred for 16 h. The solution was then diluted
with DCM and washed with aqueous HCl and H.sub.2O, then dried over
Na.sub.2SO.sub.4 and the solvent removed. The residue was purified
by silica gel chromatography, using a gradient of 20% to 100% EtOAc
in hexanes as eluent and the solvent removed. This gave 560 mg
(95%) of the product as a yellow oil.
Example 178
2-(5-(diethylamino)-2-(3-(22-hydroxy-20-(2-hydroxyethyl)-2,5,8,11,14,17-he-
xaoxa-20-azadocosyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonico-
tinamide
[0823] A mixture of 178a (85 mg, 0.085 mmol) and diethanolamine (18
mg, 0.17 mmol) in MeCN (1 mL) was heated to 80.degree. C. and
stirred for 18 h. The solution was diluted with H.sub.2O and
purified by reverse-phase HPLC eluting with a water/acetonitrile
gradient containing 0.1% TFA and lyophilized to give 43 mg (40%) of
the product as the tri-TFA salt. MS (ES, m/z) 928 [M+H].sup.+. 1H
NMR (400 MHz, cdcl3) .delta. 9.56 (t, J=6.0 Hz, 1H), 9.31 (d, J=2.5
Hz, 1H), 9.18 (d, J=9.2 Hz, 1H), 8.94 (s, 1H), 8.87 (d, J=5.1 Hz,
1H), 8.10 (s, 1H), 8.06-7.94 (m, 2H), 7.70 (s, 1H), 7.63 (d, J=7.5
Hz, 1H), 7.58-7.37 (m, 5H), 4.72 (d, J=5.9 Hz, 2H), 4.67 (s, 2H),
4.00-3.90 (m, 4H), 3.86 (d, J=4.8 Hz, 2H), 3.70 (d, J=5.3 Hz, 4H),
3.67-3.39 (m, 22H), 1.26 (t, J=7.2 Hz, 6H).
Example 179
2-(5-(diethylamino)-2-(3-(20-methyl-22-morpholino-2,5,8,11,14,17-hexaoxa-2-
0-azadocosyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamid-
e
##STR00348##
[0825] This compound was prepared using the method described for
the preparation of Example 178, using
N-methyl-2-morpholinoethanamine in place of diethanolamine. MS (ES,
m/z) 967 [M+H].sup.+.
Example 180
N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-1-(3-(4-(piperidin-1-yl)-2-(4-(3-(t-
rifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-ind-
ole-4-carboxamide
##STR00349##
[0826] Intermediate 180a: tert-butyl
1-(1H-indol-4-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
[0827] To a mixture of 1H-indole-4-carboxylic acid (322 mg, 2.00
mmol), tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate
(554 mg, 2.00 mmol), and diisopropylethylamine (700 .mu.L, 4.00
mmol) in DMF (3 mL) was added HATU (950 mg, 2.50 mmol) and the
solutions stirred for 16 h. The solvent was removed and the
resulting residue was purified by silica gel chromatography, using
a gradient of 70% to 100% EtOAc in hexanes as eluent and the
solvent removed. This gave 557 mg (66%) of the product.
Example 180
N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-1-(3-(4-(piperidin-1-yl)-2-(4-(3-(t-
rifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-ind-
ole-4-carboxamide
[0828] A mixture of 180a (524 mg, 1.25 mmol), 8.1a (755 mg, 1.25
mmol), and K.sub.2CO.sub.3 (510 mg, 3.70 mmol) in DMF (2 mL) was
stirred for 3 days, then purified by reverse-phase HPLC eluting
with a water/acetonitrile gradient containing 0.1% TFA and
lyophilized to give 16 mg (1%) of the product as the di-TFA salt.
MS (ES, m/z) 863 [M+H].sup.+
Example 181
(S)-1-oxo-1-(1-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-indol-4-yl)-5,8,11-tr-
ioxa-2-azatetradecan-14-oic acid
##STR00350## ##STR00351##
[0829] Intermediate 181a. (S)-methyl
1-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl-
)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-indole-4-carboxylate
[0830] A mixture of 142a (14.9 g, 25.7 mmol), methyl
1H-indole-4-carboxylate (4.5 g, 25.7 mmol), and Cs.sub.2CO.sub.3
(16.7 g, 51.3 mmol) in DMF (50 mL) was stirred for 15 h under an
atmosphere of N.sub.2. The suspension was filtered and the solvent
removed. The resulting residue was purified by silica gel
chromatography to give 16.2 g (88%) of the product.
Intermediate 181b.
(S)-1-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-indole-4-carboxylic
acid
[0831] A mixture of 181a (16.0 g, 22.3 mmol) and LiOH.H.sub.2O
(1.87 g, 44.5 mmol) in THF/H.sub.2O (176 mL/44 mL) was heated to
60.degree. C. and stirred for 40 h. The solution was concentrated,
then DCM added (300 mL) and washed with aqueous HCl, then dried
over Na.sub.2SO.sub.4 and the solvent removed to give 15.4 g (98%)
of the product.
Intermediate 181c. (S)-tert-butyl
1-oxo-1-(1-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-yl-
carbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-indol-4-yl)-5,8,11-triox-
a-2-azatetradecan-14-oate
[0832] To a mixture of 181b (14.7 g, 20.9 mmol), tert-butyl
3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate (6.06 g, 21.8
mmol), and diisopropylethylamine (14.5 mL, 83.4 mmol) in DMF (63
mL) was added HATU (9.93 g, 26.1 mmol), then the solution heated to
50.degree. C. and stirred for 2 h. The solvent was removed and the
resulting residue dissolved in EtOAc and washed thrice with
H.sub.2O, then dried over Na.sub.2SO.sub.4 and the solvent removed.
The resulting residue was purified by silica gel chromatography to
give 10 g (50%) of the product.
Example 181
(S)-1-oxo-1-(1-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-indol-4-yl)-5,8,11-tr-
ioxa-2-azatetradecan-14-oic acid
[0833] A mixture of 181c (12.5 g, 13.0 mmol) in a 4M HCl solution
of dioxane (120 mL) was stirred at 0.degree. C. for 1 h and then
the solvent removed. The resulting residue was dissolved in DCM and
washed with H.sub.2O, then dried over Na.sub.2SO.sub.4. The solvent
was removed and the residue was purified by silica gel
chromatography, using a gradient of 2% to 4% MeOH in DCM as eluent
and the solvent removed. This gave 9.6 g (75%) of the product as
the HCl salt. MS (ES, m/z) 907 [M+H].sup.+. .sup.1H NMR (400 MHz,
dmso) .delta. 12.14 (s, 1H), 11.95 (s, 1H), 9.16 (d, J=8.6 Hz, 1H),
8.68 (d, J=5.1 Hz, 1H), 8.29-8.18 (m, 2H), 8.14 (d, J=9.0 Hz, 1H),
7.84-7.66 (m, 3H), 7.61 (dd, J=11.5, 5.7 Hz, 2H), 7.51-7.27 (m,
4H), 7.22-7.02 (m, 5H), 6.96-6.84 (m, 1H), 5.58 (s, 2H), 5.29-5.18
(m, 1H), 3.61-3.38 (m, 14H), 3.22-3.11 (m, 4H), 2.85-2.69 (m, 2H),
2.42 (t, J=6.3 Hz, 2H), 2.06-1.88 (m, 2H), 1.87-1.70 (m, 2H),
1.70-1.58 (m, 4H), 1.54 (d, J=5.0 Hz, 2H).
Example 182
(S)-1-(1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzyl)-1H-indol-4-yl)-1-oxo-5,8,11-trio-
xa-2-azatetradecan-14-oic acid
##STR00352##
[0835] This compound was prepared using the method described for
the preparation of Example 181, using 131c in place of 142a. MS
(ES, m/z) 895 [M+H].sup.+
Example 183
3-((3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)phenoxy)methyl)benzoic acid
##STR00353##
[0836] Intermediate 183a:
2-(2-(3-hydroxybenzamido)-5-(piperidin-1-yl)phenyl)-N-(3-(trifluoromethyl-
)benzyl)isonicotinamide
[0837] To a mixture of 4.1c (91 mg, 0.20 mmol), 3-hydroxybenzoic
acid (28 mg, 0.20 mmol), and diisopropylethylamine (104 OL, 0.60
mmol) in DMF (2 mL) was added HATU (76 mg, 0.20 mmol) and the
solution stirred for 18 h. The solvent was removed and the
resulting residue purified by reverse-phase HPLC eluting with a
water/acetonitrile gradient containing 0.1% TFA and lyophilized to
give 34 mg (30%) of the product.
Example 183
3-((3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)phenoxy)methyl)benzoic acid
[0838] A mixture of 183a (34 mg, 0.059 mmol), methyl
3-(bromomethyl)benzoate (27 mg, 0.12 mmol), and K.sub.2CO.sub.3 (24
mg, 0.18 mmol) was stirred for 16 h and then filtered. The solvent
was removed and resulting residue purified by reverse-phase HPLC
eluting with a water/acetonitrile gradient containing 0.1% TFA and
lyophilized to give 18 mg (43%) of the product. MS (ES, m/z) 709
[M+H].sup.+
Example 184
3-((2-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyri-
din-2-yl)phenylcarbamoyl)phenyl)-1H-imidazol-1-yl)methyl)benzoic
acid
##STR00354##
[0840] This compound was prepared using the method described for
the preparation of Example 183, using 3-(1H-imidazol-2-yl)benzoic
acid in place of 3-hydroxybenzoic acid. MS (ES, m/z) 759
[M+H].sup.+. 1H NMR (400 MHz, dmso) .delta. 12.21 (s, 1H), 9.51 (t,
J 5=5.8 Hz, 1H), 8.81 (d, J=5.1 Hz, 1H), 8.30 (s, 1H), 8.23-8.14
(m, 2H), 8.11 (d, J=7.6 Hz, 1H), 7.88-7.71 (m, 7H), 7.66 (s, 1H),
7.55 (dd, J=18.5, 10.9 Hz, 4H), 7.41 (t, J=7.7 Hz, 1H), 7.32 (d,
J=7.7 Hz, 2H), 5.51 (s, 2H), 4.57 (d, J=5.8 Hz, 2H), 3.31 (s, 4H),
1.71 (s, 4H), 1.57 (s, 2H).
Example 185
3-((3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)benzyloxy)methyl)benzoic acid
##STR00355##
[0841] Intermediate 185a: dimethyl
3,3'-oxybis(methylene)dibenzoate
[0842] To a mixture of methyl 3-(hydroxymethyl)benzoate (500 mg,
3.01 mmol) in DMF (5 mL) cooled to 0.degree. C. was added a 60%
sodium hydride dispersion in mineral oil (180 mg). The mixture was
stirred for 0.5 h at 0.degree. C., then methyl
3-(bromomethyl)benzoate (690 mg, 3.01 mmol) was added and the
mixture stirred an additional 4 h at room temperature, then diluted
with EtOAc. The solution was washed with aqueous HCl, saturated
aqueous NaHCO.sub.3, H.sub.2O, and brine, then dried over
Na.sub.2CO.sub.3 and the solvent removed. The resulting residue was
purified by silica gel chromatography to give 450 mg (48%) of the
product 185a.
Intermediate 185b: 3,3'-oxybis(methylene)dibenzoic acid
[0843] A mixture of 185a (450 mg, 1.43 mmol) and three pellets of
NaOH in MeOH/H.sub.2O (4 mL: 4 mL) was stirred for 4 h at 0.degree.
C., then diluted with EtOAc. The solution was washed with aqueous
HCl, H.sub.2O, and brine, then dried over Na.sub.2CO.sub.3 and the
solvent removed to give 370 mg (90%) of the product 185b.
Example 185
3-((3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)benzyloxy) methyl)benzoic acid
[0844] To a mixture of 4.1c (190 mg, 0.420 mmol), 185b (370 mg,
1.26 mmol) and diisopropylethylamine (660 .mu.L, 3.80 mmol) in DMF
(3 mL) was added HATU (240 mg, 0.630 mmol) and the solution stirred
for 16 h. The solvent was removed and the residue purified by
reverse-phase HPLC eluting with a water/acetonitrile gradient
containing 0.1% TFA and lyophilized to give 25 mg (8%) of the
product. MS (ES, m/z) 723 [M+H].sup.+
Example 186
3-((3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)phenylthio)methyl)benzoic acid
##STR00356##
[0845] Intermediate 186a: 3-(3-(methoxycarbonyl)benzylthio)benzoic
acid
[0846] A mixture of 3-mercaptobenzoic acid (154 mg, 1.00 mmol),
methyl 3-(bromomethyl)benzoate (229 mg, 1.00 mmol) and
K.sub.2CO.sub.3 (414 mg, 3.00 mmol) in DMF (1 mL) was stirred for
16 h, then solvent removed. The resulting residue was purified by
silica gel chromatography to give 300 mg (90%) of the product.
Intermediate 186b: methyl
3-((3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridi-
n-2-yl)phenylcarbamoyl)phenylthio)methyl)benzoate
[0847] To a mixture of 186a (300 mg, 0.991 mmol), 4.1c (454 mg,
1.00 mmol), and diisopropylethylamine (521 .mu.L, 3.00 mmol) in DMF
(3 mL) was added HATU (570 mg, 1.5 mmol) and then stirred for 18 h.
The solvent was removed and the residue purified by silica gel
chromatography to give 462 mg (63%) of the product.
Example 186
3-((3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)phenylthio)methyl)benzoic acid
[0848] A mixture of 186b (462 mg, 0.625 mmol) and LiOH.H.sub.2O (40
(mg, 0.953 mmol) in THF/H.sub.2O (3 mL:1 mL) was stirred for 4 h,
then the solution concentrated and purified by reverse-phase HPLC
eluting with a water/acetonitrile gradient containing 0.1% TFA and
lyophilized to give 30 mg (7%) of the product. MS (ES, m/z) 725
[M+H].sup.+. 1H NMR (400 MHz, dmso) .delta. 12.34 (s, 1H), 9.55 (t,
J=5.9 Hz, 1H), 8.87 (d, J=5.1 Hz, 1H), 8.36 (s, 2H), 7.97 (s, 1H),
7.88 (d, J=5.1 Hz, 2H), 7.83-7.73 (m, 3H), 7.73-7.45 (m, 8H), 7.41
(t, J=7.7 Hz, 1H), 4.62 (d, J=5.7 Hz, 2H), 4.40 (s, 2H), 3.45 (s,
4H), 1.85 (s, 4H), 1.63 (s, 2H).
Example 187
(S)-tert-butyl
1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-tetrahydronaphth-
alen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)pyrrolid-
ine-2-carboxylate
##STR00357##
[0849] Intermediate: 187a
(S)--N.sup.1-methyl-N.sup.1-(2-oxoethyl)-N.sup.3-(4-(piperidin-1-yl)-2-(4-
-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)isophth-
alamide
[0850] To a solution of DMSO (2.07 mmol, 162 mg) in DCM (1.6 mL) at
-78.degree. C. was added a solution of oxalyl chloride (1.04 mmol,
131 mg) in DCM (0.2 mL). The mixture was stirred at -78.degree. C.
for 15 minutes. Then a solution of
(S)--N.sup.1-(2-hydroxyethyl)-N.sup.1-methyl-N.sup.3-(4-(piperidin-1-yl)--
2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)iso-
phthalamide Example 115 (0.69 mmol, 435 mg) in DCM (0.5 mL) was
added. The mixture was stirred at -78.degree. C. for 3 h.
Triethylamine (0.5 mL) was added. The mixture was slowly warmed to
room temperature. The mixture was diluted with aqueous 10% citric
acid and extracted with DCM (3.times.). The combined organic layers
was washed with water (1.times.), dried, concentrated to give a
yellow solid which was used without purification.
Example 187
(S)-tert-butyl
1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-tetrahydronaphth-
alen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)
pyrrolidine-2-carboxylate
[0851] To a solution of L-proline-t-butyl ester (0.096 mmol, 16 mg)
in ethanol (0.2 mL) were added
(S)--N.sup.1-methyl-N.sup.1-(2-oxoethyl)-N.sup.3-(4-(piperidin-1-yl)-2-(4-
-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)isophth-
alamide (0.032 mmol, 20 mg) and HOAc (0.064 mmol, 4 mg). The
mixture was stirred at room temperature for 25 minutes, and then
sodium cyanoborohydride (0.16 mmol, 10 mg) was added. The mixture
was stirred for an additional 20 minutes and quenched with water.
The yellow solid was collected via filtration and was purified by
prep HPLC to give a yellow solid (12 mg, 37%). MS (ES, m/z): 786.1
[M+H].sup.+.
Example 188
1-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-
-2-yl)phenyl)carbamoyl)phenyl)-2-methyl-1-oxo-5,8,11-trioxa-2-azatetradeca-
n-14-oic acid
##STR00358## ##STR00359##
[0852] Intermediate 188a: tert-butyl
3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)
pyridin-2-yl)phenyl)carbamoyl)benzoate
[0853] To a mixture of
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide (25a, 6.33 mmol, 2.8 g), 3-(tert-butoxycarbonyl)benzoic acid
(7.60 mmol, 1.69 g) and DIEA (31.65 mmol, 4.09 g) in DMF (15 mL)
was added HATU (7.6 mmol, 2.89 g). The mixture was stirred at
60.degree. C. for 2 hours. The reaction mixture was diluted with
ethyl acetate, washed with water (2.times.), sat. aqueous
NaHCO.sub.3 (1.times.), brine (1.times.), dried and concentrated.
The residue was purified by column to give a yellow solid (3.9 g,
95%).
Intermediate 188b:
3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)carbamoyl)benzoic acid
[0854] To tert-butyl
3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)carbamoyl)benzoate was added 4M HCl in dioxane (25 mL).
The mixture was stirred at room temperature for 3 hours,
concentrated to give a light yellow solid which was used without
further purification.
Intermediate 188c: tert-butyl
1-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)
pyridin-2-yl)phenyl)carbamoyl)phenyl)-2-methyl-1-oxo-5,8,11-trioxa-2-azat-
etradecan-14-oate
[0855] To a mixture of
3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl)carbamoyl)benzoic acid (1.81 mmol, 1.2 g), tert-butyl
5,8,11-trioxa-2-azatetradecan-14-oate (1.9 mmol, 554 mg) and DIEA
(12.67 mmol, 1.64 g) in DMF (5 mL) was added HATU (2.17 mmol, 826
mg). The mixture was stirred at 60.degree. C. for 1 hour. The
reaction mixture was diluted with ethyl acetate, washed with water
(2.times.), sat. aqueous NaHCO.sub.3 (1.times.), brine (1.times.),
dried and concentrated. The residue was purified by column to give
a syrup (1.17 g, 75%).
Example 188
1-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-
-2-yl)phenyl)carbamoyl)phenyl)-2-methyl-1-oxo-5,8,11-trioxa-2-azatetradeca-
n-14-oic acid
[0856] To a mixture of tert-butyl
1-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)
pyridin-2-yl)phenyl)carbamoyl)phenyl)-2-methyl-1-oxo-5,8,11-trioxa-2-azat-
etradecan-14-oate (1.17 g) in DCM (20 mL) was added TFA (20 mL).
The mixture was stirred for 1 hour, concentrated and lyophilized to
give a think brown syrup. MS (ES, m/z): 808.3 [M+H].sup.+.
Example 189
(S)-2-(5-(diethylamino)-2-(3-(3-((2-methoxyethyl)carbamoyl)piperidine-1-ca-
rbonyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl))isonicotinamide
##STR00360##
[0858] This compound was prepared according to the procedure
described for the synthesis of tert-butyl
1-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridi-
n-2-yl)phenyl)carbamoyl)phenyl)-2-methyl-1-oxo-5,8,11-trioxa-2-azatetradec-
an-14-oate Example 188, using
(S)--N-(2-methoxyethyl)piperidine-3-carboxamide 4.14a in place of
tert-butyl 5,8,11-trioxa-2-azatetradecan-14-oate. MS (ES, m/z):
759.4 [M+H].sup.+.
Example 190
tert-Butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S-
)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoy-
l)benzamido)
ethyl)pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
##STR00361##
[0859] Intermediate 190a:
(S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-tetrahydrona-
phthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)pyrr-
olidine-2-carboxylic acid
[0860] To (S)-tert-butyl
1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-tetrahydronaphth-
alen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)pyrrolid-
ine-2-carboxylate (90 mg) was added TFA (5 mL). The mixture was
stirred at room temperature for 6 h, concentrated and purified by
column to give a yellow solid (75 mg, 90%).
Example 190
tert-Butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S-
)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoy-
l)benzamido)ethyl)
pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
[0861] To a mixture of
(S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-tetrahydrona-
phthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)pyrr-
olidine-2-carboxylic acid (0.035 mmol, 25.7 mg), tert-butyl
5,8,11-trioxa-2-azatetradecan-14-oate 135c (0.042 mmol, 12.4 mg)
and DIEA (0.212 mmol, 27 mg) in DMF (0.15 mL) was added HATU (0.042
mmol, 16 mg). The mixture was stirred at 60.degree. C. for 1 h. The
reaction mixture was diluted with ethyl acetate, washed with water
(2.times.), brine (1.times.), dried and concentrated. 23% of the
residue was purified by prep. HPLC to give a yellow solid (4 mg,
37%). MS (ES, m/z): 1002.36 [M+H].sup.+.
Example 191
2-Methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-t-
etrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido-
)ethyl)pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic
acid
##STR00362##
[0862] Example 191
2-Methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-t-
etrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido-
)ethyl)pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic
acid
[0863] To tert-Butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4--
tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamid-
o) ethyl)
pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate (16
mg) was added TFA (2 mL). The mixture was stirred at rt for 30
minutes, concentrated and purified by prep. HPLC to give a yellow
solid (17.6 mg, 86%). MS (ES, m/z): 946.34 [M+H].sup.+.
Example 192
tert-butyl
1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-
-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzami-
do)ethyl)pyrrolidin-2-yl)-1-oxo-5,811-trioxa-2-azatetradecan-14-oate
##STR00363##
[0865] This compound was prepared according to the procedure
described for the synthesis of tert-butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4--
tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamid-
o)ethyl)pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
Example 190, using tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)
ethoxy)propanoate in place of tert-butyl
5,8,11-trioxa-2-azatetradecan-14-oate. MS (ES, m/z): 988.34
[M+H].sup.+.
Example 193
1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4-tetrahydro-
naphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)py-
rrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic acid
##STR00364##
[0867] This compound was prepared according to the procedure
described for the synthesis of
2-Methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4--
tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamid-
o)ethyl)pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic
acid Example 191, using tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)
ethoxy)propanoate in place of tert-butyl
5,8,11-trioxa-2-azatetradecan-14-oate. MS (ES, m/z): 932.38
[M+H].sup.+.
Example 194
(S)--N.sup.1-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)ca-
rbamoyl)pyridin-2-yl)phenyl)-N.sup.3-(2-hydroxyethyl)-N.sup.3-methylisopht-
halamide
##STR00365##
[0869] This compound was prepared according to the procedure
described for the synthesis of
(S)--N.sup.1-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)c-
arbamoyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-morpholinoethyl)is-
ophthalamide Example 131, using 2-(methylamino)ethanol in place of
N-methyl-2-morpholinoethanamine. MS (ES, m/z): 620.32
[M+H].sup.+.
Example 195
N.sup.1-(2-((S)-2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)p-
yrrolidin-1-yl)ethyl)-N.sup.1-methyl-N.sup.3-(4-(piperidin-1-yl)-2-(4-(((S-
)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)
pyridin-2-yl)phenyl)isophthalamide
##STR00366##
[0871] This compound was prepared according to the procedure
described for the synthesis of tert-butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4--
tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamid-
o)ethyl)pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
Example 190, using 2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine
in place of tert-butyl 5,8,11-trioxa-2-azatetradecan-14-oate. MS
(ES, m/z): 1094.47 [M+H].sup.+.
Example 196
N.sup.1-(2-((S)-2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)p-
yrrolidin-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4-(((S)-1,2,3,4-tetrahy-
dronaphthalen-1-yl)carbamoyl)pyridin-2-yl)-N.sup.1-methylisophthalamide
##STR00367##
[0873] This compound was prepared according to the procedure
described for the synthesis of
N.sup.1-(2-((S)-2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)-
pyrrolidin-1-yl)ethyl)-N.sup.1-methyl-N.sup.3-(4-(piperidin-1-yl)-2-(4-(((-
S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)
pyridin-2-yl)phenyl)isophthalamide Example 195, using
(S)--N.sup.1-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)c-
arbamoyl)
pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-oxoethyl)isophtha-
lamide in place of
(S)--N.sup.1-methyl-N.sup.1-(2-oxoethyl)-N.sup.3-(4-(piperidin-1-yl)-2-(4-
-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)isophth-
alamide. MS (ES, m/z): 1082.52 [M+H].sup.+.
Example 197
(S)--N.sup.1-(2-(4-(2,5,8,11,14,17,20,23-octaoxahexacosan-26-oyl)-1,4-diaz-
epan-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphth-
alen-1-yl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-methylisophthalamide
##STR00368## ##STR00369##
[0874] Intermediate 197a:
(S)--N.sup.1-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)c-
arbamoyl)
pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-oxoethyl)isophtha-
lamide
[0875] To a solution of DMSO (4.8 mmol, 375 mg) in DCM (3 mL) at
-78.degree. C. was added a solution of oxalyl chloride (2.4 mmol,
305 mg) in DCM (0.4 mL). The mixture was stirred at -78.degree. C.
for 15 minutes. Then a solution of
(S)--N.sup.1-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)c-
arbamoyl)pyridin-2-yl)phenyl)-N.sup.3-(2-hydroxyethyl)-N.sup.3-methylisoph-
thalamide Example 194 (1.2 mmol, 742 mg) in DCM (1.7 mL) was added
dropwise. The mixture was stirred at -78.degree. C. for 3 h and
quenched with triethylamine (0.85 mL). The mixture was stirred at
-78.degree. C. for 10 minutes, at 0.degree. C. for 10 minutes, then
diluted with water, and extracted with DCM (2.times.). The combined
organic layers was washed with water (1.times.), dried, and
concentrated. The residue was used without further
purification.
Intermediate 197b: (S)-tert-butyl
4-(2-(3-((4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carba-
moyl)pyridin-2-yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)-1,4-diazepane-
-1-carboxylate
[0876] To a mixture of
(S)--N.sup.1-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)c-
arbamoyl)
pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(2-oxoethyl)isophtha-
lamide (0.162 mmol, 100 mg) in ethanol (1 mL) were added tert-butyl
1,4-diazepane-1-carboxylate (0.324 mmol, 65 mg) and HOAc (0.324
mmol, 19.4 mg). The mixture was stirred at room temperature for 20
minutes, and then sodium cyanoborohydride (0.81 mmol, 51 mg) was
added. The mixture was stirred for an additional 1 h, diluted with
ethyl acetate, washed with sat. aqueous NaHCO.sub.3 and brine,
dried, concentrated and purified by column to give a product (70
mg, 54%).
Intermediate 197c:
(S)--N.sup.1-(2-(1,4-diazepan-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4--
((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-
-methylisophthalamide
[0877] To (S)-tert-butyl
4-(2-(3-((4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carba-
moyl)
pyridin-2-yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)-1,4-diazepan-
e-1-carboxylate was added 4M HCl in dioxane (3 mL). The mixture was
stirred at room temperature for 2 h, concentrated to give a light
yellow solid which was used without further purification.
Example 197
(S)--N.sup.1-(2-(4-(2,5,8,11,14,17,20,23-octaoxahexacosan-26-oyl)-1,4-diaz-
epan-1-yl)ethyl)-N.sup.3-(4-diethylamino)-2-(4-((1,2,3,4-tetrahydronaphtha-
len-1-yl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-methylisophthalamide
[0878] To a mixture of
(S)--N.sup.1-(2-(1,4-diazepan-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4--
((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-
-methylisophthalamide (0.024, 20 mg) and m-dPEG.sub.8-NHS ester
(0.024 mmol, 12.2 mg) in DMF (0.15 mL) was added triethylamine
(0.144 mmol, 14.6 mg). The mixture was stirred at 60.degree. C. for
1 h and purified by prep. HPLC to give a brown gel (6.3 mg, 18%).
MS (ES, m/z): 1096.55 [M+H].sup.+.
Example 198
N.sup.1-(2-((S)-2-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(methyl)carbamoy-
l)pyrrolidin-1-yl)ethyl)-N.sup.1-methyl-N.sup.3-(4-(piperidin-1-yl)-2-(4-(-
((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)isoph-
thalamide
##STR00370##
[0880] This compound was prepared according to the procedure
described for the synthesis of tert-butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-((4-(piperidin-1-yl)-2-(4-(((S)-1,2,3,4--
tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamid-
o)ethyl)pyrrolidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
Example 190, using
N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine in place of
tert-butyl 5,8,11-trioxa-2-azatetradecan-14-oate. MS (ES, m/z):
1064.42 [M+H].sup.+.
Example 199
(S)-2,5,8,11,14,17,20,23,26,29,32-undecaoxatetratriacontan-34-yl
4-(2-(3-((4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carba-
moyl)pyridin-2-yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)-1,4-diazepane-
-1-carboxylate
##STR00371##
[0882] This compound was prepared according to the procedure
described for the synthesis of
(S)--N.sup.1-(2-(4-(2,5,8,11,14,17,20,23-octaoxahexacosan-26-oyl)-1,4-dia-
zepan-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4-((1,2,3,4-tetrahydronapht-
halen-1-yl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-methylisophthalamide
Example 197, using m-dPEG.sub.11-NHS carbonate in place of
m-dPEG.sub.8-NHS ester. MS (ES, m/z): 1244.49 [M+H].sup.+.
Example 200
2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzamido)-5-(dipropyla-
mino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00372##
[0883] Example 200
2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzamido)-5-(dipropyla-
mino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0884] To a mixture of
2-(2-amino-5-(dipropylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicot-
inamide (19b, 1.27 mmol, 600 mg),
3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzoic acid (prepared
as in Example 185 2,5,9,12,15,18,21,24-octaoxahexacosan-26-ol in
place of methyl 3-(hydroxymethyl)benzoate) (1.40 mmol, 729 mg) and
DIEA (7.66 mmol, 990 mg) in DMF (4 mL) was added HATU (1.40 mmol,
534 mg). The mixture was stirred at 60.degree. C. for 1 h, diluted
with DCM, washed with water (3.times.), dried, concentrated and
purified by column to give a yellow syrup (1.01 g, 82%). MS (ES,
m/z): 971.42 [M+H].sup.+.
Example 201
(S)--N.sup.1-(2-(2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)-
piperidin-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4-((3-(trifluoromethyl)-
benzyl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-methylisophthalamide
##STR00373##
[0885] Intermediate 201a:
(S)-1-(2-(((benzyloxy)carbonyl)(methyl)amino)ethyl)piperidine-2-carboxyli-
c acid
[0886] To a mixture of benzyl methyl(2-oxoethyl)carbamate (0.47
mmol, 98 mg) and triethylamine (0.47 mmol, 48 mg) in DCE (1.7 mL)
was added (S)-methyl piperidine-2-carboxylate (0.47 mmol, 85 mg),
followed by addition of sodium triacetoxyborohydride (0.71 mmol,
150 mg). The mixture was stirred at rt for 1 h, concentrated under
reduced pressure and purified by column to give a solid product (70
mg, 47%) and a clear syrup ((S)-methyl
1-(2-(((benzyloxy)carbonyl)(methyl)amino)ethyl)piperidine-2-carboxylate,
30 mg).
Intermediate 201b: (S)-benzyl
(2-(2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)
piperidin-1-yl)ethyl)(methyl)carbamate
[0887] To a mixture of
(S)-1-(2-(((benzyloxy)carbonyl)(methyl)amino)ethyl)piperidine-2-carboxyli-
c acid (0.145 mmol, 46.4 mg),
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine (0.145 mmol, 55.6
mg), DIEA (0.725 mmol, 94 mg) in DMF (0.3 mL) was added HATU (0.16
mmol, 61 mg). The mixture was stirred at 60.degree. C. for 1 h. The
crude mixture was used in next step without purification.
Intermediate 201c:
(S)-1-(2-(methylamino)ethyl)-N-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-
-yl)piperidine-2-carboxamide
[0888] To a solution of the above crude mixture ((S)-benzyl
(2-(2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)
piperidin-1-yl)ethyl)(methyl) carbamate) in methanol (2 mL) was
added 10% Pd/C (30 mg). The mixture was stirred at rt under
hydrogen atmosphere for 1 h. The mixture was filtered and the
filtrate was concentrated under high vacuum which was used without
further purification.
Example 201
(S)--N.sup.1-(2-(2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)-
piperidin-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4-((3-(trifluoromethyl)-
benzyl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-methylisophthalamide
[0889] To a mixture of (S)-1-(2-(methylamino)
ethyl)-N-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl)piperidine-2-carbo-
xamide (0.145 mmol),
3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-
-yl)phenyl) carbamoyl) benzoic acid (0.12 mmol, 80 mg) and DIEA
(0.6 mmol, 78 mg) in DMF (0.4 mL) was added HATU (0.145 mmol, 55
mg). The mixture was stirred at 60.degree. C. for 1 h and purified
by prep. HPLC to give a yellow solid (91 mg, 52%). MS (ES, m/z):
1124.38 [M+H].sup.+.
Example 202
2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzamido)-5-cyclobutox-
yphenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00374##
[0890] Compound:
2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzamido)-5-cyclobuto-
xyphenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[0891] To a mixture of
2-(2-amino-5-cyclobutoxyphenyl)-N-(3-(trifluoromethyl)benzyl)-isonicotina-
mide 26b (1.5 mmol, 662 mg),
3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzoic acid (prepared
as in Example 185 2,5,9,12,15,18,21,24-octaoxahexacosan-26-ol in
place of methyl 3-(hydroxymethyl)benzoate) (1.65 mmol, 857 mg) and
DIEA (9.0 mmol, 1.16 g) in DMF (5 mL) was added HATU (1.65 mmol,
627 mg). The mixture was stirred at 60 OC for 1 h, diluted with
DCM, washed with water (4.times.), dried, concentrated and purified
by column to give a yellow syrup. To a solution of the syrup in DCM
(4 mL) at 0.degree. C. was added 4M HCl in dioxane (0.35 mL)
dropwise. The mixture was concentrated and triturated with dry
ether to give an orange solid (955 mg, 65%). MS (ES, m/z): 942.56
[M+H].sup.+.
Example 203
(S)--N.sup.1-(2-(2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)-
pyrrolidin-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4-((3-(trifluoromethyl-
)benzyl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-methylisophthalamide
##STR00375## ##STR00376##
[0892] Intermediate 203a. (S)-tert-butyl
1-(2-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)
carbamoyl)pyridin-2-yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)pyrrolid-
ine-2-carboxylate
[0893] To a mixture of
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide 188b (2.01 mmol, 1.33 g), 3(S)-tert-butyl
1-(2-(methylamino)ethyl)pyrrolidine-2-carboxylate (2.41 mmol, 0.551
g) and DIEA (14.08 mmol, 1.82 g) in DMF (6 mL) was added HATU (2.41
mmol, 0.918 g). The mixture was stirred at 60.degree. C. for 1 h.
The reaction mixture was diluted with ethyl acetate, washed with
water (2.times.), brine (1.times.), dried and concentrated. The
residue was purified by column to give a yellow solid (1.57 g,
98%).
Intermediate 203b.
(S)-1-(2-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl-
)
pyridin-2-yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)pyrrolidine-2-car-
boxylic acid
[0894] To a mixture of (S)-tert-butyl
1-(2-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)
carbamoyl)pyridin-2-yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)pyrrolid-
ine-2-carboxylate in DCM (3 mL) was added 4M HCl in dioxane (40
mL). The mixture was stirred at room temperature for 3 h and
concentrated to give a yellow solid, which was used without further
purification.
Example 203
(S)--N.sup.1-(2-(2-(2,5,8,11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyl)-
pyrrolidin-1-yl)ethyl)-N.sup.3-(4-(diethylamino)-2-(4-((3-(trifluoromethyl-
)benzyl)carbamoyl)pyridin-2-yl)phenyl)-N.sup.1-methylisophthalamide
[0895] To a mixture of
(S)-1-(2-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl-
)pyridin-2-yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)
pyrrolidine-2-carboxylic acid (1.32 mmol, 1.12 g),
2,5,8,11,14,17,20,23-octaoxapentacosan-25-amine (1.38 mmol, 530 mg)
and DIEA (9.21 mmol, 1.19 g) in DMF (4 mL) was added HATU (1.45
mmol, 0.551 g). The mixture was stirred at 60.degree. C. for 1 h
and purified by prep. HPLC to give a syrup (1.18 g, 62%). MS (ES,
m/z): 1110.42 [M+H].sup.+.
Example 205
(S)-2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzamido)-5-cyclob-
utoxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
##STR00377##
[0897] This compound was prepared according to the procedure
described for the synthesis of (S)-tert-butyl
16-(3-((4-cyclobutoxy-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-
pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
Example 284, using intermediate
3-(2,5,8,11,14,17,20,23,26-nonaoxaheptacosyl)benzoic acid in place
of
3-(2,2-dimethyl-4-oxo-3,7,10,13,16-pentaoxanonadecan-19-yl)benzoic
acid. MS (ES, m/z): 914.6 [M+H].sup.+.
Example 207
N1-(2-(4-((2-methoxyethyl)carbamoyl)piperazin-1-yl)ethyl)-N3-(2-(4-((3-(tr-
ifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)-N1--
methylisophthalamide
##STR00378## ##STR00379##
[0898] Intermediate 207a
[0899] Into a 100-mL round-bottom flask, was placed a solution of
3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2--
yl)phenylcarbamoyl)benzoic acid (900 mg, 1.49 mmol, 1.00 equiv) in
dichloromethane (30 mL), tert-butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate (468 mg, 1.92
mmol, 1.30 equiv), EDC.HCl (432 mg, 2.25 mmol, 1.50 equiv),
4-dimethylaminopyridine (279 mg, 2.28 mmol, 1.50 equiv). The
resulting solution was stirred for 2 h at 25.degree. C. The
resulting solution was diluted with 10 mL of water. The resulting
solution was extracted with 2.times.10 mL of dichloromethane and
the organic layers combined. The resulting mixture was washed with
1.times.5 mL of water and 2.times.5 mL of brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
This resulted in 800 mg (65%) of tert-butyl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperazine-1-carboxylate
as a light yellow syrup.
Intermediate 207b
[0900] Into a 100-mL round-bottom flask, was placed a solution of
tert-butyl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperazine-1-carboxylate
(800 mg, 0.97 mmol, 1.00 equiv) in dichloromethane (30 mL),
trifluoroacetic acid (5 g). The resulting solution was stirred for
3 h at 25.degree. C. The resulting mixture was concentrated under
vacuum. This resulted in 550 mg of crude product and 400 mg was
added to the next step. The crude product (150 mg) was purified by
Prep-HPLC with the following conditions (1#-Waters 2767-3): Column,
SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with 0.05%
TFA and CH3CN (20% CH3CN up to 38% in 6 min); Detector, Waters2545
UvDector 254&270 nm. 95.2 mg product was obtained. This
resulted in 95.2 mg of
N1-methyl-N1-(2-(piperazin-1-yl)ethyl)-N3-(4-(piperidin-1-yl)-2-(4-(3-(tr-
ifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide as
a light yellow syrup. LC-MS (ES, m/z): 728 [M+H].sup.+; H-NMR (300
MHz, CD.sub.3OD, ppm): 8.97 (d, J=5.4 Hz, 1H), 8.82 (d, J=9.0 Hz,
1H), 8.48 (s, 1H), 8.25 (d, J=2.7 Hz, 1H), 8.12.about.8.09 (m, 2H),
7.90.about.7.88 (m, 1H), 7.77.about.7.67 (m, 5H), 7.62.about.7.53
(m, 2H), 4.72 (s, 2H), 3.83 (s, 2H), 3.72.about.3.70 (m, 4H), 3.68
(s, 1H), 3.13.about.2.96 (m, 10H), 2.64.about.2.52 (m, 2H), 2.07
(d, J=4.8 Hz, 4H), 1.85 (d, J=5.4 Hz, 2H).
Intermediate 207c
[0901]
N1-(2-(4-((2-methoxyethyl)carbamoyl)piperazin-1-yl)ethyl)-N3-(2-(4--
((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phen-
yl)-N1-methylisophthalamide Into a 50-mL round-bottom flask, was
placed a solution of 207b (250 mg, 0.21 mmol, 1.05 equiv) in sodium
bicarbonate aq. (10 mL). The mixture was stirred for 20 minutes at
room temperature. The resulting solution was extracted with
3.times.10 mL of ethyl acetate and the organic layers combined. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. This resulted in 150 mg of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthalamide
free base used without purification in the next reaction.
[0902] Into a 50-mL round-bottom flask, was placed a solution of
N1-(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-
-1-yl)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthalamide
(100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (3 mL),
triethylamine (42 mg, 0.42 mmol, 3.00 equiv). This was followed by
the addition of 4-nitrophenyl carbonochloridate (31 mg, 0.15 mmol,
1.10 equiv) dropwise with stirring at 0.degree. C. The resulting
solution was stirred for 40 min at 25.degree. C. The resulting
solution was diluted with 3 mL of sodium bicarbonate. The resulting
solution was extracted with 2.times.5 mL of dichloromethane and the
organic layers combined. The resulting mixture was washed with
1.times.5 mL of water and 2.times.5 mL of Brine. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
This resulted in 110 mg (90%) of 4-nitrophenyl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperazine-1-carboxylate
as a yellow solid.
Example 207
[0903] Into a 50-mL round-bottom flask, was placed 4-nitrophenyl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperazine-1-carboxylate
207c (100 mg, 0.11 mmol, 1.00 equiv), 2-methoxyethanamine (1 ml).
The resulting solution was stirred for 4 h at 25.degree. C. The
resulting solution was diluted with 5 ml of water. The resulting
solution was extracted with 2.times.5 ml of dichloromethane and the
organic layers combined. The mixture was dried over anhydrous
sodium sulfate and concentrated under vacuum. The crude product
(100 mg) was purified by Prep-HPLC with the following conditions
(1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm 5 um;
mobile phase, water with 0.05% TFA and CH3CN (20% CH3CN up to 40%
in 6 min); Detector, Waters2545 UvDector 254&270 nm. 72.8 mg
product was obtained. This resulted in 72.8 mg (78%) of
N1-(2-(4-((2-methoxyethyl)carbamoyl)piperazin-1-yl)ethyl)-N3-(2-(4-((3-
-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)-
-N1-methylisophthalamide as a light yellow solid. LC-MS (ES, m/z):
829 [M+H].sup.+ H-NMR (300 MHz, CD3OD, ppm): 8.96 (d, J=5.1 Hz,
1H), 8.74 (d, J=9.0 Hz, 1H), 8.45 (s, 1H), 8.17.about.8.15 (m, 3H),
7.88.about.7.86 (s, 1H), 7.80 (d, J=7.5 Hz, 1H), 7.72.about.7.64
(m, 4H), 7.62.about.7.55 (m, 2H), 4.72 (s, 2H), 4.00 (s, 2H),
3.90.about.3.54 (m, 16H), 3.48.about.3.33 (m, 5H), 3.11 (s, 3H),
2.03 (d, J=4.8 Hz, 1H), 1.82 (d, J=5.1 Hz, 1H).
Example 208
N-(2-methoxyethyl)-4-(2-(methyl(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluorome-
thyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)amino)ethyl)piper-
azine-1-carboxamide
##STR00380##
[0905] This compound was prepared according to the procedure
described for the synthesis of
N-(2-methoxyethyl)-4-(2-(methyl(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluorom-
ethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)amino)ethyl)pipe-
razine-1-carboxamide Example 207 substituting tert-butyl
4-(2-(methyl(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamo-
yl)pyridin-2-yl)phenylcarbamoyl)benzyl)amino)ethyl)piperazine-1-carboxylat-
e Example 38 in place of tert-butyl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperazine-1-carboxylate
207a LC-MS (ES, m/z): 815 [M+H].sup.+ H-NMR (300 MHz, DMSO, ppm):
12.30 (s, 1H), 9.55-9.59 (t, J=6.6 Hz, 1H), 8.92-8.94 (d, J=6 Hz,
1H), 8.28-8.34 (sd, J=9 Hz, 2H), 8.11-8.14 (m, 1H), 8.04 (s, 1H),
7.94-7.96 (d, J=6 Hz, 1H), 7.85-7.86 (d, J=3 Hz, 1H), 7.56-7.71 (m,
7H), 7.31 (s, 1H), 6.92-6.95 (m, 1H), 6.73 (s, 1H), 4.63-4.64 (d,
J=3 Hz, 2H), 4.28 (s, 2H), 3.46 (s, 3H), 3.31-3.35 (m, 7H),
3.17-3.23 (m, 9H), 2.94 (s, 4H), 2.63 (s, 3H), 1.60-1.74 (m,
6H).
Example 209
N-(2-methoxyethyl)-N-methyl-4-(2-(methyl(3-(4-(piperidin-1-yl)-2-(4-(3-(tr-
ifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)amino)et-
hyl)piperazine-1-carboxamide
##STR00381##
[0907] This compound was prepared according to the procedure
described for the synthesis of
N-(2-methoxyethyl)-4-(2-(methyl(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluorom-
ethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzyl)amino)ethyl)pipe-
razine-1-carboxamide Example 208 substituting
2-methoxy-N-methylethanamine in place of 2-methoxyethanamine. LC-MS
(ES, m/z): 829 [M+H].sup.+ H-NMR (300 MHz, DMSO, ppm): 12.31 (s,
1H), 9.56 (t, J=3.6 Hz, 1H), 8.93 (d, J=6 Hz, 1H), 8.31 (d, J=6 Hz,
2H), 8.04 (s, 1H), 7.94 (d, J=9 Hz, 1H), 7.84-7.86 (m, 1H),
7.56-7.71 (m, 7H), 7.30 (d, J=9 Hz, 1H), 4.63 (d, J=3 Hz, 2H), 4.26
(s, 2H), 3.45 (t, J=6.6 Hz, 2H), 3.23-3.32 (m, 16H), 3.17 (s, 1H),
3.00 (s, 4H), 2.80 (s, 3H), 2.63 (s, 3H), 1.60-1.74 (m, 6H).
Example 210
N-(2-methoxyethyl)-N-methyl-4-(2-(methyl((6-(4-(piperidin-1-yl)-2-(4-(3-(t-
rifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)pyridin-2-yl)m-
ethyl)amino)ethyl)piperazine-1-carboxamide
##STR00382##
[0909] This compound was prepared according to the procedure
described for the synthesis of
N-(2-methoxyethyl)-N-methyl-4-(2-(methyl((6-(4-(piperidin-1-yl)-2-(4-(3-(-
trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)pyridin-2-yl)-
methyl)amino)ethyl)piperazine-1-carboxamide Example 208
substituting 2-methoxy-N-methylethanamine in place of
2-methoxyethanamine. LC-MS (ES, m/z): 830 [M+H].sup.+ H-NMR (300
MHz, DMSO, ppm): 12.81 (s, 1H), 9.57-9.55 (m, 1H), 9.05-9.03 (m,
1H), 8.50-8.47 (m, 1H), 8.27 (m, 1H), 8.10-8.06 (m, 2H), 7.89-7.87
(m, 1H), 7.79-7.52 (m, 6H), 7.27 (m, 1H), 4.65-4.63 (d, J=5.7 Hz,
3H), 4.09 (m, 3H), 3.43-3.01 (m, 22H), 2.74 (m, 3H), 1.72-1.59 (m,
6H).
Example 211
N1-(2-(4-((2-methoxyethyl)(methyl)carbamoyl)piperazin-1-yl)ethyl)-N1-methy-
l-N3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenyl)isophthalamide
##STR00383##
[0911] This compound was prepared according to the procedure
described for the synthesis of
N1-(2-(4-((2-methoxyethyl)carbamoyl)piperazin-1-yl)ethyl)-N3-(2-(4-((3-(t-
rifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)-N1-
-methylisophthalamide Example 207 substituting
methoxy-N-methylethanamine in place of 2-methoxyethanamine. LC-MS
(ES, m/z): 843 [M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD, ppm): 8.99
(d, J=5.1 Hz, 1H), 8.77 (d, J=9.0 Hz, 1H), 8.46 (s, 1H), 8.19 (m,
3H), 7.90 (m, 1H), 7.81 (d, J=7.8 Hz, 1H), 7.74.about.7.67 (m, 4H),
7.62.about.7.53 (m, 2H), 4.72 (s, 2H), 4.00 (s, 2H),
3.90.about.3.65 (m, 9H), 3.57 (d, J=5.1 Hz, 1H), 3.47 (d, J=4.8 Hz,
1H), 3.34 (s, 3H), 3.12 (s, 3H), 2.97 (s, 3H), 2.04 (d, J=4.8 Hz,
4H), 1.83 (d, J=4.2 Hz, 2H).
Example 212
tert-butyl
3-[2-(2-{2-[(4-{2-[1-(3-{[4-(diethylamino)-2-(4-{[(1S)-1,2,3,4--
tetrahydronaphthalen-1-yl]carbamoyl}pyridin-2-yl)phenyl]carbamoyl}phenyl)--
N-methylformamido]ethyl}piperazin-1-yl)carbonyl(methyl)amino]ethoxy}ethoxy-
)ethoxy]propanoate
##STR00384## ##STR00385##
[0912] Intermediate 212a
[0913] Into a 100-mL round-bottom flask, was placed a solution of
3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(diethylamino)phenyl)carbamoyl)benzoic acid (880 mg, 1.56 mmol,
1.00 equiv) in dichloromethane (10 mL), tert-butyl
4-(2-(methylamino)ethyl)piperazine-1-carboxylate (570 mg, 2.35
mmol, 1.50 equiv), EDC.HCl (0.60 g, 3.14 mmol, 2.00 equiv),
4-dimethylaminopyridine (0.19 g, 1.56 mmol, 1.00 equiv). The
resulting solution was stirred overnight at room temperature. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with ethyl acetate/petroleum ether
(1:5-1:1). This resulted in 0.8 g (65%) of tert-butyl
4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carboxylate
as a yellow solid.
Intermediate 212b
[0914] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carboxylate
(800 mg, 1.02 mmol, 1.00 equiv) in dichloromethane (5 mL),
trifluoroacetic acid (6 mL). The resulting solution was stirred
overnight at room temperature. The resulting mixture was
concentrated under vacuum. The resulting solution was diluted with
10 mL of water. The pH value of the solution was adjusted to
8.about.9 with sodium bicarbonate. The resulting solution was
extracted with 3.times.30 mL of dichloromethane and the organic
layers combined. The resulting mixture was washed with 3.times.30
mL of Brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. This resulted in 0.65 g (93%) of
N1-(2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(diethylamino)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthalami-
de as a yellow solid.
Example 212
[0915] Into a 50-mL round-bottom flask, was placed a solution of
(S)-4-nitrophenyl
4-(2-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carbo-
xylate (400 mg, 0.47 mmol, 1.00 equiv) in dichloromethane (3 mL),
triethylamine (2 mL). This was followed by the addition of a
solution of bis(trichloromethyl) carbonate (80 mg, 0.27 mmol, 0.50
equiv) in dichloromethane (4 mL) dropwise with stirring at
0.degree. C. The resulting solution was stirred for 0.5 h at room
temperature. To this was added triethylamine (2 mL), a solution of
tert-butyl 3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate
(224 mg, 0.77 mmol, 1.50 equiv) in dichloromethane (3 mL). The
resulting solution was stirred for 2 h at room temperature. The
reaction progress was monitored by LCMS. The resulting mixture was
concentrated under vacuum. The crude product (0.1 g) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with
0.05% TFA and CH.sub.3CN (5% CH.sub.3CN up to 30% in 1 min, up to
40% in 5 min); Detector, Waters2545 UvDector 254&270 nm. 21.8
mg product was obtained. This resulted in 21.8 mg (4%) of Example
212 as a yellow solid. LC-MS (ES, m/z): 1006 [M+H].sup.+ H-NMR (300
MHz, DMSO, ppm): 9.14 (m, 1H), 8.87 (m, 1H), 8.24 (m, 2H), 7.96 (m,
2H), 7.83 (m, 1H), 7.63 (m, 2H), 7.13 (m, 6H), 5.76 (m, 1H), 3.45
(m, 18H), 2.98 (m, 15H), 2.46 (m, 3H), 1.87 (m, 5H), 1.38 (m, 11H),
1.12 (m, 7H).
Example 213
(S)--N1-(2-(4-2,5,8,11,14,17,20,23-octaoxapentacosane-1,
4-diazepan-1-yl)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tet-
rahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00386##
[0916] Intermediate 213a
[0917] Into a 50-mL round-bottom flask, was placed a solution of
2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)etha-
nol (500 mg, 1.47 mmol, 1.00 equiv) in tetrahydrofuran (15 mL).
This was followed by the addition of sodium hydride (135 mg, 5.62
mmol, 3.83 equiv) in several batches at 0-5.degree. C. The
resulting solution was stirred for 15 min at room temperature. To
this was added tert-butyl 2-bromoacetate (345 mg, 1.78 mmol, 1.21
equiv). The resulting solution was allowed to react, with stirring,
for an additional 4 h at room temperature. The reaction was then
quenched by the addition of 50 mL of water/ice. The resulting
solution was extracted with 3.times.20 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
3.times.20 mL of sodium chloride. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 500 mg (75%) of
tert-butyl-2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)etho-
xy)ethoxy)ethoxy)acetate as colourless oil.
Intermediate 213b
[0918] Into a 100-mL round-bottom flask, was placed a solution of
tert-butyl
2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)e-
thoxy)acetate (500 mg, 1.10 mmol, 1.00 equiv) in dichloromethane
(20 mL). The gas of hydrochloric acid was introduced in. The
resulting solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum. This resulted in
400 mg (91%) of
2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)e-
thoxy)acetic acid as yellow oil.
Example 213
(S)--N1-(2-(4-2,5,8,11,14,17,20,23-octaoxapentacosane-1,4-diazepan-1-yl)et-
hyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
[0919] This compound was prepared according to the procedure
described for the synthesis of Example 197 using
2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)e-
thoxy)acetic acid 213b in place of m-dPEG.sub.8-NHS ester and 187a
in place of 197a LC-MS (ES, m/z): 1094 [M+H].sup.+ H-NMR (300 MHz,
CDCl.sub.3, ppm): 8.93 (d, J=5.1 Hz, 1H), 8.68-8.65 (m, 1H), 8.41
(s, 1H), 8.16-8.07 (m, 3H), 7.87-7.85 (m, 1H), 7.78-7.65 (m, 3H),
7.25-7.14 (m, 4H), 5.38 (m, 1H), 4.31 (s, 2H), 3.99-3.86 (m, 3H),
3.66-3.51 (m, 39H), 3.37-3.31 (m, 3H), 3.13-3.09 (m, 3H), 2.91-2.84
(m, 2H), 2.32-1.80 (m, 12H).
Example 214
(S)-2,5,8,11,14,17,20-heptaoxadocosan-22-yl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)-1,4-diazepane-1-
-carboxylate
##STR00387##
[0920] Intermediate 214a
[0921] Into a 100-mL round-bottom flask, was placed a solution of
4-nitrophenyl carbonochloridate (200 mg, 1.00 mmol, 1.00 equiv) in
dichloromethane (10 mL),
2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)etha-
nol (338 mg, 0.99 mmol, 1.00 equiv), triethylamine (301 mg, 2.98
mmol, 2.99 equiv). The resulting solution was stirred for 3 h at
room temperature. The resulting solution was diluted with 10 mL of
dichloromethane. The resulting mixture was washed with 2.times.10
mL of brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. This resulted in 240 mg (48%) of
2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethy-
l 4-nitrophenyl carbonate as yellow oil.
Example 214
[0922] Into a 100-mL round-bottom flask, was placed a solution of
(S)--N1-(2-(1,4-diazepan-1-yl)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(-
4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophtha-
lamide (150 mg, 0.21 mmol, 1.00 equiv) in acetonitrile (1 mL),
2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethy-
l 4-nitrophenyl carbonate (106 mg, 0.21 mmol, 1.00 equiv),
4-dimethylaminopyridine (39 mg, 0.32 mmol, 1.51 equiv). The
resulting solution was stirred overnight at 80.degree. C. in an oil
bath. The resulting mixture was washed with 2.times.20 mL of sat.
NH.sub.4Cl. The mixture was dried over sodium sulfate and
concentrated under vacuum. The crude product (100 mg) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with
0.05% TFA and CH.sub.3CN (25% CH.sub.3CN up to 38% in 6 min);
Detector, Waters2545 UvDector 254&270 nm. 35.2 mg product was
obtained. This resulted in 35.2 mg (12%) of
(S)-2,5,8,11,14,17,20-heptaoxadocosan-22-yl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)-1,4-diazepane-1-
-carboxylate as yellow oil. LC-MS (ES, m/z): 1081 [M+H].sup.+ H-NMR
(400 MHz, CD.sub.3OD, ppm): 8.93.about.8.92 (d, J=4.8 Hz, 1H),
8.61.about.8.59 (d, J=8.8 Hz, 1H), 8.38 (s, 1H), 8.15.about.8.10
(t, 2H), 7.97 (s, 1H), 7.86.about.7.84 (d, J=5.2 Hz, 1H),
7.79.about.7.70 (m, 2H), 7.59.about.7.56 (d, J=9.2 Hz, 1H),
7.28.about.7.26 (d, J=7.2 Hz, 1H), 7.18.about.7.14 (m, 3H), 5.39
(s, 1H), 4.27 (s, 2H), 4.00 (s, 3H), 3.80.about.3.72 (m, 5H), 3.63
(s, 24H), 3.57.about.3.46 (m, 10H), 3.33 (s, 2H), 3.13 (s, 3H),
2.91.about.2.86 (m, 2H), 2.24.about.2.16 (m, 3H), 2.04.about.1.90
(m, 7H), 1.78 (s, 2H).
Example 215
(S)--N1-methyl-N1-(2-(3-oxopiperazin-1-yl)ethyl)-N3-(4-(piperidin-1-yl)-2--
(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophth-
alamide
##STR00388##
[0924] This compound was prepared according to the procedure
described for the synthesis of Example 187 using piperazin-2-one in
place of L-proline-tert-butyl ester. Into a 50-mL round-bottom
flask, was placed a solution of
(S)--N1-methyl-N1-(2-oxoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetra-
hydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(100 mg, 0.16 mmol, 1.00 equiv) in ethanol (5 mL), piperazin-2-one
(20 mg, 0.20 mmol, 1.20 equiv). This was followed by the addition
of acetic acid (20 mg, 0.33 mmol, 2.20 equiv). The mixture was
allowed to react with stirring for 1 h at room temperature. To this
was added NaBH.sub.3CN (22 mg, 0.35 mmol, 2.20 equiv). The
resulting solution was stirred overnight at room temperature. The
resulting mixture was concentrated under vacuum. The pH value of
the solution was adjusted to 7 with sodium bicarbonate (2 mol/L).
The resulting solution was extracted with 3.times.20 mL of
dichloromethane and the organic layers combined and dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (120 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (20%
CH.sub.3CN up to 40% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 91.4 mg product was obtained. This resulted in 91.4
mg (54%) of
(S)--N1-methyl-N1-(2-(3-oxopiperazin-1-yl)ethyl)-N3-(4-(piperidin-1-yl)-2-
-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isopht-
halamide as a yellow solid.
[0925] LCMS (ES, m/z): 714 [M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD,
ppm): 8.94 (m, 1H), 8.70 (m, 1H), 8.40 (s, 2H), 8.12 (m, 3H), 7.85
(m, 1H), 7.72 (m, 3H), 7.17 (m, 3H), 5.39 (s, 1H), 3.94 (m, 3H),
3.56 (m, 7H), 3.09 (m, 3H), 2.86 (m, 3H), 1.95 (m, 8H).
Example 216
(S)--N1-methyl-N1-(2-(4-methyl-3-oxopiperazin-1-yl)ethyl)-N3-(4-(piperidin-
-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)pheny-
l)isophthalamide
##STR00389##
[0927] This compound was prepared according to the procedure
described for the synthesis of Example 187 using
methylpiperazin-2-one in place of L-proline-tert-butyl ester. Into
a 50-mL round-bottom flask, was placed a solution of
(S)--N1-methyl-N1-(2-oxoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetra-
hydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(100 mg, 0.16 mmol, 1.00 equiv) in ethanol (2 mL). This was
followed by the addition of a solution of 1-methylpiperazin-2-one
(18 mg, 0.16 mmol, 1.00 equiv) in ethanol (2 mL), two drop of
acetic acid. To this was added NaBH.sub.3CN (20 mg, 0.32 mmol, 2.00
equiv). The resulting solution was stirred for 2 h at room
temperature. The resulting solution was diluted with 50 mL of ethyl
acetate. The resulting mixture was washed with 2.times.20 mL of
brine. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude product (100 mg) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with
0.05% TFA and CH.sub.3CN (22% CH.sub.3CN up to 38% in 6 min);
Detector, Waters2545 UvDector 254&270 nm. 70 mg product was
obtained. This resulted in 70 mg (61%) of
(S)--N1-methyl-N1-(2-(4-methyl-3-oxopiperazin-1-yl)ethyl)-N3-(4-(piperidi-
n-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phen-
yl)isophthalamide as a yellow solid. LC-MS (ES, m/z): 728
[M+H].sup.+ H-NMR (300 MHz, DMSO, ppm): 12.25 (s, 1H), 9.18 (d,
J=8.4 Hz, 1H), 8.80 (d, J=5.1 Hz, 1H), 8.29 (d, J=13.8 Hz 2H), 7.99
(t, J=6.9 Hz, 2H), 7.86 (d, J=4.8 Hz, 1H), 7.57.about.7.67 (m, 3H),
7.10.about.7.28 (m, 5H), 5.25 (d, J=5.4 Hz, 1H), 3.92.about.3.85
(m, 4H), 3.30.about.3.54 (m, 10H), 2.78.about.2.95 (m, 9H), 1.99
(d, J=3.6 Hz, 2H), 1.72.about.1.80 (m, 6H), 1.60 (s, 2H).
Example 217
(S)--N1-(2-(bis(2-methoxyethyl)amino)ethyl)-N1-methyl-N3-(4-(piperidin-1-y-
l)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)is-
ophthalamide
##STR00390##
[0929] This compound was prepared according to the procedure
described for the synthesis of Example 187 using
bis(2-methoxyethyl)amine in place of L-proline-tert-butyl ester.
Into a 25-mL round-bottom flask, was placed a solution of
(S)--N1-methyl-N1-(2-oxoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetra-
hydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(100 mg, 0.16 mmol, 1.00 equiv) in ethanol (1 mL),
bis(2-methoxyethyl)amine (25 mg, 0.19 mmol, 1.20 equiv),
NaBH.sub.3CN (20 mg, 0.32 mmol, 2.00 equiv), acetic acid (1.0 mg,
0.02 mmol, 0.10 equiv). The resulting solution was stirred for 2 h
at 25.degree. C. The reaction was then quenched by the addition of
10 mL of water. The resulting solution was extracted with
2.times.10 mL of ethyl acetate and the organic layers combined and
dried over anhydrous sodium sulfate and concentrated under vacuum.
The crude product (100 mg) was purified by Prep-HPLC with the
following conditions (1#-Waters 2767-3): Column, SunFire Prep C18,
19*150 mm 5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN
(25% CH.sub.3CN up to 38% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 47.9 mg product was obtained. This resulted in 47.9
mg (40%) of
(S)--N1-(2-(bis(2-methoxyethyl)amino)ethyl)-N1-methyl-N3-(4-(piperidin-1--
yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)i-
sophthalamide as a yellow solid.
[0930] LC-MS (ES, m/z): 747[M+H].sup.+ H-NMR (300 MHz, DMSO, ppm):
12.24 (s, 1H), 9.50 (s, 1H), 9.20 (d, J=9 Hz, 1H), 8.89 (d, J=3 Hz,
1H), 8.24-8.32 (m, 2H), 7.99 (d, J=6 Hz, 2H), 7.86 (d, J=6 Hz, 1H),
7.60-7.69 (m, 3H), 7.30 (s, 1H), 7.10-7.24 (m, 4H), 5.25 (t, J=6.9
Hz, 1H), 3.80 (d, J=33 Hz, 5H), 3.63 (s, 6H), 3.33 (s, 12H), 2.97
(s, 4H), 2.74 (s, 2H), 1.96-2.00 (m, 2H), 1.73-1.88 (m, 6H), 1.60
(d, J=6 Hz, 2H).
Example 218
(S)--N1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)ethyl)-N1-methyl-N3-(4-(pi-
peridin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-y-
l)phenyl)isophthalamide
##STR00391##
[0932] This compound was prepared according to the procedure
described for the synthesis of Example 187 using
N,N-dimethylpiperidine-4-carboxamide in place of
L-proline-tert-butyl ester. Into a 100-mL round-bottom flask, was
placed a solution of
(S)--N1-methyl-N1-(2-oxoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetra-
hydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(100 mg, 0.16 mmol, 1.00 equiv) in ethanol (10 mL),
N,N-dimethylpiperidine-4-carboxamide (50 mg, 0.32 mmol, 2.02
equiv), acetic acid (22 mg, 0.37 mmol, 2.31 equiv). The resulting
solution was stirred for 0.5 h at room temperature. To the above
was added NaBH.sub.3CN (22 mg, 0.35 mmol, 2.20 equiv). The
resulting solution was allowed to react, with stirring, for an
additional 4 h at room temperature. The resulting mixture was
concentrated under vacuum. The pH value of the solution was
adjusted to 8 with sodium bicarbonate. aq. The resulting solution
was extracted with 3.times.20 mL of ethyl acetate and the organic
layers combined. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (100 mg)
was purified by Prep-HPLC with the following conditions (1#-Waters
2767-3): Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase,
water with 0.05% TFA and CH.sub.3CN (22% CH.sub.3CN up to 38% in 6
min); Detector, Waters2545 UvDector 254&270 nm. 51.5 mg product
was obtained. This resulted in 51.5 mg (42%) of
(S)--N1-(2-(4-(dimethylcarbamoyl)piperidin-1-yl)ethyl)-N1-methyl-N3-(4-(p-
iperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2--
yl)phenyl)isophthalamide as a light yellow solid. LC-MS (ES, m/z):
770[M+H].sup.+ H-NMR (400 MHz, DMSO, ppm): 12.26 (s, 1H),
9.18.about.9.16 (m, 2H), 8.90.about.8.88 (d, J=3.9 Hz, 1H),
8.32.about.8.25 (m, 2H), 8.02.about.7.98 (t, 2H), 7.88.about.7.87
(d, J=3.9 Hz, 1H), 7.71.about.7.64 (m, 2H), 7.60 (s, 1H), 7.28 (s,
1H), 7.20.about.7.10 (m, 4H), 5.26 (s, 1H), 3.85 (s, 11H),
3.38.about.3.30 (m, 8H), 3.04 (s, 5H), 2.96 (s, 5H),
2.83.about.2.78 (m, 5H), 2.00.about.1.91 (m, 4H), 1.86.about.1.72
(m, 9H), 1.60.about.1.59 (d, J=3.3 Hz, 2H).
Example 219
(S)-tert-butyl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)-1,4-diazepane-1-
-carboxylate
##STR00392##
[0934] This compound was prepared according to the procedure
described for the synthesis of Example 187 using tert-butyl
1,4-diazepane-1-carboxylate in place of L-proline-tert-butyl ester.
Into a 50-mL round-bottom flask, was placed a solution of
(S)--N1-methyl-N1-(2-oxoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetra-
hydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(100 mg, 0.16 mmol, 1.00 equiv) in ethanol (5 mL), tert-butyl
1,4-diazepane-1-carboxylate (50 mg, 0.25 mmol, 1.57 equiv), acetic
acid (20 mg, 0.33 mmol, 2.10 equiv). The resulting solution was
stirred for 0.5 h at room temperature. To the above was added
NaBH.sub.3CN (20 mg, 0.32 mmol, 2.00 equiv). The resulting solution
was allowed to react, with stirring, for an additional 3 h at room
temperature. The resulting mixture was concentrated under vacuum.
The pH value of the solution was adjusted to 8-9 with sodium
bicarbonate. The resulting solution was extracted with 3.times.20
mL of ethyl acetate and the organic layers combined. The mixture
was dried over anhydrous sodium sulfate and concentrated under
vacuum. The crude product (100 mg) was purified by Prep-HPLC with
the following conditions (1#-Waters 2767-3): Column, SunFire Prep
C18, 19*150 mm 5 um; mobile phase, water with 0.05% TFA and
CH.sub.3CN (25% CH.sub.3CN up to 43% in 6 min); Detector,
Waters2545 UvDector 254&270 nm. 60.2 mg product was obtained.
This resulted in 60.2 mg (47%) of (S)-tert-butyl
4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)-1,4-diazepane-1-
-carboxylate as a light yellow solid. LC-MS (ES, m/z): 814
[M+H].sup.+ H-NMR (300 MHz, DMSO, ppm): 12.23 (s, 1H), 9.38 (s,
1H), 9.18 (d, J=8.4 Hz, 1H), 8.88 (d, J=5.1 Hz, 1H), 8.31 (s, 1H),
8.23 (d, J=7.8 Hz, 1H), 7.98 (d, J=6.3 Hz, 2H), 7.85 (d, J=5.1 Hz,
1H), 7.68-7.56 (m, 3H), 7.28-7.12 (m, 5H), 5.25 (d, J=6.0 Hz, 1H),
3.82-3.46 (m, 12H), 3.30 (s, 3H), 2.96-2.51 (m, 2H), 2.07-1.99 (m,
4H), 1.83-1.72 (m, 6H), 1.59 (d, J=4.2 Hz, 1H), 1.42 (s, 9H).
Example 220
(S)--N1-methyl-N1-(2-(4-(methylsulfonyl)-1,4-diazepan-1-yl)ethyl)-N3-(4-(p-
iperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2--
yl)phenyl)isophthalamide
##STR00393##
[0935] Example 220
[0936] Into a 50-mL round-bottom flask, was placed a solution of
(S)--N1-(2-(1,4-diazepan-1-yl)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(-
4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophtha-
lamide (150 mg, 0.21 mmol, 1.00 equiv) in dichloromethane (5 mL),
methanesulfonyl chloride (40 mg, 0.35 mmol, 1.50 equiv),
triethylamine (43 mg, 0.43 mmol, 2.00 equiv). The resulting
solution was stirred for 1 h at room temperature. The resulting
mixture was washed with 1.times.20 mL of water. The mixture was
dried over anhydrous sodium sulfate and concentrated under vacuum.
The crude product (120 mg) was purified by Prep-HPLC with the
following conditions (1#-Waters 2767-3): Column, SunFire Prep C18,
19*150 mm 5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN
(25% CH.sub.3CN up to 36% in 6 min); Detector, Waters2545 UvDector
300&270 nm. 43.5 mg product was obtained. This resulted in 43.5
mg (18%) of
(S)--N1-methyl-N1-(2-(4-(methylsulfonyl)-1,4-diazepan-1-yl)ethyl)-N3-(4-(-
piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)isophthalamide as a yellow solid. LCMS (ES, m/z): 792
[M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD, ppm): 8.94 (m, 1H), 8.68
(m, 1H), 8.39 (s, 1H), 8.12 (m, 3H), 7.86 (m, 1H), 7.77 (m, 3H),
7.25 (m, 1H), 7.17 (m, 3H), 5.38 (m, 1H), 3.99 (m, 2H), 3.56 (m,
14H), 3.11 (s, 3H), 2.91 (s, 3H), 2.86 (m, 2H), 2.28 (m, 2H), 2.02
(m, 8H), 1.81 (m, 2H).
Example 221
5-{2-[N-methyl-1-(3-{[4-(piperidin-1-yl)-2-(4-{[(1S)-1,2,3,4-tetrahydronap-
hthalen-1-yl]carbamoyl}pyridin-2-yl)phenyl]carbamoyl}phenyl)formamido]ethy-
l}-2,8,11,14-tetraoxa-5-azaheptadecan-17-oic acid
##STR00394## ##STR00395##
[0937] Intermediate 221c
[0938] Into a 50-mL sealed tube, was placed tert-butyl
3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (3 g, 6.94
mmol, 1.00 equiv), 2-methoxyethanamine (30 mL). The resulting
solution was stirred overnight at 50.degree. C. The resulting
mixture was concentrated under vacuum. The resulting solution was
diluted with 200 mL of ethyl acetate. The resulting mixture was
washed with 2.times.200 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 2 g (86%) of 221c as light yellow oil.
Intermediate 221d
[0939] Into a 50-mL round-bottom flask, was placed a solution of
(S)--N1-methyl-N1-(2-oxoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetra-
hydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(200 mg, 0.32 mmol, 1.00 equiv) in ethanol (4 mL), amine 221c (160
mg, 0.48 mmol, 1.50 equiv), acetic acid (34 mg, 0.71 mmol, 2.20
equiv). The mixture was stirred overnight at room temperature. To
the above was added NaBH.sub.3CN (44 mg, 0.70 mmol, 2.20 equiv).
The resulting solution was stirred for 1 h at room temperature. The
reaction was then quenched by the addition of 20 ml of water. The
resulting solution was extracted with 2.times.100 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 2.times.100 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. This
resulted in 300 mg (100%) 221d as yellow oil.
Example 221
[0940] Into a 50-mL round-bottom flask, was placed a solution of
221d (100 mg, 0.11 mmol, 1.00 equiv) in dichloromethane (3 mL),
trifluoroacetic acid (1.5 mL). The resulting solution was stirred
for 2 h at room temperature. The resulting mixture was concentrated
under vacuum. The crude product (100 mg) was purified by Prep-HPLC
with the following conditions (1#-Waters 2767-3): Column, SunFire
Prep C18, 19*150 mm 5 um; mobile phase, water with 0.05% TFA and
CH.sub.3CN (25% CH.sub.3CN up to 37% in 6 min); Detector,
Waters2545 UvDector 254&270 nm. 46.6 mg product was obtained.
This resulted in 46.6 mg (39%) Example 221 as a yellow solid. LC-MS
(ES, m/z): 893 [M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD ppm): 8.94
(d, J=5.1 Hz, 1H), 8.67 (d, J=9 Hz, 1H), 8.40 (s, 1H),
8.15.about.8.16 (m, 2H), 8.06.about.8.11 (m, 1H), 7.86.about.7.87
(m, 1H), 7.78.about.7.85 (m, 2H), 7.63.about.7.67 (m, 1H),
7.14.about.7.28 (m, 4H), 5.39.about.5.40 (m, 1H), 3.99 (s, 4H),
3.84 (s, 1H), 3.57.about.3.64 (m, 20H), 3.44 (s, 3H), 3.14 (s, 3H),
2.84.about.2.91 (m, 2H), 2.52 (t, J=6 Hz, 2H), 2.14.about.2.17 (m,
1H), 2.03.about.2.07 (m, 7H), 1.96.about.2.00 (m, 2H).
Example 222
(S)--N1-(14-azido-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N3-(4-(diethylam-
ino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)-
-N1-methylisophthalamide
##STR00396##
[0941] Intermediate 222a
[0942] Into a 250-mL round-bottom flask, was placed a solution of
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (3 g, 13.75 mmol,
1.00 equiv) in tetrahydrofuran (100 mL), triethylamine (4.17 g,
41.21 mmol, 3.00 equiv). This was followed by the addition of
di-tert-butyl dicarbonate (9 g, 41.24 mmol, 3.00 equiv), in
portions at 0.degree. C. The resulting solution was stirred
overnight at 25.degree. C. The mixture was concentrated under
vacuum. The resulting solution was diluted with 100 mL of
dichloromethane. The resulting mixture was washed with 2.times.100
mL of Brine. The mixture was dried over anhydrous sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:1). This
resulted in 4 g (91%) of tert-butyl
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethylcarbamate as colorless
oil.
Intermediate 222b
[0943] Into a 100-mL 3-necked round-bottom flask, was placed a
solution of tert-butyl
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethylcarbamate (3.0 g, 9.43
mmol, 1.00 equiv) in N,N-dimethylformamide (40 mL). This was
followed by the addition of sodium hydride (876 mg, 21.9 mmol, 2.00
equiv, 60%), in portions at 0.degree. C. in 5 min. The resulting
solution was stirred for 0.5 h at 0.degree. C. To this was added
iodomethane (16.2 g, 114.08 mmol, 10.00 equiv) dropwise with
stirring at 0.degree. C. in 20 min. The resulting solution was
stirred for 18 h at room temperature. The resulting mixture was
concentrated under vacuum. The resulting solution was diluted with
50 mL of dichloromethane. The resulting mixture was washed with
2.times.20 mL of water. The resulting mixture was washed with
2.times.20 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. This resulted in 2200 mg
(70%) of tert-butyl
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl(methyl)carbamate as
yellow oil.
Intermediate 222c
[0944] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl(methyl)carbamate (2200
mg, 6.63 mmol, 1.00 equiv) in dichloromethane (5 mL). This was
followed by the addition of 2,2,2-trifluoroacetic acid (3 mL)
dropwise with stirring at 0.degree. C. The resulting solution was
stirred for 1 h at 25.degree. C. in an oil bath. The resulting
mixture was concentrated under vacuum. The resulting solution was
diluted with 5 mL of methanol. The pH value of the solution was
adjusted to 12 with sodium hydroxide (0.5 mol/L). The resulting
mixture was concentrated under vacuum. The residue was dissolved in
10 mL of dichloromethane. The solids were filtered out. The
resulting mixture was concentrated under vacuum. This resulted in
1230 mg (80%) of
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N-methylethanamine as yellow
oil. LC-MS (ES, m/z) 233 [M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD,
ppm): 3.78-3.74 (m, 2H), 3.70-3.67 (m, 10H), 3.42-3.39 (m, 2H),
3.23-3.20 (m, 2H), 2.74 (s, 3H).
Example 222
[0945] Into a 100-mL round-bottom flask, was placed a solution of
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenyl)-N3-formyl-N3-(2-oxoethyl)isophthalamide (160
mg, 0.27 mmol, 1.00 equiv) in ethanol (3 mL),
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N-methylethanamine (90 mg,
0.39 mmol, 1.50 equiv), acetic acid (27 mg, 0.56 mmol, 2.20 equiv).
The resulting solution was stirred overnight at room temperature.
To the above was added NaBH.sub.3CN (36 mg, 0.57 mmol, 2.20 equiv).
The resulting solution was stirred for 2 h at room temperature. The
mixture was concentrated under vacuum. The crude product (160 mg)
was purified by Prep-HPLC with the following conditions (1#-Waters
2767-3): Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase,
water with 0.05% TFA and CH.sub.3CN (hold 30% CH.sub.3CN in 6 min);
Detector, Waters2545 UvDector 254&270 nm. 20 mg product was
obtained. This resulted in 20 mg (6%) of
(S)--N1-(14-azido-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N3-(4-(diethyla-
mino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl-
)-N1-methylisophthalamide as a yellow solid. LC-MS (ES, m/z): 834
[M+H].sup.+ H-NMR (400 MHz, CD.sub.3OD, ppm): 8.806 (s, 1H), 8.515
(d, J=8.4 Hz, 1H), 8.246 (s, 1H), 7.987.about.8.032 (m, 2H),
7.734.about.7.767 (m, 2H), 7.600.about.7.676 (m, 2H), 7.369 (d, J=8
Hz, 1H), 7.146 (d, J=7.2 Hz, 1H), 7.016.about.7.067 (m, 3H), 5.258
(t, J=5.6 Hz, 1H), 3.883 (s, 1H), 3.808 (s, 2H), 3.544.about.3.599
(m, 8H), 3.514 (s, 10H), 3.209.about.3.244 (m, 8H), 3.000 (d, J=8.8
Hz, 6H), 2.716.about.2.783 (m, 2H), 1.775.about.2.039 (m, 4H),
1.558 (d, J=6.8 Hz, 1H), 1.113 (t, J=6.8 Hz, 6H).
Example 223
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl-
)pyridin-2-yl)phenyl)-N3-methyl-N3-(17-methyl-1-morpholino-4-oxo-8,11,14-t-
rioxa-3,5,17-triazanonadecan-19-yl)isophthalamide
##STR00397## ##STR00398##
[0946] Intermediate 223a
[0947] Into a 100-mL round-bottom flask, was placed a solution of
(S)--N1-(14-azido-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N3-(4-(diethyla-
mino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl-
)-N1-methylisophthalamide (500 mg, 0.60 mmol, 1.00 equiv) in
tetrahydrofuran/water (20/2 mL), triphenylphosphine (350 mg, 1.34
mmol, 2.23 equiv). The resulting solution was stirred overnight at
40.degree. C. The resulting mixture was concentrated under vacuum.
The residue was applied onto a silica gel column with
dichloromethane:methanol (10:1). This resulted in 350 mg (72%) of
(S)--N1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N3-(4-(diethyla-
mino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl-
)-N1-methylisophthalamide as a yellow solid.
Intermediate 223b
[0948] Into a 100-mL round-bottom flask, was placed a solution of
(S)--N1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N3-(4-(diethyla-
mino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl-
)-N1-methylisophthalamide (300 mg, 0.37 mmol, 1.00 equiv) in
dichloromethane (30 mL), triethylamine (112.5 mg, 1.11 mmol, 3.00
equiv), 4-nitrophenyl carbonochloridate (74.6 mg, 0.37 mmol, 1.00
equiv). The resulting solution was stirred overnight at room
temperature. The resulting mixture was washed with 2.times.30 mL of
brine. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. This resulted in 320 mg (89%) of
(S)-4-nitrophenyl
1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethyl-1-oxo-8,11,14-trioxa-2,5--
diazahexadecan-16-ylcarbamate as a yellow solid.
Example 223
[0949] Into a 25-mL round-bottom flask, was placed a solution of
(S)-4-nitrophenyl
1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethyl-1-oxo-8,11,14-trioxa-2,5--
diazahexadecan-16-ylcarbamate (200 mg, 0.21 mmol, 1.00 equiv) in
acetonitrile (5 mL). This was followed by the addition of
2-morpholinoethanamine (26 mg, 0.20 mmol, 0.97 equiv) and
4-dimethylaminopyridine (38 mg, 0.31 mmol, 1.51 equiv). The
resulting solution was stirred for 4 h at 80.degree. C. in an oil
bath. The resulting mixture was concentrated under vacuum. The
crude product (200 mg) was purified by Prep-HPLC with the following
conditions (1#-PreP-HPLC-001(SHIMADZU)): Column, SunFire Prep C18,
19*150 mm 5 um; mobile phase, CH3CN and water with 0.05% TFA (20%
CH3CN up to 35% in 6 min, up to 100% in 1 min, down to 20% in 0.7
min); Detector, Waters2545 UvDector 254&220 nm. This resulted
in 80.3 mg (28%) of
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenyl)-N3-methyl-N3-(17-methyl-1-morpholino-4-oxo-8,11,14--
trioxa-3,5,17-triazanonadecan-19-yl)isophthalamide as yellow oil.
LC-MS (ES, m/z): 965 [M+H].sup.+ H-NMR (300 MHz, CD3OD, ppm): 8.899
(d, J=5.1 Hz, 1H), 8.304 (s, 1H), 8.080.about.8.109 (m, 2H),
7.815.about.7.837 (m, 1H), 7.707.about.7.755 (m, 3H),
7.188.about.7.196 (m, 2H), 7.130.about.7.175 (m, 3H),
5.348.about.5.389 (m, 1H), 3.916.about.3.993 (m, 6H),
3.500.about.3.715 (m, 22H), 3.209.about.3.482 (m, 2H), 3.110 (d,
J=6.3 Hz, 6H), 2.837.about.2.911 (m, 3H), 2.131.about.2.200 (m,
1H), 1.204.about.1.251 (m, 6H).
Example 224
(S)--N1-(1-amino-14-methyl-1-oxo-5,8,11-trioxa-2,14-diazahexadecan-16-yl)--
N3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyri-
din-2-yl)phenyl)-N1-methylisophthalamide
##STR00399##
[0951] This compound was prepared according to the procedure
described for the synthesis of
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenyl)-N3-methyl-N3-(17-methyl-1-morpholino-4-oxo-8,11,14--
trioxa-3,5,17-triazanonadecan-19-yl)isophthalamide Example 223
substituting ammonia in methanol in place of
2-morpholinoethanamine. Into a 100-mL round-bottom flask, was
placed a solution of (S)-4-nitrophenyl
1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethyl-1-oxo-8,11,
14-trioxa-2,5-diazahexadecan-16-ylcarbamate (100 mg, 0.10 mmol,
1.00 equiv) in NMP (5 mL), methanol (saturated with NH.sub.3) (5
mL). The resulting solution was stirred for 3 h at room
temperature. The resulting mixture was washed with 2.times.30 mL of
water. The resulting mixture was concentrated under vacuum. The
crude product (100 mg) was purified by Prep-HPLC with the following
conditions (1#-PreP-HPLC-001(SHIMADZU)): Column, SunFire Prep C18,
19*150 mm 5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN
(22% CH.sub.3CN up to 38% in 6 min, up to 100% in 1 min, down to
22% in 0.7 min); Detector, Waters2545 UvDector 254&220 nm. This
resulted in 26 mg (21%) of
(S)--N1-(1-amino-14-methyl-1-oxo-5,8,11-trioxa-2,14-diazahexadecan-6-yl)--
N3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyri-
din-2-yl)phenyl)-N1-methylisophthalamide as yellow oil. LC-MS (ES,
m/z): 851[M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD, ppm):
8.96.about.8.94 (d, J=5.1 Hz, 1H), 8.71.about.8.68 (m, 1H), 8.38
(s, 1H), 8.16.about.8.12 (m, 2H), 7.88 (s, 1H), 7.87.about.7.86 (m,
1H), 7.78.about.7.73 (m, 2H), 7.58.about.7.54 (m, 1H),
7.25.about.7.15 (m, 4H), 5.39 (s, 1H), 3.93 (s, 5H),
3.76.about.3.61 (m, 12H), 3.57.about.3.48 (m, 3H), 3.27.about.3.23
(m, 2H), 3.13.about.3.09 (m, 5H), 2.91.about.2.84 (m, 3H),
2.05.about.1.91 (m, 5H), 1.31.about.1.22 (m, 6H).
Example 225
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl-
)pyridin-2-yl)phenyl)-N3-(1-hydroxy-3-(2-hydroxyethyl)-17-methyl-4-oxo-8,1-
1,14-trioxa-3,5,17-triazanonadecan-19-yl)-N3-methylisophthalamide
##STR00400##
[0953] This compound was prepared according to the procedure
described for the synthesis of
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenyl)-N3-methyl-N3-(17-methyl-1-morpholino-4-oxo-8,11,14--
trioxa-3,5,17-triazanonadecan-19-yl)isophthalamide Example 223
substituting 2,2'-azanediyldiethanol in place of
2-morpholinoethanamine. Into a 100-mL round-bottom flask, was
placed a solution of (S)-4-nitrophenyl
1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethyl-1-oxo-8,11,14-trioxa-2,5--
diazahexadecan-16-ylcarbamate (150 mg, 0.15 mmol, 1.00 equiv) in
acetonitrile (10 mL), 2,2'-azanediyldiethanol (20 mg, 0.19 mmol,
1.24 equiv), 4-dimethylaminopyridine (28 mg, 0.23 mmol, 1.49
equiv). The resulting solution was stirred for 4 h at 80.degree. C.
in an oil bath. The resulting mixture was concentrated under
vacuum. The residue was dissolved in 20 mL of dichloromethane. The
resulting mixture was washed with 2.times.30 mL of NH.sub.4Cl (aq).
The mixture was dried over sodium sulfate and concentrated under
vacuum. The crude product (150 mg) was purified by Prep-HPLC with
the following conditions (1#-PreP-HPLC-001(SHIMADZU)): Column,
SunFire Prep C18, 19*150 mm 5 um; mobile phase, CH.sub.3CN and
water with 0.05% TFA (22% CH.sub.3CN to 38% in 6 min, up to 100% in
1 min, down to 22% in 0.7 min); Detector, Waters2545 UvDector
254&220 nm. This resulted in 11.7 mg (6%) of
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenyl)-N3-(1-hydroxy-3-(2-hydroxyethyl)-17-methyl-4-oxo-8,-
11,14-trioxa-3,5,17-triazanonadecan-19-yl)-N3-methylisophthalamide
as yellow oil. LC-MS (ES, m/z): 939 [M+H].sup.+ H-NMR (300 MHz,
CD.sub.3OD, ppm) 8.96.about.8.94 (d, J=5.1 Hz, 1H), 8.74.about.8.72
(m, 1H), 8.39 (s, 1H), 8.17.about.8.12 (m, 2H), 7.89.about.7.87 (m,
2H), 7.78.about.7.73 (m, 2H), 7.61.about.7.56 (m, 1H), 7.25 (s,
1H), 7.18.about.7.16 (m, 3H), 5.41.about.5.37 (m, 1H),
4.05.about.3.92 (m, 4H), 3.80.about.3.39 (m, 26H), 3.13.about.3.10
(m, 6H), 2.94.about.2.9 (m, 3H), 2.19.about.1.86 (m, 4H),
1.26.about.1.22 (m, 6H).
Example 226
3-N-[4-(diethylamino)-2-(4-{[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbam-
oyl}pyridin-2-yl)phenyl]-1-N-(1-methanesulfonamido-12-methyl-3,6,9-trioxa--
12-azatetradecan-14-yl)-1-N-methylbenzene-1,3-dicarboxamide
##STR00401##
[0954] Example 266
[0955] Into a 50-mL round-bottom flask, was placed a solution of
(S)--N1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N3-(4-(diethyla-
mino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl-
)-N1-methylisophthalamide (40 mg, 0.05 mmol, 1.00 equiv) in
dichloromethane (2 mL), methanesulfonyl chloride (8.5 mg, 0.07
mmol, 1.50 equiv), triethylamine (10 mg, 0.10 mmol, 2.00 equiv).
The resulting solution was stirred for 1 h at room temperature. The
resulting solution was diluted with 10 mL of dichloromethane. The
resulting mixture was washed with 1.times.20 mL of water and
1.times.20 mL of brine. The mixture was dried over sodium sulfate
and concentrated under vacuum. The crude product (50 mg) was
purified by Prep-HPLC with the following conditions
(1#-PreP-HPLC-001(SHIMADZU)): Column, SunFire Prep C18, 19*150 mm 5
um; mobile phase, CH.sub.3CN and water with 0.05% TFA (22%
CH.sub.3CN up to 38% in 6 min, up to 100% in 1 min, down to 22% in
0.7 min); Detector, Waters2545 UvDector. This resulted in 29 mg
(48%) of
3-N-[4-(diethylamino)-2-(4-{[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carba-
moyl}pyridin-2-yl)phenyl]-1-N-(1-methanesulfonamido-12-methyl-3,6,9-trioxa-
-12-azatetradecan-14-yl)-1-N-methylbenzene-1,3-dicarboxamide,
Example 226 as brown oil. LC-MS (ES, m/z): 886 [M+H].sup.+ H-NMR
(300 MHz, CD.sub.3OD, ppm): 8.94.about.8.92 (d, J=5.1 Hz, 1H), 8.60
(s, 1H), 8.35 (s, 1H), 8.15.about.8.10 (m, 2H), 7.86.about.7.70 (m,
4H), 7.41 (s, 1H), 7.27.about.7.25 (m, 1H), 7.20.about.7.16 (m,
3H), 5.40.about.5.36 (m, 1H), 3.94 (s, 5H), 3.73.about.3.62 (m,
12H), 3.58.about.3.54 (m, 3H), 3.24.about.3.21 (t, 3H),
3.21.about.3.08 (m, 6H), 2.95 (s, 3H), 2.91.about.2.86 (m, 2H),
2.21.about.1.85 (m, 5H), 1.26.about.1.21 (t, 6H).
Example 227
(S)--N1-(2-(4-2,5,8,11,14,17,20,23-octaoxapentacosanepiperazin-1-yl)ethyl)-
-N3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyr-
idin-2-yl)phenyl)-N1-methylisophthalamide
##STR00402##
[0957] This compound was prepared according to the scheme for the
synthesis of Example 213 substituting 212b in place of 213c. Into a
50-mL round bottom flask, was placed a solution of
N1-(2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(diethylamino)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthalami-
de (100 mg, 0.15 mmol, 1.00 equiv) in dichloromethane (10 mL),
EDC.HCl (43 mg, 0.22 mmol, 1.50 equiv), 4-dimethylaminopyridine
(35.5 mg, 0.29 mmol, 2.00 equiv),
2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)e-
thoxy)acetic acid 213b (70 mg, 0.18 mmol, 1.21 equiv). The
resulting solution was stirred for 2 h at room temperature. The
resulting mixture was washed with 5.times.20 mL of NH.sub.4Cl. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. The crude product (100 mg) was purified by Prep-HPLC
with the following conditions (1#-Waters 2767-3): Column, Xbridge
Prep C18, 5 um, 19*100 mm; mobile phase, water with 0.05% TFA and
CH.sub.3CN (5% CH.sub.3CN up to 48% in 1 min, up to 59% in 5 min);
Detector, Waters2545 UV Detector 254&270 nm. 58 mg product was
obtained. This resulted in 58 mg (37%) of
(S)--N1-(2-(4-2,5,8,11,14,17,20,23-octaoxapentacosanepiperazin-1-yl)ethyl-
)-N3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)py-
ridin-2-yl)phenyl)-N1-methylisophthalamide as yellow oil. LC-MS
(ES, m/z): 1068 [M+H].sup.+ H-NMR (400 MHz, CD.sub.3OD, ppm): 8.94
(s, 1H), 8.38 (m, 1H), 8.17 (s, 1H), 8.13 (m, 2H), 7.95 (m, 1H),
7.87-7.79 (m, 3H), 7.74 (m, 1H), 7.27-7.14 (m, 4H), 5.40 (t, 1H),
4.30-4.0 (m, 7H), 3.7-3.6 (m, 46H), 3.35 (m, 4H), 3.13 (s, 3H),
2.87 (m, 2H), 2.16-1.92 (m, 4H), 1.30-1.22 (m, 6H).
Example 228
(S)--N1-(2-(4-2,5,8,11,14,17,20,23-octaoxapentacosanepiperazin-1-yl)ethyl)-
-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylc-
arbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00403##
[0958] Intermediate 228a
[0959] Into a 100-mL round-bottom flask, was placed a solution of
3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(piperidin-1-yl)phenyl)carbamoyl)benzoic acid (2 g, 3.48 mmol,
1.00 equiv) in dichloromethane (20 mL), EDC.HCl (1 g, 5.22 mmol,
1.50 equiv), 4-dimethylaminopyridine (640 mg, 5.25 mmol, 1.51
equiv), tert-butyl 4-(2-(methylamino)ethyl)piperazine-1-carboxylate
(1.02 g, 4.20 mmol, 1.21 equiv). The resulting solution was stirred
for 3 h at room temperature. The resulting mixture was washed with
3.times.20 mL of NH.sub.4Cl (aq). The mixture was dried over sodium
sulfate and concentrated under vacuum. This resulted in 1.5 g (54%)
of tert-butyl
4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carboxylate
as a yellow solid.
Intermediate 228b
[0960] Into a 50-mL round-bottom flask, was placed a solution of
tert-butyl
4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carboxylate
(1.4 g, 1.75 mmol, 1.00 equiv) in dichloromethane (15 mL). To the
above hydrogen chloride (g) was introduced in. The resulting
solution was stirred for 3 h at room temperature. The resulting
mixture was concentrated under vacuum. This resulted in 1.3 g (88%)
of
N1-(2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(piperidin-1-yl)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthala-
mide (4HCl salt) as a yellow solid.
[0961] This compound was prepared according to the procedure
described for the synthesis of Example 227 substituting 228b in
place of 212b. Into a 50-mL round bottom flask, was placed a
solution of
N1-(2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)pyridin-2-yl)--
4-(piperidin-1-yl)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthala-
mide (100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (12 mL),
EDC.HCl (40 mg, 0.20 mmol, 1.49 equiv), 4-dimethylaminopyridine (50
mg, 0.41 mmol, 3.01 equiv),
2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)e-
thoxy)acetic acid 213b (65 mg, 0.16 mmol, 1.20 equiv). The
resulting solution was stirred for 2 h at room temperature. The
resulting mixture was washed with 5.times.20 mL of NH.sub.4Cl. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. The crude product (100 mg) was purified by Prep-HPLC
with the following conditions (1#-Waters 2767-3): Column, Xbridge
Prep C18, 5 um, 19*100 mm; mobile phase, water with 0.05% TFA and
CH.sub.3CN (5% CH3CN up to 48% in 1 min, up to 59% in 5 min);
Detector, Waters2545 UvDector 254&270 nm. 22.5 mg product was
obtained. This resulted in 22.5 mg (15%) of Example 228 as yellow
oil. LC-MS (ES, m/z): 1081 [M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD,
ppm): 8.82 (s, 1H), 8.24 (m, 2H), 8.00 (s, 2H), 7.77 (m, 1H), 7.64
(m, 2H), 7.43 (s, 1H), 7.24 (m, 1H), 7.15-7.07 (m, 4H), 5.34 (m,
1H), 4.23-4.07 (m, 2H), 3.74-3.50 (m, 32H), 3.33 (m, 4H), 3.18-3.02
(m, 7H), 2.83-2.58 (m, 6H), 2.19 (m, 3H), 2.01-1.60 (m, 3H),
1.60-1.58 (m, 6H), 1.30 (m, 1H).
Example 229
tert-butyl
3-[2-(2-{2-[methyl(4-{2-[N-methyl-1-(3-{[4-(piperidin-1-yl)-2-(-
4-{[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl}pyridin-2-yl)phenyl]c-
arbamoyl}phenyl)formamido]ethyl}piperazin-1-yl)carbonylamino]ethoxy}ethoxy-
)ethoxy]propanoate
##STR00404##
[0963] This compound was prepared according to the procedure
described for the synthesis of Example 207 substituting 228b in
place of 207b. Into a 100-mL round-bottom flask, was placed a
solution of 4-nitrophenyl
4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carboxylate
(1.34 g, 1.55 mmol, 1.00 equiv) in acetonitrile (1 mL), tert-butyl
3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate 135c (900
mg, 3.09 mmol, 1.99 equiv), 4-dimethylaminopyridine (189 mg, 1.55
mmol, 1.00 equiv). The resulting solution was heated to reflux
overnight. The resulting mixture was concentrated under vacuum. The
residue was dissolved in 30 mL of dichloromethane. The resulting
mixture was washed with 3.times.30 mL of NH.sub.4Cl (aq) and
5.times.30 mL of water. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. This resulted in 1.4 g of
crude product and 1.3 g was added to the next step. The crude
product (100 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (31%
CH.sub.3CN up to 46% in 5 min); Detector, Waters2545 UvDector
254&270 nm. 50.2 mg product was obtained. This resulted in 1.3
g (82%) of tert-butyl
3-(2-(2-(2-(1-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)-N-methylpiperazi-
ne-4-carboxamido)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.
LC-MS (ES, m/z): 1039 [M+Na].sup.+. H-NMR (300 MHz, CD.sub.3OD,
ppm): 8.964-8.947 (m, 1H), 8.821-8.791 (d, J=9.0 Hz, 1H), 8.418 (s,
1H), 8.192 (s, 1H), 8.145-8.088 (s, 2H), 7.885-7.880 (m, 1H),
7.867-7.862 (m, 1H), 7.786-7.662 (m, 2H), 7.225 (m, 1H),
7.177-7.158 (m, 3H), 5.425-5.320 (m, 1H), 4.009 (s, 2H),
3.866-3.848 (m, 1H), 3.736-3.433 (m, 30H), 3.124 (s, 3H),
2.987-2.972 (m, 3H), 2.909-2.862 (m, 2H), 2.519-2.450 (m, 3H),
2.068-1.809 (m, 10H), 1.473-1.448 (m, 13H).
Example 230
(S)-2,5,8,11,14,17,20-heptaoxadocosan-22-yl
4-(2-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carbo-
xylate
##STR00405##
[0965] This compound was prepared according to the procedure
described for the synthesis of Example 214 substituting 212b in
place of 213c. Into a 8-mL sealed tube, was placed a solution of
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenyl)-N3-methyl-N3-(2-(piperazin-1-yl)ethyl)isophthalamid-
e (150 mg, 0.22 mmol, 1.00 equiv) in acetonitrile (5 mL),
2,5,8,11,14,17,20-heptaoxadocosan-22-yl 4-nitrophenyl carbonate
(165 mg, 0.33 mmol, 1.50 equiv), 4-dimethylaminopyridine (53 mg,
0.43 mmol, 2.00 equiv). The resulting solution was stirred for 5 h
at 90.degree. C. in an oil bath. The resulting mixture was
concentrated under vacuum. The resulting solution was diluted with
10 ml of water. The resulting solution was extracted with
3.times.30 mL of dichloromethane and the organic layers combined.
The resulting mixture was washed with 3.times.30 mL of NH.sub.4Cl
aq. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The crude product (100 mg) was purified
by Prep-HPLC with the following conditions
(1#-UV1-SHIMADZU-SPD-20A): Column, SunFire Prep C18, 19*150 mm 5
um; mobile phase, water with 0.05% TFA and CH.sub.3CN (30%
CH.sub.3CN up to 50% in 6 min); Detector, Waters2545 UvDector
254&220 nm. 85.6 mg product was obtained. This resulted in 85.6
mg (28%) of (S)-2,5,8,11,14,17,20-heptaoxadocosan-22-yl
4-(2-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazine-1-carbo-
xylate as a yellow solid.
[0966] LC-MS (ES, m/z): 1055 [M+H].sup.+ H-NMR (300 MHz,
CD.sub.3OD, ppm): 8.92 (d, J=5.1 Hz, 1H), 8.60 (s, 1H), 8.35 (s,
1H), 8.13 (t, J=7.5 Hz, 2H), 7.69-7.85 (m, 4H), 7.44-7.46 (m, 1H),
7.26 (d, J=6.6 Hz, 1H), 7.14-7.19 (m, 3H), 5.38 (s, 1H), 4.26-4.86
(m, 3H), 3.99 (s, 2H), 3.63-3.74 (m, 31H), 3.52-3.61 (m, 6H),
3.31-3.34 (m, 5H), 3.09-3.12 (m, 3H), 2.84-2.91 (m, 2H), 1.90-1.97
(m, 4H), 1.21-1.26 (m, 6H).
Example 231
3-N-[4-(diethylamino)-2-(4-{[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbam-
oyl}pyridin-2-yl)phenyl]-1-N-(2-{4-[(2-{2-[2-(3-{4-[2-(2-hydroxyethoxy)eth-
yl]piperazin-1-yl}-3-oxopropoxy)ethoxy]ethoxy}ethyl)(methyl)carbamoyl]pipe-
razin-1-yl}ethyl)-1-N-methylbenzene-1,3-dicarboxamide
##STR00406##
[0967] Intermediate 231a
[0968] Into a 50-mL round-bottom flask, was placed a solution of
(S)-tert-butyl
1-(4-(2-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazin-1-yl)-
-2-methyl-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate (200 mg, 0.20
mmol, 1.00 equiv) in dichloromethane (10 mL), trifluoroacetic acid
(2 mL). The resulting solution was stirred for 2 h at room
temperature. The reaction progress was monitored by LCMS. The
resulting mixture was concentrated under vacuum. The crude product
(0.1 g) was purified by Prep-HPLC with the following conditions
(1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm 5 um;
mobile phase, water with 0.05% TFA and CH.sub.3CN (23% CH.sub.3CN
up to 35% in 6 min); Detector, Waters2545 UvDector 254&270 nm.
20 mg product was obtained. This resulted in 18.1 mg (7%) of
Example 231a as a yellow solid.
[0969] LC-MS (ES, m/z): 950[M+H].sup.+ H-NMR (300 MHz, DMSO, ppm):
11.88 (s, 1H), 9.56 (s, 1H), 9.15 (m, 1H), 8.87 (m, 1H), 8.25 (m,
2H), 8.12 (m, 2H), 7.97 (m, 1H), 7.83 (m, 2H), 7.67 (m, 5H), 5.23
(m, 1H), 2.37-2.73 (m, 32H), 2.45 (m, 3H), 1.81 (m, 5H), 1.23 (m,
6H).
Example 231
[0970] Into a 50-mL sealed tube, was placed a solution of
(S)-1-(4-(2-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylc-
arbamoyl)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazin-1-
-yl)-2-methyl-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic acid (1000
mg, 0.32 mmol, 1.00 equiv, 30%) in dichloromethane (20 mL),
2-(2-(piperazin-1-yl)ethoxy)ethanol (110 mg, 0.63 mmol, 2.00
equiv), EDC.HCl (120 mg, 0.63 mmol, 2.00 equiv),
4-dimethylaminopyridine (38 mg, 0.31 mmol, 1.00 equiv). The
resulting solution was stirred for two days at room temperature.
The resulting solution was diluted with 30 mL of dichloromethane.
The resulting mixture was washed with 4.times.50 mL of NH.sub.4Cl
aq. The resulting mixture was concentrated under vacuum. The crude
product (100 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 5 um,
19*150 mm; mobile phase, water with 0.05% TFA and CH.sub.3CN (25%
CH.sub.3CN up to 40% in 6 min); Detector, UV 220&254 nm. This
resulted in 9.8 mg (2%) of Example 231 as a yellow solid. LC-MS
(ES, m/z): 1106 [M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD, ppm):
8.94-8.95 (d, J=3 Hz, 1H), 8.70-8.72 (d, 1H), 8.38 (s, 1H),
8.11-8.16 (m, 2H), 7.71-7.94 (m, 4H), 7.49-7.51 (d, 1H), 7.19-7.27
(m, 1H), 7.12-7.17 (m, 3H), 5.36-5.40 (m, 1H), 5.45 (m, 1H),
3.82-3.86 (m, 2H), 3.55-3.78 (m, 28H), 3.39-3.41 (m, 7H), 3.11 (s,
3H), 2.97 (s, 3H), 2.83-2.90 (m, 2H), 2.69-2.71 (m, 2H), 1.87-2.23
(m, 4H), 1.21-1.25 (t, 6H).
Example 232
3-N-[4-(diethylamino)-2-(4-{[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbam-
oyl}pyridin-2-yl)phenyl]-1-N-methyl-1-N-(2-{4-[methyl(2-{2-[2-(2-{methyl[2-
S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]carbamoyl}ethoxy)ethoxy]ethoxy}eth-
yl)carbamoyl]piperazin-1-yl}ethyl)benzene-1,3-dicarboxamide
##STR00407##
[0972] This compound was prepared according to the procedure
described for the synthesis of Example 231 substituting
(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol in place of
2-(2-(piperazin-1-yl)ethoxy)ethanol. Into a 8-mL sealed tube, was
placed a solution of
(S)-1-(4-(2-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylc-
arbamoyl)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazin-1-
-yl)-2-methyl-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic acid (100
mg, 0.11 mmol, 1.00 equiv) in dichloromethane (5 mL),
(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol (30 mg, 0.15
mmol, 1.50 equiv), EDC.HCl (40 mg, 0.21 mmol, 2.00 equiv),
4-dimethylaminopyridine (20 mg, 0.16 mmol, 1.50 equiv). The
resulting solution was stirred overnight at room temperature. The
resulting mixture was concentrated under vacuum. The crude product
(100 mg) was purified by Prep-HPLC with the following conditions
(1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm 5 um;
mobile phase, water with 0.05% TFA and CH.sub.3CN (22% CH.sub.3CN
up to 34% in 6 min); Detector, Waters2545 UvDector 254&220 nm.
7.1 mg product was obtained. This resulted in 7.1 mg (5%) of
Example 232 as a Pale-yellow solid. LC-MS (ES, m/z): 1127
[M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD, ppm): 8.94 (d, J=5.1 Hz,
1H), 8.61 (s, 1H), 8.36 (s, 1H), 8.10-8.16 (m, 2H), 7.86 (dd, J=5.1
Hz, 2H), 7.69-7.80 (m, 2H), 7.46-7.49 (m, 1H), 7.14-7.27 (m, 4H),
5.38 (t, J=6.0 Hz, 1H), 4.00 (d, J=6.3 Hz, 3H), 3.41-3.81 (m, 37H),
3.09-3.14 (m, 5H), 2.67-2.97 (m, 10H), 1.91-1.98 (m, 4H), 1.21-1.26
(m, 6H).
Example 233
(S)-1-oxo-1-(3-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-5,8,11-trioxa-
-2-azatetradecan-14-oic acid
##STR00408##
[0974] This compound was prepared according to the procedure
described for the synthesis of Example 10.1 substituting 142a in
place of 4.1c. LC-MS (ES, m/z): 900 [M+H].sup.+. H-NMR (300 MHz,
CD.sub.3OD, ppm): 8.911-8.895 (s, 1H), 8.821-8.791 (d, J=9.0 Hz,
1H), 8.422 (s, 1H), 8.203-8.195 (s, 1H), 7.950 (s, 1H), 7.839-7.811
(m, 3H), 7.756-7.725 (m, 1H), 7.624-7.470 (m, 4H), 7.365-7.314 (m,
1H), 7.246 (s, 1H), 7.143 (s, 3H), 5.377 (s, 1H), 4.326 (s, 2H),
3.715-3.465 (m, 18H), 2.843 (m, 2H), 2.504-2.463 (m, 2H),
2.078-1.836 (s, 4H).
Example 234
(S)-2-(3-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcar-
bamoyl)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)acetic
acid
##STR00409##
[0976] This compound was prepared according to the procedure
described for the synthesis of Example 143 substituting 142a in
place of 143a. LC-MS (ES, m/z): 711.88 [M-2HCl+H].sup.+ H-NMR (300
MHz, DMSO, ppm): 12.69 (s, 1H), 9.28 (s, 1H), 8.95 (d, J=5.1 Hz,
1H), 8.50 (d, J=18.6 Hz, 1H), 7.94-7.90 (m, 2H), 7.78 (d, J=7.8 Hz,
2H), 7.60 (d, J=7.5 Hz, 1H), 7.52-7.46 (m, 1H), 7.24-7.05 (m, 8H),
5.26 (d, J=4.8 Hz, 1H), 4.37 (s, 1H), 2.75 (d, J=13.5 Hz, 1H),
1.98-1.67 (m, 2H).
Example 235
(S)-3-methyl-2-oxo-1-(3-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronap-
hthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-6,9,-
12-trioxa-3-azapentadecan-15-oic acid
##STR00410##
[0978] This compound was prepared according to the procedure
described for the synthesis of Example 144 substituting 142a in
place of 143a. LC-MS (ES, m/z): 928 [M-2HCl+H].sup.+ H-NMR (300
MHz, CDCl.sub.3, ppm): 13.64 (s, 1H), 8.99 (s, 2H), 8.84 (s, 1H),
8.50 (s, 1H), 7.95 (d, J=20.7 Hz, 4H), 7.48.about.7.62 (m, 3H),
7.33 (s, 1H), 7.14.about.7.28 (m, 6H), 5.49 (s, 1H), 4.21 (s, 2H),
3.47.about.3.74 (m, 20H), 2.78.about.3.11 (m, 5H), 2.35.about.2.71
(m, 4H), 1.80.about.2.30 (m, 7H).
Example 236
(S)-2-(2-(3-((3-(15-(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)-3-methyl--
2,15-dioxo-6,9,12-trioxa-3-azapentadecyl)phenylthio)methyl)benzamido)-5-(p-
iperidin-1-yl)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
##STR00411##
[0980] This compound was prepared according to the procedure
described for the synthesis of Example 231 substituting Example 235
in place of 231a. A solution of
(S)-3-methyl-2-oxo-1-(3-(3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydrona-
phthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-6,9-
,12-trioxa-3-azapentadecan-15-oic acid (120 mg, 0.13 mmol, 1.00
equiv) in dichloromethane (5 mL),
2-(2-(piperazin-1-yl)ethoxy)ethanol (33.7 mg, 0.19 mmol, 1.50
equiv), N-(3-dimethylaminopropyl)-N.sub.i.sup.--ethylcarbodiimide
hydrochloride (49.7 mg, 0.26 mmol, 2.00 equiv). The resulting
solution was stirred overnight at room temperature. The resulting
solution was diluted with 50 mL of ethyl acetate. The resulting
mixture was washed with 2.times.20 mL of brine. The mixture was
dried over sodium sulfate and concentrated under vacuum. The crude
product (100 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (30%
CH.sub.3CN up to 42% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 20 mg product was obtained. This resulted in 20 mg
(14%) of
(S)-2-(2-(3-((3-(15-(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)-3-methyl-
-2,15-dioxo-6,9,12-trioxa-3-azapentadecyl)phenylthio)methyl)benzamido)-5-(-
piperidin-1-yl)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamid-
e as a yellow solid. LC-MS (ES, m/z): 1084 [M+H].sup.+ H-NMR (300
MHz, DMSO, ppm): 12.19 (s, 1H), 9.65 (s, 1H), 9.19 (d, J=8.4 Hz,
1H), 8.91 (d, J=15.1 Hz, 1H), 8.28 (d, J=12.9 Hz, 2H), 7.90 (s,
1H), 7.85 (d, J=4.8 Hz, 1H), 7.75 (d, J=7.5 Hz, 1H),
7.44.about.7.57 (m, 8H), 7.10.about.7.22 (m, 8H), 7.01 (d, J=2.4
Hz, 1H), 5.25 (d, J=6.6 Hz, 1H), 4.34 (s, 1H), 4.05 (s, 1H),
3.50.about.3.80 (m, 8H), 3.30.about.3.40 (m, 8H), 1.95 (s, 2H),
1.80 (s, 2H), 1.90.about.2.10 (m, 2H), 1.50.about.1.80 (m, 8H).
Example 237
(S)-1-(3-(4-chloro-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridi-
n-2-yl)phenylcarbamoyl)phenyl)-2-methyl-1-oxo-5,8,11-trioxa-2-azatetradeca-
n-14-oic acid
##STR00412##
[0981] Intermediate 237a
[0982] Into a 100-mL three-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of 2-bromo-4-chlorobenzenamine (10 g, 48.43 mmol, 1.00
equiv) in DMSO (30 mL),
4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)--
1,3,2-dioxaborolane (18.5 g, 72.86 mmol, 1.50 equiv), potassium
acetate (12.2 g, 124.36 mmol, 2.57 equiv), Pd(dppf)Cl.sub.2 (1.1 g,
1.50 mmol, 0.03 equiv). The resulting solution was stirred
overnight at 80.degree. C. in an oil bath. The resulting mixture
was concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:50). This
resulted in 5 g (41%) of
4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine
as a white solid.
[0983] LC-MS (ES, m/z): 254 [M+H].sup.+ H-NMR (400 MHz, CDCl.sub.3,
ppm): 1.51 (s, 12H), 6.53 (d, J=6.6 Hz, 1H), 7.15 (m, 1H), 7.73 (m,
1H).
Intermediate 237b
[0984] Into a 500-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
4-chloro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine
(5.75 g, 22.72 mmol, 1.25 equiv) in dioxane (240 mL),
(S)-2-bromo-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide (6
g, 18.18 mmol, 1.00 equiv), Pd(dppf)Cl.sub.2 (1.81 g, 2.47 mmol,
0.14 equiv), a solution of sodium carbonate (9.6 g, 90.57 mmol,
4.98 equiv) in water (96 mL). The resulting solution was stirred
overnight at 80.degree. C. in an oil bath. The resulting mixture
was concentrated under vacuum. The resulting mixture was diluted
with 50 mL of water. The resulting solution was extracted with
2.times.100 mL of ethyl acetate and the organic layers combined.
The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. The residue was applied onto a silica
gel column with ethyl acetate/petroleum ether (1:5.about.1:2). This
resulted in 3.5 g (48%) of
(S)-2-(2-amino-5-chlorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isoni-
cotinamide as a yellow solid. LC-MS (ES, m/z): 378 [M+H].sup.+
H-NMR (300 MHz, CDCl.sub.3, ppm): 8.72 (d, J=5.1 Hz, 1H), 7.96 (s,
1H), 7.56.about.7.51 (m, 2H), 7.36 (d, J=8.1 Hz, 1H),
7.23.about.7.12 (m, 4H), 6.72 (d, J=8.7 Hz, 1H), 6.48 (d, J=8.1 Hz,
1H), 6.3.about.5.65 (m, 2H), 5.45.about.5.41 (m, 1H),
2.94.about.2.80 (m, 2H), 2.23.about.2.19 (m, 1H), 2.05.about.1.91
(m, 3H).
##STR00413##
Example 237
[0985] This compound was prepared according to the procedure
described for the synthesis of Example 188 substituting 237b in
place of 25b. LC-MS (ES, m/z): 743 [M-HCl+H].sup.+ H-NMR (300 MHz,
CDCl.sub.3, ppm): 13.15 (s, 1H), 0.86 (s, 1H), 8.66 (d, J=8.1 Hz,
1H), 8.24 (s, 1H), 8.07 (m, 2H), 7.828 (s, 1H), 7.821 (s, 1H),
7.75.about.7.56 (m, 2H), 7.54 (d, J=21.3 Hz, 1H), 7.47.about.7.43
(m, 1H), 7.22.about.7.14 (m, 3H), 7.02.about.6.92 (m, 1H),
5.46.about.5.44 (m, 1H), 3.81.about.3.58 (m, 16H), 3.17.about.3.10
(m, 3H), 2.86.about.2.85 (m, 2H), 2.51.about.2.47 (t, 2H),
2.20.about.2.03 (m, 2H), 2.01.about.1.91 (m, 3H).
Example 238
3-{2-[2-(2-{1-[3-({4-chloro-2-[4-({[3-(trifluoromethyl)phenyl]methyl}carba-
moyl)pyridin-2-yl]phenyl}carbamoyl)phenyl]-N-methylformamido}ethoxy)ethoxy-
]ethoxy}propanoic acid
##STR00414##
[0987] This compound was prepared according to the procedure
described for the synthesis of Example 188 substituting 21b in
place of 25b. LC-MS (ES, m/z): 771.30 [M+H].sup.+
Example 239
(S)-1-(3-(3-(4-chloro-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyr-
idin-2-yl)phenylcarbamoyl)benzylthio)phenyl)-3-methyl-2-oxo-6,9,12-trioxa--
3-azapentadecan-15-oic acid
##STR00415##
[0989] This compound was prepared according to the procedure
described for the synthesis of Example 144 substituting 237b in
place of the aniline starting material 4c. (LC-MS (ES, m/z): 879
[M-HCl+H].sup.+ H-NMR (300 MHz, DMSO, ppm): 12.94 (s, 1H), 12.08
(s, 1H), 9.26 (d, J=8.4 Hz, 1H), 8.96 (d, J=5.1 Hz, 1H), 8.60 (d,
J=8.7 Hz, 1H), 8.412 (s, 1H), 8.09 (s, 1H), 8.08.about.7.91 (m,
2H), 7.91 (d, J=7.5 Hz, 1H), 7.61.about.7.48 (m, 3H),
7.22.about.7.13 (m, 2H), 7.01 (d, J=5.1 Hz, 1H), 5.27 (s, 1H), 4.36
(s, 2H), 3.66.about.3.48 (m, 7H), 3.45.about.3.32 (m, 15H), 3.29
(s, 2H), 2.84-2.80 (m, 4H), 2.44.about.2.38 (m, 3H),
2.02.about.1.80 (m, 4H).
Example 240
tert-butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)--
1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)be-
nzamido)ethyl)piperidin-2-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
##STR00416##
[0990] Intermediate 240a
[0991] Into a 100-mL round-bottom flask, was placed a solution of
(S)--N1-methyl-N1-(2-oxoethyl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetra-
hydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
(350 mg, 0.56 mmol, 1.00 equiv) in ethanol (20 mL),
(S)-piperidine-2-carboxylic acid (216 mg, 1.67 mmol, 2.00 equiv).
This was followed by the addition of acetic acid (2 mL). The
mixture was stirred for overnight at room temperature. To this was
added NaBH.sub.3CN (77 mg, 1.22 mmol, 2.20 equiv). The resulting
solution was stirred for 2 h at room temperature. The resulting
mixture was concentrated under vacuum. The residue was dissolved in
50 mL of ethyl acetate. The resulting mixture was washed with
1.times.20 mL of water. The mixture was dried over sodium sulfate
and concentrated under vacuum. The residue was applied onto a
silica gel column with methanol:dichloromethane (1:5). This
resulted in 300 mg (73%) of
(S)-1-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)-1,2,3,4-tetrahydron-
aphthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piper-
idine-2-carboxylic acid as a yellow solid.
Example 240
[0992] Into a 50-mL round-bottom flask, was placed a solution of
(S)-1-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)-1,2,3,4-tetrahydronaph-
thalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperidi-
ne-2-carboxylic acid (140 mg, 0.19 mmol, 1.00 equiv) in
dichloromethane (3 mL), EDC.HCl (73 mg, 0.38 mmol, 2.00 equiv),
4-dimethylaminopyridine (47 mg, 0.38 mmol, 2.00 equiv), tert-butyl
3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate 135c (110
mg, 0.38 mmol, 2.00 equiv). The resulting solution was stirred
overnight at room temperature. The resulting mixture was washed
with NH.sub.4Cl aq. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The crude product (140 mg)
was purified by Prep-HPLC with the following conditions (1#-Waters
2767-3): Column, Xbridge Prep C18, 5 um, 19*100 mm; mobile phase,
water with 0.03% NH.sub.3H.sub.2O and CH.sub.3CN (65% CH.sub.3CN up
to 78% in 6 min); Detector, Waters2545 UvDector 254&270 nm.
49.3 mg product was obtained. This resulted in 49.3 mg (26%) of
tert-butyl
2-methyl-1-((S)-1-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)-1,2,3,4-te-
trahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)et-
hyl)piperidin-2-yl)-1-oxo-5, 8,11-trioxa-2-azatetradecan-14-oate as
a yellow solid. LC-MS (ES, m/z): 1016 [M+H].sup.+ H-NMR (300 MHz,
CD.sub.3OD, ppm): 8.84 (s, 1H), 8.29-8.22 (m, 2H), 8.03-8.01 (m,
2H), 7.79-7.78 (m, 1H), 7.66-7.64 (m, 2H), 7.47 (s, 1H), 7.28-7.26
(m, 1H), 7.18-7.12 (m, 4H), 5.36-5.35 (m, 1H), 3.67-3.53 (m, 16H),
3.26-3.22 (m, 5H), 3.12-3.03 (m, 4H), 2.90-2.80 (m, 5H), 2.70-2.60
(m, 1H), 2.46-2.42 (m, 2H), 2.30-2.20 (m, 1H), 2.19-2.10 (m, 1H),
2.05-1.85 (m, 3H), 1.77-1.76 (m, 5H), 1.65-1.63 (m, 4H), 1.44-1.42
(m, 11H).
Example 241
tert-butyl
3-{2-[2-(2-{1-[(2S,4R)-4-hydroxy-1-{2-[N-methyl-1-(3-{[4-(piper-
idin-1-yl)-2-(4-{[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]carbamoyl}pyridin-
-2-yl)phenyl]carbamoyl}phenyl)formamido]ethyl}pyrrolidin-2-yl]-N-methylfor-
mamido}ethoxy)ethoxy]ethoxy}propanoate
##STR00417##
[0994] This compound was prepared according to the procedure
described for the synthesis of Example 240 substituting
(2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid in place of
(S)-piperidine-2-carboxylic acid LC-MS (ES, m/z): 1018 [M+H].sup.+
H-NMR (300 MHz, DMSO, ppm): 12.25.about.12.09 (m, 1H),
9.19.about.9.16 (d, J=8.4 Hz, 1H), 8.86 (s, 1H), 8.28 (s, 1H),
8.19.about.8.18 (m, 1H), 7.92.about.7.84 (m, 3H), 7.62 (s, 2H),
7.38 (s, 1H), 7.19.about.7.10 (m, 6H), 5.24 (s, 1H),
3.58.about.3.51 (m, 4H), 3.45 (s, 12H), 3.22.about.3.18 (m, 5H),
3.00.about.2.72 (m, 10H), 2.41.about.2.27 (m, 3H), 1.99.about.1.78
(m, 7H), 1.66.about.1.56 (m, 7H), 1.33 (s, J=3.3 Hz, 10H), 1.25 (s,
2H).
Example 242
tert-butyl
2-methyl-1-((S)-4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)--
1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)be-
nzamido)ethyl)morpholin-3-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
##STR00418##
[0996] This compound was prepared according to the procedure
described for the synthesis of Example 240 substituting
(S)-morpholine-3-carboxylic acid in place of
(S)-piperidine-2-carboxylic acid.
[0997] LC-MS (ES, m/z): 1018 [M+H].sup.+ H-NMR (300 MHz,
CD.sub.3OD, ppm): 8.93.about.8.91 (d, J=5.4 Hz, 1H),
8.58.about.8.55 (d, J=8.7 Hz, 1H), 8.36 (s, 1H), 8.23 (s, 1H),
8.13.about.8.11 (d, J=6.9 Hz, 1H), 7.90.about.7.83 (m, 3H),
7.75.about.7.70 (m, 1H), 7.54.about.7.52 (d, J=6.6 Hz, 1H),
7.28.about.7.26 (d, J=7.8 Hz, 1H), 7.20.about.7.14 (m, 3H),
5.40.about.5.37 (m, 1H), 4.51.about.4.45 (m, 2H), 4.25.about.4.21
(m, 1H), 4.09.about.4.04 (m, 1H), 3.88 (s, 1H), 3.69.about.3.54 (m,
23H), 3.53.about.3.52 (m, 2H), 3.15.about.3.12 (m, 1H),
3.10.about.3.08 (m, 4H), 3.00 (s, 2H), 2.89.about.2.86 (m, 3H),
2.49.about.2.45 (m, 2H), 2.00 (s, 1H), 1.95.about.1.94 (m, 8H),
1.78.about.1.76 (m, 2H), 1.44 (s, 9H).
Example 243
2-methyl-1-((S)-4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)-1,2,3,4-tet-
rahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)eth-
yl)morpholin-3-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic
acid
##STR00419##
[0999] A solution of tert-butyl
2-methyl-1-((S)-4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)-1,2,3,4-te-
trahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)et-
hyl)morpholin-3-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oate
Example 242 (100 mg, 0.10 mmol, 1.00 equiv) in dichloromethane (4
mL), trifluoroacetic acid (2 mL). The resulting solution was
stirred for 1 h at room temperature. The resulting mixture was
concentrated under vacuum. The crude product (80 mg) was purified
by Prep-HPLC with the following conditions (1#-Waters 2767-3):
Column, SunFire Prep C18, 19*150 mm 5 um; mobile phase, water with
0.05% TFA and CH.sub.3CN (5% CH.sub.3CN up to 28% in 1 min, up to
38% in 6 min); Detector, Waters2545 UvDector 254&270 nm. 8.4 mg
product was obtained. This resulted in 8.4 mg (7%) of
2-methyl-1-((S)-4-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-((S)-1,2,3,4-te-
trahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)et-
hyl)morpholin-3-yl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oic acid
as a yellow solid. LC-MS (ES, m/z): 962 [M+H].sup.+ H-NMR (300 MHz,
CD.sub.3OD, ppm): 8.93 (d, J=5.1 Hz, 1H), 8.65 (d, J=9.3 Hz, 1H),
8.39 (s, 1H), 8.24 (s, 1H), 8.14-8.11 (m, 1H), 8.03-8.02 (m, 1H),
7.86-7.84 (m, 2H), 7.76-7.72 (m, 1H), 7.64-7.61 (m, 1H), 7.28-7.25
(m, 1H), 7.18-7.14 (m, 3H), 5.39 (m, 1H), 4.50-4.45 (m, 2H),
4.30-4.20 (m, 1H), 4.09-4.05 (m, 1H), 3.86-3.43 (m, 25H), 3.21 (s,
1H), 3.10-3.08 (m, 3H), 3.00 (s, 1H), 2.91-2.84 (m, 2H), 2.57-2.51
(m, 2H), 2.04-1.79 (m, 10H).
Example 244
(S)-tert-butyl
1-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-
-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperidine-4-car-
boxylate
##STR00420##
[1001] This compound was prepared according to the procedure
described for the synthesis of Example 187 substituting tert-butyl
piperidine-4-carboxylate in place of L-proline-t-butyl ester.
[1002] LC-MS (ES, m/z): 799 [M+H].sup.+ H-NMR (300 MHz, DMSO, ppm):
12.19 (s, 1H), 9.19.about.9.17 (d, J=7.8 Hz, 1H), 9.03 (s, 1H),
8.89.about.8.87 (d, J=5.1 Hz, 1H), 8.30 (s, 1H), 8.23.about.8.20
(d, J=9.3 Hz, 1H), 8.00.about.7.97 (d, J=9.0 Hz, 2H),
7.86.about.7.84 (d, J=4.8 Hz, 1H), 7.68.about.7.63 (m, 2H), 7.49
(s, 1H), 7.20.about.7.13 (m, 5H), 5.25 (s, 1H), 3.84 (s, 3H), 3.39
(s, 3H), 3.31.about.3.26 (m, 5H), 2.96 (s, 6H), 2.78.about.2.73 (m,
2H), 2.12.about.1.98 (m, 5H), 1.84.about.1.59 (m, 11H),
1.44.about.1.40 (m, 10H).
Example 245
(S)-2-(2-(3-(3-methyl-3-(2-morpholinoethyl)ureido)benzamido)-5-(piperidin--
1-yl)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
##STR00421##
[1003] Intermediate 245a
[1004] Into a 25-mL round-bottom flask, was placed a solution of
N-methyl-2-morpholinoethanamine (162.8 mg, 1.13 mmol, 1.00 equiv)
in dichloromethane (5 mL), triethylamine (114.1 mg, 1.13 mmol, 1.00
equiv). This was followed by the addition of methyl
3-isocyanatobenzoate (200 mg, 1.13 mmol, 1.00 equiv), in portions.
The resulting solution was stirred for 0.5 h at room temperature.
The residue was applied onto a silica gel column with
dichloromethane/methanol (500:1-100:1). This resulted in 333 mg
(92%) of methyl 3-(3-methyl-3-(2-morpholinoethyl)ureido)benzoate as
a yellow semi-solid.
Intermediate 245b
[1005] Into a 50-mL round-bottom flask, was placed a solution of
methyl 3-(3-methyl-3-(2-morpholinoethyl)ureido)benzoate (479 mg,
1.49 mmol, 1.00 equiv) in tetrahydrofuran (6 mL), a solution of
sodium hydroxide (477.6 mg, 11.94 mmol, 8.00 equiv) in water (3
mL). The resulting solution was stirred for 4 h at room
temperature. The reaction progress was monitored by TLC, LCMS
(dichloromethane/methanol=2:1). The resulting mixture was
concentrated under vacuum. The pH value of the solution was
adjusted to 6-7 with hydrogen chloride (2 mol/L). The resulting
solution was extracted with 2.times.20 mL of ethyl acetate and the
organic layers combined. The resulting mixture was washed with
2.times.20 mL of sodium chloride (aq). The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(400:1-20:1). This resulted in 600 mg (92%) of
3-(3-methyl-3-(2-morpholinoethyl)ureido)benzoic acid as a light
yellow solid.
Example 245
[1006] Into a 50-mL round-bottom flask, was placed
2-(2-amino-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide (200 mg, 0.47 mmol, 1.00 equiv),
3-(3-methyl-3-(2-morpholinoethyl)ureido)benzoic acid (143 mg, 0.47
mmol, 0.99 equiv), EDC.HCl (135 mg, 0.70 mmol, 1.50 equiv),
4-dimethylaminopyridine (86 mg, 0.70 mmol, 1.50 equiv),
dichloromethane (5 mL). The resulting solution was stirred for 2 h
at room temperature. The reaction progress was monitored by
LCMS/TLC (dichloromethane/methanol=10:1). The resulting solution
was diluted with 20 mL of water. The resulting solution was
extracted with 3.times.20 mL of dichloromethane and the organic
layers combined. The resulting mixture was washed with 2.times.20
mL of NH.sub.4Cl (aq). The mixture was dried over anhydrous sodium
sulfate. The crude product was purified by Prep-HPLC with the
following conditions (1#-Waters 2767-3): Column, SunFire Prep C18,
19*150 mm 5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN
(24% CH.sub.3CN up to 34% in 6 min); Detector, Waters2545 UvDector
254&270 nm. This resulted in 95.8 mg (19%) of Example 245 as a
white solid.
[1007] LC-MS (ES, m/z): 716 [M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD,
ppm): 8.95-8.93 (d, J=5.1 Hz, 1H), 8.71-8.68 (d, J=9 Hz, 1H), 3.39
(s, 1H), 8.20-8.11 (m, 1H), 7.86-7.84 (m, 1H), 7.72-7.64 (m, 1H),
7.53-7.48 (m, 2H), 7.27-7.25 (d, J=6.9 Hz, 1H), 7.17-7.13 (m, 4H),
5.38 (s, 1H), 4.00 (s, 2H), 3.83-3.80 (m, 4H), 3.69-3.65 (t, J=5.4
Hz, 6H), 3.44-3.40 (m, 2H), 3.18 (s, 4H), 2.87-2.85 (d, J=6.6 Hz,
2H), 2.04-1.81 (m, 10H).
Example 246
(S)--N1-(2-(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)-2-oxoethyl)-N1-met-
hyl-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenyl)isophthalamide
##STR00422##
[1009] Into a 100-mL round-bottom flask, was placed a solution of
(S)-2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen--
1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)acetic acid
(200 mg, 0.31 mmol, 1.00 equiv) in dichloromethane (10 mL), EDC.HCl
(113 mg, 0.59 mmol, 1.90 equiv), 4-dimethylaminopyridine (80 mg,
0.65 mmol, 2.11 equiv), 2-(2-(piperazin-1-yl)ethoxy)ethanol (103
mg, 0.59 mmol, 1.91 equiv). The resulting solution was stirred
overnight at room temperature. The resulting solution was diluted
with 30 mL of dichloromethane. The resulting mixture was washed
with 2.times.30 mL of NH.sub.4C. aq. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The crude
product (200 mg) was purified by Prep-HPLC with the following
conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150 mm
5 um; mobile phase, water with 0.05% TFA and CH.sub.3CN (23%
CH.sub.3CN up to 34% in 6 min); Detector, Waters2545 UvDector
254&270 nm. 57.6 mg product was obtained. This resulted in 57.6
mg (23%) of
(S)--N1-(2-(4-(2-(2-hydroxyethoxy)ethyl)piperazin-1-yl)-2-oxoethyl)-N1-me-
thyl-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamo-
yl)pyridin-2-yl)phenyl)isophthalamide as a yellow solid. LC-MS (ES,
m/z): 802 [M+H].sup.+ H-NMR (300 MHz, DMSO, ppm): 12.38 (s, 1H),
9.94 (s, 1H), 9.21.about.9.19 (d, J=8.4 Hz, 1H), 8.95.about.8.90
(m, 1H), 8.00.about.7.95 (m, 2H), 7.87.about.7.84 (m, 3H),
7.67.about.7.54 (m, 3H), 7.30.about.7.13 (m, 5H), 5.27.about.5.25
(m, 1H), 3.79.about.3.69 (m, 3H), 3.57.about.3.11 (m, 16H),
3.00.about.2.92 (m, 4H), 2.78 (s, 2H), 2.00 (s, 2H),
1.85.about.1.79 (m, 6H), 1.55 (s, 2H).
Example 247
3-(2-(2-(2-(3-(3-((30S)-3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)c-
arbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)pheny-
l)propoxy)ethoxy)ethoxy)ethoxy)propanoic acid
##STR00423## ##STR00424##
[1010] Intermediate 247a
[1011] Into a 1-L round-bottom flask, was placed a solution of
Triethylene glycol (56.76 g, 378.40 mmol, 0.90 equiv) in
tetrahydrofuran (400 mL). This was followed by the addition of
sodium hydride (10 g, 416.67 mmol, 1.00 equiv), in portions at
0-5.degree. C. in 10 min. To this was added a solution of
3-bromoprop-1-yne (50 g, 420.17 mmol, 1.00 equiv) in toluene (50
mL) dropwise with stirring at room temperature. The resulting
solution was stirred for 2 h at room temperature. The reaction
progress was monitored by LCMS. The solids were filtered out. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with petroleum ether/ethyl acetate
(10:1-1:1). This resulted in 30.1 g (37%) of
2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol as yellow oil.
Intermediate 247b
[1012] Into a 1000-mL round-bottom flask, was placed a solution of
2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol (22.5 g, 119.68 mmol,
1.00 equiv) in tetrahydrofuran (200 mL), sodium (83 mg, 3.61 mmol,
0.03 equiv). This was followed by the addition of a solution of
tert-butyl acrylate (15.3 g, 119.53 mmol, 1.00 equiv) in
tetrahydrofuran (100 mL) dropwise with stirring. The resulting
solution was stirred for 3 h at room temperature. The reaction
progress was monitored by LCMS. The pH value of the solution was
adjusted to 7-8 with 1N hydrochloric acid. The resulting solution
was diluted with 300 mL of water. The resulting solution was
extracted with 3.times.200 ml of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 1.times.200
mL of water. The resulting mixture was washed with 1.times.200 mL
of sodium chloride (aq). The resulting mixture was concentrated
under vacuum. This resulted in 31.3 g (79%) of tert-butyl
3-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)propanoate as
yellow oil.
Intermediate 247c
[1013] Into a 1000-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
3-iodophenol (7 g, 31.82 mmol, 1.01 equiv) in tetrahydrofuran (200
mL), copper(I) iodide (600 mg, 3.16 mmol, 0.10 equiv),
Pd(PPh.sub.3).sub.2Cl.sub.2 (2.22 g, 3.16 mmol, 0.10 equiv),
triethylamine (6.4 g, 63.37 mmol, 2.00 equiv). This was followed by
the addition of tert-butyl
3-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)propanoate (10 g,
31.65 mmol, 1.00 equiv) dropwise with stirring at 0-5.degree. C. in
20 min. The resulting solution was stirred for 2 h at room
temperature. The reaction progress was monitored by TLC/LCMS (1:1
ethyl acetate/petroleum ether). The reaction was then quenched by
the addition of 200 ml of water. The resulting solution was
extracted with 3.times.200 ml of ethyl acetate and the organic
layers combined. The resulting mixture was washed with 1.times.100
mL of water. The resulting mixture was washed with 3.times.100 mL
of sodium chloride (aq). The resulting mixture was concentrated
under vacuum. The residue was applied onto a silica gel column with
petroleum ether/ethyl acetate (10:1-1:2). This resulted in 7 g
(43%) of tert-butyl
3-(2-(2-(2-(3-(3-hydroxyphenyl)prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)propan-
oate as a brown oil.
Intermediate 247d
[1014] Into a 250-mL round-bottom flask, was placed a solution of
tert-butyl
3-(2-(2-(2-(3-(3-hydroxyphenyl)prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)propan-
oate (5 g, 12.25 mmol, 1.00 equiv) in methanol/dichloromethane
(20/20 mL). This was followed by the addition of Palladium carbon
(5 g, 47.17 mmol, 3.85 equiv) and hydrogen gas The resulting
solution was stirred overnight at 35.degree. C. in an oil bath. The
reaction progress was monitored by LCMS. The solids were filtered
out. The resulting mixture was concentrated under vacuum. This
resulted in 4.5 g (86%) of tert-butyl
3-(2-(2-(2-(3-(3-hydroxyphenyl)propoxy)ethoxy)ethoxy)ethoxy)propanoate
as yellow oil.
Intermediate 247e
[1015] Into a 1000-mL round-bottom flask, was placed a solution of
tert-butyl
3-(2-(2-(2-(3-(3-hydroxyphenyl)propoxy)ethoxy)ethoxy)ethoxy)propanoate
(6 g, 14.53 mmol, 1.00 equiv) in dichloromethane (100 mL),
triethylamine (9 g, 89.11 mmol, 6.13 equiv). This was followed by
the addition of a solution of (trifluoromethane)sulfonyl
trifluoromethanesulfonate (12 g, 42.54 mmol, 2.93 equiv) in
dichloromethane (50 mL) dropwise with stirring at 0-5.degree. C. in
5 min. The resulting solution was stirred for 1 h at 0-5.degree. C.
in a water/ice bath. The reaction progress was monitored by LCMS.
The reaction was then quenched by the addition of 100 ml of water.
The resulting solution was extracted with 3.times.100 mL of ethyl
acetate and the organic layers combined. The resulting mixture was
washed with 4.times.100 mL of sodium chloride (aq). The resulting
mixture was concentrated under vacuum. This resulted in 10 g
(crude) of tert-butyl
3-(2-(2-(2-(3-(3-(trifluoromethylsulfonyloxy)phenyl)propoxy)ethoxy)ethoxy-
)ethoxy) propanoate as a brown oil.
Intermediate 247f
[1016] Into a 50-mL 3-necked round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of 3-(mercaptomethyl)benzoic acid (2.5 g, 0.015 mol, 1.01
equiv) in xylene (12.5 mL), potassium carbonate (1.01 g, 0.9 mmol,
0.50 equiv). The resulting solution was stirred for 30 min at
25.degree. C. Into another 250-mL 3-necked round-bottom flask
purged and maintained with an inert atmosphere of nitrogen, was
added a solution of tert-butyl
3-(2-(2-(2-(3-(3-(trifluoromethylsulfonyloxy)phenyl)propoxy)ethoxy)ethoxy-
)ethoxy)propanoate (8 g, 0.015 mol, 1.00 equiv) in xylene (40 mL),
Pd.sub.2(dba).sub.3 (1 g), Xantphos (1 g). The resulting solution
was stirred for 20 min at 25.degree. C. and then added to the above
reacting solution. The resulting solution was stirred overnight at
135.degree. C. in an oil bath. The reaction progress was monitored
by LCMS. The resulting mixture was concentrated under vacuum. The
pH value of the solution was adjusted to 5.about.6 with 1N
hydrochloric acid. The resulting solution was extracted with
3.times.50 ml of ethyl acetate and the organic layers combined and
concentrated under vacuum. The residue was applied onto a silica
gel column with petroleum ether/ethyl acetate (10:1-1:1). This
resulted in 2.6 g (28%) of
3-((3-(3-(2-(2-(2-(3-tert-butoxy-3-oxopropoxy)ethoxy)ethoxy)ethoxy)propyl-
)phenylthio)methyl)benzoic acid as a brown solid.
[1017] LC-MS (ES, m/z): 561[M-H].sup.-. H-NMR (300 MHz, CDCl.sub.3,
ppm): 7.965-7.940 (d, J=7.5 Hz, 1H), 7.882 (s, 1H), 7.561-7.535 (d,
J=7.8 Hz, 1H), 7.418-7.366 (m, 1H), 7.177-7.161 (d, J=4.8 Hz, 2H),
7.052 (s, 1H), 7.026-6.997 (m, 1H), 4.117 (s, 2H), 3.748-3.566 (m,
15H), 3.428-3.383 (t, J=6.6 Hz, 2H), 2.607-2.495 (m, 4H),
1.859-1.763 (m, 2H), 1.454 (s, 9H).
Intermediate 247g
[1018] Into a 100-mL round-bottom flask, was placed a solution of
2-(2-amino-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide (909.6 mg, 2.14 mmol, 1.00 equiv) in
dichloromethane (15 mL),
3-((3-(3-(2-(2-(2-(3-tert-butoxy-3-oxopropoxy)ethoxy)ethoxy)etho-
xy)propyl)phenylthio)methyl)benzoic acid (1.2 g, 2.14 mmol, 1.00
equiv), EDC.HCl (614.0 mg, 3.20 mmol, 1.50 equiv),
4-dimethylaminopyridine (390.7 mg, 3.20 mmol, 1.50 equiv). The
resulting solution was stirred overnight at room temperature. The
reaction progress was monitored by LCMS/TLC (petroleum ether:ethyl
acetate=1:1). The resulting solution was diluted with 20 mL of
NH.sub.4Cl aq. The resulting solution was extracted with 2.times.20
mL of dichloromethane and the organic layers combined. The
resulting mixture was washed with 2.times.20 mL of brine. The
mixture was dried over anhydrous sodium sulfate. The solids were
filtered out. The resulting mixture was concentrated under vacuum.
The residue was applied onto a silica gel column with petroleum
ether/ethyl acetate (20:1.about.4:1). This resulted in 1.6 g (70%)
of tert-butyl
3-(2-(2-(2-(3-(3-((22S)-3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)-
carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)phen-
yl)propoxy)ethoxy)ethoxy)ethoxy)propanoate as brown oil.
Example 247
[1019] Into a 250-mL round-bottom flask, was placed a solution of
tert-butyl
3-(2-(2-(2-(3-(3-((30S)-3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)-
carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzylthio)phen-
yl)propoxy)ethoxy)ethoxy)ethoxy)propanoate (1.2 g, 1.24 mmol, 1.00
equiv) in dichloromethane (20 mL), trifluoroacetic acid (20 mL).
The resulting solution was stirred for 2 h at room temperature. The
reaction progress was monitored by LCMS. The resulting mixture was
concentrated under vacuum. The pH value of the solution was
adjusted to 5.about.6 with sat. sodium carbonate. The resulting
solution was extracted with 3.times.10 mL of dichloromethane and
the organic layers combined and concentrated under vacuum. The
residue was dissolved in 20 mL of acetonitrile, 20 mL of water, 1
mL of hydrochloric acid and lyophilized. This resulted in 0.67 g
(50%) of
3-(2-(2-(2-(3-(3-((30S)-3-((2-(4-(((S)-1,2,3,4-tetrahydronaphtha-
len-1-yl)carbamoyl)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)benzyl-
thio)phenyl)propoxy)ethoxy)ethoxy)ethoxy)propanoic acid
dihydrochloride as a brown semi-solid. LC-MS (ES, m/z): 915
[M-2HCl+H].sup.+. H-NMR (300 MHz, CD.sub.3OD, ppm): 8.969-8.951 (d,
J=5.4 Hz, 1H), 8.798-8.768 (m, 1H), 8.481 (s, 1H), 8.296-8.287 (m,
2H), 7.918-7.901 (m, 4H), 7.867-7.837 (m, 2H), 7.517-7.469 (m, 1H),
7.255-7.110 (m, 6H), 7.031-7.009 (m, 1H), 5.393 (m, 1H), 4.250 (s,
2H), 3.793-3.757 (m, 4H), 3.694-3.600 (m, 2H), 3.589-3.546 (m,
10H), 3.490-3.460 (m, 2H), 3.351-3.314 (m, 2H), 2.886-2.857 (m,
2H), 2.596-2.492 (m, 4H), 2.128 (s, 5H), 2.026-1.999 (d, 2H), 1.874
(s, 3H), 1.756-1.730 (m, 2H).
Example 248
3-[2-(2-{2-[N-methyl-1-(3-{[4-(piperidin-1-yl)-2-[4-({[3-(trifluoromethyl)-
phenyl]methyl}carbamoyl)pyridin-2-yl]phenyl]carbamoyl}phenyl)formamido]eth-
oxy}ethoxy)ethoxy]propanoic acid
##STR00425##
[1021] This compound was prepared according to the procedure
described for the synthesis of Example 188 substituting 4.1e in
place of 25b.
[1022] LC-MS (ES, m/z): 820 [M+H].sup.+. H-NMR (300 MHz,
CDCl.sub.3, ppm): 8.976-8.959 (d, 1H), 8.830-8.800 (d, J=9.0 Hz,
1H), 8.457 (s, 1H), 8.161-8.095 (d, 3H), 7.903-7.881 (m, 1H),
7.727-7.567 (m, 7H), 4.724 (s, 2H), 3.826 (s, 2H), 3.709-3.492 (m,
16H), 3.177-3.096 (m, 3H), 2.513-2.444 (m, 3H), 2.059-2.043 (s,
4H), 1.846-1.828 (s, 2H).
Example 249
3-[2-(2-{2-[N-methyl-1-(3-{[4-(piperidin-1-yl)-2-(4-{[(1S)-1,2,3,4-tetrahy-
dronaphthalen-1-yl]carbamoyl}pyridin-2-yl)phenyl]carbamoyl}phenyl)formamid-
o]ethoxy}ethoxy)ethoxy]propanoic acid
##STR00426##
[1024] This compound was prepared according to the procedure
described for the synthesis of Example 188 substituting 126e in
place of 25b.
[1025] LC-MS (ES, m/z): 792[M-2HCl+H].sup.+ H-NMR (400 MHz,
CDCl.sub.3, ppm): 12.90 (s, 1H), 11.725.about.11.778 (m, 1H),
8.677.about.8.861 (m, 3H), 7.888.about.8.222 (m, 5H),
7.445.about.7.658 (m, 2H), 7.245.about.7.262 (m, 1H),
7.062.about.7.147 (m, 3H), 5.412 (s, 1H), 3.394.about.3.748 (m,
18H), 2.740.about.3.072 (m, 5H), 2.246.about.2.875 (m, 4H),
2.043.about.2.104 (m, 5H), 1.853.about.1.992 (m, 3H),
1.230.about.1.929 (m, 2H).
Example 250
1-N-(2-{2-[2-(3-{4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl}-3-oxopropoxy)-
ethoxy]ethoxy}ethyl)-1-N-methyl-3-N-[4-(piperidin-1-yl)-2-(4-{[(1S)-1,2,3,-
4-tetrahydronaphthalen-1-yl]carbamoyl}pyridin-2-yl)phenyl]benzene-1,3-dica-
rboxamide
##STR00427##
[1027] This compound was prepared according to the procedure
described for the synthesis of Example 231 substituting Example 249
in place of 231a. LC-MS (ES, m/z): 948 [M+H].sup.+ H-NMR (300 MHz,
CD.sub.3OD, ppm): 8.914.about.8.931 (m, 1H), 8.676 (d, J=9 Hz, 1H),
8.398 (s, 1H), 8.033.about.8.084 (m, 3H), 7.851.about.7.872 (m,
1H), 7.615.about.7.771 (m, 3H), 7.263.about.7.286 (m, 1H),
7.136.about.7.220 (m, 3H), 8.369.about.5.410 (m, 1H), 3.824 (s,
4H), 3.538.about.3.736 (m, 23H), 3.338.about.3.398 (m, 3H),
3.090.about.3.171 (m, 4H), 2.865.about.2.888 (m, 2H), 2.650 (s,
2H), 1.989.about.2.007 (m, 1H), 1.795.about.1.922 (m, 9H).
Example 251
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
##STR00428##
[1028] Intermediate 251a
[1029] Into a 500-mL round-bottom flask, was placed a solution of
3-iodobenzoic acid (9.92 g, 40.00 mmol, 1.00 equiv) in DMF (100
mL), 1-(bromomethyl)benzene (6.84 g, 40.00 mmol, 1.00 equiv),
potassium carbonate (11.04 g, 80.00 mmol, 2.00 equiv). The
resulting solution was stirred for 2 h at room temperature. The
solids were filtered out and the filtrate was concentrated under
vacuum. The residue was diluted with 50 mL of water and extracted
with 2.times.50 mL of ethyl acetate. The combined organic layers
were washed with 2.times.50 mL of sodium chloride, dried over
anhydrous sodium sulfate and concentrated under vacuum to give 13.1
g (97%) of benzyl 3-iodobenzoate as light brown oil
Intermediate 251b
[1030] Into a 250-mL three-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of benzyl
3-iodobenzoate (10.7 g, 31.66 mmol, 1.00 equiv) in THF (100 mL),
tert-butyl
3-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)propanoate (10 g,
31.65 mmol, 1.00 equiv), copper(I) iodide (601 mg, 3.16 mmol, 0.10
equiv), Pd(PPh.sub.3).sub.2Cl.sub.2 (2.222 g, 3.17 mmol, 0.10
equiv), triethylamine (6.39 g, 63.27 mmol, 2.00 equiv). The
resulting solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum and the residue was
diluted with 50 mL of water. The resulting solution was extracted
with 3.times.50 mL of ethyl acetate and the organic layers
combined. The resulting mixture was washed with 3.times.50 mL of
brine. The mixture was dried over anhydrous sodium sulfate. The
solids were filtered out. The resulting mixture was concentrated
under vacuum. The residue was applied onto a silica gel column with
petroleum ether/ethyl acetate (20:1.about.2:1). This resulted in
10.7 g (64%) of benzyl
3-(3-(2-(2-(2-(3-tert-butoxy-3-oxopropoxy)ethoxy)ethoxy)ethoxy)prop-1-yny-
l)benzoate as brown oil.
Intermediate 251c
[1031] Into a 100-mL round-bottom flask, was placed a solution of
benzyl
3-(3-(2-(2-(2-(3-tert-butoxy-3-oxopropoxy)ethoxy)ethoxy)ethoxy)prop-1-yny-
l)benzoate (5.8 g, 11.03 mmol, 1.00 equiv) in methanol (50 mL)
followed by Palladium on carbon (2.8 g). The mixture was stirred
under one atmosphere of hydrogen for 24 h at 35.degree. C. The
solids were filtered out and the filtrate was concentrated under
vacuum. The residue was applied onto a silica gel column with
petroleum ether/ethylacetate (10:1-1:1). This resulted in 2.8 g
(58%) of
3-(3-(2-(2-(2-(3-tert-butoxy-3-oxopropoxy)ethoxy)ethoxy)ethoxy)propyl)ben-
zoic acid as light yellow oil. LC-MS (ES, m/z): 463 [M+Na].sup.+
H-NMR (300 MHz, CDCl3, ppm): 7.96 (m, 2H), 7.42 (m, 2H), 3.75-3.59
(m, 14H), 3.48 (t, J=6.3 Hz, 2H), 2.78 (t, J=7.2 Hz, 2H), 2.52 (t,
J=6.6 Hz, 2H), 1.99-1.90 (m, 2H), 1.45 (s, 9H).
##STR00429##
Intermediate 251d: tert-butyl
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
[1032] To a solution of
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide (1.77 g, 4.0 mmol),
3-(2,2-dimethyl-4-oxo-3,7,10,13,16-pentaoxanonadecan-19-yl)benzoic
acid (1.70 g, 3.86 mmol) and DIPEA (1.47 g, 11.4 mmol) in DMF (20
ml) was added HATU (1.56 g, 4.10 mmol). The reaction mixture was
stirred for 30 minutes, at which time additional
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide (0.06 g, 0.14 mmol) was added. After stirring an additional
25 minutes, the reaction mixture was concentrated under vacuum. The
residue was dissolved in DCM (200 mL), washed with water
(4.times.50 mL), dried (Na.sub.2SO.sub.4) and concentrated to
dryness. Purification by flash chromatography on silica gel (50% to
100% EtOAc in hexanes) gave the title compound (2.58 g) as an
oil.
Example 251
TFA salt:
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl-
)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
[1033] tert-Butyl
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
(2.58 g, 2.67 mmol) was dissolved in DCM (5 mL) and TFA (5 mL) was
added dropwise. The resulting solution was stirred for 20 minutes
and then concentrated at reduced pressure. The residue was
dissolved in 50% ACN/water (6 mL) and freeze-dried. Toluene (10 mL)
was added and the mixture concentrated under reduced pressure. ACN
(100 mL) was added to the mixture, concentrated under reduced
pressure and died under vacuum to give a TFA salt of the title
compound (3.18 g) as an orange oil. MS (ES, m/z): 809.4
[M+H].sup.+.
Example 251
HCl salt:
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl-
)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
[1034] To tert-butyl
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
(1.31 g, 1.51 mmol) was added 4N HCl in dioxane (5.68 mL, 22.7
mmol). After stirring for 1 hour, the solvent was removed under a
stream of nitrogen. Dioxane (5 mL) was added and then removed under
a stream of nitrogen. The residue was then dried under vacuum. The
resulting oil was combined with the product of another run (0.17
mmol), dissolved in 50% ACN/water (20 mL) and freeze-dried to give
a HCl salt of the title compound (1.41 g) as a light pink solid.
.sup.1H NMR (400 MHz, CD.sub.3OD, ppm) .delta. 9.52 (m, 0.3H), 8.96
(d, J=5.3 Hz, 1H), 8.79 (d, J=9.0 Hz, 1H), 8.44 (s, 1H), 5.15 (d,
J=2.7 Hz, 1H), 7.93 (dd, J.sub.AB=5.3 Hz, J.sub.AC=1.6 Hz, 1H),
7.80-7.77 (m, 2H), 7.69 (d, J=2.6 Hz, 1H), 7.68-7.64 (m, 2H),
7.56-7.50 (m, 2H), 7.48-7.46 (m, 2H), 4.68 (s, 2H), 3.77 (quar,
J=7.2 Hz, 4H), 3.67-3.47 (m, 16H), 2.80 (dd, J.sub.AB=9.5 Hz,
J.sub.AC=7.4, 2H), 2.47 (t, J=6.2 Hz, 2H), 1.94-1.90 (m, 2H), 1.22
(t, J=7.2 Hz, 6H). MS (ES, m/z): 809.5 [M+H].sup.+.
Example 251
Na salt:
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
[1035] A hydrochloride salt of
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
(4.20 g, 4.76 mmol) was partitioned between EtOAc (70 mL) and water
(50 mL). The pH was adjusted to 5.5 with 1N NaOH (7.5 mL), the
layers were separated and the aqueous layer was extracted with
EtOAc (2.times.50 mL). The combined organic layers were washed with
water (25 mL) and brine (25 mL), then dried (Na2SO4 and
concentrated to give the free base of the title compound as a
yellow oil (3.96 g). The free base was dissolved in ACN (25 mL) and
water (15 mL). 1N NaOH (4.75 mL) was added and the resulting
solution was freeze-dried to give the sodium salt of the title
compound as a yellow powder. .sup.1H NMR (400 MHz, CD.sub.3OD, ppm)
.delta. 8.80 (d, J=5.3 Hz, 1H), 8.16 (s, 1H), 8.00 (d, J=9.0 Hz,
1H), 7.74 (dd, J.sub.AB=5.0 Hz, J.sub.AC=1.5 Hz, 1H), 7.69-7.65 (m,
3H), 7.61 (d, J=7.5 Hz, 1H), 7.53 (d, J=9.2 Hz, 1H), 7.50-7.48 (m,
1H), 7.39-7.37 (m, 2H), 7.07 (d, J=6.0 Hz, 1H), 6.87 (dd,
J.sub.AB=9.2 Hz, J.sub.AC=2.9 Hz, 1H), 4.65 (s, 2H), 3.65 (t, J=6.9
Hz, 2H), 3.62-3.52 (m, 12H), 3.50-3.41 (m, 6H), 2.76 (t, J=7.3 Hz,
2H), 2.39 (t, J=6.8 Hz, 2H), 1.94-1.87 (m, 2H), 1.18 (t, J=7.0 Hz,
6H). MS (ES, m/z): 809.4 [M+H].sup.+.
Example 252
3-(2-(2-(2-(3-(3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-
pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)phenyl)propoxy)ethoxy)eth-
oxy)ethoxy)propanoic acid
##STR00430##
[1037] This compound was prepared according to the procedure
described for the synthesis of Example 251 substituting 126e in
place of 25b. Into a 50-mL round-bottom flask, was placed a
solution of
3-(3-(2-(2-(2-(3-tert-butoxy-3-oxopropoxy)ethoxy)ethoxy)ethoxy)propyl)ben-
zoic acid (1.308 g, 2.97 mmol, 1.00 equiv) in dichloromethane (15
mL),
2-(2-amino-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-
-1-yl)isonicotinamide (1.26 g, 2.96 mmol, 0.99 equiv), EDC.HCl
(854.8 mg, 4.46 mmol, 1.50 equiv), 4-dimethylaminopyridine (544 mg,
4.46 mmol, 1.50 equiv). The resulting solution was stirred
overnight at room temperature. The reaction progress was monitored
by LCMS/TLC (DCM:MeOH=10:1). The resulting mixture was washed with
2.times.20 mL of NH.sub.4Cl aq. The resulting mixture was washed
with 2.times.20 mL of Brine. The resulting mixture was concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:10.about.1:1). This resulted in
2.0 g (79%) of tert-butyl
3-(2-(2-(2-(3-(3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl-
)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)phenyl)propoxy)ethoxy)et-
hoxy)ethoxy)propanoate as yellow oil.
##STR00431##
Example 252
[1038] Into a 100-mL round-bottom flask was placed a solution of
tert-butyl
3-(2-(2-(2-(3-(3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl-
)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)phenyl)propoxy)ethoxy)et-
hoxy)ethoxy)propanoate (2.3 g, 2.71 mmol, 1.00 equiv) in
dichloromethane (20 mL), trifluoroacetic acid (20 mL). The
resulting solution was stirred for 2 h at room temperature. The
resulting mixture was concentrated under vacuum. The resulting
solution was diluted with 20 mL of dichloromethane. The gas of HCl
was introduced in. The mixture was stirred for 0.5 h, then
concentrated under vacuum. This resulted in 1.60 g (68%) of
3-(2-(2-(2-(3-(3-((2-(4-(((S)-1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl-
)pyridin-2-yl)-4-(piperidin-1-yl)phenyl)carbamoyl)phenyl)propoxy)ethoxy)et-
hoxy)ethoxy)propanoic acid (HCl salt) as a yellow solid. LC-MS (ES,
m/z): 793 [M-2HCl+H].sup.+ H-NMR (300 MHz, CD3OD, ppm): 9.03 (d,
J=5.7 Hz, 1H), 8.58 (s, 1H), 8.35 (s, 1H), 8.12 (m, 1H), 8.08 (m,
2H), 7.70 (m, 2H), 7.46 (m, 2H), 7.15 (m, 4H), 5.33 (t, J=6.0 Hz,
1H), 3.80-3.47 (m, 20H), 2.81-2.76 (m, 4H), 2.56-2.52 (t, J=6.0 Hz,
2H), 2.16 (m, 5H), 1.94-1.87 (m, 7H).
Example 253
Example A.2
(S)-16-(3-(4-(chloro)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyr-
idin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
##STR00432##
[1040] (S)-tert-butyl
16-(3-(4-chloro-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate. To
a solution of
(S)-2-(2-amino-5-chlorophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isoni-
cotinamide 237b (1.02 g, 2.7 mmol),
3-(2,2-dimethyl-4-oxo-3,7,10,13,16-pentaoxanonadecan-19-yl)benzoic
acid 251c (1.19 g, 2.7 mmol), DIPEA (1.04 g, 8.1 mmol) and DMAP
(190 mg, 1.55 mmol) in DMF (20 ml) was added HATU (1.13 g, 2.97
mmol). The reaction mixture was heated at 65.degree. C. for 24
hours, then cooled and concentrated. The residue was combined with
another run (0.28 mmol scale), dissolved in DCM (150 mL), washed
with water (4.times.50 mL), dried (Na.sub.2SO.sub.4) and
concentrated to dryness. Purification by flash chromatography on
silica gel (10% to 30% EtOAc in DCM) gave the title compound (1.44
g).
(S)-16-(3-(4-(chloro)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)py-
ridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid. Following the procedures described in Example 251, using
(S)-tert-butyl
16-(3-(4-chloro-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
gave a HCl salt of the title compound. MS (ES, m/z): 744.2
[M+H].sup.+.
Example 254
2-(2-(3-((S)-3-(2-methoxyethylcarbamoyl)piperidine-1-carbonyl)benzamido)-5-
-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahydronaphthalen-1-yl)isonico-
tinamide
##STR00433##
[1042] This compound was prepared using the method described for
the preparation of Example 4.14 using
(S)-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)benzoic acid 126g in place of 4.1e.
Purification by reverse-phase HPLC eluting with a water/ACN
gradient containing 0.1% TFA gave a TFA salt of the title compound.
MS (ES, m/z): 743.7 [M+H].sup.+.
Example 255
2-(2-(3-((S)-3-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(methyl)carbamoyl)p-
iperidine-1-carbonyl)benzamido)-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4--
tetrahydronaphthalen-1-yl)isonicotinamide
##STR00434##
[1044] This compound was prepared using the method described for
the preparation of Example 4.14 using
(S)-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)benzoic acid 126g in place of 4.1e
and N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine 135c.1 in
place of 2-methoxyethanamine. Purification by reverse-phase HPLC
eluting with a water/ACN gradient containing 0.1% TFA gave a TFA
salt of the title compound. MS (ES, m/z): 1021.5 [M+H].sup.+.
Example 256
2-(2-(3-((S)-3-(2,5,8,11,14,17,20-heptaoxadocosan-22-ylcarbamoyl)piperidin-
e-1-carbonyl)benzamido)-5-(piperidin-1-yl)phenyl)-N--((S)-1,2,3,4-tetrahyd-
ronaphthalen-1-yl)isonicotinamide
##STR00435##
[1046] This compound was prepared using the method described for
the preparation of Example 4.14 using
(S)-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)benzoic acid 126g in place of 4.1e
and 2,5,8,11,14,17,20-heptaoxadocosan-22-amine 135c.6 in place of
2-methoxyethanamine. Purification by reverse-phase HPLC eluting
with a water/ACN gradient containing 0.1% TFA gave a TFA salt of
the title compound. MS (ES, m/z): 1007.5 [M+H].sup.+.
Example 257
(S)-2-(2-(3-(16-(3-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(methyl)carbamo-
yl)piperidin-1-yl)-16-oxo-4,7,10,13-tetraoxahexadecyl)benzamido)-5-(diethy-
lamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00436## ##STR00437##
[1047] Intermediate 257a
[1048] To a solution of Boc-(S)-nipecotic acid (137 mg, 0.60 mmol),
N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine 135c.1 (310 mg,
0.88 mmol) and DIPEA (335 mg, 2.6 mmol) in DMF (3 mL) was added
HATU (285 mg, 0.75 mmol). The reaction was stirred for 1 hour and
then the DMF was removed under vacuum. The residue was added to
saturated aqueous NaHCO.sub.3 (10 mL) and extracted with DCM
(3.times.20 mL). The combined organic layers were dried (Na2SO4)
and concentrated to give (S)-tert-butyl
3-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(methyl)carbamoyl)piperidine-1--
carboxylate (720 mg).
Intermediate 257b
[1049] Trifluoroacetic acid (2 mL) was added to a solution of
(S)-tert-butyl
3-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(methyl)carbamoyl)piperidine-1--
carboxylate (720 mg) in DCM (2 mL) and stirred at RT for 30
minutes. The solvents were removed under vacuum to give a TFA salt
of
(S)--N-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-N-methylpiperidine-3-car-
boxamide (760 mg).
Example 257
(S)-2-(2-(3-(16-(3-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(methyl)carbamo-
yl)piperidin-1-yl)-16-oxo-4,7,10,13-tetraoxahexadecyl)benzamido)-5-(diethy-
lamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1050] To a solution of
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
Example 251 in place of 4.1e and
2,5,8,11,14,17,20-heptaoxadocosan-22-amine in place of
2-methoxyethanamine. To a solution of
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
(50 mg, 0.062 mmol), intermediate 257b (50 mg, 0.086 mmol) and
DIPEA (31 uL, 0.18 mmol) in DMF (1.0 mL) was added HATU (27 mg,
0.070 mmol). The reaction was stirred for 90 minutes and then the
DMF was removed under vacuum. Purification by reverse-phase HPLC
eluting with a water/ACN gradient containing 0.1% TFA gave a TFA
salt of the title compound (65 mg). MS (ES, m/z): 1255.5
[M+H].sup.+.
Example 258
2-(2-(3-(16-(4-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-3-oxopiperazin-1--
yl)-16-oxo-4,7,10,13-tetraoxahexadecyl)benzamido)-5-(diethylamino)phenyl)--
N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00438##
[1052] This compound was prepared using the same method described
for the preparation of Example 257 using a TFA salt of
1-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)piperazin-2-one 135c.5
in place of intermediate 257b. .sup.1H NMR (400 MHz, CD.sub.3OD,
ppm) .delta. 9.44 (t, J=6.0 Hz, 0.4 H), 8.92 (d, J=5.0 Hz, 1H),
8.74 (d, J=8.6 Hz, 1H), 8.39 (s, 1H), 7.99 (br s, 1H), 7.87 (dd,
J.sub.AB=5.1 Hz, J.sub.AC=1.2 Hz, 1H), 7.80-7.76 (m, 2H), 7.69 (s,
1H), 7.64 (d, J=7.6 Hz, 1H), 7.58-7.50 (m, 3H), 7.46 (d, J=5.0 Hz),
4.68 (s, 2H), 4.18 (s, 0.8 H), 4.09 (s, 1.2H), 3.76-3.66 (m, 8H),
3.63-3.45 (m, 44H), 3.31 (s, 3H), 2.80 (t (J=7.4 Hz, 2H), 2.64-2.54
(m, 2H), 1.95-1.87 (m, 2H), 1.20 (t, J=7.2 Hz, 6H). MS (ES, m/z):
1213.5 [M+H].sup.+.
Example 259
2-(5-(diethylamino)-2-(3-(23-methyl-24-oxo-2,5,8,11,14,17,20,27,30,33,36-u-
ndecaoxa-23-azanonatriacontan-39-yl)benzamido)phenyl)-N-(3-(trifluoromethy-
l)benzyl)isonicotinamide
##STR00439##
[1054] This compound was prepared using the same method described
for the preparation of Example 257 using a
N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine 135c.1 in place
of a TFA salt of
(S)--N-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-N-methylpiperidine-3-car-
boxamide. MS (ES, m/z): 1144.4 [M+H].sup.+.
Example 260
2-(5-(diethylamino)-2-(3-(24-oxo-2,5,8,11,14,17,20,27,30,33,36-undecaoxa-2-
3-azanonatriacontan-39-yl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)i-
sonicotinamide
##STR00440##
[1056] This compound was prepared using the same method described
for the preparation of Example 257 using
2,5,8,11,14,17,20-heptaoxadocosan-22-amine 135c.6 in place of a TFA
salt of
(S)--N-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-N-methylpiperidine-3--
carboxamide. MS (ES, m/z): 1130.5 [M+H].sup.+.
Example 261
(S)-2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)benzamido)-5-(-
diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
##STR00441##
[1057] Intermediate 261a
[1058] Into a 500-mL round-bottom flask, was placed a solution of
2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)e-
thoxy)ethanol (15 g, 39.06 mmol, 1.00 equiv) in tetrahydrofuran
(150 mL). This was followed by the addition of sodium hydride (1.9
g, 79.17 mmol, 1.01 equiv), in portions at 0-5.degree. C. in 5 min.
To this was added a solution of 3-bromoprop-1-yne (9.3 g, 78.81
mmol, 2.02 equiv) in toluene (20 mL) dropwise with stirring at
0-5.degree. C. in 5 min. The resulting solution was stirred for 1 h
at 0-5.degree. C. in a water/ice bath. The reaction progress was
monitored by LCMS/TLC (ethyl acetate/petroleum ether=1:1). The
solids were filtered out. The resulting mixture was concentrated
under vacuum. This resulted in 15.9 g (96%) of
3-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethox-
y)ethoxy)ethoxy)prop-1-yne as brown oil
Intermediate 261b
[1059] Into a 250-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
3-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethox-
y)ethoxy)ethoxy)prop-1-yne (12.7 g, 30.09 mmol, 1.00 equiv) in
tetrahydrofuran (150 mL), benzyl 3-iodobenzoate (15.9 g, 47.04
mmol, 1.56 equiv), CuI (720 mg, 3.79 mmol, 0.13 equiv),
Pd(PPh.sub.3).sub.2Cl.sub.2 (2.65 g, 3.77 mmol, 0.13 equiv),
triethylamine (7.6 g, 75.25 mmol, 2.50 equiv). The resulting
solution was stirred for 2 h at room temperature. The reaction
progress was monitored by LCMS/TLC (ethyl acetate/petroleum
ether=4:1). The resulting mixture was concentrated under vacuum.
The resulting solution was diluted with 200 mL of water. The
resulting solution was extracted with 3.times.150 of ethyl acetate
and the organic layers combined. The resulting mixture was washed
with 3.times.100 mL of sodium chloride (aq). The resulting mixture
was concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:2-ethyl
acetate). This resulted in 12.8 g (65%) of benzyl
3-(3-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)et-
hoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate as brown oil.
Intermediate 261c
[1060] Into a 1000-mL round-bottom flask, was placed a solution of
benzyl
3-(3-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)et-
hoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate (23 g, 36.39 mmol, 1.00
equiv) in methanol (200 mL), Palladium carbon (20 g). Hydrogen gas
was introduced to the reaction vessel The resulting solution was
stirred overnight at room temperature. The reaction progress was
monitored by LCMS/TLC (ethyl acetate/petroleum ether=4:1). The
solids were filtered out. The resulting mixture was concentrated
under vacuum. This resulted in 17.2 g (80%) of
3-(3-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)et-
hoxy)ethoxy)ethoxy)propyl)benzoic acid as brown oil. LC-MS (ES,
m/z): 547[M+H].sup.+. H-NMR (300 MHz, CDCl.sub.3, ppm): 7.948-7.920
(m, 2H), 7.425-7.280 (m, 2H), 5.763 (s, 2H), 3.673-3.390 (m, 38H),
2.801-2.750 (t, J=7.8 Hz, 2H), 1.985-1.893 (m, 2H)
##STR00442##
Example 261
(S)-2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)benzamido)-5-(-
diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
[1061] To a solution of 261c (10.9 g, 20.0 mmol, 1.5 eq) in DCM
(100 mL) under N.sub.2 was added oxalyl dichloride (3.04 g, 23.9
mmol, 1.8 eq) and DMF (catalytic). After 1 hour, the solvent was
removed and the crude acid chloride dissolved in dry DCM (30 mL).
The resulting solution was added dropwise to a solution of 131c
(5.5 g, 13.3 mmol, 1 eq) and TEA (5.4 g, 53.2 mmol, 4 eq) in dry
DCM (66 mL) at 0.degree. C. The reaction mixture was allowed to
come to room temperature under an atmosphere of N.sub.2. After 1
hour, the resulting solution was diluted with DCM (40 mL), washed
with water (3.times.75 mL) and brine, and dried over
Na.sub.2SO.sub.4 to give 10.4 g of
(S)-2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)benzamido)-5--
(diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
(98% purity) as a yellow oil. MS (ES, m/z) 943.5 [M+H].sup.+;
.sup.1H NMR (400 MHz, d.sub.6DMSO) .delta. 11.57 (s, 1H), 9.13 (d,
J=8.6 Hz, 1H), 8.85 (d, J=5.1 Hz, 1H), 8.21 (s, 1H), 8.04 (d, J=9.0
Hz, 1H), 7.81 (dd, J=5.1, 1.5 Hz, 1H), 7.70-7.63 (m, 2H), 7.46-7.37
(m, 2H), 7.22-7.02 (m, 5H), 6.85 (dd, J=9.1, 2.9 Hz, 1H), 5.28-5.19
(m, 1H), 3.55-3.45 (m, 32H), 3.44-3.35 (m, 8H), 3.31 (s, 3H), 3.22
(s, 3H), 2.81-2.74 (m, 2H), 2.74-2.66 (m, 2H), 2.04-1.91 (m, 2H),
1.88-1.71 (m, 4H), 1.12 (t, J=7.0 Hz, 6H).
Example 262
2-(2-(3-(16-(4-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)benzoyl)-
piperazin-1-yl)-16-oxo-4,7,10,13-tetraoxahexadecyl)benzamido)-5-(diethylam-
ino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00443## ##STR00444##
[1062] Intermediate 262b:
2-(5-(diethylamino)-2-(3-(16-oxo-16-(piperazin-1-yl)-4,7,10,13-tetraoxahe-
xadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1063] To a mixture of
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
(292 mg, 0.36 mmol), tert-butyl piperazine-1-carboxylate (75 mg,
0.40 mmol) and DIPEA (142 mg, 1.1 mmol) in DMF (3 mL) was added
HATU (160 mg, 0.42 mmol). After 30 minutes, the solvent was removed
under vacuum and the residue was dissolved in DCM (50 mL). This was
washed with water (4.times.25 mL), dried (Na.sub.2SO.sub.4) and
concentrated. The resulting oil was dissolved in DCM (2 mL) and TFA
(2 mL) was added dropwise. After 30 minutes, the solvents were
removed under vacuum. The residue was dissolved in 50% ACN/water
(30 mL) and freeze dried to give the title compound (560 mg) as a
TFA salt.
Example 262
2-(2-(3-(16-(4-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)benzoyl)-
piperazin-1-yl)-16-oxo-4,7,10,13-tetraoxahexadecyl)benzamido)-5-(diethylam-
ino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1064] To a solution of a TFA salt of
2-(5-(diethylamino)-2-(3-(16-oxo-16-(piperazin-1-yl)-4,7,10,13-tetraoxahe-
xadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
(50 mg, 0.041 mmol),
3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)benzoic acid 261c
(22 mg, 0.041 mmol) and DIPEA (26 mg, 0.20 mmol) in DMF (1.0 mL)
was added HATU (27 mg, 0.070 mmol). The reaction was stirred for 90
minutes and then the DMF was removed under vacuum. Purification by
reverse-phase HPLC eluting with a water/ACN gradient containing
0.1% TFA gave a TFA salt of the title compound (33 mg). MS (ES,
m/z): 1405.6 [M+H].sup.+.
Example 263
2-(5-(diethylamino)-2-(3-(16-(4-(4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ph-
enyl)piperazin-1-yl)-16-oxo-4,7,10,13-tetraoxahexadecyl)benzamido)phenyl)--
N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00445##
[1065] Intermediate 263a:
2-(5-(diethylamino)-2-(3-(16-(4-(4-hydroxyphenyl)piperazin-1-yl)-16-oxo-4-
,7,10,13-tetraoxahexadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)-
isonicotinamide
[1066] To a solution of
16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
(300 mg, 0.37 mmol), 4-(piperazin-1-yl)phenol (71 mg, 0.40 mmol)
and DIPEA (142 mg, 1.1 mmol) in DMF (3 mL) was added HATU (160 mg,
0.42 mmol). After 30 minutes, the solvent was removed under vacuum
and the residue was dissolved in DCM (50 mL). This was washed with
water (4.times.25 mL), dried (Na.sub.2SO.sub.4) and concentrated to
give the title compound (379 mg).
Example 263
2-(5-(diethylamino)-2-(3-(16-(4-(4-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ph-
enyl)piperazin-1-yl)-16-oxo-4,7,10,13-tetraoxahexadecyl)benzamido)phenyl)--
N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1067] Finely ground K.sub.2CO.sub.3 (54 mg, 039 mmol) was added to
a solution of
2-(5-(diethylamino)-2-(3-(16-(4-(4-hydroxyphenyl)piperazin-1-yl)-16-oxo-4-
,7,10,13-tetraoxahexadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)-
isonicotinamide (125 mg, 0.13 mmol) and
2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (50 mg,
0.16 mmol) in DMF (0.30 mL), and was heated at 70.degree. C. for 3
hours with stirring. The reaction mixture was cooled to room
temperature and another portion of
2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (75 mg,
0.34 mmol) was added. The mixture was stirred for 3 days at room
temperature and then 5 hours at 70.degree. C. Water (10 mL) was
added to the cooled reaction mixture and extracted with DCM
(3.times.10 mL). The combined organic layers were dried
(Na.sub.2SO.sub.4) and concentrated. Purification by reverse-phase
HPLC eluting with a water/ACN gradient containing 0.1% TFA gave a
TFA salt of the title compound (80 mg). .sup.1H NMR (400 MHz,
CD.sub.3OD, ppm) .delta. 9.44 (t, J=5.0 Hz, 0.6H), 8.93 (dd,
J.sub.AB=5.3 Hz, J.sub.AC=0.6 Hz, 1H), 8.84 (d, J=9.0 Hz, 1H), 8.40
(s, 1H), 8.09 (d, J=2.5 Hz, 1H), 7.88 (dd, J.sub.AB=5.1 Hz.
J.sub.AC=0.5 Hz, 1H), 7.80 (m, 2H), 7.69 (s, 1H), 7.65-7.52 (m,
4H), 7.47 (dd, J.sub.AB=4.1 Hz, J.sub.AC=1.2 Hz, 2H), 7.09 (d,
J=9.0 Hz, 2H), 6.88 (d, J=9.2 Hz), 4.69 (d, J=4.3 Hz 2H), 4.04 (m,
2H), 3.78-3.68 (m, 12H), 3.66-3.63 (m, 2H), 3.62-3.52 (m, 16H),
3.51-3.45 (m, 4H), 3.31 (s, 3H), 3.22 (t, J=4.1 Hz, 2H), 3.16 (t,
J=4.1 Hz, 2H), 2.80 (t, J=7.4 Hz, 2H), 2.64 (t, J=6.3 Hz, 2H), 1.91
(m, 2H), 1.20 (t, J=7.1 Hz, 6H). MS (ES, m/z): 1115.4
[M+H].sup.+.
Example 264
1-(3-(3-(4-chloro-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)ph-
enylcarbamoyl)benzylthio)phenyl)-1-oxo-5,8,11-trioxa-2-azatetradecan-14-oi-
c acid
##STR00446##
[1069] This compound was prepared using the method described for
the preparation of Example 10.1 using
3-(3-(4-chloro-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phen-
ylcarbamoyl)benzylthio)benzoic acid (Example 8.25) in place of
3-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)benzylthio)benzoic acid (8.1) to give a TFA
salt of the title compound. MS (ES, m/z): 879.3 [M+H].sup.+.
Example 265
2-(2-(3-(2,5,8,11,14,17,20,23-octaoxa-26-thiaheptacosan-27-yl)benzamido)-5-
-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00447##
[1070] Example 265
2-(2-(3-(2,5,8,11,14,17,20,23-octaoxa-26-thiaheptacosan-27-yl)benzamido)-5-
-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1071] To a solution of
2-(2-(3-(chloromethyl)benzamido)-5-(diethylamino)phenyl)-N-(3-(trifluorom-
ethyl)benzyl)isonicotinamide 143a (715 mg, 1.2 mmol) and
S-2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl ethanethioate 135c.3
(590 mg, 1.33 mmol) in DMF (10 mL) was added 4.3 M NaOMe in MeOH
(0.37 mL, 1.6 mmol) and stirred at room temperature for 15 minutes.
The reaction mixture was added to water (35 mL) and extracted with
DCM (3.times.50 mL). The combined organic layers were washed with
water (25 mL), dried (Na2SO4) and concentrated at reduced pressure.
The residue was purified by flash chromatography on silica gel (1%
to 5% MeOH in DCM). The purified product was dissolved in 50%
ACN/water and TFA (410 mg, 3.6 mmol) was added. Lyophylization gave
a TFA salt of the title compound (1.34 g) as a light yellow oil. MS
(ES, m/z): 959.4 [M+H].sup.+.
Example 266
2-(5-(diethylamino)-2-(3-(1-hydroxy-3,6,9,12-tetraoxapentadec-14-yn-15-yl)-
benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00448##
[1072] Intermediate 266a.0
[1073] To a suspension of sodium hydride (60% in oil, 740 mg, 18.5
mmol) in THF (50 mL) at 0.degree. C. was added tetraethylene glycol
(4.0 g, 20.6 mmol). After stirring for 15 minutes, propargyl
bromide (80% in toluene, 2.00 mL, 18.0 mmol) was added slowly. The
reaction was allowed to warm to RT and stirred 16 hours. Solids
were removed by filtration and rinsed with MTBE (3.times.20 mL).
The combined filtrates were concentrated and purified by flash
chromatography on silica gel (EtOAc) to give
3,6,9,12-tetraoxapentadec-14-yn-1-ol (2.14 g).
Intermediate 266a:
2-(5-(diethylamino)-2-(3-iodobenzamido)phenyl)-N-(3-(trifluoromethyl)benz-
yl)isonicotinamide
[1074] To a solution of
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide (440 mg, 1.0 mmol), 3-iodobenzoic acid (248 mg, 1.0 mmol)
and DIPEA (387 mg, 3.0 mmol) in DMF (5 mL) was added HATU (418 mg,
1.1 mmol). After one hour, the reaction mixture was added to EtOAc
(150 mL) washed with water (5.times.50 mL) and saturated aqueous
NaCl (25 mL), dried (Na.sub.2SO.sub.4) and concentrated. The
residue was triturated with DCM (3 mL) to give a solid (718 mg)
which was dried under vacuum.
Example 266
2-(5-(diethylamino)-2-(3-(1-hydroxy-3,6,9,12-tetraoxapentadec-14-yn-15-yl)-
benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1075] To a slurry of
2-(5-(diethylamino)-2-(3-iodobenzamido)phenyl)-N-(3-(trifluoromethyl)benz-
yl)isonicotinamide (385 mg, 0.57 mmol),
3,6,9,12-tetraoxapentadec-14-yn-1-ol (175 mg, 0.75 mmol), Et.sub.3N
(3 mL) and THF (2 mL) was added
bis(triphenylphosphine)palladium(II)dichloride (12 mg, 0.017 mmol)
and CuI (10 mg, 0.053 mmol) and purged well with nitrogen. The
reaction mixture was stirred for 13 hours, then concentrated under
vacuum and combined with the crude product from another run (0.15
mmol scale). Purification by flash chromatography on silica gel
eluting (1% to 5% MeOH in DCM) gave the title compound (349 mg).
.sup.1H NMR (400 MHz, CDCl.sub.3, ppm) .delta..quadrature.12.51 (s,
1H), 8.83 (d, J=5.3 Hz, 1H), 8.42 (d, J=9.0 Hz, 1H), 8.21 (s, 1H),
7.99 (t, J=1.6 Hz, 1H), 7.94 (d, J=8.0 Hz, 1H), 7.75-7.68 (m, 2H),
7.65 (s, 1H), 7.60 (d, J=7.3 Hz, 1H), 7.58-7.54 (m, 2H), 7.48 (t,
J=7.6 Hz, 1H), 7.42 (t, J=7.9 Hz, 1H), 6.98 (d, J=2.6 Hz, 1H), 6.76
(d, J=8.8 Hz, 1H), 4.76 (d, J=5.9 Hz, 2H), 4.48 (s, 2H), 3.82-3.80
(m, 2H), 3.72-3.70 (m, 2H), 3.67-3.63 (m, 4H), 3.60 (s, 4H),
3.53-3.51 (m, 2H), 3.32 (quar, J=7.2 Hz, 4H), 2.90 (s, 1H), 1.13
(t, J=6.8 Hz, 6H). MS (ES, m/z): 777.4 [M+H].sup.+.
Example 267
2-(5-(diethylamino)-2-(3-(1-hydroxy-3,6,9,12-tetraoxapentadecan-15-yl)benz-
amido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00449##
[1076] Example 267
2-(5-(diethylamino)-2-(3-(1-hydroxy-3,6,9,12-tetraoxapentadecan-15-yl)benz-
amido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1077] A mixture of
2-(5-(diethylamino)-2-(3-(1-hydroxy-3,6,9,12-tetraoxapentadec-14-yn-15-yl-
)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
(107 mg, 0.014 mmol) and 10% palladium on carbon (water content
50%, 40 mg) in methanol (3 mL) was stirred under one atmosphere of
H.sub.2 for 1 hour. The mixture was filtered and concentrated under
vacuum to give the title compound (92 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3, ppm) .delta..quadrature.12.13 (s, 1H), 8.81 (d, J=5.2
Hz, 1H), 8.39 J=9.0 Hz, 1H), 8.15 (s, 1H), 7.78 (d, J=7.7 Hz, 1H),
7.71 (s, 1H), 7.69 (dd, J.sub.AB=5.1 Hz, J.sub.AC=1.4 Hz, 1H), 7.64
(s, 1H), 7.63-7.54 (m, 3H), 7.47 (t, J=7.5 Hz, 1H), 7.37 (t, J=7.6
Hz, 1H), 7.32 (d, J=7.9 Hz, 1H), 6.95 (d, J=2.8 Hz, 1H), 7.67 (dd,
J.sub.AB=9.0 Hz, J.sub.AC=2.3 Hz, 1H), 4.74 (d, J=6.1 Hz, 2H),
3.66-3.56 (m, 14H), 3.53-3.51 (m, 2H), 3.48 (t, J=6.5 Hz, 2H), 3.32
(quar, J=7.0 Hz, 4H), 2.96 (br s, 1H), 2.77 (t, J=7.2 Hz, 2H),
1.98-1.91 (m, 2H), 1.13 (t, J=6.9 Hz, 6H). MS (ES, m/z): 781.4
[M+H].sup.+.
Example 268
2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacos-28-yn-29-yl)benzamido)-5-(-
diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00450##
[1078] Example 268
[1079] This compound was prepared using the method described for
the preparation of Example 266 using
2,5,8,11,14,17,20,23,26-nonaoxanonacos-28-yne 261a in place of
3,6,9,12-tetraoxapentadec-14-yn-1-ol. Purification by flash
chromatography on silica gel (1% to 4% MeOH in DCM) gave the title
compound. .sup.1H NMR (400 MHz, CDCl.sub.3, ppm)
.delta..epsilon.12.57 (s, 1H), 8.82 (d, J=5.3 Hz, 1H), 8.41 (d,
J=9.0 Hz, 1H), 8.22 (s, 1H), 7.99 (t, J=1.5 Hz, 1H), 7.93 (dt,
J.sub.AB=8.3 Hz, J.sub.AC=1.8 Hz, 1H), 7.75-7.80 (m, 2H), 7.66 (s,
1H), 7.62 (d, J=8.3 Hz, 1H), 7.57-7.54 (m, 2H), 7.49 (d, J=7.6 Hz,
1H), 7.43 (t, J=7.8 Hz), 9.99 (d, J=3.0 Hz, 1H), 6.75 (dd,
J.sub.AB=8.5 Hz, J.sub.AC=2.9 Hz, 1H), 4.75 (d, J=5.9 Hz, 2H), 4.47
(s, 2H), 3.81-3.78 (m, 2H), 3.72-3.69 (m, 2H), 3.65-3.50 (m, 26H),
3.35 (s, 3H), 3.31 (quar, J=7.0 Hz, 4H), 1.12 (t, J=7.0 Hz, 6H). MS
(ES, m/z): 967.4 [M+H].sup.+.
Example 269
2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)benzamido)-5-(diet-
hylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00451##
[1080] Example 269
[1081] This compound was prepared using the method described for
the preparation of Example 269 using
2-(2-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacos-28-yn-29-yl)benzamido)-5--
(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
(Example 267) in place of
2-(5-(diethylamino)-2-(3-(1-hydroxy-3,6,9,12-tetraoxapentadec-14-yn-15-yl-
)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide.
.sup.1H NMR (400 MHz, CDCl.sub.3, ppm) .delta..quadrature.12.30 (s,
1H), 8.81 (m, 1H), 8.46 (s, 1H), 8.21 (s, 1H), 7.79 (d, J=7.4 Hz,
1H), 7.76-7.68 (m, 3H), 7.65 (s, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.55
(d, J=7.6 Hz, 1H), 7.49-7.45 (t, J=7.8 Hz, 1H), 7.38 (t, J=7.4 Hz,
1H), 7.33 (d, J=7.9 Hz, 1H), 7.12 (s, 1H), 6.83 (s, 1H), 4.74 (d,
J=6.0 Hz, 2H), 3.65-3.45 (m, 34H), 3.40-3.30 (m, 4H), 3.35 (s, 3H),
2.78 (t, J=7.2 Hz, 2H), 1.96-1.92 (m, 2H), 1.15 (s, J=7.0 Hz, 6H).
MS (ES, m/z): 971.5 [M+H].sup.+.
Example 270
2-(2-(3-(1-amino-3,6,9,12-tetraoxapentadecan-15-yl)benzamido)-5-(diethylam-
ino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00452##
[1082] Intermediate 270a: benzyl
3-(3-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate
[1083] Into a 500-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of benzyl
3-iodobenzoate (25.68 g, 66.19 mmol, 1.00 equiv) in tetrahydrofuran
(300 mL), 2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethanol
(15.36 g, 66.21 mmol, 1.00 equiv), copper(I) iodide (1.26 g, 6.63
mmol, 0.10 equiv), Pd(PPh.sub.3).sub.2Cl.sub.2 (4.65 g, 6.62 mmol,
0.10 equiv), triethylamine (13.4 g, 132.67 mmol, 2.00 equiv). The
resulting solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with petroleum ether/ethyl acetate
(1:1). This resulted in 20 g (68%) of benzyl
3-(3-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate
as a brown oil.
Intermediate 270b: benzyl
3-(1-(tosyloxy)-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate
[1084] Into a 500-mL 3 neck round-bottom flask purged and
maintained with an inert atmosphere of nitrogen, was placed a
solution of benzyl
3-(1-hydroxy-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate (25.2
g, 56.88 mmol, 1.00 equiv) in dichloromethane (300 mL),
triethylamine (17.2 g, 170.30 mmol, 3.00 equiv). This was followed
by the addition of a solution of 4-methylbenzene-1-sulfonyl
chloride (16.3 g, 85.34 mmol, 1.50 equiv) in dichloromethane (100
mL) dropwise with stirring at 0.degree. C. The resulting solution
was stirred overnight at room temperature. The resulting mixture
was concentrated under vacuum. The residue was applied onto a
silica gel column with petroleum ether/ethyl acetate (5:1-1:1).
This resulted in 31 g (91%) of benzyl
3-(1-(tosyloxy)-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate as a
brown oil.
Intermediate 270c benzyl
3-(1-azido-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate
[1085] Into a 1000-mL round-bottom flask, was placed a solution of
benzyl
3-(1-(tosyloxy)-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate
(35.4 g, 59.30 mmol, 1.00 equiv) in N,N-dimethylformamide (400 mL),
sodium bicarbonate (10 g, 119.05 mmol, 2.00 equiv), sodium azide
(11 g, 169.23 mmol, 3.00 equiv). The resulting solution was stirred
overnight at 80.degree. C. The resulting solution was diluted with
200 mL of water. The resulting solution was extracted with
3.times.100 mL of ethyl acetate and the organic layers combined.
The resulting mixture was washed with 3.times.100 mL of NaHCO.sub.3
aq. The mixture was dried over anhydrous sodium sulfate and
concentrated under vacuum. This resulted in 25 g (90%) of benzyl
3-(1-azido-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate as brown
oil.
Intermediate 270d: benzyl
3-(1-amino-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate
[1086] Into a 500-mL round-bottom flask, was placed a solution of
benzyl 3-(1-azido-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate
(23 g, 49.15 mmol, 1.00 equiv) in tetrahydrofuran (200 mL), water
(20 mL), triphenylphosphine (25.7 g, 98.09 mmol, 2.00 equiv). The
resulting solution was stirred for 3 h at room temperature. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a silica gel column with dichloromethane:methanol
(100:1-50:1). This resulted in 15 g (69%) of benzyl
3-(1-amino-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate as
pale-yellow oil.
Intermediate 270e benzyl
3-(2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicos-19-yn-20-yl)benzoat-
e
[1087] Into a 500-mL round-bottom flask, was placed a solution of
benzyl 3-(1-amino-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate
(15 g, 33.94 mmol, 1.00 equiv) in dichloromethane (200 mL),
triethylamine (6.85 g, 67.82 mmol, 2.00 equiv). This was followed
by the addition of a solution of di-tert-butyl dicarbonate (13.7 g,
62.84 mmol, 2.00 equiv) in dichloromethane (50 mL) dropwise with
stirring at 0.degree. C. The resulting solution was stirred for 5 h
at room temperature. The resulting mixture was concentrated under
vacuum. The residue was applied onto a silica gel column with
petroleum ether/ethyl acetate (5:1-1:1). This resulted in 16 g
(87%) of benzyl
3-(2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicos-19-yn-20-yl)benzoat-
e as pale-yellow oil.
Intermediate 270f
3-(2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicosan-20-yl)benzoic
acid
[1088] Into a 500-mL round-bottom flask, was placed a solution of
benzyl
3-(2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicos-19-yn-20-yl)benzoat-
e (16 g, 29.52 mmol, 1.00 equiv) in methanol (200 mL), Palladium
carbon (10 g). Hydrogen gas was introduced into the reaction
vessel. The resulting solution was stirred for 3 h at room
temperature. The solids were filtered out. The resulting mixture
was concentrated under vacuum. The residue was applied onto a
silica gel column with ethyl acetate/petroleum ether (1:5-1:1).
This resulted in 7 g (52%) of
3-(2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicosan-20-yl)benzoic
acid as pale-yellow oil. LC-MS (ES, m/z): 456 [M+H].sup.+ H-NMR
(300 MHz, DMSO, ppm): 7.76 (dd, J=6.0 Hz, 2H), 7.37-7.47 (m, 2H),
6.73 (s, 1H), 3.35-3.52 (m, 16H), 3.05 (dd, J=11.7 Hz, 2H), 2.69
(t, J=7.5 Hz, 2H), 1.76-1.85 (m, 2H), 1.36 (s, 9H).
##STR00453##
Intermediate 270g: tert-butyl
15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecylcarbamate
[1089] To a solution of 25b (1.81 g, 4.1 mmol, 1.0 eq) and 270f
(1.96 g, 4.3 mmol, 1.05 eq) in DMF (20 mL) was added DIEA (2.2 g,
16.4 mmol, 4.0 eq) and HATU (1.71 g, 4.51 mmol, 1.1 equiv). After
40 minutes the solvent was removed and the residue diluted with
EtOAc (200 mL). The resulting solution was washed with water
(4.times.75 mL), brine, and dried over Na.sub.2SO.sub.4.
Purification on SiO.sub.2 (220 g, 0-100% EtOAc) gave 3.45 g (95%)
of the product as a yellow oil.
Example 270
2-(2-(3-(1-amino-3,6,9,12-tetraoxapentadecan-15-yl)benzamido)-5-(diethylam-
ino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1090] To a solution of compound 270g (3.45 g, 3.9 mmol) in
dichloromethane (15 mL) was added TFA (5 mL). The reaction was
stirred overnight, diluted with dichloromethane (10 mL) and
partitioned with water (25 mL). NaOH was added to bring the
resulting solution to pH 6 and obtain 2.69 g of
2-(2-(3-(1-amino-3,6,9,12-tetraoxapentadecan-15-yl)benzamido)-5-(diethyla-
mino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide as the
free base. MS (ES, m/z) 780.4 [M+H].sup.+
Example 271
2-(2-(3-(1-(3-(2,5,8,11,14,17,20,23,26-nonaoxanonacosan-29-yl)phenyl)-1-ox-
o-5,8,11,14-tetraoxa-2-azaheptadecan-17-yl)benzamido)-5-(diethylamino)phen-
yl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00454##
[1091] Example 271
[1092] This compound was prepared using the method described for
the preparation of Example 262 substituting Example 270 in place of
262b in the reaction sequence. Purification by reverse-phase HPLC
eluting with a water/ACN gradient containing 0.1% TFA gave a TFA
salt of the title compound. MS (ES, m z): 1308.6 [M+H].sup.+.
Example 272
2-(2-(3-(1-(4-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(2-methoxy
ethyl)carbamoyl)phenylsulfonamido)-3,6,9,12-tetraoxapentadecan-15-yl)benz-
amido)-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamid-
e
##STR00455## ##STR00456##
[1093] Intermediate 272a:
4-(N-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)py-
ridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecyl)sulfamoyl)b-
enzoic acid
[1094] A solution of Example 270 (200 mg, 0.25 mmol, 1.0 eq) and
triethylamine (50.5, 0.50 mmol, 2.0 eq) in dichloromethane (5 mL)
under N.sub.2 was cooled to 0.degree. C. 4-(chlorosulfonyl)benzoic
acid (55.15 mg, 0.25 mmol, 1.0 eq) was added and the reaction
warmed to room temperature and monitored by LCMS. After 2 hours,
the resulting solution was diluted with dichloromethane (20 mL) and
washed with water (2.times.20 mL). The organic layer was acidified
to pH 5 with 1N HCl and washed with water (20 mL), brine, and dried
over Na.sub.2SO.sub.4. Removing the solvent resulted in 172 mg of
4-(N-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)py-
ridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecyl)sulfamoyl)b-
enzoic acid as an oil.
Example 272
2-(2-(3-(1-(4-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(2-methoxyethyl)carb-
amoyl)phenylsulfonamido)-3,6,9,12-tetraoxapentadecan-15-yl)benzamido)-5-(d-
iethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
[1095] To a solution of 272a (50 mg, 0.0518 mmol, 1.0 eq) in
dimethylformamide (0.26 mL) was added
N-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxadocosan-22-amine
135c.2 (18.3 mg, 0.0518 mmol, 1.0 eq), DIEA (33.4 mg, 0.259 mmol,
5.0 eq) and HATU (21.7 mg, 0.0569 mmol, 1.1 eq). The resulting
solution was stirred for 1 hour at which LCMS indicated complete
conversion. The reaction mixture was diluted with
acetonitrile/water (1:1, 2 mL), acidified with TFA, and purified by
reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA. The product was obtained as 26.5 mg as an
oil. MS (ES, m/z) 1343.4 [M+H].sup.+; .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.98 (dd, J=5.4, 0.7 Hz, 1H), 8.62 (d, J=8.9
Hz, 1H), 8.49 (dd, J=1.5, 0.8 Hz, 1H), 8.17 (d, J=2.7 Hz, 1H), 8.01
(dd, J=5.4, 1.6 Hz, 1H), 7.86 (d, J=8.4 Hz, 2H), 7.79-7.71 (m, 3H),
7.69 (s, 1H), 7.64 (d, J=7.4 Hz, 1H), 7.62-7.48 (m, 4H), 7.48-7.40
(m, 2H), 4.68 (s, 2H), 3.85-3.68 (m, 7H), 3.68-3.54 (m, 31H),
3.54-3.33 (m, 18H), 3.22 (s, 1H), 3.00 (t, J=5.4 Hz, 2H), 2.83-2.73
(m, 2H), 1.90 (tt, J=12.7, 6.3 Hz, 2H), 1.22 (t, J=7.2 Hz, 6H).
Example 273
2-(5-(diethylamino)-2-(3-(23-methyl-24-oxo-2,5,8,11,14,17,20,28,31,34,37-u-
ndecaoxa-23,25-diazatetracontan-40-yl)benzamido)phenyl)-N-(3-(trifluoromet-
hyl)benzyl)isonicotinamide
##STR00457##
[1097] To a solution of triphosgene (2.0 mg, 0.0069 mmol, 0.3 eq)
in dry DCM (0.25 mL) was added TEA (5.0 mg, 0.05 mmol, 2.0 eq) and
Example 270 (20 mg, 0.025 mmol, 1.0 eq). After 15 minutes, a
solution of N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine
(135c.1) in DCM (0.25 mL) was added and the reaction stirred at
room temperature. After 30 minutes the solvent was removed and the
crude residue diluted with acetonitrile/water (1:1, 2 mL). The
resulting solution was purified by reverse phase HPLC eluting with
a water/CH.sub.3CN gradient containing 0.05% TFA to give 13.6 mg of
the title compound as an oil. MS (ES, m/z) 1159.4 [M+H].sup.+.
Example 274
2-(5-(diethylamino)-2-(3-(1-hydroxy-3-(2-hydroxyethyl)-4-oxo-8,11,14,17-te-
traoxa-3,5-diazaicosan-20-yl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzy-
l)isonicotinamide
##STR00458##
[1099] A solution of Intermediate 270 (20 mg, 0.25 mmol, 1.0 eq) in
dichloromethane (0.25 mL) was added dropwise to a solution of CDI
(4.5 mg, 0.028 mmol, 1.1 eq) in dichloromethane (0.25 mL). After 50
minutes the solvent was removed and the residue dissolved in
acetonitrile (0.5 mL). 2,2'-azanediyldiethanol (2.89 mg, 0.0275
mmol, 1.1 eq) and DMAP (1 mg) was added and the reaction heated to
50.degree. C. After 45 minutes the reaction was removed from heat,
diluted with acetonitrile/water (1:1, 1.5 mL), and purified by
reverse phase HPLC eluting with a water/CH.sub.3CN gradient
containing 0.05% TFA to give 13.0 mg of the title compound as an
oil. MS (ES, m/z) 911.3 [M+H].sup.+.
Examples 275-283
[1100] The compounds listed in Table 9 were prepared by the
procedures described in Example 257 from acids Examples 251, 302
and 303 substituting appropriate amines in the coupling. Mass
spectral data (ES, positive ion mode) is provided for each
compound.
TABLE-US-00010 TABLE 9 Starting Acid Mass Example (Example #)
Structure Spectrum 275 303 ##STR00459## 1186.5 [M + H] 276 303
##STR00460## 1156.5 [M + H] 277 303 ##STR00461## 908.5 [M + H] 278
303 ##STR00462## 924.3 [M + H] 279 302 ##STR00463## 1146.5 [M + H]
280 302 ##STR00464## 1116.5 [M + H] 281 251 ##STR00465## 912.4 [M +
H] 282 302 ##STR00466## 868.5 [M + H] 283 302 ##STR00467## 884.4 [M
+ H]
Example 284
(S)-tert-butyl
16-(3-((4-cyclobutoxy-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-
pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
##STR00468##
[1101] Example 284
(S)-tert-butyl
16-(3-((4-cyclobutoxy-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-
pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
[1102] To a mixture of
(S)-2-(2-amino-5-cyclobutoxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-
isonicotinamide 132b (0.048 mmol, 20 mg),
3-(2,2-dimethyl-4-oxo-3,7,10,13,16-pentaoxanonadecan-19-yl)benzoic
acid (0.053 mmol, 24 mg) and DIEA (0.29 mmol, 38 mg) in DMF (0.16
mL) was added HATU (0.053 mmol, 20 mg). The mixture was stirred at
60.degree. C. for 1 h and purified by prep. TLC to give a yellow
syrup (13.8 mg, 34%). MS (ES, m/z): 836.07 [M+H].sup.+.
Example 285
(S)-16-(3-((4-cyclobutoxy-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamo-
yl)pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
##STR00469##
[1103] Example 285
(S)-16-(3-((4-cyclobutoxy-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamo-
yl)
pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oi-
c acid
[1104] To (S)-tert-butyl
16-(3-((4-cyclobutoxy-2-(4-((1,2,3,4-tetrahydronaphthalen-1-yl)carbamoyl)-
pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oate
Example 284 was added trifluoracetic acid (1 mL). The mixture was
stirred for 5 minutes, concentrated and purified by prep. TLC to
give a yellow syrup (7.2 mg, 64%). MS (ES, m/z):
780.5[M+H].sup.+.
Example 286
(S)-2-(2-(3-(2,5,8,11,14,17,20,23-octaoxa-26-thiaheptacosan-27-yl)benzamid-
o)-5-(diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotin-
amide
##STR00470##
[1105] Example 286
(S)-2-(2-(3-(2,5,8,11,14,17,20,23-octaoxa-26-thiaheptacosan-27-yl)benzamid-
o)-5-(diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotin-
amide
[1106] This compound was prepared from Compound 131c according to
the procedure described in Example 265 using
S-2,5,8,11,14,17,20,23-octaoxapentacosan-25-yl ethanethioate as the
protected thiol. MS (ES, m/z) 931.5 [M+H].sup.+.
Example 287
2-(2-(3-(1-(4-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl(methyl)carbamoyl)ph-
enylsulfonamido)-3,6,9,12-tetraoxapentadecan-15-yl)benzamido)-5-(diethylam-
ino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00471##
[1108] This compound was prepared from
4-(N-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)py-
ridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecyl)sulfamoyl)b-
enzoic acid 272a by following the procedure described in Example
272 using N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine
135c.1 as the amine component in this coupling. MS (ES, m/z) 1299.5
[M+H].sup.+.
Example 288
2-(2-(3-(1-(4-(4-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-3-oxopiperazine-
-1-carbonyl)phenylsulfonamido)-3,6,9,12-tetraoxapentadecan-15-yl)benzamido-
)-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00472##
[1110] This compound was prepared from
4-(N-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)py-
ridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecyl)sulfamoyl)b-
enzoic acid 272a by following the procedure described in Example
272 using
1-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)piperazin-2-one 135c.5
as the amine component in this coupling. MS (ES, m/z) 1368.4
[M+H].sup.+.
Example 289
3-(N-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyr-
idin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecyl)sulfamoyl)be-
nzoic acid
##STR00473##
[1112] This compound was prepared from Intermediate 270 according
to the procedure described in Example 272 using
3-(chlorosulfonyl)benzoic acid as the sulfonyl chloride. MS (ES,
m/z) 964.6 [M+H].sup.+.
Example 290
4-(4-(16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyr-
idin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecane)piperazin-1-
-ylsulfonyl)benzoic acid
##STR00474##
[1113] Example 290
4-(4-(16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyr-
idin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecane)piperazin-1-
-ylsulfonyl)benzoic acid
[1114] To a solution of
2-(5-(diethylamino)-2-(3-(16-oxo-16-(piperazin-1-yl)-4,7,10,13-tetraoxahe-
xadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
262b (50 mg, 0.0505 mmol, 1.0 eq) in DMF (1 mL) was added TEA (19.5
mg, 0.152 mmol, 3.0 eq) and finally 4-(chlorosulfonyl)benzoic acid
(11.1 mg, 0.0505 mmol, 1.0 eq). After 2 hours, the resulting
solution was diluted with acetonitrile/water solution (1:1, 2 mL),
acidified with TFA and purified by reverse phase HPLC eluting with
a water/CH.sub.3CN gradient containing 0.05% TFA. The product was
obtained as 15.8 mg of an oil. MS (ES, m/z) 1061.5 [M+H].sup.+.
Example 291
2-(5-(diethylamino)-2-(3-(16-oxo-16-(4-tolylpiperazin-1-yl)-4,7,10,13-tetr-
aoxahexadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinami-
de
##STR00475##
[1116] This compound was prepared from 262b according to the
procedure described in Example 290 using 4-methylbenzene-1-sulfonyl
chloride as the sulfonyl chloride. MS (ES, m/z) 1031.4
[M+H].sup.+.
Example 292
2-(5-(diethylamino)-2-(3-(16-(4-(isopropylsulfonyl)piperazin-1-yl)-16-oxo--
4,7,10,13-tetraoxahexadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl-
)isonicotinamide
##STR00476##
[1118] This compound was prepared from 262b according to the
procedure described in Example 290 using propane-2-sulfonyl
chloride as the sulfonyl chloride. MS (ES, m/z) 983.9
[M+H].sup.+.
Example 293
16-(3-(4-(16-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl-
)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecane)piperaz-
ine-1-carbonyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
##STR00477##
[1120] To a solution of
2-(5-(diethylamino)-2-(3-(16-oxo-16-(piperazin-1-yl)-4,7,10,13-tetraoxahe-
xadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
262b (56.1 mg, 0.072 mmol, 1.0 eq) and
4-(2,2-dimethyl-4-oxo-3,7,10,13,16-pentaoxanonadecan-19-yl)benzoic
acid 251c (31.7 mg, 0.72 mmol, 1.0 eq) in DMF (0.5 mL) was added
DIEA (46.5 mg, 0.36 mmol, 5.0 eq) and HATU (30.1 mg, 0.0792 mmol,
1.1 eq). After 4 hours the resulting solution was diluted with
EtOAc (10 mL) and washed with water (3.times.5 mL) and brine, and
dried over Na.sub.2SO.sub.4. The solvent was removed and the
resulting crude material diluted with dichloromethane (2 mL). TFA
(0.5 mL) was added and the reaction stirred for 30 minutes to
remove the ester. The solvent was removed and the resulting residue
diluted with acetonitrile/water (1:1, 2 mL) and purified by reverse
phase HPLC eluting with a water/CH.sub.3CN gradient containing
0.05% TFA. The product was obtained as 55.2 mg of an oil. MS (ES,
m/z) 1243.5 [M+H].sup.+.
Example 294
3-(4-(N-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecyl)sulfamoyl-
)phenyl)propanoic acid
##STR00478##
[1121] Example 294
3-(4-(N-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecyl)sulfamoyl-
)phenyl)propanoic acid
[1122] This compound was prepared from Example 270 according to the
procedure described in Example 272 using
3-(4-(chlorosulfonyl)phenyl)propanoic acid as the sulfonyl
chloride. MS (ES, m/z) 992.9 [M+H].sup.+; .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 9.42 (t, J=5.9 Hz, 1H), 8.92 (d, J=5.2 Hz, 1H),
8.80 (d, J=9.2 Hz, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 7.87 (dd,
J=5.2, 1.5 Hz, 1H), 7.83-7.75 (m, 2H), 7.71-7.66 (m, 3H), 7.64 (d,
J=7.5 Hz, 1H), 7.60-7.48 (m, 3H), 7.46 (d, J=5.0 Hz, 2H), 7.35 (d,
J=8.5 Hz, 2H), 4.68 (s, 2H), 3.72 (q, J=7.1 Hz, 4H), 3.65-3.53 (m,
9H), 3.52-3.46 (m, 5H), 3.42-3.37 (m, 2H), 3.36-3.31 (m, 2H),
2.98-2.89 (m, 4H), 2.83-2.75 (m, 2H), 2.59 (t, J=7.5 Hz, 2H), 1.91
(dq, J=12.8, 6.3 Hz, 2H), 1.20 (t, J=7.2 Hz, 6H).
Example 295
2-(5-(diethylamino)-2-(3-(1-(4-(23-(2-methoxyethyl)-24-oxo-2,5,8,11,14,17,-
20-heptaoxa-23-azahexacosan-26-yl)phenylsulfonamido)-3,6,9,12-tetraoxapent-
adecan-15-yl)benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamid-
e
##STR00479##
[1124] This compound was prepared from compound Example 294
according to the procedure described in Example 272 using
N-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxadocosan-22-amine as
the amine component in this coupling. MS (ES, m/z) 1371.6
[M+H].sup.+.
Example 296
2-(5-(diethylamino)-2-(3-(1-(4-(24-oxo-2,5,8,11,14,17,20-heptaoxa-23-azahe-
xacosan-26-yl)phenylsulfonamido)-3,6,9,12-tetraoxapentadecan-15-yl)benzami-
do)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide
##STR00480##
[1126] This compound was prepared from compound Example 294
according to the procedure described in Example 272 using
2,5,8,11,14,17,20-heptaoxadocosan-22-amine as the amine component
in this coupling. MS (ES, m/z) 1313.6 [M+H].sup.+.
Example 297
16-(4-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)py-
ridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecylcarbamoyl)ph-
enyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
##STR00481##
[1127] Example 297
16-(4-(15-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)py-
ridin-2-yl)phenylcarbamoyl)phenyl)-3,6,9,12-tetraoxapentadecylcarbamoyl)ph-
enyl)-4,7,10,13-tetraoxahexadecan-1-oic acid
[1128] This compound was prepared from Example 270 the procedure
described in Example 293 using
4-(2,2-dimethyl-4-oxo-3,7,10,13,16-pentaoxanonadecan-19-yl)benzoic
acid as the acid component in the coupling. MS (ES, m/z) 1146.6
[M+H].sup.+.
Example 298
31-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-4,7,10,13,16,19,22,25,28-nonaoxahentriacontan--
1-oic acid
##STR00482##
[1129] Intermediate 298a:
3,6,9,12,15,18,21,24-octaoxaheptacos-26-yn-1-ol
[1130] Into a 500-mL round-bottom flask, was placed a solution of
3,6,9,12,15,18,21-heptaoxatricosane-1,23-diol (6.7 g, 18.11 mmol,
1.00 equiv) in tetrahydrofuran (200 mL). This was followed by the
addition of sodium hydride (724 mg, 18.10 mmol, 1.00 equiv, 60%) in
several batches at 0-5.degree. C. in 30 min. The resulting solution
was stirred for 30 min at 0.degree. C. To this was added a solution
of 3-bromoprop-1-yne (2.24 g, 18.82 mmol, 1.04 equiv) in
tetrahydrofuran (100 mL) dropwise with stirring at 0-5.degree. C.
in 1 h. The reaction progress was monitored by LCMS. The resulting
solution was allowed to react, with stirring, for an additional 1 h
at room temperature. The solids were filtered out. The residue was
applied onto a silica gel column with dichloromethane:methanol
(50:1). This resulted in 3 g (40%) of intermediate 298a as light
yellow oil.
##STR00483##
Intermediate 298b: tert-butyl
3-(2-(2-(2-(2-(2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)eth-
oxy)ethoxy)ethoxy)ethoxy)propanoate
[1131] Into a 500-mL round-bottom flask, was placed a solution of
2-(2-(2-(2-(2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy-
)ethoxy)ethoxy)ethanol (22.3 g, 54.66 mmol, 1.00 equiv) in
tetrahydrofuran (100 mL), Na (75 mg, 3.26 mmol, 0.06 equiv). This
was followed by the addition of a solution of tert-butyl acrylate
(8.4 g, 65.62 mmol, 1.20 equiv) in tetrahydrofuran (100 mL)
dropwise with stirring. The resulting solution was stirred
overnight at room temperature. The pH value of the solution was
adjusted to 7 with hydrogen chloride (1 mol/L). The resulting
mixture was concentrated under vacuum. The residue was applied onto
a silica gel column with dichloromethane/methanol (200:1). This
resulted in 14.5 g (49%) of intermediate 298b as yellow oil.
##STR00484##
Intermediate 298c
[1132] Into a 250-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
tert-butyl
3-(2-(2-(2-(2-(2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)eth-
oxy)ethoxy)ethoxy)ethoxy)propanoate (10.1 g, 18.84 mmol, 1.00
equiv) in tetrahydrofuran (200 mL), benzyl 3-iodobenzoate (7 g,
20.71 mmol, 1.00 equiv), copper(I) iodide (358 mg, 1.88 mmol, 0.10
equiv), Pd(PPh.sub.3)Cl.sub.2 (1.32 g, 1.88 mmol, 0.10 equiv),
triethylamine (3.8 g, 37.62 mmol, 2.00 equiv). The resulting
solution was stirred for 3 h at room temperature. The resulting
mixture was concentrated under vacuum. The residue was dissolved in
100 mL of ethyl acetate. The solids were filtered out. The filtrate
was washed with 3.times.100 mL of brine. The mixture was dried over
anhydrous sodium sulfate and concentrated under vacuum. The residue
was applied onto a silica gel column with dichloromethane/methanol
(100:1). This resulted in 6.4 g (46%) of intermediate 298c as red
oil.
##STR00485##
Intermediate 298d:
3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19,22,25,28,31-decaoxatetratriacontan--
34-yl)benzoic acid
[1133] Into a 250 mL roundbottom flask, was placed a solution of
intermediate 298c (6.4 g, 8.58 mmol, 1.00 equiv) in methanol (100
mL), Palladium carbon (6.5 g, 60.19 mmol, 7.02 equiv). Hydrogen gas
was introduced into the reaction vessel. The resulting solution was
stirred overnight at room temperature. The solids were filtered
out. The resulting mixture was concentrated under vacuum. This
resulted in 5.6 g (99%) of intermediate 298d as dark green oil.
LC-MS (ES, m/z): 683 [M+Na].sup.+ H-NMR (300 MHz, CDCl.sub.3, ppm):
7.93 (m, 2H), 7.38 (m, 2H), 3.75-3.60 (m, 36H), 3.48 (t, 2H), 3.13
(m, 4H), 2.79 (t, 2H), 2.53 (t, 2H), 1.95 (m, 2H), 1.47 (s,
9H).
##STR00486##
Intermediate 298e: tert-butyl
31-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin--
2-yl)phenylcarbamoyl)phenyl)-4,7,10,13,16,19,22,25,28-nonaoxahentriacontan-
-1-oate
[1134] To a solution of
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide 25b 1.4 g, 3.16 mmol, 1.1 eq) and
3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19,22,25,28,31-decaoxatetratriacontan--
34-yl)benzoic acid (1.95 g, 2.95 mmol, 1.0 eq) in DMF (15 mL) was
added DIEA (1.63 g, 12.64 mmol, 4.3 eq) and HATU (1.32 g, 3.48
mmol, 1.2 eq). After 1 hour the solvent was removed and the
resulting residue diluted with EtOAc (150 mL), washed with water
(4.times.75 mL) and brine, and dried over Na.sub.2SO.sub.4. The
crude reaction mixture was purified by flash column chromatography
(80 g SiO.sub.2, 0 to 4% MeOH in DCM) to give 2.28 g of
intermediate 298e as a yellow oil.
##STR00487##
Example 298
31-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-4,7,10,13,16,19,22,25,28-nonaoxahentriacontan--
1-oic acid
[1135] Intermediate 298e (2.28 g, 2.1 mmol) was dissolved in
dichloromethane (10 mL) and TFA (5 mL) was added. The reaction was
stirred at room temperature for one hour at which point solvent was
removed. The TFA salt was dissolved in EtOAc (15 mL) and
partitioned with water (10 mL). The pH was adjusted to 5.5 with 1N
HCl and the organic layer diluted with EtOAc (75 mL), washed with
water (50 mL). The aqueous layer was extracted with additional
EtOAc (3.times.50 mL) until no color remained. The combined organic
layers were washed with brine and dried over Na.sub.2SO.sub.4 to
give 1.99 g of the free base. This was dissolved in acetonitrile (5
mL) and water (2 mL), NaOH was added (1 eq), and the resulting
solution lyophilized to give the 1.81 g of Example 298 as a yellow
powder. MS (ES, m/z) 1029.6 [M+H].sup.+. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.99 (dd, J=5.5, 0.7 Hz, 1H), 8.54-8.49 (m,
2H), 8.20 (d, J=2.7 Hz, 1H), 8.07 (dd, J=5.5, 1.6 Hz, 1H), 7.79
(dd, J=8.9, 2.7 Hz, 1H), 7.76-7.70 (m, 2H), 7.69 (s, 1H), 7.64 (d,
J=7.5 Hz, 1H), 7.57 (d, J=7.9 Hz, 1H), 7.53 (d, J=7.6 Hz, 1H),
7.46-7.41 (m, 2H), 4.67 (s, 2H), 3.77 (q, J=7.2 Hz, 4H), 3.68 (t,
J=6.3 Hz, 2H), 3.63-3.53 (m, 31H), 3.47 (t, J=6.2 Hz, 2H), 3.29
(dt, J=3.3, 1.7 Hz, 8H), 2.81-2.74 (m, 2H), 2.50 (t, J=6.3 Hz, 2H),
1.23 (t, J=7.2 Hz, 6H).
Example 299
22-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-4,7,10,1316,19-hexaoxadocosan-1-oic
acid
##STR00488##
[1136] Intermediate 299a:
3,6,9,12,15-pentaoxaoctadec-17-yn-1-ol
[1137] Into a 1000-mL 3-necked round-bottom flask, was placed a
solution of 3,6,9,12-tetraoxatetradecane-1,14-diol (60 g, 251.78
mmol, 0.90 equiv) in tetrahydrofuran (300 mL). This was followed by
the addition of sodium hydride (6.7 g, 0.66 equiv, 60%) at
0-10.degree. C. The mixture was stirred for 0.5 h at 0-10.degree.
C. To this was added a solution of 3-bromoprop-1-yne (33.32 g,
280.00 mmol, 1.00 equiv) in tetrahydrofuran (100 mL) dropwise with
stirring in 1.5 h. The resulting solution was stirred for 2 h at
0.about.10.degree. C. The solids were filtered out. The resulting
mixture was concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether
(4:1.about.2:1). This resulted in 32.1 g (41%) of intermediate 299a
as light yellow oil.
##STR00489##
Intermediate 299b
[1138] Into a 1000-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
3,6,9,12,15-pentaoxaoctadec-17-yn-1-ol (62.2 g, 225.12 mmol, 1.00
equiv) in tetrahydrofuran (500 mL), sodium (155.3 mg, 6.75 mmol,
0.03 equiv). The mixture was stirred for 30 minutes at room
temperature. This was followed by the addition of a solution of
tert-butyl acrylate (28.8 g, 224.65 mmol, 1.00 equiv) in
tetrahydrofuran (100 mL) dropwise with stirring. The resulting
solution was stirred overnight at room temperature. The pH value of
the solution was adjusted to 7 with hydrogen chloride (1.2N mol/1).
The resulting mixture was concentrated under vacuum. The residue
was dissolved in 500 ml of ethyl acetate. The mixture was dried
over anhydrous sodium sulfate and concentrated under vacuum. The
residue was applied onto a silica gel column with petroleum
ether/ethyl acetate (8:1.about.1:1). This resulted in 44 g (48%) of
intermediate 299b as light yellow oil.
##STR00490##
Intermediate 299c: tert-butyl
22-(3-(benzyloxycarbonyl)phenyl)-4,7,10,13,16,19-hexaoxadocos-21-yn-1-oat-
e
[1139] Into a 500-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
tert-butyl 4,7,10,13,16,19-hexaoxadocos-21-yn-1-oate (37.48 g,
92.66 mmol, 1.00 equiv) in tetrahydrofuran (200 mL), benzyl
3-iodobenzoate (34.5 g, 102.04 mmol, 1.10 equiv), copper(I) iodide
(1.77 g, 9.29 mmol, 0.10 equiv), Pd(PPh.sub.3).sub.2Cl.sub.2 (6.50
g, 9.26 mmol, 0.10 equiv), triethylamine (18.72 g, 185.35 mmol,
2.00 equiv). The resulting solution was stirred for 4 h at room
temperature. The resulting mixture was concentrated under vacuum.
The residue was dissolved in 200 ml of ethyl acetate. The solids
were filtered out. The resulting mixture was concentrated under
vacuum. The residue was applied onto a silica gel column with
petroleum ether/ethyl acetate (2:1.about.1:2). This resulted in
19.2 g (34%) of intermediate 299c as brown oil.
##STR00491##
Intermediate 299d
[1140]
3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19,22-heptaoxapentacosan-25-yl)b-
enzoic acid. Into a 250-mL round-bottom flask, was placed a
solution of tert-butyl
22-(3-(benzyloxycarbonyl)phenyl)-4,7,10,13,16,19-hexaoxadocos-21-yn-1-oat-
e (12.5 g, 20.36 mmol, 1.00 equiv) in methanol (200 mL), Palladium
on carbon (25 g). Hydrogen gas was introduced into the reaction
vessel. The resulting solution was stirred for 5 h at room
temperature. The solids were filtered out. The resulting mixture
was concentrated under vacuum. The crude product was washed with
2.times.30 mL of n-hexane. This resulted in 9.8 g (87%) of
intermediate 299d as brown oil. LC-MS (ES, m/z): 551 [M+Na].sup.+
H-NMR (400 MHz, CDCl.sub.3, ppm): 7.93.about.7.90 (m, 2H),
7.37.about.7.31 (m, 2H), 4.68 (s, 2H), 3.72.about.3.56 (m, 22H),
3.48.about.3.42 (m, H), 2.75 (tri, Jl=5.4 Hz, Jr=5.7 Hz, 2H), 2.50
(tri, Jl=4.8 Hz, Jr=5.1 Hz, 2H), 1.94.about.1.87 (m, 2H),
1.43.about.1.38 (m, 9H).
##STR00492##
Example 299
22-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-4,7,10,13,16,19-hexaoxadocosan-1-oic
acid
[1141] This compound was prepared from
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide 25b using the procedures described in Example 251 using
3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19,22-heptaoxapentacosan-25-yl)benzoic
acid 299d as the protected acid component in the coupling. MS (ES,
m/z) 897.9 [M+H].sup.+; .sup.1H NMR (400 MHz, d.sub.6 DMSO) .delta.
11.77 (s, 1H), 10.60 (t, J=5.9 Hz, 1H), 8.78 (d, J=5.2 Hz, 1H),
8.50 (s, 1H), 7.81 (d, J=5.1 Hz, 1H), 7.76 (s, 2H), 7.73 (s, 1H),
7.68 (s, 1H), 7.65-7.58 (m, 3H), 7.58-7.53 (m, 2H), 7.49 (t, J=7.9
Hz, 1H), 7.36-7.26 (m, 2H), 6.99 (d, J=3.0 Hz, 1H), 6.79 (dd,
J=9.0, 3.0 Hz, 1H), 4.57 (d, J=6.0 Hz, 2H), 3.56-3.30 (m, 43H),
2.68-2.58 (m, 2H), 2.07 (t, J=7.5 Hz, 2H), 1.77 (p, J=6.1 Hz, 2H),
1.09 (t, J=7.0 Hz, 6H).
Example 300
19-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-
-yl)phenylcarbamoyl)phenyl)-4,7,10,13,16-pentaoxanonadecan-1-oic
acid
##STR00493##
[1143] This compound was prepared according to the procedure
described for the synthesis of Example 251 substituting
2,2'-(2,2'-oxybis(ethane-2,1-diyl)bis(oxy))diethanol for
triethylene glycol as a starting material. MS (ES, m/z) 853.6
[M+H].sup.+. .sup.1H NMR (400 MHz, d.sub.6DMSO) .delta. 11.81 (s,
1H), 10.76 (s, 1H), 8.77 (d, J=5.1 Hz, 1H), 8.55 (s, 1H), 7.82 (d,
J=5.0 Hz, 1H), 7.78 (s, 1H), 7.72-7.66 (m, 2H), 7.64-7.52 (m, 4H),
7.48 (t, J=7.7 Hz, 1H), 7.35-7.24 (m, 2H), 6.98 (d, J=3.0 Hz, 1H),
6.78 (dd, J=8.8, 3.0 Hz, 1H), 4.57 (d, J=5.7 Hz, 3H), 3.57-3.30 (m,
37H), 2.67-2.57 (m, 3H), 2.08 (t, J=7.5 Hz, 2H), 1.82-1.71 (m, 2H),
1.09 (t, J=7.0 Hz, 7H).
Example 302
(S)-16-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamo-
yl)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
##STR00494##
[1144] Example 302
(S)-16-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamo-
yl)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,
7,10,13-tetraoxahexadecan-1-oic acid
[1145] This compound was prepared according to the procedure
described for the synthesis of Example 251 substituting 131c in
place of 25b. MS (ES, m/z) 781.4 [M+H].sup.+.
Example 303
16-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
##STR00495##
[1146] Example 303
16-(3-(4-(piperidin-1-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oic
acid
[1147] This compound was prepared according to the procedure
described for the synthesis of Example 251 substituting 4.1c in
place of 25b. MS (ES, m/z) 821.5 [M+H].sup.+.
Example 304
(S)-22-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamo-
yl)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13,16,19-hexaoxadocosan-1-o-
ic acid
##STR00496##
[1149] This compound was prepared from 131c according to the
procedures described in Example 251 using
3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19,22-heptaoxapentacosan-25-yl)benzoic
acid 299d as the protected acid component. MS (ES, m/z) 869.6
[M+H].sup.+; .sup.1H NMR (400 MHz, d.sub.6 DMSO) .delta. 11.63 (s,
1H), 9.38 (d, J=8.3 Hz, 1H), 8.79 (d, J=5.2 Hz, 1H), 8.29 (s, 1H),
7.88 (d, J=9.0 Hz, 1H), 7.79 (d, J=6.3 Hz, 1H), 7.69 (s, 1H),
7.65-7.58 (m, 1H), 7.39-7.31 (m, 2H), 7.17-6.97 (m, 6H), 6.79 (dd,
J=10.2, 1.5 Hz, 1H), 5.23-5.12 (m, 1H), 3.53-3.31 (m, 36H),
2.78-2.70 (m, 2H), 2.68-2.59 (m, 3H), 2.03-1.87 (m, 5H), 1.84-1.73
(m, 4H), 1.09 (t, J=6.9 Hz, 6H).
Example 306
(S)-19-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamo-
yl)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13,16-pentaoxanonadecan-1-o-
ic acid
##STR00497##
[1151] This compound was prepared from 131c according to the
procedures described in Example 251 and Example 300 using
3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19-hexaoxadocosan-22-yl)benzoic
acid as the protected acid component. MS (ES, m/z) 825.9
[M+H].sup.+.
Examples 320-326
[1152] The compounds listed in table 10 were prepared by the
procedures described in Examples 262 and 272 from amine 270 and
270.1. Mass spectral data (ES, positive ion mode) is provided for
each compound.
##STR00498##
Intermediate 270.1
(S)-2-(2-(3-(1-amino-3,6,9,12-tetraoxapentadecan-15-yl)benzamido)-5-(diet-
hylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)isonicotinamide
[1153] This compound was prepared from
(S)-2-(2-amino-5-(diethylamino)phenyl)-N-(1,2,3,4-tetrahydronaphthalen-1--
yl)isonicotinamide 131c according to the procedures described in
Example 270 using 270f as the protected acid. MS (ES, m/z) 752.4
[M+H].sup.+.
TABLE-US-00011 TABLE 10 Method Exam- from Mass ple Example
Structure Spectrum 320 272 ##STR00499## 964.6 [M + H] 321 272
##STR00500## 952.5 [M + H] 322 262 ##STR00501## 914.6 [M + H] 323
262 ##STR00502## 846.5 [M + H] 324 262 ##STR00503## 857.4 [M + H]
325 262 ##STR00504## 872.5 [M + H] 326 262 ##STR00505## 863.5 [M +
H]
Example 327
(S)--N1-(2-(4-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-3-oxopiperazin-1-y-
l)ethyl)-N3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarba-
moyl)pyridin-2-yl)phenyl)-N1-methylisophthalamide
##STR00506##
[1155]
(S)--N1-(2-(4-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-3-oxopipera-
zin-1-yl)ethyl)-N3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1--
ylcarbamoyl)pyridin-2-yl)phenyl)-N1-methylisophthalamide: This
compound was prepared from 197a according to the procedure
described in Example 197 using
1-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)piperazin-2-one 135c.5
as the amine. MS (ES, m/z) 1024.4 [M+H].
Example 328
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl-
)pyridin-2-yl)phenyl)-N3-(23-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxa-2-
3-azapentacosan-25-yl)-N3-methylisophthalamide
##STR00507##
[1156] Example 328
(S)--N1-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl-
)pyridin-2-yl)phenyl)-N3-(23-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxa-2-
3-azapentacosan-25-yl)-N3-methylisophthalamide
[1157] This compound was prepared from 197a according to the
procedure described in Example 197 using
N-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxadocosan-22-amine as
the amine. MS (ES, m/z) 999.4 [M+H].sup.+.
Example 329
tert-butyl
3-methyl-1-[N-methyl-1-(3-{[4-(piperidin-1-yl)-2-(4-{[(1S)-1,2,-
3,4-tetrahydronaphthalen-1-yl]carbamoyl}pyridin-2-yl)phenyl]carbamoyl}phen-
yl)formamido]-6,9,12-trioxa-3-azapentadecan-15-oate
##STR00508##
[1158] Example 329
[1159] This compound was prepared from intermediate 187a according
to the procedure described in Example 197 using tert-butyl
5,8,11-trioxa-2-azatetradecan-14-oate as the amine. MS (ES, m/z)
905.3 [M+H].sup.+.
Example 330
2-(2-(2-(3-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)-N,N,N-triethylet-
hanaminium
##STR00509##
[1160] Intermediate 330a.0. Benzyl
3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate
[1161] This compound was prepared in a manner analogous to that
described in Example 270b from benzyl 3-iodobenzoate by
substituting
2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethanol for the
alkyne.
Intermediate 330a
[1162] Into a 100-mL round-bottom flask, was placed a solution of
benzyl
3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate
(300 mg, 0.54 mmol, 1.00 equiv) in butanone (5 mL), a solution of
triethylamine (2 mL) in ethanol (2 mL). The resulting solution was
stirred overnight at 80.degree. C. in an oil bath. The resulting
mixture was concentrated under vacuum. This resulted in 250 mg
(96%) of
2-(2-(2-(3-(3-(benzyloxycarbonyl)phenyl)prop-2-ynyloxy)ethoxy)ethoxy)-N,N-
,N-triethylethanaminium as brown oil.
Intermediate 330b
[1163] Into a 100-mL round-bottom flask, was placed a solution of
2-(2-(2-(3-(3-(benzyloxycarbonyl)phenyl)prop-2-ynyloxy)ethoxy)ethoxy)-N,N-
,N-triethylethanaminium (250 mg, 0.52 mmol, 1.00 equiv) in methanol
(20 mL), Palladium carbon (250 mg). Hydrogen gas was introduced
into the reaction vessel. The resulting solution was stirred
overnight at room temperature. The solids were filtered out. The
resulting mixture was concentrated under vacuum. This resulted in
200 mg (97%) of
2-(2-(2-(3-(3-carboxyphenyl)propoxy)ethoxy)ethoxy)-N,N,N-triethylethanami-
nium as brown oil.
Example 330
[1164] Into a 100-mL round-bottom flask, was placed a solution of
2-(2-(2-(3-(3-carboxyphenyl)propoxy)ethoxy)ethoxy)-N,N,N-triethylethanami-
nium (107 mg, 0.27 mmol, 1.19 equiv) in dichloromethane (20 mL),
EDC.HCl (65 mg, 0.34 mmol, 1.50 equiv), 4-dimethylaminopyridine (42
mg, 0.34 mmol, 1.52 equiv),
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide (100 mg, 0.23 mmol, 1.00 equiv). The resulting solution was
stirred overnight at room temperature. The resulting solution was
diluted with 30 mL of dichloromethane. The resulting mixture was
washed with 2.times.100 mL of NH.sub.4Cl (aq). The mixture was
dried over sodium sulfate and concentrated under vacuum. The crude
product (150 mg) was purified by Prep-HPLC with the following
conditions (1#-Pre-HPLC-001(SHIMADZU)): Column, SunFire Prep C18,
19*150 mm 5 um; mobile phase, water with 0.05% TFA and CH3CN (27%
CH3CN up to 45% in 6 min, up to 100% in 1 min, down to 27% in 0.7
min); Detector, Waters2545 UvDector 254&220 nm. This resulted
in 28.1 mg (15%) of
2-(2-(2-(3-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)-N,N,N-triethyle-
thanaminium as yellow oil. LC-MS (ES, m/z): 820 [M+H].sup.+ H-NMR
(400 MHz, CD3OD, ppm): 8.95 (s, 1H), 8.82 (d, J=9.2 Hz, 1H), 8.46
(s, 1H), 8.14 (s, 1H), 7.92.about.7.91 (m, 1H), 7.85.about.7.83 (m,
2H), 7.72.about.7.67 (m, 2H), 7.62.about.7.51 (m, 5H), 4.72 (s,
2H), 3.86 (s, 2H), 3.78.about.3.72 (m, 4H), 3.66.about.3.60 (m,
8H), 3.55.about.3.47 (m, 4H), 3.43.about.3.37 (m, 6H),
2.85.about.2.83 (m, 2H), 1.99.about.1.95 (m, 2H), 1.30.about.1.23
(m, 14H).
Example 331
1-(2-(2-(2-(3-(4-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoy-
l)pyridin-2-yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethyl)-1-azoni-
a-bicyclo[2.2.2]octane
##STR00510##
[1165] Intermediate 331a
[1166] Into a 50-mL round-bottom flask, was placed a solution of
benzyl
3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate
(300 mg, 0.54 mmol, 1.00 equiv) in methanol (3 mL), Palladium
carbon (1.0 g). Hydrogen gas was introduced into the reaction
vessel. The resulting solution was stirred for 2 days at 25.degree.
C. The reaction progress was monitored by LCMS, TLC (ethyl
acetate/petroleum ether=1:1). The solids were filtered out. The
resulting mixture was concentrated under vacuum. This resulted in
0.2 g (79%) of
3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid as
a yellow crude solid.
Intermediate 331b
[1167] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed
2-(2-amino-5-(diethylamino)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti-
namide (150 mg, 0.34 mmol, 1.00 equiv),
3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid
(190 mg, 0.41 mmol, 1.20 equiv), EDCl (97.6 mg, 0.51 mmol, 1.50
equiv), 4-dimethylaminopyridine (62.2 mg, 0.51 mmol, 1.50 equiv),
dichloromethane (2 mL). The resulting solution was stirred
overnight at 25.degree. C. The resulting mixture was washed with
2.times.2 mL of brine. The mixture was dried over anhydrous sodium
sulfate and concentrated under vacuum. The residue was applied onto
a silica gel column with ethyl acetate/petroleum ether (1:2). This
resulted in 200 mg (66%) of
2-(2-(2-(3-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethyl
4-methylbenzenesulfonate as yellow oil.
Example 331
[1168] Into a 25-mL round-bottom flask, was placed a solution of
2-(2-(2-(3-(4-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (200 mg, 0.22 mmol, 1.00 equiv) in
butanone (2 mL), quinuclidine (5 g, 44.97 mmol, 200.00 equiv). The
resulting solution was stirred overnight at 25.degree. C. The
resulting mixture was concentrated under vacuum. The crude product
(200 mg) was purified by Prep-HPLC with the following conditions
(1#-Pre-HPLC-001(SHIMADZU)): Column, SunFire Prep C18, 19*150 mm 5
um; mobile phase, water with 0.05% TFA and CH.sub.3CN (27%
CH.sub.3CN up to 47% in 6 min, up to 100% in 1 min, down to 27% in
0.7 min); Detector, Waters2545 UvDector 254&220 nm. This
resulted in 97.4 mg (52%) of
1-(2-(2-(2-(3-(4-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamo-
yl)pyridin-2-yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethyl)-1-azon-
ia-bicyclo[2.2.2]octane as a yellow semi-solid. LC-MS (ESI, m/z):
831[M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD, ppm): .delta. 8.97 (d,
J=3 Hz, 1H), 8.84 (d, J=9 Hz, 1H), 8.45 (s, 1H), 8.16 (s, 1H),
7.91-7.93 (m, 1H), 7.83-7.86 (m, 2H), 7.56-7.73 (m, 5H), 7.51-7.53
(m, 2H), 4.73 (s, 2H), 3.89 (s, 2H), 3.73-3.80 (m, 4H), 3.61-3.66
(m, 8H), 3.49-3.56 (m, 8H), 3.34-3.36 (m, 2H), 2.85 (t, J=9 Hz,
2H), 2.12-2.14 (m, 1H), 1.94-2.01 (m, 8H), 1.25 (t, J=7.2 Hz,
6H).
Example 332
N-(3-(trifluoromethyl)benzyl)-2-(5-(diethylamino)-2-(3-(3-(2-(2-(2-(2-(3-h-
ydroxy-2,2-bis(hydroxymethyl)propoxy)ethoxy)ethoxy)ethoxy)ethoxy)propyl)be-
nzamido)phenyl)isonicotinamide
##STR00511##
[1169] Intermediate 332a
[1170] Into a 100-mL round-bottom flask, was placed
2,2-bis(hydroxymethyl)propane-1,3-diol (15 g, 110.29 mmol, 1.00
equiv), 1,1,1-triethoxyethane (20.2 mL, 1.00 equiv),
4-methylbenzenesulfonic acid (947 mg, 5.51 mmol, 0.05 equiv). The
resulting solution was stirred for 0.5 h at 100.degree. C. in an
oil bath. The temperature was increased to 130.degree. C. and the
mixture was stirred for 0.5 h. The solids were filtered out. The
resulting mixture was concentrated under vacuum. The residue was
applied onto a Al.sub.2O.sub.3 column with ethyl acetate/petroleum
ether (1:10.about.1:1). This resulted in 2 g (10%) of
(1-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methanol as a white
solid.
Intermediate 332b
[1171] Into a 100-mL 3-necked round-bottom flask, was placed a
solution of 266a.0 (2 g, 8.19 mmol, 1.00 equiv, 95%) in
dichloromethane (10 mL), pyridine (15 mL). This was followed by the
addition of 4-methylbenzene-1-sulfonyl chloride (3.27 g, 17.21
mmol, 2.00 equiv), in portions at 0-10.degree. C. The resulting
solution was stirred overnight at room temperature. The resulting
solution was diluted with 200 mL of ethyl acetate. The resulting
mixture was washed with 1.times.30 mL of water and 2.times.30 mL of
10% hydrogen chloride. The resulting mixture was washed with
1.times.30 mL of sodium bicarbonate and 1.times.30 mL of brine. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
ethyl acetate/petroleum ether (1:1). This resulted in 1.2 g (32%)
of 2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethyl
4-methylbenzenesulfonate as light brown oil.
Intermediate 332c
[1172] Into a 50-mL 3-necked round-bottom flask, was placed a
solution of
(1-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methanol (750 mg,
3.75 mmol, 1.50 equiv, 80%) in N,N-dimethylformamide (10 mL). This
was followed by the addition of sodium hydride (150 mg, 6.25 mmol,
2.00 equiv), in portions at 0-5.degree. C. To this was added
2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (1.2 g, 2.64 mmol, 1.00 equiv, 85%). The
resulting solution was stirred overnight at room temperature. The
resulting solution was diluted with 150 mL of ethyl acetate. The
resulting mixture was washed with 3.times.20 mL of Brine. The
mixture was dried over sodium sulfate and concentrated under
vacuum. The residue was applied onto a silica gel column with ethyl
acetate/petroleum ether (1:2). This resulted in 690 mg (63%) of
1-methyl-4-((2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)methy-
l)-2,6,7-trioxa-bicyclo[2.2.2]octane as brown oil.
Intermediate 332d
[1173] Into a 50-mL round-bottom flask purged and maintained with
an inert atmosphere of nitrogen, was placed a solution of
1-methyl-4-((2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)methy-
l)-2,6,7-trioxa-bicyclo[2.2.2]octane (690 mg, 1.66 mmol, 1.00
equiv, 90%) in tetrahydrofuran (10 mL), benzyl 3-iodobenzoate (623
mg, 1.75 mmol, 1.00 equiv, 95%), Pd(PPh.sub.3).sub.2Cl.sub.2 (130
mg, 0.19 mmol, 0.10 equiv), copper(I) iodide (35 mg, 0.18 mmol,
0.10 equiv), triethylamine (373 mg, 3.69 mmol, 2.00 equiv). The
resulting solution was stirred for 4 h at room temperature. The
resulting solution was diluted with 150 mL of ethyl acetate. The
resulting mixture was washed with 3.times.30 mL of Brine. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was applied onto a Al.sub.2O.sub.3 column
with ethyl acetate/petroleum ether (1:2). This resulted in 270 mg
(25%) of benzyl
3-(3-(2-(2-(2-(2-((1-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methoxy-
)ethoxy)ethoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate as a brown
oil.
Intermediate 332e
[1174] Into a 50-mL round-bottom flask, was placed a solution of
benzyl
3-(3-(2-(2-(2-(2-((1-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methoxy-
)ethoxy)ethoxy)ethoxy)ethoxy)prop-1-ynyl)benzoate (270 mg, 0.42
mmol, 1.00 equiv, 90%) in methanol (5 mL), Palladium carbon (270
mg), triethylamine (3 drops). Hydrogen gas was introduced into the
reaction vessel. The resulting solution was stirred overnight at
room temperature. The solids were filtered out. The resulting
mixture was concentrated under vacuum. This resulted in 200 mg
(86%) of
3-(3-(2-(2-(2-(2-((1-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methoxy-
)ethoxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid as brown oil.
Intermediate 332f
[1175] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(diethylamino)phenyl)isonicoti-
namide (190 mg, 0.39 mmol, 1.00 equiv, 90%) in dichloromethane (8
mL),
3-(3-(2-(2-(2-(2-((1-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methoxy-
)ethoxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid (200 mg, 0.32
mmol, 1.00 equiv, 80%), EDC.HCl (154 mg, 0.80 mmol, 2.00 equiv),
4-dimethylaminopyridine (98 mg, 0.80 mmol, 2.00 equiv). The
resulting solution was stirred for 4 h at room temperature. The
resulting solution was diluted with 200 mL of ethyl acetate. The
resulting mixture was washed with 3.times.20 mL of Brine. The
mixture was dried over anhydrous sodium sulfate and concentrated
under vacuum. The residue was applied onto a silica gel column with
dichloromethane/methanol (100:1). This resulted in 260 mg (51%) of
intermediate 232f as brown oil.
Example 332
[1176] Into a 50-mL round-bottom flask, was placed a solution of
N-(3-(trifluoromethyl)benzyl)-2-(5-(diethylamino)-2-(3-(3-(2-(2-(2-(2-((1-
-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methoxy)ethoxy)ethoxy)ethoxy-
)ethoxy)propyl)benzamido)phenyl)isonicotinamide (250 mg, 0.19 mmol,
1.00 equiv, 70%) in methanol (8 mL), hydrogen chloride (12M) (1
mL). The resulting solution was stirred for 4 h at room
temperature. The pH value of the solution was adjusted to 5-6 with
sodium carbonate. The resulting mixture was concentrated under
vacuum. The resulting solution was diluted with 20 mL of methanol.
The solids were filtered out. The resulting mixture was
concentrated under vacuum. The crude product (200 mg) was purified
by Prep-HPLC with the following conditions
(1#-Pre-HPLC-001(SHIMADZU)): Column, SunFire Prep C18, 19*150 mm 5
um; mobile phase, water with 0.05% TFA and CH.sub.3CN (30%
CH.sub.3CN up to 48% in 6 min, up to 100% in 1 min, down to 30% in
0.7 min); Detector, Waters2545 UvDector 254&220 nm. This
resulted in 137.4 mg (79%) of
N-(3-(trifluoromethyl)benzyl)-2-(5-(diethylamino)-2-(3-(3-(2-(2-(2-(2-(3--
hydroxy-2,2-bis(hydroxymethyl)propoxy)ethoxy)ethoxy)ethoxy)ethoxy)propyl)b-
enzamido)phenyl)isonicotinamide as brown oil. LC-MS (ES, m/z): 899
[M+H].sup.+ H-NMR (300 MHz, CD.sub.3OD, ppm): 8.97 (d, J=3 Hz, 1H),
8.82 (d, J=9 Hz, 1H), 8.43 (s, 1H), 8.06 (s, 1H), 7.91-7.93 (m,
1H), 7.82-7.84 (m, 2H), 7.56-7.72 (m, 5H), 7.50-7.52 (m, 2H), 4.72
(s, 2H), 3.73-3.80 (m, 4H), 3.59-3.65 (m, 22H), 3.45 (s, 2H),
2.82-2.87 (m, 2H), 1.93-1.99 (m, 2H), 1.22-1.27 (m, 6H).
Example 333
(S)--N.sup.1-Methyl-N.sup.1-(23-methyl-2,5,8,11,14,17,20-heptaoxa-23-azape-
ntacosan-25-yl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthalen--
1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00512##
[1177]
(S)--N.sup.1-Methyl-N.sup.1-(23-methyl-2,5,8,11,14,17,20-heptaoxa-2-
3-azapentacosan-25-yl)-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaph-
thalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
[1178] Sodium cyanoborohydride (0.75 g, 11.9 mmol) was added
portionwise to
(S)--N.sup.1-methyl-N.sup.1-(2-oxoethyl)-N.sup.3-(4-(piperidin-1-yl)-2-
-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isopht-
halamide 187a (1.5 g, 2.38 mmol),
N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine 135c.1 (2.52 g,
7.14 mmol) and acetic acid (0.41 mL, 7.14 mmol) in ethanol (15 mL)
and the mixture stirred overnight at room temperature. The reaction
was diluted with ethyl acetate, washed with saturated aqueous
sodium bicarbonate and brine, dried (MgSO.sub.4). The residue was
purified by PTLC (10% MeOH/20% ethyl acetate/dichloromethane) to
give product as an orange oil (0.85 g, 37%); MS (ES, m/z): 969
[M+H].sup.+; NMR (400 MHz, CDCl.sub.3, ppm): .delta. 12.8 (s, 1H);
8.80 (s, 1H); 8.55 (d, J=8.8 Hz, 1H); 8.10 (s, 1H); 7.98-8.02 (m,
2H); 7.47-7.55 (m, 3H); 7.06-7.24 (m, 5H); 6.69 (m, 1H); 5.41 (m,
1H).
Example 334
(S)--N.sup.1-(2-(4-(2,5,8,11,14,17,20-Heptaoxadocosan-22-yl(methyl)carbamo-
yl)piperidin-1-yl)ethyl)-N1-methyl-N3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-te-
trahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide
##STR00513##
[1179] Example 334
[1180] DIEA (0.068 mL, 0.392 mmol) was added to
(S)-1-(2-(N-methyl-3-(4-(piperidin-1-yl)-2-(4-(1,2,3,4-tetrahydronaphthal-
en-1-ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzamido)ethyl)piperidine-4-
-carboxylic acid (prepared from Example 244 by acidic hydrolysis)
(58.1 mg, 0.0783 mmol),
N-methyl-2,5,8,11,14,17,20-heptaoxadocosan-22-amine 135c.1 (35.9
mg, 0.102 mmol), and HATU (38.7 mg, 0.102 mmol) in DMF (2 mL) and
the mixture stirred for 2 hours at room temperature. The reaction
was diluted with water and extracted with ethyl acetate. The
extract was washed with water and brine, dried (MgSO.sub.4), and
evaporated. The residue was purified by PTLC (10% methanol/20%
ethyl acetate/dichloromethane) to give product as an orange foam
(1.2 g, 73%); MS (ES, m/z): 1080 [M+H].sup.+; NMR (400 MHz,
DMSO-d.sub.6, ppm): .delta. 12.05 (m, 1H); 9.16 (d, J 8.8 Hz, 1H);
8.85 (d, J 4.8 Hz, 1H); 8.27 (s, 1H); 8.16 (d, J 8.8 Hz, 1H); 7.95
(m, 1H); 7.85 (d, J 4.8 Hz, 1H); 7.60 (m, 2H); 7.40 (s, 1H);
7.09-7.20 (m, 4H); 5.20-5.30 (m, 1H); 3.40-3.65 (m, 21H); 3.18-3.24
(m, 5H); 2.75-3.20 (m, 7H); 1.99 (m, 2H); 1.80 (m, 2H); 1.65 (m,
4H); 1.56 (m, 2H); 1.23-1.28 (m, 6H).
Example 335
N.sup.1-(4-(Diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenyl)-N.sup.3-(23-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxa-23-a-
zapentacosan-25-yl)-N.sup.3-methylisophthalamide,
trifluoroacetate
##STR00514##
[1181] Intermediate 335a. Benzyl
23-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxa-23-azapentacosan-25-yl(met-
hyl)carbamate
[1182] Sodium triacetoxyborohydride (2.21 g, 10.4 mmol) was added
portionwise at room temperature to benzyl
methyl(2-oxoethyl)carbamate (1.66 g, 8.03 mmol),
N-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxadocosan-22-amine
135c.2 (3.19 g, 8.03 mmol), and acetic acid (0.92 mL, 16.1 mmol) in
THF (50 mL). The mixture was stirred for 2 hours, diluted with
ethyl acetate, washed with saturated aqueous sodium bicarbonate and
brine, dried (Mg.sub.2SO.sub.4) and evaporated. The residue was
purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane)
to give product as an oil (2.58 g, 55%); MS for
C.sub.29H.sub.52N.sub.2O.sub.10 m/z 589 (M+H).sup.+.
Intermediate 335b.
N.sup.1-(2,5,8,11,14,17,20-Heptaoxadocosan-22-yl)-N.sup.1-(2-methoxyethyl-
)-N.sup.2-methylethane-1,2-diamine
[1183] Benzyl
23-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxa-23-azapentacosan-25-yl(met-
hyl)carbamate 335a (2.58 g, 4.38 mmol) and palladium on carbon
(10%, wet, 0.6 g) in methanol (30 mL) were stirred under a hydrogen
atmosphere (balloon) for 2 hours. The mixture was filtered through
celite and evaporated to give product as an oil (1.9 g, 99%); MS
(ES, m/z): 455 [M+H].sup.+.
Example 335
[1184] DIEA (1.40 mL, 8.05 mmol) was added to a mixture of the
3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl-
)phenylcarbamoyl)benzoic acid 25b (1.07 g),
N.sup.1-(2,5,8,11,14,17,20-heptaoxadocosan-22-yl)-N-(2-methoxyethyl)-N.su-
p.2-methylethane-1,2-diamine 335b (1.07 g, 1.61 mmol) and HATU
(0.80 g, 2.09 mmol) in DMF (8 mL) and the reaction stirred for 2
hours at room temperature. The reaction was diluted with water and
extracted with ethyl acetate. The extract was washed with water and
brine, dried (MgSO.sub.4), and evaporated. The residue was purified
by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give
the title compound as an orange oil (1.2 g, 73%); MS (ES, m/z):
1029 [M+H].sup.+; NMR (400 MHz, DMSO-d.sub.6, ppm): .delta. 9.52
(m, 2H); 8.90 (d, J=5.2 Hz, 1H); 8.25 (s, 1H); 7.98 (m, 2H); 7.84
(m, 2H); 7.54-7.70 (m, 6H); 4.62 (d, J=5.6 Hz, 2H); 3.80-3.88 (m,
4H); 3.74 (m, 2H); 3.60 (m, 2H); 3.42-3.56 (m, XH); 3.38-3.41 (m,
2H); 3.32 (m, 2H); 3.22 (s, 3H); 1.12 (t, J=6.8 Hz, 6H).
Example 336
tert-Butyl
3-[2-[2-[2-[2-[[3-[[4-(diethylamino)-2-[5-[[3-(trifluoromethyl)-
phenyl]methylcarbamoyl]-2-pyridyl]phenyl]carbamoyl]benzoyl]-methyl-amino]e-
thyl-(2-methoxyethyl)amino]ethoxy]ethoxy]ethoxy]propanoate
##STR00515##
[1186] Example 336 was prepared as described in Example 335
substituting tert-butyl 2,8,11,14-tetraoxa-5-azaheptadecan-17-oate
135c.4 in place of
N-(2-methoxyethyl)-2,5,8,11,14,17,20-heptaoxadocosan-22-amine to
prepare tert-butyl
5-(2-methoxyethyl)-8,11,14-trioxa-2,5-diazaheptadecan-17-oate DIEA
(2.04 mL, 11.7 mmol) was added to a mixture of the
3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl-
)phenylcarbamoyl)benzoic acid 25b (2.34 mmol), tert-butyl
5-(2-methoxyethyl)-8,11,14-trioxa-2,5-diazaheptadecan-17-oate (0.92
g, 2.34 mmol) and HATU (1.15 g, 3.04 mmol) in DMF (15 mL) and the
reaction stirred for 2 hours at room temperature. The reaction was
diluted with water and extracted with ethyl acetate. The extract
was washed with water and brine, dried (MgSO.sub.4), and
evaporated. The residue was purified by PTLC (10% methanol/20%
ethyl acetate/dichloromethane) to give product as an orange oil
(2.13 g, 94%); MS (ES, m/z): 967 [M+H].sup.+; NMR (400 MHz,
DMSO-d.sub.6, ppm): .delta. 11.8 (m, 1H); 9.49 (m, 1H); 8.87 (d,
J=5.2 Hz, 1H); 8.23 (s, 1H); 8.03 (s, 1H); 7.95 (m, 1H); 7.79 (m,
1H); 7.69 (s, 1H); 7.55-7.65 (m, 5H); 7.06 (d, J=2.8 Hz, 1H); 6.86
(dd, J=2.8 and 9.2 Hz, 1H); 4.60 (d, J=5.6 Hz, 2H); 3.83 (m, 2H);
3.52 (m, 2H); 3.36-3.60 (m, 20H); 3.06 (m, 2H); 3.01 (m, 2H); 2.95
(m, 2H); 2.88 (m, 3H); 2.73 (s, 3H); 2.38 (m, 2H); 1.37 (s, 9H);
1.13 (t, J=6.8 Hz, 6H).
Example 337
N.sup.1-(4-(Diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenyl)-N3-(3-(2-methoxyethyl)-17,17-dimethyl-15-oxo-6,9,12-trioxa-3-
,16-diazaoctadecyl)-N.sup.3-methylisophthalamide
##STR00516##
[1188] tert-Butyl
3-[2-[2-[2-[2-[[3-[[4-(diethylamino)-2-[5-[[3-(trifluoromethyl)phenyl]met-
hylcarbamoyl]-2-pyridyl]phenyl]carbamoyl]benzoyl]-methyl-amino]ethyl-(2-me-
thoxyethyl)amino]ethoxy]ethoxy]ethoxy]propanoate (0.101 g, 0.105
mmol) Example 336 and hydrochloric acid (4N in dioxane, 3 mL) were
stirred for 4 hours at room temperature and then evaporated to give
the carboxylic acid,
3-[2-[2-[2-[2-[[3-[[4-(diethylamino)-2-[5-[[3-(trifluoromethyl)phen-
yl]methylcarbamoyl]-2-pyridyl]phenyl]carbamoyl]benzoyl]-methyl-amino]ethyl-
-(2-methoxyethyl)amino]ethoxy]ethoxy]ethoxy]propanoic acid, as a
white solid. DIEA (0.091 mL, 0.525 mmol) was added to a mixture of
the acid, tert-butylamine (7.65 mg, 0.105 mmol) and HATU (48 mg,
0.126 mmol) in DMF (1 mL) and the reaction stirred for 2 hours at
room temperature. The reaction was diluted with water and extracted
with ethyl acetate. The extract was washed with water and brine,
dried (MgSO.sub.4), and evaporated. The residue was purified by
PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give
product as an orange foam (30 mg, 30%); MS (ES, m/z): 966
[M+H].sup.+; NMR (400 MHz, DMSO-d.sub.6, ppm): .delta. 11.8 (m,
1H); 9.53 (m, 1H); 8.85 (d, J=5.2 Hz, 1H); 8.23 (m, 1H); 8.06 (m,
1H); 7.91 (m, 1H); 7.86 (s, 1H); 7.81 (m, 1H); 7.70 (m, 1H);
7.54-7.66 (m, 5H); 7.37 (m, 1H); 7.06 (d, J=2.8 Hz, 1H); 6.86 (dd,
J=2.8 and 9.2 Hz, 1H); 4.61 (d, J=6.0 Hz, 2H); 3.36-3.56 (m, 15H);
3.22 (m, 3H); 3.14 (m, 1H); 3.06 (m, 2H); 3.01 (m, 2H); 2.92 (m,
2H); 2.72 (m, 2H); 2.60 (m, 1H); 2.40 (m, 2H); 2.23 (m, 2H); 1.21
(s, 9H); 1.12 (t, J=6.8 Hz, 6H).
Example 338
N.sup.1-(4-(Diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenyl)-N.sup.3-(3-(2-methoxyethyl)-16-methyl-18-morpholino-15-oxo-6-
,9,12-trioxa-3,16-diazaoctadecyl)-N.sup.3-methylisophthalamide
##STR00517##
[1190] Example 338 was prepared as described in Example 337
substituting N-methyl-2-morpholinoethanamine in place of
tert-butylamine. MS (ES, m/z): 1035 [M+H].sup.+; NMR (400 MHz,
DMSO-d.sub.6, ppm): .delta. 11.8 (m, 1H); 9.49 (m, 1H); 8.86 (d,
J=5.2 Hz, 1H); 8.23 (s, 1H); 8.05 (m, 1H); 7.91 (m, 1H); 7.86 (m,
1H); 7.80 (m, 1H); 7.70 (m, 1H); 7.55-7.66 (m, 4H); 7.06 (d, J=2.8
Hz, 1H); 6.86 (dd, J=2.8 and 9.2 Hz, 1H); 4.61 (d, J=6 Hz, 2H);
3.30-3.3.64 (m, 25H); 3.23 (m, 4H); 3.14 (m, 2H); 3.11 (m, 1H);
3.01 (m, 1H); 2.90-2.94 (m, 4H); 2.79 (s, 3H); 2.71 (m, 2H); 2.60
(m, 1H); 2.38 (m, 6H); 1.13 (t, J=6.8 Hz, 6H).
Example 339
(S)-tert-Butyl
1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethyl-1-oxo-8,11,14-trioxa-2,5--
diazahexadecan-16-ylcarbamate
##STR00518##
[1191] Intermediate 339a: Benzyl
14-azido-3-methyl-6,9,12-trioxa-3-azatetradecyl(methyl)carbamate
[1192] Sodium triacetoxyborohydride (3.55 g, 16.8 mmol) was added
portionwise at room temperature to benzyl
methyl(2-oxoethyl)carbamate (2.68 g, 12.9 mmol),
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N-methylethanamine 222c (3.00
g, 12.9 mmol), and acetic acid (2 equiv.) in THF (20 mL). The
mixture was stirred for 2 hours, diluted with ethyl acetate, washed
with saturated aqueous sodium bicarbonate and brine, dried
(Mg.sub.2SO.sub.4) and evaporated. The residue was purified by
Combiflash purification system (ethyl acetate/dichloromethane) to
give product as an oil (3.19 g, 58%); MS (ES, m/z): 424
[M+H].sup.+.
Intermediate 339b: tert-Butyl
N-[2-[2-[2-[2-[2-(benzyloxycarbonylamino)ethyl-(2-methoxyethyl)amino]etho-
xy]ethoxy]ethoxvy]ethyl]carbamate
[1193] Triphenylphosphine (1.80 g, 6.89 mmol) was added to benzyl
14-azido-3-methyl-6,9,12-trioxa-3-azatetradecyl(methyl)carbamate
(2.92 g, 6.89 mmol) in THF (30 mL) and the mixture stirred for 5
hours at room temperature. Water (0.25 mL) was added, the mixture
stirred at 50.degree. C. overnight, and then evaporated under
vacuum. The residue was dissolved in DCM (30 mL) and DIEA (1.80 mL,
10.3 mmol), and di-tert-butyl dicarbonate (1.65 g, 7.58 mmol) in
DCM (3 mL) added dropwise at 0.degree. C. The mixture was allowed
to warm to room temperature, washed with water and brine, dried
(Mg.sub.2SO.sub.4) and evaporated. The residue was purified by
Combiflash purification system (ethyl acetate/dichloromethane) to
give product as an oil (2.99 g, 87%); MS (ES, m/z): 498
[M+H].sup.+.
Intermediate 339c: tert-Butyl
5-methyl-8,11,14-trioxa-2,5-diazahexadecan-16-ylcarbamate
[1194] tert-Butyl
N-[2-[2-[2-[2-[2-(benzyloxycarbonylamino)ethyl-(2-methoxyethyl)amino]-eth-
oxy]ethoxy]ethoxy]ethyl]carbamate (2.99 g) and palladium on carbon
(10%, wet, 0.6 g) in methanol (30 mL) were stirred under a hydrogen
atmosphere (balloon) for 2 hours. The mixture was filtered through
celite and evaporated to give product as an oil (2.18 g,
quantitative).
Example 339
[1195] (S)-tert-Butyl
3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyri-
din-2-yl)phenylcarbamoyl)benzoate (1.48 g, 2.39 mmol) and
hydrochloric acid (4M in dioxane, 10 mL) were stirred at room
temperature for 4 hours and then evaporated to dryness to give
product as a white solid. DIEA (2.08 mL, 11.9 mmol) was added to
(S)-3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)-
pyridin-2-yl)phenylcarbamoyl)benzoic acid (1.48 g, 2.39 mmol),
tert-butyl
5-methyl-8,11,14-trioxa-2,5-diazahexadecan-16-ylcarbamate (0.87 g,
2.39 mmol) and HATU (1.09 g, 2.87 mmol) in DMF (15 mL) and the
mixture stirred for 2 hours at room temperature. The mixture was
diluted with water and extracted with ethyl acetate. The extract
was washed with water and brine, dried (Mg.sub.2SO.sub.4) and
evaporated. The residue was purified by PTLC (10% methanol/20%
ethyl acetate/dichloromethane) to give product as a yellow oil ( );
MS (ES, m/z): 909 [M+H].sup.+; NMR (400 MHz, DMSO-d.sub.6, ppm):
.delta. 9.13 (d, J=8.4 Hz, 1H); 8.83 (d, J=5.2 Hz, 1H); 8.21 (s,
1H); 8.03 (m, 1H); 7.90-7.92 (m, 1H); 7.86 (s, 1H); 7.81 (d, J=4.4
Hz, 1H); 7.58-7.61 (m, 2H); 7.09-7.19 (m, 4H); 7.06 (d, J=2.8 Hz,
1H); 6.85 (dd, J=2.8 and 9.2 Hz, 1H); 6.72 (m, 1H); 5.23 (m, 1H);
3.33-3.57 (m, 19H); 2.96-3.08 (m, 4H); 2.91 (m, 1H); 2.72-2.80 (m,
2H); 2.24-2.38 (m, 2H); 1.92-2.02 (m, 2H); 1.90 (m, 1H); 1.72-1.84
(m, 2H); 1.35 (s, 9H); 1.12 (t, J=7.2 Hz, 6H).
Example 340
N.sup.1-[2-[2-[2-[2-[2-(Adamantane-1-carbonylamino)ethoxy]ethoxy]ethoxy]et-
hyl-methyl-amino]ethyl]-N.sup.3-[4-(diethylamino)-2-[5-[[3-(trifluoromethy-
l)phenyl]methylcarbamoyl]-2-pyridyl]phenyl]-N.sup.1-methyl-benzene-1,3-dic-
arboxamide
##STR00519##
[1196] Intermediate 340a
[1197] (S)-tert-Butyl
1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)p-
yridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethyl-1-oxo-8,11,14-trioxa-2,5--
diazahexadecan-16-ylcarbamate Example 339 (1.08 g, 1.23 mmol) and
hydrochloric acid in dioxane (4N, 20 mL) were stirred for 4 hours
at room temperature and then evaporated to dryness to give the
intermediate
(S)--N.sup.1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N.sup.3-(4-
-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)-N.sup.1-methylisophthalamide tetrahydrochloride 340a as
a foam (1.2 g, quantitative); MS (ES, m/z): 808 [M+H].sup.+.
Example 340
[1198] DIEA (0.12 mL, 0.666 mmol) was added to
(S)--N.sup.1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N.sup.3-(4-
-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)-N.sup.1-methylisophthalamide tetrahydrochloride 340a
(0.106 g, 0.111 mmol), 1-adamantanecarboxylic acid (20.1 mg, 0.111
mmol) and HATU (51 mg, 0.133 mmol) in DMF (2 mL) and the mixture
stirred for 2 hours at room temperature. The reaction was diluted
with ethyl acetate, washed with water and brine, dried (MgSO.sub.4)
and evaporated. The residue was purified by PTLC (10% methanol/20%
ethyl acetate/dichloromethane) to give product as a yellow foam
(0.076 g, 70%); MS (ES, m/z): 972 [M+H].sup.+; NMR (400 MHz,
DMSO-d.sub.6, ppm): .delta. 11.8 (m, 1H); 9.13 (d, J=8.8 Hz, 1H);
8.83 (d, J=5.2 Hz, 1H); 8.21 (s, 1H); 8.03 (m, 1H); 7.95 (s, 1H);
7.91 (m, 1H); 7.86 (m, 1H); 7.81 (d, J=4.8 Hz, 1H); 7.58 (m, 2H);
7.29 (t, J=5.2 Hz, 1H); 7.09-7.19 (m, 4H); 7.05 (m, 1H); 6.85 (dd,
J=2.8 and 9.2 Hz, 1H); 5.22 (m, 1H); 3.30-3.52 (m, 16H); 3.25 (m,
2H); 2.88-3.05 (m, 6H); 2.70-2.83 (2H); 2.33 (m, 2H); 1.70-2.04 (m,
15); 1.56-1.68 (m, 6H); 1.12 (t, J=6.8 Hz, 6H).
Example 341
(S)--N.sup.1-(4-(Diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarb-
amoyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(3-methyl-16-oxo-6,9,12--
trioxa-3,15-diazaheptadecyl)isophthalamide
##STR00520##
[1199] Example 341
[1200] DIEA (0.12 mL, 0.66 mmol) was added to
(S)--N.sup.1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N.sup.3-(4-
-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)-N.sup.1-methylisophthalamide tetrahydrochloride 340a
(0.105 g, 0.11 mmol) and acetic anhydride (0.0125 mL, 0.132 mmol)
in DCM (5 mL) and the mixture stirred for 2 hours at room
temperature. The reaction was diluted with DCM, washed with water
and brine, dried (MgSO.sub.4) and evaporated. The residue was
purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane)
to give product as a yellow foam (0.089 g, 95%); MS (ES, m/z): 852
[M+H].sup.+; NMR (400 MHz, DMSO-d.sub.6, ppm): .delta. 11.4 (m,
1H); 9.13 (d, J=8.8 Hz, 1H); 8.83 (d, J=5.6 Hz, 1H); 8.21 (s, 1H);
8.02 (m, 1H); 7.91 (m, 1H); 7.85 (m, 1H); 7.81 (d, J=4.4 Hz, 1H);
7.58-7.59 (m, 2H); 7.09-7.19 (m, 4H); 7.06 (d, J=3.2 Hz, 1H); 6.85
(dd, J=3.2 and 9.2 Hz, 1H); 5.23 (m, 1H); 3.24-3.56 (m, 18H); 3.15
(q, J=5.6 Hz, 2H); 3.00 (m, 2H); 2.91 (m, 2H); 2.76-2.79 (m, 2H);
2.63 (m, 1H); 2.57 (m, 1H); 2.46 (m, 1H); 2.33 (m, 1H); 2.29 (m,
2H); 1.93-2.04 (m, 2H); 1.89 (m, 1H); 1.70-1.84 (m, 2H); 1.77 (s,
3H); 1.12 (t, J=6.8 Hz, 6H).
Example 342
(S)--N.sup.1-(4-(Diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarb-
amoyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(14-methyl-1-oxo-1-(pyri-
din-3-yl)-5,8,11-trioxa-2,14-diazahexadecan-16-yl)isophthalamide
##STR00521##
[1201] Example 342
[1202] DIEA (0.11 mL, 0.654 mmol) was added to
(S)--N.sup.1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N.sup.3-(4-
-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)-N.sup.1-methylisophthalamide tetrahydrochloride 340a
(0.104 g, 0.109 mmol), nicotinic acid (13.4 mg, 0.109 mmol) and
HATU (49 mg, 0.131 mmol) in DMF (2 mL) and the mixture stirred for
2 hours at room temperature. The reaction was diluted with ethyl
acetate, washed with water and brine, dried (MgSO.sub.4) and
evaporated. The residue was purified by PTLC (10% methanol/20%
ethyl acetate/dichloromethane) to give product as a yellow foam
(0.079 g, 80%); MS (ES, m/z): 915 [M+H].sup.+; NMR (400 MHz,
DMSO-d.sub.6, ppm): .delta. 11.7 (m, 1H); 9.13 (d, J=8.4 Hz, 1H);
8.98 (m, 1H); 8.83 (d, J 4.4 Hz, 1H); 8.68-8.70 (m, 2H); 8.21 (s,
1H); 8.15-8.18 (m, 1H); 8.02 (m, 1H); 7.92 (m, 1H); 7.86 (m, 1H);
7.80 (d, J 4.8 Hz, 1H); 7.59 (m, 2H); 7.47-7.50 (m, 1H); 7.11-7.19
(m, 4H); 7.06 (d, J 2.8 Hz, 1H); 6.85 (dd, J 2.8 and 9.2 Hz, 1H);
5.22 (m, 1H); 3.32-3.64 (m, 18H); 3.14 (m, 1H); 3.00 (m, 2H); 2.92
(m, 2H); 2.77 (m, 2H); 2.32 (m, 1H); 1.70-2.04 (m, 5H); 1.12 (t, J
6.8 Hz, 6H).
Example 343
(S)--N.sup.1-(4-(Diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarb-
amoyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(14-methyl-1-oxo-1-(tetr-
ahydro-2H-pyran-4-yl)-5,8,11-trioxa-2,14-diazahexadecan-16-yl)isophthalami-
de
##STR00522##
[1203] Example 343
[1204] DIEA (0.11 mL, 0.654 mmol) was added to
(S)--N.sup.1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N.sup.3-(4-
-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)-N.sup.1-methylisophthalamide tetrahydrochloride 340a
(0.101 g, 0.106 mmol), tetrahydropyran-4-yl-carboxylic acid (13.8
mg, 0.106 mmol) and HATU (48 mg, 0.127 mmol) in DMF (2 mL) and the
mixture stirred for 2 hours at room temperature. The reaction was
diluted with ethyl acetate, washed with water and brine, dried
(MgSO.sub.4) and evaporated. The residue was purified by PTLC (10%
methanol/20% ethyl acetate/dichloromethane) to give product as a
yellow foam (0.071 g, 73%); MS (ES, m/z): 921 [M+H].sup.+; NMR (400
MHz, DMSO-d.sub.6, ppm): .delta. 11.7 (m, 1H); 9.13 (d, J=8.4 Hz,
1H); 8.83 (d, J=5.2 Hz, 1H); 8.21 (s, 1H); 8.02 (m, 1H); 7.92 (m,
1H); 7.87 (m, 1H); 7.76-7.84 (m, 1H); 7.60 (m, 1H); 7.08-7.20 (m,
4H); 7.06 (d, J=2.8 Hz, 1H); 6.84 (dd, J=2.8 and 9.2 Hz, 1H); 5.22
(m, 1H); 3.80-3.84 (m, 2H); 3.20-3.66 (m, 17H); 3.12-3.20 (m, 2H);
3.00 (m, 3H); 2.93 (m, 2H); 2.72-2.82 (m, 2H); 2.26-2.38 (m, 2H);
1.98 (m, 2H); 1.79 (m, 2H); 1.51-1.56 (m, 4H); 1.12 (t, J=6.8 Hz,
6H).
Example 344
(S)--N.sup.1-(4-(Diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarb-
amoyl)pyridin-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(14-methyl-1-oxo-1-(thia-
zol-4-yl)-5,8,11-trioxa-2,14-diazahexadecan-16-yl)isophthalamide
##STR00523##
[1205] Example 344
[1206] DIEA (0.11 mL, 0.654 mmol) was added to
(S)--N.sup.1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N.sup.3-(4-
-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)-N.sup.1-methylisophthalamide tetrahydrochloride 340a
(0.101 g, 0.106 mmol), thiazole-5-carboxylic acid (14.2 mg, 0.110
mmol) and HATU (50 mg, 0.132 mmol) in DMF (2 mL) and the mixture
stirred for 2 hours at room temperature. The reaction was diluted
with ethyl acetate, washed with water and brine, dried (MgSO.sub.4)
and evaporated. The residue was purified by PTLC (10% methanol/20%
ethyl acetate/dichloromethane) to give product as a yellow foam
(0.073 g, 75%); MS (ES, m/z): 921 [M+H].sup.+; NMR (400 MHz,
DMSO-d.sub.6, ppm): .delta. 11.7 (m, 1H); 9.19 (s, 1H); 9.13 (d, J
8.4 Hz, 1H); 8.83 (d, J 4.4 Hz, 1H); 8.80 (m, 1H); 8.46 (s, 1H);
8.21 (s, 1H); 8.03 (m, 1H); 7.90 (m, 2H); 7.81 (d, J 4.8 Hz, 1H);
7.60 (m, 2H); 7.08-7.20 (m, 4H), 7.05 (d, J 2.8 Hz, 1H); 6.85 (dd,
J 2.8 and 9.2 Hz, 1H); 5.22 (m, 1H); 3.20-3.66 (m, 20H); 3.13 (m,
2H); 3.00 (m, 2H); 2.93 (m, 2H); 2.76 (m, 2H); 1.97 (m, 2H); 1.78
(m, 2H); 1.12 (t, J 6.8 Hz, 6H).
Example 345
(S)--N.sup.1-(4-(Diethylamino)-2-(4-(1,2,3,
4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-yl)phenyl)-N.sup.3-(1-(4-h-
ydroxyphenyl)-14-methyl-1-oxo-5,8,11-trioxa-2,14-diazahexadecan-16-yl)-N.s-
up.3-methylisophthalamide
##STR00524##
[1207] Example 345
[1208] DIEA (0.11 mL, 0.654 mmol) was added to
(S)--N.sup.1-(14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N.sup.3-(4-
-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarbamoyl)pyridin-2-
-yl)phenyl)-N.sup.1-methylisophthalamide tetrahydrochloride 340a
(0.101 g, 0.106 mmol), 4-acetoxybenzoic acid (19.1 mg, 0.106 mmol)
and HATU (48 mg, 0.127 mmol) in DMF (2 mL) and the mixture stirred
for 2 hours at room temperature. The reaction was diluted with
ethyl acetate, washed with water and brine, dried (MgSO.sub.4) and
evaporated. The residue was purified by PTLC (10% methanol/20%
ethyl acetate/dichloromethane) to give the intermediate
(S)-4-(1-(3-(4-(diethylamino)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarb-
amoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethyl-1-oxo-8,11,14-trio-
xa-2,5-diazahexadecan-16-ylcarbamoyl)phenyl acetate as a yellow
foam (0.082 g, 75%); MS (ES, m/z): 972 [M+H].sup.+. Ammonia in
methanol (2M, 4 mL) was added and the mixture stirred overnight at
room temperature. The reaction was evaporated and the residue
purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane)
to give product as a yellow foam (0.065 g, 83%); MS (ES, m/z): 928
[M+H].sup.+; NMR (400 MHz, DMSO-d.sub.6, ppm): .delta. 11.7 (m,
1H); 9.93 (s, 1H); 9.13 (d, J=8.4 Hz, 1H); 8.83 (d, J=5.2 Hz, 1H);
8.21 (m, 2H); 7.96-8.06 (m, 1H); 7.84-7.94 (m, 2H); 7.80 (d, J=4.8
Hz, 1H); 7.70 (dd, J=2.0 and 6.8 Hz, 2H); 7.60 (m, 2H); 7.09-7.19
(m, 4H); 7.06 (d, J=3.2 Hz, 1H); 6.85 (dd, J=2.8 and 8.8 Hz, 1H);
6.77 (m, 2H); 5.23 (m, 1H); 3.35-3.60 (m, 25H); 2.99 (m, 3H); 2.92
(m, 2H); 2.33 (m, 1H); 1.90-2.04 (m, 3H); 1.70-1.86 (m, 2H); 1.12
(t, J=6.8 Hz, 6H).
Example 346
N.sup.1-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-
-2-yl)phenyl)-N.sup.3-methyl-N.sup.3-(3,17,17-trimethyl-16-oxo-6,9,12-trio-
xa-3,15-diazaoctadecyl)isophthalamide
##STR00525##
[1209] Example 346
[1210] The compound was prepared as described in Examples 339
substituting 25b in place of 131c. DIEA (1.47 mL, 8.45 mmol) was
added to
3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl-
)phenylcarbamoyl)benzoic acid, dihydrochloride (1.12 g, 1.69 mmol),
tert-butyl
5-methyl-8,11,14-trioxa-2,5-diazahexadecan-16-ylcarbamate 339c
(0.61 g, 1.69 mmol) and HATU (0.77 g, 2.03 mmol) in DMF (8 mL) and
the mixture stirred for 2 hours at room temperature. The mixture
was diluted with water and extracted with ethyl acetate. The
extract was washed with water and brine, dried (Mg.sub.2SO.sub.4)
and evaporated. The residue was purified by Combiflash
chromatography system (methanol/dichloromethane gradient) to give
product as a yellow oil (1.46 g, 94%); MS (ES, m/z): 920
[M+H].sup.+.
Example 347
(S)-16-(3-(4-(cyclopentyloxy)-2-(4-(1,2,3,4-tetrahydronaphthalen-1-ylcarba-
moyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-1-oi-
c acid
##STR00526##
[1211] Example 347
[1212] This compound was prepared as described in Example 251
substituting 133a in place of 25b. MS (ES, m/z): 794
[M+H].sup.+.
Example 348
Procedure for the Measurement of NaP2b-Mediated P.sub.i
Transport
[1213] Materials.
[1214] HEK293 cells were obtained from the American Type Culture
collection and propagated per their instructions. Expression clones
for rat and human NaP2b (SLC34A2) were obtained from Open
Biosystems (Catalog numbers MRN1768-9510282, and MHS1010-99823026,
respectively). The sequence of the human protein was mutated to
insert a threonine after residue 37, and to introduce a N39D
mutation.
[1215] Inhibition of P.sub.i Transport.
[1216] The rate of phosphate (Pi) uptake into HEK293 cells was
measured using a modification of the method described by Mohrmann
et al. (Mohrmann, I., Mohrmann, M., Biber, J., and Murer, H. (1986)
Am. J. Phys. 250(3 Pt 1):G323-30.) Transfected HEK293 cells were
treated with a pharmacological agent to minimize endogenous
PiT-mediated phosphate transport activity, such that the only
remaining sodium-dependent phosphate transport activity is that
which was bestowed by introduction of the NaP2b genes.
[1217] Cells were seeded into 96-well plates at 25,000 cells/well
and cultured overnight. Lipofectamine 2000 (Invitrogen) was used to
introduce the NaP2b cDNA, and the cells were allowed to approach
confluence during a second overnight incubation. Medium was
aspirated from the cultures, and the cells were washed once with
choline uptake buffer (14 mM Tris, 137 mM choline chloride, 5.4 mM
KCl, 2.8 mM CaCl.sub.2, 1.2 mM MgSO.sub.4, 100 uM KH.sub.2PO.sub.4,
1 mg/mL Bovine Serum Albumin, pH 7.4). Cells were then overlayed
with either choline uptake buffer or sodium uptake buffer (14 mM
Tris, 137 mM sodium chloride, 5.4 mM KCl, 2.8 mM CaCl.sub.2, 1.2 mM
MgSO.sub.4, 100 uM KH.sub.2PO.sub.4, PiT-silencing agent, 1 mg/mL
Bovine Serum Albumin, pH 7.4) containing 6-9 uCi/mL .sup.33P
orthophosphoric acid (Perkin Elmer) and test compound. Each
compound was tested at twelve concentrations ranging from 0.1 nM to
30 uM. Assays were run in duplicate.
[1218] After incubation for 3-30 minutes at room temperature, assay
mixtures were removed, and the cells were washed twice with ice
cold stop solution (137 mM sodium chloride, 14 mM Tris, pH 7.4).
Cells were lysed by addition of 20 .mu.L 0.1% Tween 80 followed by
100 .mu.L scintillation fluid, and counted using a TopCount (Perkin
Elmer).
[1219] pIC50 (the negative log of the IC50) values of the test
compounds were calculated using GraphPad Prism. Preliminary studies
showed that under these conditions, sodium-dependent Pi uptake was
linear for at least 30 min and tolerated 0.6% (v/v) DMSO without
deleterious effects.
[1220] To ascertain if an inhibitor was competitive for binding
with phosphate, the procedure was repeated, but raising the
concentration of the substrate in the assay mixture from 0.1 to 2.1
mM phosphate. Compounds that maintained their potency for
inhibition of NaPi2b in the presence of 2.1 vs 0.1 mM phosphate
were considered to not be competitive with respect to
phosphate.
TABLE-US-00012 TABLE 11 Inhibitory activity of compounds against
rat and human NaP2b Values reported as pIC50. pIC50 range for rat
pIC50 range for Competitive with Example Nap2b human NaP2b* respect
to Pi?** PFA 2-3 Yes 1.10 5.1-6.0 1.1 5.1-6.0 5.1-6.0 No 1.11 4.5-5
1.12 5.1-6.0 1.13 5.1-6.0 1.14 5.1-6.0 1.15 5.1-6.0 1.16 4.5-5 1.17
5.1-6.0 1.18 5.1-6.0 1.19 4.5-5 1.2 4.5-5 1.20 4.5-5 1.21 4.5-5
1.22 5.1-6.0 1.23 5.1-6.0 1.24 5.1-6.0 1.25 5.1-6.0 1.26 5.1-6.0
1.27 4.5-5 1.28 5.1-6.0 1.29 5.1-6.0 1.30 5.1-6.0 1.3 5.1-6.0 1.31
5.1-6.0 1.32 5.1-6.0 1.33 5.1-6.0 1.34 5.1-6.0 1.35 5.1-6.0 1.36
5.1-6.0 1.36 5.1-6.0 1.37 5.1-6.0 1.38 4.5-5 1.39 5.1-6.0 1.4
5.1-6.0 1.40 5.1-6.0 1.42 5.1-6.0 1.43 5.1-6.0 1.44 5.1-6.0 1.45
5.1-6.0 1.46 5.1-6.0 1.47 5.1-6.0 1.48 5.1-6.0 1.49 5.1-6.0 1.5
5.1-6.0 1.6 5.1-6.0 1.7 5.1-6.0 1.8 4.5-5 1.9 4.5-5 2 4.5-5 3.1
5.1-6.0 5.1-6.0 3.10 5.1-6.0 4.5-5 3.2 4.5-5 3.3 4.5-5 3.4 4.5-5
3.5 5.1-6.0 3.6 4.5-5 4.5-5 3.7 4.5-5 4.5-5 3.8 4.5-5 3.9 4.5-5
4.10 4.5-5 4.1 4.5-5 4.11 5.1-6.0 4.12 5.1-6.0 4.13 5.1-6.0 4.14
5.1-6.0 4.15 5.1-6.0 4.16 4.5-5 4.17 4.5-5 4.18 4.5-5 4.19 5.1-6.0
5.1-6.0 4.20.1 5.1-6.0 4.2 5.1-6.0 4.20.2 5.1-6.0 4.21 5.1-6.0 4.22
4.5-5 4.23 4.5-5 4.24 5.1-6.0 4.25 5.1-6.0 4.26 5.1-6.0 >6.0
4.27 5.1-6.0 4.28 5.1-6.0 4.29 5.1-6.0 4.30 5.1-6.0 4.3 5.1-6.0
4.31 4.5-5 4.32 5.1-6.0 4.4 4.5-5 4.5 5.1-6.0 4.6 4.5-5 4.7 4.5-5
4.8 5.1-6.0 4.9 4.5-5 5.1 5.1-6.0 5.2 4.5-5 6.1 4.5-5 6.2 4.5-5 7
4.5-5 8.10 4.5-5 8.1 4.5-5 8.1 >6.0 >6.0 No 8.11 4.5-5 8.12
4.5-5 8.13 4.5-5 8.14 5.1-6.0 8.15 5.1-6.0 8.16 5.1-6.0 8.17
>6.0 8.18 >6.0 No 8.19 5.1-6.0 8.2 5.1-6.0 8.20 5.1-6.0 8.21
5.1-6.0 5.9 8.22 5.1-6.0 8.23 5.1-6.0 8.25 5.1-6.0 >6.0 8.26
4.5-5 No 8.27 4.5-5 8.3 5.1-6.0 8.4 5.1-6.0 8.5 5.1-6.0 8.6 5.1-6.0
8.7 5.1-6.0 8.8 >6.0 8.9 5.1-6.0 9.1 5.1-6.0 9.2 5.1-6.0 >6.0
9.3 5.1-6.0 10.10 5.1-6.0 10.1 5.1-6.0 >6.0 No 10.11 5.1-6.0
10.12 5.1-6.0 10.2 4.5-5 10.3 4.5-5 10.4 4.5-5 10.5 4.5-5 10.6
5.1-6.0 10.7 5.1-6.0 10.8 4.5-5 10.9 4.5-5 11.1 5.1-6.0 11.2
5.1-6.0 11.3 4.5-5 11.4 4.5-5 12.1 5.1-6.0 12.2 4.5-5 14 4.5-5 15
5.1-6.0 16 5.1-6.0 17 5.1-6.0 18 5.1-6.0 19 5.1-6.0 20 5.1-6.0 21
5.1-6.0 22 4.5-5 24 5.1-6.0 25 >6.0 >6.0 26 5.1-6.0 27
5.1-6.0 28 5.1-6.0 29 5.1-6.0 30 5.1-6.0 31 4.5-5 32 4.5-5 33 4.5-5
34 4.5-5 35 5.1-6.0 36 5.1-6.0 37 >6.0 >6.0 No 38 4.5-5 39
5.1-6.0 40 4.5-5 41 4.5-5 42 4.5-5 43 4.5-5 44 4.5-5 45 4.5-5 46
4.5-5 47 4.5-5 48 5.1-6.0 49 5.1-6.0 50 5.1-6.0 51 5.1-6.0 53
5.1-6.0 54 4.5-5 55 5.1-6.0 56 4.5-5 57 4.5-5 58 5.1-6.0 59 5.1-6.0
60 4.5-5 61 4.5-5 62 4.5-5 63 5.1-6.0 64 4.5-5 65 4.5-5 66 4.5-5 67
4.5-5 68 4.5-5 69 4.5-5 70 4.5-5 71 4.5-5 72 4.5-5 73 4.5-5 74
4.5-5 75 4.5-5 76 4.5-5 77 5.1-6.0 78 4.5-5 79 4.5-5 80 5.1-6.0
5.1-6.0 No 81 5.1-6.0 82 5.1-6.0 83 5.1-6.0 84 5.1-6.0 85 5.1-6.0
86 5.1-6.0 87 4.5-5 88 4.5-5 89 5.1-6.0 90 4.5-5 91 4.5-5 92
5.1-6.0 93 4.5-5 94 4.5-5 95 4.5-5 96 4.5-5 97 5.1-6.0 5.1-6.0 98
4.5-5 99 4.5-5 100 5.1-6.0 101 5.1-6.0 102 4.5-5 103 4.5-5 104
4.5-5 105 5.1-6.0 106 4.5-5 108 4.5-5 109 5.1-6.0 110 5.1-6.0 111
4.5-5 112 5.1-6.0
113 5.1-6.0 114 5.1-6.0 115 >6.0 >6.0 116 5.1-6.0 117 5.1-6.0
5.1-6.0 118 5.1-6.0 119 >6.0 270 5.1-6.0 331 5.1-6.0 330 5.1-6.0
332 >6.0 >6.0 263 5.1-6.0 >6.0 294 >6.0 >6.0 290
4.5-5.0 5.1-6.0 291 5.1-6.0 >6.0 292 5.1-6.0 >6.0 295 5.1-6.0
296 5.1-6.0 5.1-6.0 293 5.1-6.0 5.1-6.0 297 5.1-6.0 5.1-6.0 272
5.1-6.0 5.1-6.0 287 5.1-6.0 5.1-6.0 288 5.1-6.0 5.1-6.0 257 5.1-6.0
>6.0 258 5.1-6.0 259 5.1-6.0 5.1-6.0 260 5.1-6.0 >6.0 262
5.1-6.0 5.1-6.0 271 5.1-6.0 >6.0 298 5.1-6.0 5.1-6.0 304 >6.0
>6.0 306 >6.0 >6.0 299 5.1-6.0 >6.0 300 5.1-6.0 >6.0
320 >6.0 321 5.1-6.0 322 5.1-6.0 323 >6.0 324 >6.0 326
>6.0 325 >6.0 225 4.5-5.0 224 5.1-6.0 344 >6.0 343 5.1-6.0
342 5.1-6.0 345 5.1-6.0 347 >6.0 133 5.1-6.0 346 5.1-6.0 341
5.1-6.0 340 5.1-6.0 289 5.1-6.0 5.1-6.0 226 >6.0 5.1-6.0 253
>6.0 >6.0 223 4.5-5.0 <4.5 339 >6.0 >6.0 273 5.1-6.0
5.1-6.0 274 5.1-6.0 5.1-6.0 338 5.1-6.0 5.1-6.0 247 5.1-6.0 5.1-6.0
239 >6.0 >6.0 261 >6.0 >6.0 337 5.1-6.0 5.1-6.0 179
5.1-6.0 5.1-6.0 178 5.1-6.0 5.1-6.0 182 >6.0 >6.0 285 >6.0
>6.0 205 >6.0 >6.0 284 5.1-6.0 5.1-6.0 232 4.5-5.0 4.5-5.0
177 5.1-6.0 5.1-6.0 176 5.1-6.0 5.1-6.0 175 5.1-6.0 5.1-6.0 336
5.1-6.0 5.1-6.0 269 5.1-6.0 >6.0 266 5.1-6.0 5.1-6.0 335 5.1-6.0
5.1-6.0 174 5.1-6.0 >6.0 172 5.1-6.0 >6.0 171 5.1-6.0 >6.0
170 5.1-6.0 >6.0 169 >6.0 >6.0 203 5.1-6.0 5.1-6.0 268
>6.0 >6.0 267 >6.0 >6.0 281 >6.0 >6.0 202 5.1-6.0
>6.0 275 5.1-6.0 5.1-6.0 276 5.1-6.0 5.1-6.0 277 5.1-6.0 5.1-6.0
278 5.1-6.0 5.1-6.0 303 5.1-6.0 >6.0 201 5.1-6.0 5.1-6.0 230
5.1-6.0 5.1-6.0 243 4.5-5.0 4.5-5.0 231 4.5-5.0 4.5-5.0 167 4.5-5.0
4.5-5.0 251 5.1-6.0 >6.0 173 >6.0 >6.0 164 5.1-6.0 >6.0
163 5.1-6.0 5.1-6.0 222 >6.0 >6.0 214 5.1-6.0 5.1-6.0 213
4.5-5.0 5.1-6.0 242 >6.0 >6.0 200 5.1-6.0 >6.0 159 >6.0
>6.0 279 5.1-6.0 5.1-6.0 280 >6.0 >6.0 282 >6.0 5.1-6.0
283 >6.0 5.1-6.0 302 >6.0 >6.0 212 >6.0 >6.0 229
>6.0 >6.0 227 5.1-6.0 5.1-6.0 132 >6.0 >6.0 236 >6.0
>6.0 286 >6.0 >6.0 161 5.1-6.0 5.1-6.0 181 >6.0 >6.0
168 >6.0 >6.0 166 5.1-6.0 5.1-6.0 265 >6.0 >6.0 199
5.1-6.0 198 4.5-5.0 334 4.5-5.0 328 5.1-6.0 5.1-6.0 160 >6.0
>6.0 158 >6.0 >6.0 255 5.1-6.0 245 4.5-5.0 128 5.1-6.0 241
5.1-6.0 228 5.1-6.0 237 5.1-6.0 252 >6.0 >6.0 197 5.1-6.0 196
5.1-6.0 5.1-6.0 240 5.1-6.0 333 5.1-6.0 157.1 5.1-6.0 256 5.1-6.0
165 5.1-6.0 157 >6.0 195 5.1-6.0 194 >6.0 327 5.1-6.0 154
4.5-5.0 153 4.5-5.0 152 5.1-6.0 151 5.1-6.0 150 4.5-5.0 155 4.5-5.0
246 5.1-6.0 127 4.5-5.0 250 5.1-6.0 149 5.1-6.0 148 5.1-6.0 142
>6.0 5.1-6.0 193 4.5-5.0 192 >6.0 >6.0 191 4.5-5.0 190
5.1-6.0 5.1-6.0 180 5.1-6.0 144 >6.0 >6.0 145 4.5-5.0 147
5.1-6.0 221 4.5-5.0 131 >6.0 189 5.1-6.0 235 >6.0 146 5.1-6.0
329 5.1-6.0 254 >6.0 >6.0 244 5.1-6.0 5.1-6.0 220 >6.0
5.1-6.0 219 >6.0 >6.0 162 >6.0 >6.0 234 >6.0 >6.0
143 >6.0 >6.0 129 5.1-6.0 188 5.1-6.0 5.1-6.0 216 >6.0
>6.0 215 >6.0 >6.0 211 5.1-6.0 249 5.1-6.0 187 >6.0
5.1-6.0 233 5.1-6.0 5.1-6.0 218 5.1-6.0 141 5.1-6.0 140 5.1-6.0 139
4.5-5.0 264 4.5-5.0 217 >6.0 138 5.1-6.0 5.1-6.0 137 5.1-6.0 136
5.1-6.0 135 5.1-6.0 134 5.1-6.0 185 5.1-6.0 >6.0 121 5.1-6.0 125
5.1-6.0 210 4.5-5.0 126 >6.0 5.1-6.0 186 5.1-6.0 124 5.1-6.0 123
5.1-6.0 122 5.1-6.0 5.1-6.0 208 4.5-5.0 207 4.5-5.0 130 5.1-6.0 120
5.1-6.0 248 4.5-5.0 184 5.1-6.0 183 5.1-6.0 5.1-6.0 238 4.5-5.0 209
5.1-6.0 *A blank indicates not tested **Indicates compound is
considered to not be competitive with respect to phosphate. A blank
indicates not tested for competitive inhibition.
Example 349
In Vivo Assay
Bolus Phosphorus Challenge
[1221] It has been demonstrated that the hyperphosphatemic response
to a single oral dose of phosphorus is significantly dampened in
mice deficient in the Nap2b gene (Sabbagh et al, J. Am Soc
Nephrol., 20(11):2348-58 (2009)). By pretreating animals with a low
phosphorus diet followed by the subsequent dosing of a phosphorus
bolus, serum phosphorus levels were monitored after 30 minutes as a
surrogate for intestinal phosphorus absorption. These investigators
showed that as a result of Nap2b deletion, the rise in serum
phosphorus was reduced by about 40%. This indicates that the
theoretical maximum effect on phosphorus absorption a Nap2b
inhibitor could have in mice is 40% as indicated by the serum Pi.
The in vivo bolus phosphorus challenge model used here mimics this
model in rats.
[1222] Male, 7-week-old Sprague-Dawley rats (Charles-River
laboratories international, Hollister, Calif.) were allowed to
acclimatize for a minimum of 3 days before switching to a synthetic
low-phosphorus diet (TD.85010, Harlan Teklad, Madison, Wis.) which
contains 0.1% phosphorus and 0.6% calcium. At day 5, testing
compounds or vehicle alone (as indicated) were orally administered
at the indicated dose in a volume of 5 ml/kg, followed by a bolus
gavage of monobasic sodium phosphate (1 mmol in 1 ml) 15 min after
compound dosing. Serum was collected via retroorbital bleeding 30
min post phosphate bolus and phosphate levels were determined
utilizing an ACE ALERA blood chemistry analyzer (Alfa Wassermann
Diagnostic Technologies, West Caldwell, N.J.).
[1223] The extent of inhibition by test compounds on the elevation
of serum phosphate levels in response to the bolus of phosphorus is
shown in Table 12 (data are expressed as % Inhibition, with 6-10
animals per data point). The differences between groups were
evaluated by one-way analysis of variance with Dunnett's post hoc
tests.
TABLE-US-00013 TABLE 12 Inhibition of Uptake of Phosphorus from the
Intestine as Measured using the Bolus Phosphorus Challenge Model %
Inhibition of Example Drug Dose Serum P elevation Significance 21
30 10-20 n.s. 1.32 30 20-30 *** 4.4 30 40-50 *** 51 30 10-20 n.s.
80 30 20-30 *** 14 30 10-20 n.s. 1.1 30 20-30 ** *p < 0.05,
versus vehicle by Dunnett's post hoc test. **p < 0.01, versus
vehicle by Dunnett's post hoc test. ***p < 0.001, versus vehicle
by Dunnett's post hoc test.
Example 350
In Vivo Evaluation Procedure
Co-Dosing in Chow
[1224] Male, 7-week-old Sprague-Dawley rats (Charles-River
laboratories international, Hollister, Calif.) were allowed to
acclimate for a minimum of 3 days. The experiment was initiated by
switching animals to a synthetic diet (0.6% phosphorus and 0.6%
calcium, Harlan Teklad TD.84122) for four days. After this time,
the animals were placed into metabolic cages for daily monitoring
of food and water consumption, as well as urine and fecal
collections. Test compounds were incorporated into the powdered
diet listed above containing 3% chocolate flavoring (w/w, BioServ
#7345) at 1.3 mg test compound per gram of diet to achieve an
average daily nominal dose of 100 mg/kg/day. The actual dose
received by each animal was later determined by measuring prepared
diet consumption and body weight. Urine samples were collected in
three daily periods from 24-48, 48-72, and 72-96 hours of drug
dosing. Averaging these three 24 h periods allows for the more
representative measurements of urination, fecal excretion, food
consumption and water uptake for each animal. Phosphorus levels in
the urine were determined by anion exchange chromatography using a
Dionex ICS-3000 ion chromatography system. Urine samples were
diluted 1:500 or 1:1000 and injected onto an IonPac AS18 analytical
column (2.times.250 mm) using a potassium hydroxide eluent. Elution
of urine phosphate ions was monitored via conductivity detector and
reported as ppm relative to a standard ion solution containing
phosphate. Daily urinary P output relative to the P consumed in the
prepared diet for each animal was calculated. The percentage
inhibition of phosphorus absorption was estimated by determining
the reduction of this ratio compared to the control group (animals
with no drug in chow). The differences between the means of control
and treated groups were evaluated by t tests. In all experiments,
one group was always included that had Renvela powder blended into
their chow at 0.9% targeting a dose of 750 mg/kg. Typically this
resulted in an approximately 15% inhibition of Urine Pout/P
consumed.
TABLE-US-00014 TABLE 13 Inhibition of Uptake of Phosphorus from the
Intestine as Measured using the Co-Dosing in Chow Model Mean drug
dose, Mean % inhibition Example mg/kg/day Urine Pout/P consumed
t-test 25 74 10-30 *** 37 101 .ltoreq.10 * 188 110 10-30 ** 162 100
10-30 *** 144 100 .ltoreq.10 * 142 100 .ltoreq.10 ns 252 90 10-30 *
237 130 .ltoreq.10 ns 265 120 .ltoreq.10 * 166 120 10-30 *** 181
120 .ltoreq.10 ** 161 120 .ltoreq.10 * 286 130 10-30 ** 200 100
10-30 * 163 100 .ltoreq.10 ns 164 100 .ltoreq.10 ns 173 90
.ltoreq.10 ns 251 50 .ltoreq.10 ns 203 100 .ltoreq.10 ** 335 100
.ltoreq.10 ** 269 100 .ltoreq.10 ** 327 100 10-30 ** 261 100 10-30
* 300 50 .ltoreq.10 * 299 50 10-30 ** 298 50 10-30 *** 272 50
.ltoreq.10 ns *p < 0.05 versus control; **p < 0.01 versus
control; ***p < 0.001 versus control
Example 351
Stability of Compounds in Simulated Gastric and Intestinal
Fluid
[1225] Test compounds were incubated at 1-20 .mu.M in simulated
gastric fluid (SGF; standard USP solution with 3 mg/mL pepsin) or
simulated intestinal fluid (SIF; standard USP solution with 3 mg/mL
pancreatin) for 3 hr or 6 hr. HPLC-UV or HPLC-MS were used to
determine test compound levels using peak area %. Results (Table
14) were reported as the percentage of test compound remaining
after incubation in a given condition relative to test compound
present at t=0 in the same condition.
TABLE-US-00015 TABLE 14 Percentage of Compound Remaining in
Simulated Gastric and Intestinal Fluids Incubation % remaining, %
remaining, Example Time SIF SGF 117 6 hr >80% >80% 25 6 hr 80
>80% 8.25 6 hr >80% >80% 26 6 hr 60-80% >80% 37 6 hr
>80% >80% 8.21 6 hr >80% >80% 8.1 6 hr >80% 60-80%
8.6 6 hr >80% >80% 209 6 hr 60-80% >80% 238 6 hr >80%
>80% 248 6 hr >80% >80% 126 6 hr >80% >80% 210 6 hr
>80% >80% 137 6 hr >80% >80% 138 6 hr 40-60% >80%
264 6 hr >80% 40-60% 162 6 hr >80% >80% 254 6 hr >80%
>80% 146 6 hr 60-80% >80% 235 6 hr >80% >80% 131 6 hr
>80% >80% 147 6 hr >80% >80% 144 6 hr >80% >80%
191 6 hr >80% >80% 193 6 hr >80% >80% 142 6 hr >80%
>80% 148 6 hr >80% >80% 149 6 hr >80% >80% 250 6 hr
>80% >80% 246 6 hr >80% >80% 150 6 hr >80% >80%
151 6 hr 40-60% >80% 152 6 hr >80% >80% 327 6 hr >80%
>80% 157 6 hr >80% >80% 165 6 hr >80% >80% 256 6 hr
>80% >80% 157.1 6 hr >80% >80% 157.1 6 hr >80%
>80% 333 6 hr >80% >80% 240 6 hr >80% >80% 196 6 hr
>80% >80% 252 6 hr >80% >80% 237 6 hr >80% >80%
255 6 hr >80% >80% 158 6 hr 20-40% >80% 160 6 hr 40-60%
>80% 328 6 hr >80% >80% 199 6 hr >80% >80% 265 6 hr
>80% >80% 166 6 hr >80% >80% 168 6 hr >80% >80%
181 6 hr >80% >80% 161 6 hr >80% >80% 286 6 hr >80%
>80% 200 6 hr >80% >80% 163 6 hr 60-80% >80% 164 6 hr
60-80% >80% 173 6 hr >80% >80% 251 6 hr >80% >80%
275 6 hr >80% >80% 202 6 hr >80% >80% 281 6 hr 20-40%
>80% 203 6 hr >80% >80% 169 6 hr 60-80% >80% 170 6 hr
60-80% >80% 171 6 hr >80% >80% 172 6 hr >80% >80%
174 6 hr >80% >80% 335 6 hr >80% >80% 269 6 hr >80%
>80% 205 6 hr >80% >80% 285 6 hr >80% 60-80% 182 6 hr
>80% >80% 261 6 hr 60-80% >80% 261 6 hr >80% >80%
239 6 hr >80% 60-80% 339 6 hr >80% <20% 253 6 hr >80%
60-80%
Example 352
Determination of Compound Cmax and AUC
[1226] Sprague-Dawley rats were orally gavaged with test article at
a nominal dose of 2.5 or 10 mg/kg and blood was collected at 0.5,
1, 2 and 4 h. Blood samples were processed to plasma using
K.sub.2EDTA as an anticoagulant. Plasma samples were treated with
acetonitrile containing an internal standard, precipitated proteins
removed by centrifugation. Supernatants were analyzed by LC-MS/MS
and compound concentrations were determined by interpolation from a
standard curve prepared in plasma. Table 15 illustrates data from
the pharmacokinetic profiling of selected example compounds. All
compounds were orally dosed at the dosage shown, and
pharmacokinetic parameters determined.
TABLE-US-00016 TABLE 15 Pharmacokinetic Profiling of Selected
Example Compounds Actual Oral Cmax AUC Example Dose (mg/kg) (ng/mL)
(ng .times. hr/mL) 8.1 3-15 <10 <30 37 3-15 <10 <30 26
3-15 <30 <30 25 3-15 <30 <30 8.25 3-15 <30 >50
8.6 3-15 <50 >50 1.1 3-15 <50 >50 8.21 3-15 <30
<30 80 3-15 <10 <10 80 3-15 <10 <30 209 3-15 <30
<30 238 3-15 <10 <10 248 3-15 <10 <10 126 3-15
<10 <30 210 3-15 <10 <30 137 3-15 <10 <10 138
3-15 <10 <10 264 3-15 <10 <10 141 3-15 >50 >50
218 3-15 <10 <30 233 3-15 <10 <10 249 3-15 <10
<30 211 3-15 <10 <30 215 3-15 <10 <10 216 3-15
<10 <10 188 3-15 <10 <10 143 3-15 <10 <10 234
3-15 <10 <30 162 3-15 <10 <10 254 3-15 <10 <10
146 3-15 <10 <10 131 3-15 <30 <50 147 3-15 <10
<10 144 3-15 <10 <10 191 3-15 <10 <10 193 3-15
<10 <30 142 3-15 <10 <10 148 3-15 <10 <10 149
3-15 <10 <10 250 3-15 <10 <10 246 3-15 <10 <10
150 3-15 <10 <10 151 3-15 <10 <10 152 3-15 <10
<10 327 3-15 <10 <10 195 3-15 <10 <10 157 3-15
<10 <10 165 3-15 <10 <30 256 3-15 <10 <10 157.1
3-15 <10 <30 333 3-15 <30 <50 240 3-15 <10 <10
196 3-15 >50 >50 252 3-15 <30 <30 255 3-15 <10
<10 158 3-15 <10 <10 160 3-15 <10 <10 199 3-15
<10 <10 265 3-15 <30 <30 166 3-15 <10 <10 166
3-15 <10 <10 166 15-40 >50 <50 168 3-15 <10 <30
181 3-15 <30 <30 161 3-15 <10 <10 161 3-15 <10
<10 286 3-15 <10 <10 286 3-15 <10 <10 200 3-15
<30 <30 251 3-15 <10 <10 281 3-15 <10 <10 335
3-15 <10 >50 269 3-15 <10 <10 285 3-15 <30 <50
261 3-15 <50 >50 239 15-40 <30 <30 339 3-15 <10
<30 253 15-40 <10 <10 300 15-40 <10 <30 299 15-40
<30 <30 298 15-40 <30 <30 271 15-40 <30 >50 262
15-40 <10 <50 272 15-40 <10 <10 297 3-15 <10 <30
294 3-15 <10 >50 LLOQ = Lower Limit of Quantification
Example 353
Fecal Recovery of Orally Administered Compounds
[1227] Quantitative determination of test compound level in feces
after oral gavage was performed using the same set of animals used
to determine test compound concentration in plasma (Example 352).
The animals were kept in metabolic cages and feces were collected
from the time of dosing until 48 hr after dosing. Upon collection,
feces were dried by lyophilization and ground to a visually
homogenous powder. Duplicate samples of ground feces from each
individual animal were weighed out and extracted using organic
solvent. Extracted samples were then diluted into mobile phase and
test compound levels were quantitatively determined by LC-MS/MS
analysis as described in Example 352 except that the standard curve
was prepared in a feces matrix. Extraction conditions were not
optimized for individual compounds, and thus may represent a
minimal level of recovery.
TABLE-US-00017 TABLE 16 Fraction of Orally Administered Compound
Recovered in Feces 48 Hours after Dosing % recovered Example in
feces 8.1 <20 37 <20 26 <20 25 20-80 8.3 <20 8.6 20-80
1.1 20-80 8.21 >80 80 20-80 137 <20 138 <20 264 <20 162
20-80 265 <20 166 >80 181 >80 161 >80 286 <20 200
20-80 251 >80 335 >80 269 <20 261 <20 300 20-80 299
20-80 298 >80 271 20-80 262 20-80 272 >80 294 >80
Example 354
In Vivo Evaluation Procedure
CKD Rats
[1228] To assess the ability of selected example compounds to
impact the progression of chronic kidney disease (CKD), 5/6
nephrectomy (5/6Nx) rat model of CKD was used. A commonly used
model to study various aspects of CKD, the 5/6Nx rat is not
normally hyperphosphatemic unless challenged with phosphate in the
diet and co-administration of active vitamin D (Shobeiri et. al.,
Am J Nephrol 2010; 31:471-481, Vascular Calcification in Animal
Models of CKD: A Review). (Lopez et al. 2006, J Am Soc Nephrol 17:
795-804. Calcimimetic R-568 Decreases Extraosseous Calcifications
in Uremic Rats Treated with Calcitriol). 5/6 Nx rats were obtained
from Charles River Labs (CRL, Hollister, Calif.). Upon arrival, the
surgeries and extent of kidney damage in the animals were assessed
by measuring serum creatinine, P, Ca, and BUN. Based on this
analysis, rats with inconsistent kidney function were removed from
the study and the remainder of the cohort was divided in to evenly
stratified test groups. The remaining animals were then placed on
the same synthetic diet used in the drug-in-chow studies (Example
350), except the P levels were adjusted to 0.9% P. Drugs are
blended into this chow to achieve the required dosing rate. At this
time, rats were also started on an activated Vitamin D regimen in
which they were injected intraperitoneally with calcitriol at 80
ng/kg three times a week. Once a week, serum was collected via
retro orbital bleeding for analysis of serum P and creatinine
utilizing an ACE ALERA blood chemistry analyzer. As reported by the
Lopez group, substantial hyperphosphatemia was achieved after two
weeks as well as measurable vascular and soft tissue calcification.
Additionally, serum creatinine is doubled compared to untreated
5/6Nx rats and serum FGF-23 levels are significantly elevated. The
data in Table 14 details the results for three independent studies
in these 5/6 Nx rats. Unless otherwise indicated, the data shown is
from the serum collected at 2 weeks after initiation of the
treatment regimen. In addition, for study #3, during the third week
of the study, the animals were placed in metabolic cages for two
days, and urine collected for the final 24 hours. Using the
measured levels of serum and urine creatinine, the creatinine
clearance was calculated, and found to be 1.9 for vehicle, 1.9 for
Renvela, 2.3 for Example 166 and 2.8 mL/min/kg for the combination
group. The difference between the combination group and vehicle was
statistically significant, with a p<0.05.
[1229] These results support the concept that treatment of 5/6Nx
kidney damaged animals with a NaP2b inhibitor results in a reduced
rate of progression of loss of kidney function, as shown by the
improved trends in accepted markers of kidney disease progression,
including serum creatinine, and glomerular filtration rate (GFR;
creatinine clearance). The improvement appears to be mediated by
reductions in serum P as well as overall P homeostasis, as
evidenced by reduced levels of serum FGF23, a recognized indicator
of whole-body P and recognized indicate of CKD progression (Zisman,
A. L. and Wolf, M, Recent advances in the rapidly evolving field of
fibroblast growth factor 23 in chronic kidney disease, Curr Opin
Nephrol Hypertens. 2010 July; 19(4):335-42.) It is worth noting
that in study #3, the treatment with the combination of Example 166
with the P binder Renvela results in greater than expected
improvement (statistically significant improvements in serum P,
serum Cre, FGF-23 and GFR), suggesting that these agents may be
working synergistically through distinct but overlapping
mechanisms.
TABLE-US-00018 TABLE 14 Parameters for CKD rats after two weeks of
treatment Avg % Drug in Study Ser P, Ser CRE, FGF23, weight chow #
n mg/dL mg/dL pg/mL gain Vehicle 1 7 12 1.5 >15,000 17 Renvela 1
7 9.2* 1.1 >15,000 23 Example 25 1 6 10 1.3 ~10,000 18 Example
261 1 5 9.7 1.0 >15,000 23 Vehicle 2 9 12.6 1.6 2.2 .times.
10.sup.5 21 Renvela 2 8 10 1.3 1.3 .times. 10.sup.5 29 Example 166
2 8 11 1.2 1.0 .times. 10.sup.5 27 Vehicle 3 10 11.sup..sctn.
1.2.sup..sctn. 2.8 .times. 10.sup.5.sctn..sctn. 27.sup..sctn..sctn.
Renvela 3 11 10.sup..sctn. 1.3.sup..sctn. 1.7 .times.
10.sup.5.sctn..sctn. 32.sup..sctn..sctn. Example 166 3 11
10.sup..sctn. 1.0.sup..sctn. 1.2 .times. 10.sup.5.sctn..sctn.
35.sup..sctn..sctn. Example 3 10 8.4**.sup..sctn. 0.9*.sup..sctn.
1.1 .times. 10.sup.5*.sup..sctn..sctn. 33.sup..sctn..sctn. 166 +
renvela Ser P = Serum P, mg/dL Ser CRE = serum Creatinine, mg/dL
FGF23 = serum FGF23 levels, pg/mL, measured using the Mouse FGF-23
(C-Terminal) ELISA kit from Immutopics (San Clemente, California)
Avg % weight gain = average % body weight since initiation of study
.sup..sctn.Data taken at 3 weeks after initiation of study
.sup..sctn..sctn.Data taken at 4 weeks after initiation of study *p
< 0.05, versus vehicle **p < 0.01, versus vehicle
[1230] All of the U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, foreign
patent applications and non-patent publications referred to in this
specification are incorporated herein by reference, in their
entirety to the extent not inconsistent with the present
description.
[1231] From the foregoing it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended
claims.
* * * * *